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Synthèse du mémoire  
Introduction 
I. Le tissu adipeux et l'obésité 
 
La perception du tissu adipeux a considérablement changé au cours de 
ces dernières décennies avec la spectaculaire augmentation de l'incidence de 
l'obésité et sa morbidité associée. Au niveau mondial, mais plus particulièrement 
dans les pays industrialisés, l'obésité compte à présent parmi l’une des plus 
grandes préoccupations de santé publique. Même si cette maladie chronique a 
une étiologie multifactorielle, elle peut être simplement définie par une 
augmentation de l'accumulation de la graisse corporelle. Chez la majorité des 
patients, l’obésité est la conséquence d’un apport énergétique supérieur à la 
dépense. Peu de thérapies médicales sont actuellement reconnues et elles 
visent en général un ou plusieurs des mécanismes suivants: prévention de 
l'absorption des graisses, diminution de l'appétit et augmentation du métabolisme 
corporel. 
Pour étudier les mécanismes liés à l’obésité, plusieurs modèles de 
rongeurs sont disponibles, permettant d’être en mesure d’émettre des 
hypothèses applicables à l’homme. Parmi ces modèles animaux ils existent par 
exemple des souris présentant des altérations concernant la leptine, une 
hormone qui régule les réserves de graisses dans l'organisme et l'appétit, parfois 
dite « hormone de la satiété ». Les souris  ob/ob, sont mutées génétiquement au 
niveau du gène codant la leptine; et les souris db/db sont mutées au niveau du 
récepteur à la leptine. Très utilisés aussi ce sont les souris DIO (diet-induced 
obesity), chez lesquelles l’obésité est induite par un régime alimentaire riche en 
lipides. 
Le tissu adipeux est susceptible aux changements diététiques, en effet il 
est sensible à l'insuline sécrétée suite aux repas, ainsi qu’à l’adrénaline produite 
lors d’un stress. De plus, un bon fonctionnement du système nerveux est requis 
pour détecter l'état des réserves énergétiques et faire correspondre les apports 
avec les dépenses. Des réponses métaboliques et comportementales sont ainsi 
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déclenchées, visant à maintenir l'équilibre énergétique. Dans l'ensemble, cet 
équilibre est sensible à divers facteurs, y compris des hormones, des 
neurotransmetteurs et des facteurs psychologiques et culturels. 
Les adipocytes sont équipés de la machinerie biochimique nécessaire pour 
fonctionner efficacement en tant que site de stockage du carburant de 
l'organisme. Pour ce faire, ils sont aussi bien responsables de la conversion des 
acides gras libres en triglycérides permettant la lipogénèse (stockage des corps 
gras), que du processus inverse, la lipolyse (libération des corps gras). Outre ces 
deux fonctions fondamentales, le tissu adipeux est crucial pour l'activité du 
système endocrinien via sa fonction sécrétrice, qui est indispensable pour le 
maintien de l'homéostasie dans l’organisme. Des peptides et autres facteurs 
agissant de façon endocrine ou paracrine (adipokines/adipocytokines), sont 
libérés par ce tissu et/ou par sa fraction stroma vasculaire, et vont exercer des 
effets métaboliques très variés. Parmi ceux-ci on compte des adipocytokines pro-
inflammatoires qu’on trouve augmentées en relation avec l’obésité tel que la 
leptine, la resistine, le TNF-α, l’IL-6 et le PAI-1; ainsi que d’autres adipokines 
comme l’adiponectine, l’apeline,  l’adipsine et le FGF21. 
Les deux principaux types de tissu adipeux sont le blanc et le brun. 
Typiquement, le tissu adipeux blanc représente environ 20% du poids corporel 
chez l’homme et 28% chez la femme (Thompson et al., 2012)  mais chez les 
personnes obèses, il peut représenter jusqu’à 80% de ce poids. L'obésité est 
accompagnée d'une hausse généralisée des dépôts de tissu adipeux blanc en 
raison de l'hyperplasie (augmentation du nombre des adipocytes) et de 
l'hypertrophie (augmentation de la taille des adipocytes) (Dulloo et al., 2010). Les 
caractéristiques principales des adipocytes blancs sont le stockage d’excès 
d'énergie sous forme triglycérides dans de grosses gouttelettes uniloculaires, et 
la libération de cette énergie sous la forme d'acides gras libres dans des 
situations de besoin énergétique, comme le jeun, ou en réponse à un stimulus 
tel que la sécrétion d’adrénaline. 
De leur côté, les adipocytes bruns stockent des triglycérides sous forme 
multiloculaire, de sorte qu’ils puissent être rapidement utilisés comme 
combustible pour la production de chaleur à travers un processus biochimique, 
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le "découplage" mitochondrial de la phosphorylation oxydative des acides gras 
libres (Sethi and Vidal-Puig, 2007). Chez les mammifères, le tissu adipeux brun 
peut dissiper l’énergie lipidique  sous forme de chaleur dans un processus appelé 
thermogenèse sans frisson (Bartelt and Heeren, 2014). En effet les adipocytes 
bruns expriment au niveau de leur membrane mitochondriale interne une 
protéine de 32 kDa appelée UCP1 (protéine de découplage 1) permettant une 
dissipation du gradient électrochimique de protons généré par la respiration sous 
forme de chaleur (Cannon, 2004). Le tissu adipeux brun est donc unique en 
raison de sa fonction dans la thermogénèse comme forme de dépense 
énergétique, cette énorme capacité thermogénique apportant une contribution 
substantielle au métabolisme énergétique de l’organisme. Par ailleurs, il peut être 
distingué du tissu adipeux blanc morphologiquement par une vascularisation plus 
riche et une plus grande densité mitochondriale.  
Récemment, une troisième catégorie d’adipocytes distincts des adipocytes 
blancs et bruns a été décrite. Ce sont des adipocytes bruns inductibles, qui ont 
été nommés des « adipocytes beiges/brite » (Giralt and Villarroya, 2013). Les 
adipocytes beiges sont notamment présents au sein du tissu adipeux blanc. Leur 
processus d’activation est décrit comme le '' brunissement ''. Ce phénomène est 
caractérisé par l'expression d'UCP1 et il entraîne des effets métaboliques 
bénéfiques. Le froid ainsi que l’activation de la voie β3-adrénergique ont été 
reconnues entre autres comme activateurs du brunissage.  
Finalement, dès leur développement, les trois types d’adipocytes sont bien 
distincts avec une expression différentielle de nombreux gènes (Baboota et al., 
2015). L’utilisation de différentes lignées cellulaires (3T3-L1, 3T3F442A, 
C3H10T1/2, préadipocytes bruns, etc.) a permis récemment de mettre à jour le 
contrôle transcriptionnel au cours de la différenciation adipocytaire ainsi que les 
fonctions des adipocytes. L'une des caractéristiques qui permettent de mieux 
distinguer ces trois types d’adipocytes est la quantité de mitochondries. 
II. Les Mitochondries et l'homéostasie énergétique 
Une fonction mitochondriale normale est nécessaire et requise pour la 
préservation d’un équilibre approprié entre le stockage et la dépense 
énergétique. Un excès de nutriments mène à des dysfonctionnements 
Synthèse du mémoire en français 
 
mitochondriaux, qui sont accompagnés  d’effets indirects sur le métabolisme des 
lipides et du glucose (Bournat et Brown, 2010).  
 
Les mitochondries sont des organelles qui fournissent environ 90% de 
l'énergie requise pour le bon fonctionnement de la cellule eucaryote (Tao et al., 
2014). L’énergie fournie par le glucose et les lipides contenus dans les aliments 
est transformée en ATP (adénosine-5′-triphosphate), de sorte qu’elle puisse être 
utilisée par la cellule. Ceci est possible grâce aux deux processus que sont la 
glycolyse et l’oxydation des acides gras. La glycolyse est un processus anaérobie 
transformant le glucose en pyruvate avec une faible production d'énergie 
comparativement à la respiration aérobie. Le processus d’oxydation des acides 
gras se caractérise quant à lui par une série de réactions diminuant la taille des 
acides gras. En fonction de la source de substrats, soit la glycolyse soit 
l’oxydation des acides gras prédomine pour produire de l'ATP. 
 
Le cycle de Krebs, également connu comme cycle de l'acide citrique, est au 
centre du métabolisme énergétique des cellules et sert de base pour la 
production d'énergie via l'acétyl-CoA, un intermédiaire commun de la 
métabolisation du glucose et des acides gras. Deux cofacteurs, le NADH 
(nicotinamide adénine dinucléotide) et le FAD (flavine adénine dinucléotide), sont 
produits au sein du cycle de Krebs. Par leur intermédiaire, des électrons sont 
transportés successivement à travers les complexes de la chaîne de respiration 
mitochondriale, jusqu'à ce qu'ils soient reçus par l’O2 pour générer du H2O et 
conduire à la production d'ATP. 
 
La chaîne de respiration mitochondriale réunit cinq complexes enzymatiques  
présents dans la membrane mitochondriale interne (Lancaster, 2002) et 
désignés, avec le transporteur de phosphate inorganique et la translocase 
ATP/ADP, sous le nom de système OXPHOS. Ce système est constitué de 
protéines codées par les génomes nucléaires et mitochondriaux  (van Waveren 
et Moraes, 2008) aux caractéristiques très différentes. La majorité des protéines 
impliquées dans la fonction mitochondriale sont codées au niveau nucléaire puis 
synthétisées dans le cytosol et pour ensuite rejoindre la mitochondrie (Elstner et 
al., 2009). 
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III. L’épissage de l'ARN pré-messager 
 
L’ARN pré-messager sera soit maturé suite au phénomène d’épissage en 
ARN messager pour être traduit en protéine, soit il exercera une fonction d’ARN 
non-codant. L’épissage est le processus par lequel des portions de l'ARN pré-
messager, appelées introns, sont clivées, de sorte que l’ensemble des 
séquences restantes,  nommées exons, soient associées pour former le produit 
final l’ARN messager qui suivra par la suite des modifications post-
transcriptionnelles.  
L’épissage joue un rôle essentiel dans le phénotype des cellules eucaryotes 
supérieures. Certaines fonctions tissulaires sont étroitement associés aux 
évènements d’épissage tissu spécifiques (Wang et Burge, 2008; Taliaferro et al, 
2011). Bien que la majorité des exons soient inclue dans l’ARN messager final, 
certains exons, ou des parties d'exons, peuvent être, dans certaines cellules ou 
dans des conditions spécifiques, éliminés à partir des ARN messager. Un même 
transcrit d'ARN peut être remanié de différentes façons et aboutir à des 
messagers, donc des protéines, très différentes. Ce processus est appelé 
épissage alternatif, et joue un rôle central dans la génération de protéomes 
complexes à partir de génomes définis. L'épissage alternatif s'applique à la 
grande majorité de nos gènes (>90%) et génère une considérable diversité 
protéique qui est modulée qualitativement en fonction du type de tissu ou au 
cours du développement d'un organisme (Modrek and Lee 2002). 
 
Un épissage efficace nécessite, trois éléments dont les séquences sont 
plus ou moins conservées, permettent la définition des introns avant leur 
excision. Ces éléments sont  le site donneur ou site d’épissage 5’,  le site 
accepteur ou site d’épissage 3’, et le point de branchement, précédé par un tract 
polypyrimidine (Wahl et al., 2009). Outre ces trois éléments, d'autres séquences 
influencent l’épissage. En fonction de leur emplacement et leur activité, ces 
séquences sont soit des activateurs d'épissage exoniques (ESE) ou introniques 
(ISE), soit des inhibiteurs d'épissage exoniques (ESS) ou introniques (ISS). 
Certaines protéines reconnaissent les sites activateurs pour promouvoir 
l'épissage (protéines SR), et d’autres, au contraire, reconnaissent les sites 
inhibiteurs pour l’empêcher (hnRNP). 
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Le processus d’épissage comprend deux étapes impliquant des réactions de 
trans-estérification. La première est une attaque nucléophile du 2’-OH du ribose 
de l’adénosine du point de branchement sur le phosphate du site 5’ d’épissage. 
La seconde est une attaque du phosphate au niveau du site 3’ d’épissage par le 
3’OH libéré précédemment en 5’. Ainsi les exons sont liés entre eux et l’intron est 
éliminé sous forme de lasso. Ces réactions sont réalisées grâce à un complexe 
multi-protéiniques appelé le spliceosome (Matera et Wang, 2014). Cette 
machinerie reconnait des séquences consensus spécifiques qui aident à définir 
les sites d’épissage. 
Le spliceosome est une structure très dynamique qui subit des réarrangements 
constants au cours du processus d’épissage. Son assemblage sur le transcrit 
cible requiert la liaison et la libération de différentes petites ribonucléoprotéines 
nucléaires, ainsi que d’autres facteurs d'épissage. 
 
Des mutations dans les séquences normales d’épissage ont été décrites comme 
ayant un lien étroit avec des maladies. En effet, dans de nombreuses pathologies 
comme les maladies génétiques ou le cancer, le processus d’épissage est altéré  
(Orengo et Cooper, 2007;. Tazi et al, 2009). C’est le cas du syndrome progérique 
(HGPS: Hutchinson-Gilford progeria syndrome) caractérisé par un vieillissement 
accéléré de l’organisme. À l’origine de ce syndrome une mutation synonyme 
(C>T) au niveau de l’exon 11 du gène LMNA codant pour les lamines A/C, induit 
l’utilisation exacerbée d’un site d’épissage cryptique et la production massive 
d’une protéine tronquée; appelée progérine. Cet épissage est régulé de façon 
opposée par deux protéines SR : SRSF1 (favorisant l’utilisation du site cryptique) 
et SRSF6 (promouvant l’utilisation du site authentique) (Lopez-Mejia et al., 2011). 
Cet exemple d’anomalie d’épissage a constitué le cœur du travail de criblage in 
vitro effectué chez ABIVAX afin de trouver de petites molécules ciblant la 
modulation pharmacologique de cet épissage alternatif. Ainsi, un composé, 
l’ABX300, a été sélectionné suite à ce crible et mon travail de thèse a porté sur 
l’étude de son mode d’action et l’identification de nouveaux analogues. 
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Résultats 
 
I. Recherche du mode d'action d’ABX300 
 
Il a été démontré au sein du laboratoire du Pr Tazi que les isoformes du 
gène LMNA issu d’un épissage alternatif jouent des rôles opposés sur le 
métabolisme lipidique et énergétique (Lopez-Mejia et al., 2014). Ces travaux 
suggèrent que la modulation pharmacologique de cet épissage pourrait 
représenter une approche nouvelle et originale dans le traitement de l’obésité. 
Cette hypothèse a été testée dans les travaux ici présentés en utilisant 2 
systèmes de criblage complémentaires, et ceci afin d’identifier un potentiel 
modulateur de l’épissage présentant un impact sur le métabolisme énergétique. 
Un premier crible basé sur la localisation de SRSF1, qui a été suivie par 
microscopie; et un second sur la base de l'événement d`épissage qui se produit 
entre les exons 11 et 12 du gène LMNA dans le cadre de HGPS (C>T à 
activation de progérine 5'SS). Un système rapporteur de l’épissage du gène 
LMNA basé sur l’activité de la luciférase nous a permis de rendre compte de 
l’utilisation des sites 5’ authentique et cryptique d’épissage. Un composé appelé 
ABX300 a ainsi été sélectionné. Les données générées montrent aussi 
qu’ABX300 interagit directement avec SRSF1 avec pour conséquence un effet 
potentiel sur l’épissage de LMNA. 
ABX300 a été testé par la suite sur deux modèles murins d’obésité, un modèle 
de souris génétiquement modifiées (ob/ob et db/db) et un modèle nutritionnel. 
L’administration journalière de la molécule a conduit à une perte de poids chez 
ces animaux. 
Comme évoqué précedement, mon travail de thèse a consisté à déterminer le 
mécanisme d’action de la molécule ABX300, ainsi que son impact sur le 
métabolisme. Les résultats ont montré qu’ABX300 n’a pas d’effet ni sur la 
différenciation adipocytaire, ni sur le contenu en triglycérides au sein de lignées 
cellulaires (cellules 3T3-L1 et  préadipocytes de tissu adipeux brun). Cependant, 
des analyses in vivo de « pair-feeding », des analyses PET-scan, et des études 
en cages métaboliques, ont montré une différence entre les groupes traités et 
non-traités au niveau de leur  prise alimentaire, la consommation d'oxygène et la 
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source énergétique utilisée. Parallèlement une série d'approches 
transcriptomiques ont permis de mettre en évidence une importante modulation 
par ABX300 de microRNA dont les cibles sont mitochondriales, et ceci en 
absence d’une restructuration globale du profil d'épissage. 
Ces travaux montrent que l’identification de modulateurs de l'épissage alternatif 
du gène LMNA est une stratégie innovante et prometteuse pour la découverte de 
molécules bioactives dans le traitement de l’obésité. 
 
II. Identification d’autres molécules ciblant l’épissage du gène 
LMNA basées sur l’analogie à la molécule ABX300 
 
En raison de plusieurs inconvénients empêchant le  développement 
clinique de l’ABX300, l'identification de nouvelles molécules « back-up » 
(principalement des analogues d’ABX300, mais non exclusivement), ciblant 
l’épissage de LMNA, et ayant donc théoriquement un impact sur l'évolution du 
poids, a constitué le second objectif de mon travail de thèse. Idéalement, ces 
molécules seraient dépourvues d’effets secondaires indésirables mais 
conserveraient  l'activité et l'efficacité d’ABX300 sur le poids. Pour cela, des 
modifications chimiques ont été apportées au squelette principal de la molécule 
ABX300. 
De nombreuses molécules (887 plus exactement) de la chimiothèque 
d’ABIVAX ont ainsi été criblées puis en partie (21 molécules) testées in vivo dans 
des modèles de souris DIO mais malheureusement, aucune n’a montré un effet 
sur l’obésité. 
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Discussion 
 
Les récentes preuves indiquant que le gène LMNA joue activement un rôle 
dans le métabolisme (Tang et al., 2011; Liu et al., 2012) ont été complétées avec 
la découverte au sein de notre laboratoire des fonctions antagonistes que les 
différentes isoformes issues de ce gène exercent sur la dépense énergétique et 
la durée de vie (Lopez-Mejia et al., 2014). Nos études renforcent donc la 
proposition du gène LMNA comme cible pharmacologique potentielle dans le 
traitement de l'obésité. 
Mon travail de thèse a abordé la compréhension du mécanisme d’action 
d’ABX300, une molécule modulatrice de l’épissage du gène LMNA avec un net 
effet sur l’obésité. 
Concernant le système rapporteur de criblage in vitro, il serait pertinent de tester 
l’effet d’ABX300 sur le mini-gène WT/non muté correspondant. En faisant ceci, 
nous pourrions nous affranchir de tout effet potentiel de la drogue sur la 
transcription et pourrions vraiment utiliser cette construction avec une meilleure 
fiabilité. 
Par ailleurs, comme il a été établi une interaction entre SRSF1 et ABX300, on ne 
peut pas exclure que d’autres membres de la famille n’interagissent aussi avec 
la molécule. Il serait certainement très intéressant de poursuivre le même type 
d'analyse avec d'autres protéines SR, notamment SRSF6 et SRSF5, deux 
protéines qui ont été rapportées comme ayant un rôle opposé à celui de SRSF1 
sur cet épissage en particulier (Fong et al, 2009;. Lopez-Mejia et al., 2011).  
De plus, dans des études futures, il serait également intéressant d’analyser 
comment ABX300 pourrait affecter les interactions des protéines SR avec les 
ARNm, par co-IP ou CLIP-Seq. 
De plus, lorsque l’ensemble des épissages spécifiques du tissu adipeux a été 
évalué, nous n’avons pas pu déterminer un effet global d’ABX300 sur l’épissage. 
Néanmoins la réalisation d’analyses complémentaires du séquençage de l’ARN 
à haut débit (HTS) pourrait permettre d’avoir une vision globale du génome, et 
d’obtenir des informations concernant la biogénèse des microRNA. 
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Ce sont les microRNA ciblant spécifiquement des gènes qui participent à des 
processus mitochondriaux qui sont modulés par ABX300. Ce résultat suggère 
fortement que la molécule a un effet  sur le fonctionnement de cette organelle. 
Bien que nous ayons échoué à identifier une hausse hypothétique de l’activité 
mitochondriale, nous pensons que le traitement avec ABX300 est 
inexorablement lié à un fonctionnement accru de cet organite. Néanmoins des 
analyses beaucoup plus complètes devraient être réalisées pour confirmer cette 
hypothèse. De plus, l’évaluation de l’activité locomotrice des animaux ainsi que 
la possibilité d’une mise en place d’un processus de browning, se présentent 
comme indispensables pour la bonne finalisation de l’étude du mode d’action de 
la molécule ABX300. 
Enfin, la possibilité que ce soit le métabolite et non la molécule ABX300  elle-
même qui soit responsable des effets observés phénotypiquement devrait être 
étudiée. 
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PREFACE 
 
Metabolism, from the Greek Μεταβολισμός, metabolē change, from metaballein to 
change, from meta- + ballein to throw. 
1. The sum total of the chemical processes that occur in living organisms, 
resulting in growth, production of energy, elimination of waste material, etc. 
2. The sum total of the chemical processes affecting a particular substance in the 
body   ! carbohydrate metabolism, iodine metabolism. 
From the Collins dictionary 
The first documented references of metabolism date from the XIIIth century: 
“Both the body and its parts are in a continuous state of dissolution and nourishment, so 
they are inevitably undergoing permanent change.” 
Ibn al-Nafis (1260) 
However, it was not until four centuries later, that it took place the first experiment 
considered to be the one studying human metabolism. It was performed by Santorio 
Santorio and published in 1614 in his work entitled “Ars de statica medicina”. This book 
summarized his observations for a period of over 30 years in which he weighed himself 
recurrently; before and after sleeping, working, drinking, fasting, eating and excreting. 
He designed a movable platform attached to a steelyard scale that allowed for the 
quantification of changes in body weight of subjects who partook in their daily activities 
on the platform. After years of self-experimentation, he applied his device to the study of 
patients. 
When analyzing his results, thus comparing the weights, he found out that most of the 
ingested food was lost through what he called Perspiratio insensibilis or insensible 
perspiration of the body. This concept designates how many grams the body loses during 
a certain period of time.  
For his pioneering and detailed balance studies, he clearly deserves the title of founding 
father of metabolic studies. The importance and significance of weight measurement in 
medicine was revealed for the first time in this work, which makes Santorio still 
celebrated as the predecessor of experimental physiology. 
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EMOTION AND PERSPIRATIO INSENSIBILIS (Weights and Confri) 
Referring to “Ars de Statica Medicina” from Santorio Santorio 
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ABSTRACT 
 
The discovery within our laboratory that the different LMNA isoforms play 
opposite roles on metabolism  (Lopez-Mejia et al., 2014), led to the proposal that 
pharmacologically modulating this splicing could be a novel and original approach 
for the treatment of obesity. In this thesis I have challenged this proposal by 
performing experiments in order to identify potential modulators of splicing with 
impact on energy metabolism. Following an initial screen, a compound termed 
ABX300 was selected and tested on animal models of obesity. Specific 
modulation of the LMNA splicing by ABX300 was confirmed using splicing 
reporters. Moreover, our data show that ABX300 interacts directly with SRSF1 to 
mediate its effect on LMNA splicing. 
The daily treatment with ABX300 lead to a weight loss in both, genetically 
modified mouse models and diet induced obesity mouse models. During my PhD 
I have established the mode of action of ABX300, along with its impacts on 
metabolism. Results demonstrated that ABX300 did not have an effect on 
adipocytes differentiation, nor in triglycerides content on in vitro cell lines (3T3-L1 
and BAT preadipocytes). However, in vivo analysis, by means of pair-feeding 
experiments, Microcomputed tomography analysis, and metabolic chambers, 
among others, exhibited differences in between treated and untreated groups 
regarding food intake, oxygen consumption and fuel source. Concurrently, a 
series of transcriptomic approaches showed that ABX300 modulates the 
expression of miR whose targets encode proteins involved in mitochondrial 
functioning, but did not have an effect on global pre- mRNA splicing.  
This work validates the screening for modulators of the LMNA alternative splicing 
as a promising strategy for the identification of bio-active small molecules and 
therefore promotes a complementary approach in the treatment of obesity. 
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INTRODUCTION 
CHAPTER I: Adipose Tissue and Obesity 
Adipose Tissue: a complex and heterogeneous organ 
 
Considering fat as probably the most popular conversation topic nowadays, 
excepting weather and politics, it is surprising that the physiology of adipose 
tissue (AT), has been scarcely studied until forty years ago. Excess fat used to 
be associated with wealth, but this is no longer the case. Instead, obesity is now 
recognized as a risk factor for many diseases, such as insulin resistance, 
hypertension, hyperlipidemia, type 2 diabetes (T2D), and coronary heart disease. 
Indeed, the perception of AT has changed considerably with the dramatic 
increase in the incidence of obesity and obesity-related comorbidities over the 
past decades. These comorbidities are mostly related with the deposition of fat in 
the abdominal cavity. Even though fat distribution varies considerably inter- and 
intra-species, abdominal and subcutaneous represent the two main depots of 
white adipose tissue (WAT) generally described for mammals. Besides 
anatomical differences in between them, divergences have been also depicted at 
the cellular, molecular, physiological, and clinical level. Hundreds of genes have 
been shown to have a depot-dependent expression in both humans (Vidal, 2001; 
Vohl et al., 2004) and rodents (Gesta et al., 2006). Remarkably, metabolic 
complications are associated with this distribution. The relationships to health are 
different according to the emplacement of the WAT discrete depots susceptibility. 
In general, accumulation of WAT in the upper part of the body (abdominal obesity) 
is associated with detrimental effects on metabolic health and mortality (Ibrahim, 
2010), whereas lower-body fat accumulation (gluteofemoral obesity) is 
associated with protective effects (Karpe and Pinnick, 2015). 
Typically, AT makes up approximately 20% of body weight in men and 28% 
in women (Thompson et al., 2012), but in obese people it can expand manifold 
to more than 80% of body weight. Obesity is accompanied by a widespread 
increase in WAT deposits due to  hyperplasia (increase in the adipocytes number) 
and hypertrophy (increase in the adipocytes size) of white adipocytes (Dulloo et 
al., 2010). Despite the slowly occurring turnover in humans, the total number of 
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adipocytes appears to be relatively constant throughout adult life under normal 
healthy conditions (Spalding et al., 2008). Adipocytes typically constitute 80 to 
90% of AT volume, yet only 60 to 70% of cell number (Langin D, Frühbeck G, 
Frayn KN, 2009). The image of fat which was limited to a triglyceride (TG)-storage 
tissue is progressively disappearing since recent years studies describe AT as 
no former simply a fat store, but a vital, complex endocrine organ. It is avidly 
being acknowledged as such, due to the discovery of its role as a producer of 
certain cytokines with endocrine, paracrine, and autocrine actions (Sikaris, 2004). 
AT major functions’, encompassing its secretory role, will be described further in 
this manuscript (I.3). 
I.1 – Composition of Adipose Tissue 
 
Adipose tissue has thus been rebaptised as an adipose organ. It is 
composed in mammals of different kinds of adipocytes which are crucial for 
energy storage/mobilization and endocrine activity (Figure 1). Mature white 
adipocytes consist of a single large lipid droplet which “pushes” the cell nucleus 
against the plasmatic membrane. These droplets are the major components of 
WAT. The other cell types therein present constitute together the AT stromal 
vascular fraction (SVF). These are: precursor cells (including pre-adipocytes), 
fibroblasts, immune cells and vascular cells. These particular last-ones include 
both vascular smooth muscle cells and endothelial cells, which are associated 
with the major blood vessels. The blood vessels in AT are required for the proper 
flow of nutrients and O2 to adipocytes, and they are the conduits that allow for the 
distribution of adipokines (described in I.4b). Vascular cells also secrete, and are 
responsive to AT-secreted proteins. On the other hand, immune cells (including 
macrophages and T-cells), have major roles in determining the status of the 
tissue. Particularly in obese people, there may be an increase in macrophages 
and other leukocytes. This occurs because immune cells are attracted into the 
AT by the altered secretory profile, coming from hypertrophic and hyperactive 
adipocytes that limit O2 supply, rendering the tissue hypoxic and ultimately 
leading to AT dysfunction (Xu et al., 2003). To sum up, it can be concluded that 
the factors that are secreted by these different cellular components of AT, present 
themselves as being crucial for the maintenance of homeostasis throughout the 
whole organism. 
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Figure 1: Components of the adipose organ. 
 
Image from Ouchi et al., 2011. 
I.2 – Types of Adipose Tissue 
 
The two most popular features of white adipocytes are to store energy 
excess as TG, in the so-described large unilocular droplets, and to release this 
energy in the form of Free Fatty Acids (FFA). In contrast, brown adipocytes store 
TG in multilocular adipocytes as quick-access fuel for heat production through 
mitochondrial “uncoupling” of oxidative phosphorylation of FFA (Sethi and Vidal-
Puig, 2007). BAT (Brown Adipose Tissue) in rodents is mainly concentrated in 
the interscapular region. However, physiologically relevant brown adipocytes can 
also be found in other areas, including typical WAT depots, the hind limbs and 
the intermuscular AT (Cinti, 2005; Almind et al., 2007; Xue et al., 2007) (Figure 
2A). Morphologically, BAT can be distinguished from WAT by a richer 
vascularization, and a more abundant mitochondrial density. BAT is unique due 
to its function in thermogenic energy expenditure (EE). It possesses an enormous 
thermogenic capacity, making a substantial contribution to the whole-body 
energy metabolism. 
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Figure 2: Brown, white and beige adipocytes; anatomical sites in mice and 
humans. 
 
A) Interscapular, gonadal and inguinal adipocytes deposits are presented for mice. 
The neck and the supraclavicular stretch containing mixed populations are 
exhibited for humans. Adapted from Bartelt and Heeren, 2014. 
 
B) Different types of AT are present within the relatively restricted region of the 
human neck. Adapted from Nedergaard and Cannon, 2013. 
 
Browning/Whitening 
 
Recently, a third kind of adipocytes has been described, the so called 
beige, brown-in-white, or brite adipocytes (Giralt and Villarroya, 2013). These are 
inducible brown adipocytes, which are distinct from both white and brown 
adipocytes (Figure 2B). The appearance and activation of these cells within 
WAT, is referred to as ‘‘browning’’. This phenomenon is hallmarked by the 
expression of UCP1 and the exertion of beneficial metabolic effects. It will be 
more extensively developed in the “Obesity Treatment approaches” section (I.5).  
B)
A)
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Brite adipocytes are thermogenic brown-like adipocytes which appear in mouse 
WAT upon particular stimuli such as β3-adrenergic activation or cold exposure. 
Ez-Zoubir and colleagues, have latterly described a unique type of cells which 
are able to differentiate into cells which exhibit the key properties of human white 
adipocytes, and convert into functional brown adipocytes upon PPARγ activation. 
These cells have been named hMADS (human multipotent adipose-derived stem 
cells) (Elabd et al., 2009; Pisani et al., 2011). The potential of inducing even small 
amounts of brown fat in adult humans could provide a new approach to the 
treatment and prevention of obesity and its metabolic complications. Decisively, 
many genes are differentially expressed in mature white, brown and beige 
adipocytes (Baboota et al., 2015). These include Cidea, DIO2, PPARα, PGC-1α, 
and other factors involved in mitochondrial biogenesis and function (Table 1).  
As opposed to this “browning” program, Hill and colleagues propose the 
presence of a “whitening” program, that occurs in adipocytes under conditions of 
chronic nutrient excess, and that would be critical for regulating AT remodeling 
under these conditions (Hill, 2015). 
 
Table 1: Differentially expressed genes in brown, beige and white adipocytes.  
 
Adapted from Harms and Seale, 2013. 
 
 
Developmental
origin in mice
Key 
Transcription
factors
Enriched 
markers
Immunohistochemistry
with anti-Ucp1
Location
in humans
Location
in mice
Developmental
origin in mice
Enriched 
markers
Activators
W
h
it
e
B
ro
w
n
B
e
ig
e
B
e
ig
e
Neck
Interscapular
(newborns)
(Perirenal?)
Interscapular
Cervical
Axillary
Perirenal
(Endocardial?)
Myf5+ cells
Zic1
Lhx8
Eva1
Pdk4
Epsti1
miR-206
miR-133b
C/ebpβ
Prdm16
Pgc-1α
Ppar-α
Ebf2
TR
Cold
Thiazolidinediones
Natriuretic peptides
Thyroid hormone
Fgf21, Bmp7, Bmp8b
Orexin
Supraclavicular
(Paraspinal?)
Interspresed
within WAT
Subcutaneous
fat> visceral fat
Myf5- cells
Cd137
Tbx1
Tmem26
Cited1
Shox2
C/ebpβ
Prdm16
Pgc-1α
(Ppar-α?)
Cold
Thiazolidinediones
Natriuretic peptides
(Thyroid hormone?)
Fgf21
Irisin
Beneath the skin
(subcutaneous)
Around internal
organs (visceral) 
Bone marrow
Intermuscular
Breast tissue
Gonadal
Retroperitoneal
Mesenteric
Omental
Inguinal
Subscapular
Pericardial
Popliteal
Myf5- cells
Tcf21
Tle3
Lep
Resistin
HoxC8
Igfbp3
Inhbb
High-fat diet
Insulin/IGF1
RIP140 
TIF2
Bmp2,Bmp4
Krox20
Klf4
C/EBPα ,β,δ
PPARγ
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I.3 – Origin and Development of Adipose Tissue 
 
The developmental patterns of WAT and BAT are also distinct. In rodents, 
WAT develops mainly shortly after birth, being present first in the perigonadal and 
subcutaneous depots, and only later in the omental depot. In humans, WAT 
development begins early in midgestation and by birth, it is well developed in both 
the visceral and subcutaneous depots. Anyhow, WAT depots gradually increase 
throughout life. BAT emerges earlier than WAT during fetal development. It is at 
its maximal size relative to body weight at birth, when the requirements for no- 
shivering thermogenesis are most needed, and then involutes in both humans 
and rodents with aging (Cannon, 2004). 
At the cellular level, both appear to originate from mesodermal/mesenchymal 
stem cells (MSC), although several factors are involved in the development of 
one versus the other (Figure 3). Amidst others, bone morphogenetic proteins 
(BMPs), nodal, wingless (Wnt), and fibroblast growth factors (FGFs) control fat 
developmental signaling systems. The exact number of intermediate stages 
between the pluripotent state, the preadipocyte, and the mature adipocyte 
remains today uncertain. Nonetheless, it is believed that once committed, the 
MSC will give rise to undifferentiated precursors (osteoblast, adipoblast/ 
preadipocyte, and myoblast), which, upon the expression of key transcription 
factors, will enter a differentiation program to acquire their specific functions 
(Gesta et al., 2007). At the level of preadipocytes (or myoblasts), the cells are 
already considered like committed to a specific differentiation. However, due to 
the lack of definite molecular markers, it should be noted that precursor cells and 
preadipocytes can be at least partly overlapping populations. Mature adipocytes 
will essentially develop from precursor cells known as preadipocytes by 
accumulating triacylglycerol (TAG).  
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Figure 3: Developmental lineages of adipocytes.  
 
Schematic representation of the possible developmental origins of murine adipocytes. 
Solid arrows represent conclusions from in vivo lineage tracing studies; dotted lines 
represent conclusions inferred from ex vivo or in vitro studies. Adapted from Rosenwald 
and Wolfrum, 2014. 
 
Different cellular models (see next section), substantially 3T3-L1 cells 
have facilitated the study of the adipocyte differentiation process. Of note, cell 
proliferation and cell differentiation are two biological processes very closely 
related. Adipocyte differentiation is more accurately known as adipogenesis, and 
it might be described as a sequence of events characterized by the expression 
of specific markers which will allow for the acquisition of the phenotype of mature 
adipocytes. In fact, adipogenesis requires a prior proliferation stage. Once 
confluence accomplished, contact inhibition will prompt a growth-arrest and 
clonal expansion phase will follow. This is a stage caused by hormonal 
embryonic stem cells
Developmental/Patterning genes
Wnt pathway
BMPs/TGF/Nodal pathway
FGF pathway
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stimulation consisting on a limited number of mitoses which represents a 
milestone for the differentiation process. The indispensability of clonal expansion 
has been elegantly shown by Fajas and colleagues. Their experiments showed 
no differentiation following the blockage of this phase (Fajas, 2003). Growth-
arrest and clonal expansion constitute the first steps to take place on the 
transition from preadipocyte to adipocyte, which additionally counts among its 
ranks: early differentiation, and terminal differentiation. A transcriptional cascade 
involving members of the C/EBPs family and the nuclear receptor PPARγ, 
orchestrates this process (Figure 4). The different members composing the 
C/EBP family are sequentially expressed during adipocyte differentiation. Early 
expression of C/EBPβ and C/EBPδ promotes later expression of C/EBPα and 
PPARγ (Figure 5) (Farmer, 2006). 
 
Figure 4: Induction of adipogenesis by a cascade of transcription factors. 
 
Exposure of preadipocytes to a cocktail of adipogenic inducers and fetal bovine serum 
(FBS) activates expression of several transcription factors that converge on PPARγ and 
C/EBPα induction. Together, these factors oversee terminal adipogenesis. Image from 
Farmer, 2006. 
 
PPARγ has been shown to be necessary and sufficient for adipocyte 
differentiation. It is required for maintenance of the terminal differentiated state of 
adipocytes. Proof being that the expression of a dominant-negative PPARγ or its 
inducible knock-out (KO) induced respectively dedifferentiation in 3T3-L1 cells, 
or death of mature adipocytes in vivo. Moreover, experiments performed by 
Zebisch and colleagues showed the dramatic effects of adding or not a PPARγ 
agonist to the cell culture media of adipocytes. The mere addition of this 
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compound, called rosiglitazone, permitted to achieve virtually complete 
differentiation of 3T3-L1 cells, whereas in contrast, only few of them succeeded 
differentiating into adipocytes in rosiglitazone’s absence  (Zebisch et al., 2012). 
This has earned PPARγ the position of “master regulator of adipogenesis”. 
PPAR-γ has an indispensable function in adipogenesis and an inseparable 
relationship with obesity, providing windows of opportunities for its treatment and 
for its associated metabolic syndromes (Shao et al., 2015).  
There are at least three isoforms of PPAR gamma (γ1, γ2, γ3), which differ at 
their 5’ ends, each under the control of its own promoter (Martin et al., 1998). 
PPARγ2 is mostly found in AT and the intestine (Fajas et al., 1997). Mature 
adipocytes are also noticeable by the presence of makers of terminal 
differentiation, such as FABP4 (Fatty Acid Binding Protein 4), GLUT4 (Glucose 
transporter type 4) and FAS (Fatty-Acid Synthase) (Rosen and MacDougald, 
2006).  
 
Figure 5: Progression of differentiation on 3T3-L1 cells. 
 
The major identified events of preadipocyte differentiation are presented chronologically. 
Areas labeled by gene names represent periods of gene expression during the 
differentiation program. The distinct stages of differentiation (very early, early, 
intermediate and late) are also depicted. Image from Ntambi and Kim, 2000. 
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Cellular models 
 
Recently, considerable light has been shed on the cell biology and the 
transcriptional control underlying adipocytes differentiation thanks to the 
accessibility of various cell lines. Besides primary preadipocytes, diverse cellular 
models are currently available to help us understand and identify the molecular 
mechanisms involved within the differentiation process. Since the development 
of the murine adipose 3T3-L1 cell culture system by Green and colleagues, this 
one has become the most popular cellular model for the study of adipocytes 
differentiation (Green and Kehinde, 1975). But additional cell lines, like 
3T3F442A and C3H10T1/2, are also used. Nevertheless, it is important to realize 
that even if they are handy, these remain solely cellular models. Despite being 
considered good tools for the study of WAT, they do not express all WAT markers. 
For example, 3T3-L1 cells produce little, if any, leptin compared to normal white 
adipocytes (Gesta et al., 2007). In addition, in vitro differentiation of 3T3-L1 
adipocytes is known to be easily disrupted by a variety of pharmacologic 
interventions, suggesting a rather delicate balance between terminal 
differentiation and continued proliferation that may not accurately reflect in vivo 
adipogenesis. 
It is obvious that the signals received by the adipocyte precursors in vivo are very 
complex and cannot be one hundred percent reproduced on in vitro cellular 
models.  A transcriptomic study sustained this idea by showing that the cell 
program associated with in vivo adipocyte differentiation was substantially more 
complex than the data obtained with cellular models (Soukas et al., 2001). When 
comparing in vitro and in vivo differentiation, a great part of the characteristics of 
the fat cells were similar, expressing many of the same genes. All the same, what 
varied was the expression pattern. Therefore, to avail oneself of animal models 
comes as essential in the end.  
Brown preadipocyte cell lines have also been immortalized but they prevail 
much less extensively characterized (Rosen and Spiegelman, 2000). Created 
from single newborn mice of different KO models (Klein et al., 2002; Whittle et 
al., 2012), they are known to retain the main characteristics of primary cells 
including UCP1 expression. They display sensitive and diverse metabolic 
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responses to insulin and adrenergic stimulation and have proven to be useful in 
the characterization of UCP regulation and the role of key insulin signaling 
elements for insulin action. 
I.4 – Functions of Adipose Tissue 
 
The best-known function of WATs is to store nutrients in the form of TG for 
energy demands, such as starvation, and to mobilize them under particular stimuli 
such as adrenaline signaling. These two roles are undeniable, but besides AT 
possesses a secretory function. An important number of peptides and other 
factors that can act in an endocrine or paracrine fashion are released by AT, 
which makes it increasingly identified as a fundamental, complex endocrine 
organ, and not simply as a fat stock. 
In mammals, BAT can both store nutrients as lipids and dissipate their 
energy as heat in a process called nonshivering thermogenesis (Bartelt and 
Heeren, 2014). Brown adipocytes express in their mitochondrial inner membrane 
(MIM) a 32 kDa protein called UCP1 (uncoupling protein 1), that allows for 
dissipation of the proton electrochemical gradient generated by respiration in the 
form of heat (Cannon, 2004). After BAT, skeletal muscle is the other important 
organ for thermogenesis (Himms-Hagen, 2004). Depots of UCP1-positive brown 
adipocytes have been identified, interspersed between skeletal muscle bundles 
in the legs of obesity-resistant strains of rodents, suggesting that “ectopic brown 
adipocytes” may play an important role in the regulation of whole-body energy 
homeostasis (Almind et al., 2007). In mice, BAT induction by cold exposure of β3 
agonists, resulted in promoted EE, reduced adiposity, and protection from Diet 
Induced Obesity (DIO) (Ghorbani et al., 1997; Guerra et al., 1998). Conversely, 
BAT ablation led to reduced EE, diabetes, hyperlipidemia and obesity (Rothwell 
et al., 1983; Bouchard, 1990; Lowell et al., 1993). Interestingly, mice lacking 
UCP1 were cold-sensitive but not obese (Maes et al., 1997). Taken together, 
these genetic models suggest that BAT might influence whole-body energy 
metabolism in ways not fully explained by the expression of UCP-1. However, it 
is clear that overexpression of this protein in WAT results in reduced adiposity 
(Mifflin et al., 1990).  
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In humans, gradual reduction in the levels of BAT is known to take place 
with ageing, and this phenomenon seems to be accelerated in individuals with 
obesity. The amount of metabolically active brown adipocytes seems to be 
particularly low in patients with this one pathology or with T2D (Bartelt and 
Heeren, 2014). Furthermore it has been proposed that decreased BAT function 
in rodents would participate in the origin of these diseases. 
I.4a – Fat Deposition and Fat Mobilization 
 
Energy balance in animals is governed by the first law of thermodynamics, 
and is often expressed as a simple equation: 
Energy Intake = energy expended + energy stored 
As this law must be obeyed, any treatment for obesity must have an effect on one 
of the equation components. Despite this simple reality, treatment of this 
condition remains an unresolved challenge, and fat continues accumulating in 
human beings reflecting the imbalance existing in between the processes of 
deposition and mobilization. Because the body's capacity to store is finite and 
relatively small, long-term imbalances are reflected in changes in the amount of 
TAG stored in adipocytes (Shi and Burn, 2004). In other words: in leanness, 
weight maintenance, or obesity. Multiple mechanisms regulate these processes 
and in general, regulation is reciprocal so that fatty acids flow "in" and "out" of the 
adipocyte according to the nutritional and physiological state of the organism 
(Figure 6A). 
Adipocytes are equipped with the biochemical machinery to function 
effectively as the body’s fuel store. To do this, they must mediate the conversion 
of FFA to TG for storage, also called lipogenesis (see section I.4a1), and the 
breakdown of TG to FFA and glycerol, or lipolysis (see section I.4a2) (Figure 6B). 
This is a tissue exquisitely designed to respond to acute changes in nutritional 
cues. For example, it is insulin-sensitive (insulin stimulates glucose uptake and 
lipogenesis and inhibits lipolysis) and subject to adrenergic regulation 
(epinephrine stimulates lipolysis and adaptive thermogenesis). 
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Finally, energy balance requires an ability of the brain to detect the status of 
energy stores and match energy intake with expenditure, triggering metabolic and 
behavioral responses designed to maintain energy balance (section I.4a3). 
 
 
Figure 6: Energy balance. 
 
A) Energy intake depends upon the balance between caloric intake and EE. 
Adapted from Rosen and Spiegelman, 2006. 
 
B) Schematization of lipids metabolism. Adapted from Sethi and Vidal-Puig, 2007. 
 
I.4a1 – Triglycerides Synthesis in WAT: Lipogenesis 
 
Through lipogenesis and subsequent TG synthesis, our organism can 
efficiently store energy in the form of fats. Lipogenesis is the process by which 
acetyl-CoA, a central metabolic intermediate, is converted to FAs. Latter TG 
synthesis can be apprehended as the creation of FAs from acetyl-CoA and 
A)
B)
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malonyl-CoA precursors, through the action of enzymes called fatty acid 
synthases (FAS). This is indeed a very important part of the lipogenesis process, 
which – together with glycolysis – functions to create fats from blood sugar. 
 
Glycolysis is the metabolic pathway that converts glucose into pyruvate. 
Along the process, glycerol 3-phosphate (G3P) is produced. During lipogenesis, 
G3P is esterified with three molecules of FA to synthesize fat. Depending on the 
nutritional and hormonal status of the body, the availability of FA and glucose will 
vary, and thus TG synthesis will vary too. In the fed state, liver and WAT will 
capture FA and glucose from diet, which are later stored as TG into lipid droplets. 
Within the adipocyte we can distinguish two different TG synthesis mechanisms. 
Either they will be formed by harvesting circulating FAs from food (I.3a1.1), either 
by de novo lipogenesis from carbohydrate precursors (I.3a1.2).  
I.4a1.1 – Lipogenesis from diet 
 
Indeed, it is a fact that fat mobilization fluctuates along the day. After 
meals, the dietary lipids undergo digestion by bile salts within the intestines. And 
only afterwards, they are hydrolyzed by pancreatic enzymes, to become FAs. 
Under this form, lipids will penetrate the intestinal absorptive cells, or enterocytes. 
They are ensuing secreted into the lymphatic system under the form of 
chylomicrons to finally enter the bloodstream. Once there, these lipids are 
hydrolyzed into glycerol and AG by the LPL (lipoprotein lipase). This is a 
fascinating multifunctional enzyme, whose activity is increased following elevated 
plasma insulin levels, and who contributes to the many aspects of obesity and 
other metabolic disorders that relate to insulin action, energy balance, and body 
weight regulation (Wang and Eckel, 2009; Thompson et al., 2012). The released 
FAs are transported to other tissues by albumin. To enter the adipocytes, they 
either diffuse, either utilize specific transporters, like FABP2. 
 
Figure 7 depicts the uptake of FAs through NEFA and lipoproteins, together with 
the formation of lipid droplets in the adipocytes. Green arrows follow the path of 
lipid storage in the postprandial state. Blue arrows illustrate the degradation and 
subsequent release of lipid droplets in the post-absorptive state, to provide 
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energy for other tissues. And black arrows indicate glucose uptake by adipocytes 
for de novo synthesis of FAs which will be developed in the following section. 
 
 
Figure 7: Formation of Lipid Droplets. 
 
Uptake of fatty acids through NEFA and lipoproteins and formation of lipid droplets in 
adipocytes. Image from Mardinoglu et al., 2013. 
 
I.4a1.2 – De novo lipogenesis 
 
 
De novo lipogenesis is the metabolic pathway that synthesizes FAs from 
excess carbohydrates. These FAs are released into the bloodstream in the form 
of VLDL, and can then be incorporated into TGs for energy storage. Though it 
also takes place in adipocytes, de novo lipogenesis is mainstream in liver. In 
obesity, it has been revealed to be down regulated in AT from mice and humans 
(Ortega et al., 2010), suggesting an adaptive process in order to limit an ongoing 
increase of fat mass. 
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The increase of insulin after a meal causes the activation 
(dephosphorylation in this case) of the enzyme responsible for the transformation 
of Acetyl-CoA into malonyl-CoA, whose name is acetyl-CoA carboxylase (ACC). 
This conversion entails the renewal of carbohydrates into FAs. On the contrary, 
during starvation and exercise, epinephrine and glucagon are released into the 
bloodstream, leading to the inactivation (phosphorylation) of ACC, and inhibition 
of lipogenesis in favor of FA oxidation via beta-oxidation (see chapter II). 
Phosphorylation of ACC is mostly carried out by AMPK (AMP-activated protein 
kinase), which is activated following ATP is depletion, thus 5'AMP rise. AMPK 
acts as a master metabolic sensor, regulating several intracellular systems 
including the cellular uptake of glucose, the β-oxidation of FA and the biogenesis 
GLUT4 and mitochondria. The energy-sensing capability of AMPK can be 
attributed to its ability to detect and react to fluctuations in AMP and ATP (Sethi 
and Vidal-Puig, 2007). Indeed, concentrations of AMP and ATP in the cell act as 
a measure of the energy needs. This is a useful way to ensure that glucose is not 
diverted down a storage pathway in times when ATP levels are low. Glucose and 
insulin act synergistically to stimulate the expression of lipogenic enzymes, such 
as ACC, FAS DGAT (Diglyceride acyltransferase) or GPAT (G3P 
acyltransferase) (Lenhard, 2011).  
 
I.4a2 – Fatty Acids degradation: Lipolysis 
 
The key process in fat catabolism and the provision of energy substrate 
during times of nutrient deprivation (fasting) or enhanced energy demand 
(exercise) is the hydrolytic cleavage of stored TG, also known as lipolysis (Figure 
8). Since WAT is the primary fuel reserve in mammals, this is the site where this 
mechanism takes place. Lipolysis is translated in terms of generation of FAs and 
glycerol, which will be released from adipocytes to the bloodstream. A complex, 
hormonally controlled regulatory network regulates its initiation, ultimately 
activating key intracellular enzymes called lipases that will hydrolyze the TG 
(Zechner et al., 2009).  
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Figure 8: Lipolysis and Lipid Signaling. 
 
Lipid intermediates involved in cellular signaling are generated by anabolic and catabolic 
reactions in distinct cellular compartments. Image from Zechner et al., 2012. 
 
Lipolysis occurs in three stages, with different cytosolic lipases performing 
in each of them: Firstly, ATGL (Adipose triglyceride lipase) will catalyze the 
conversion from TAG to DAG (diacylglycerols). Subsequently, HSL (Hormone-
sensitive lipase) will mediate the next hydrolysis in order to obtain MG 
(monoacylglycerols). Finally, MGL (Monoacylglycerol lipase) will allow for the 
acquisition of glycerol. It is important to mention that a FA is released at each 
stage. This process is affected in multiple steps. To date, numerous effectors, 
including adipokines, hormones and cytokines, have been described as being 
anti-lipolytic (insulin), or pro-lipolytic (epinephrine, norepinephrine, growth 
hormone, glucagon, and glucocorticoids).  
I.4a2.1 – Insulin (anti-lipolytic effect) 
 
Changing insulin concentrations largely determines fat mobilization. 
Insulin and insulin-like growth factor represent the most potent inhibitory 
hormones in lipolysis. Their effects are primarily communicated through the 
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insulin receptor (IR) (Langin, 2006). In peripheral tissues, insulin auto-
phosphorylates the IR, leading to activation of the PI3K enzyme system which 
then activates PKB/AKT. Recently, a team working on development of 
pharmacologically active small compounds, has found a synthetic PI3K inhibitor 
which increases EE and hyper-activates BAT in mice (Ortega-Molina et al., 2012). 
I. 4a2.2 – Adrenergic regulation (pro-lipolytic effect) 
 
The lipases’ activation befalls principally through the initiation of 
adrenergic pathways, largely dependent on β-adrenoceptor (β-AR) stimulation. 
While in human WAT only two subtypes of β-AR induce lipolysis, mouse 
adipocytes express three subtypes of β-ARs: b1-AR, b2-AR, and b3-AR. The 
relative distribution of β-AR determines the lipolytic activity in a cell type- and 
tissue -specific manner (Zechner et al., 2009). Adipocytes of patients with obesity 
have a higher density of β-3 AR and lower insulin receptor density, a situation 
that has several metabolic consequences. In mice were the α2/β-AR balance was 
genetically manipulated, Valet and colleagues showed an influence on fat mass 
due to an interaction between β3-AR and α2 genes, along with the diet. 
Adrenergic pathways depend on the sympathetic nervous system (SNS) 
innervations in WAT, which are presented as indispensable. Two catecholamines 
appear as essential: adrenaline/epinephrine and noradrenaline/norepinephrine 
(Ardilouze et al., 2004). When they bind to β-AR, G proteins are stimulated, that 
in turn activate AC (Adenylate Cyclase), generating a rise in cAMP levels which 
translates in an elevated activity of PKA. Target proteins of PKA include HSL and 
perilipin, a lipid-droplet associated protein, whose phosphorylation induces an 
increased release of FAs and glycerol from AT up to 100-fold.  
Lipolysis is crucial for all the rest of the organs, including BAT, where the 
generated FAs will be used for UCP1 activation for thermogenesis and 
mitochondrial β –oxidation, among others. Regulated increases in thermogenesis 
occur in brown adipocytes with the stimulation of β-AR, initiating a signal 
transduction cascade that converts the catabolic end products of macronutrients 
(carbohydrates, fats  and proteins) into mitochondrial fuel (Tseng et al., 2010).  
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I.4a3 –Regulation of appetite and satiety  
 
As we have previously seen, excessive food intake together with a 
sedentary lifestyle are to a large degree at the origin of obesity in humans. 
Interest in the control of feeding has increased in parallel to the evolution of the 
obesity epidemics and the rise in the incidence of metabolic diseases. Metabolic 
signals emanate from peripheral organs, the gastrointestinal tract, and AT. These 
signals target the brain to regulate feeding, EE and hormones. In response, the 
brain triggers metabolic and behavioral feedback designed to maintain the 
equilibrium (Ahima and Antwi, 2008). Overall, energy balance is responsive to 
various factors, including hormones (I.3a3.1), neural inputs (I.3a3.2), and 
psychological and cultural factors (I.3a3.3) (Figure 9) (Abizaid et al., 2006). A 
thematic review on the current knowledge on the homeostatic regulation of 
energy balance was published last year by Marc Schneeberger and colleagues 
(Schneeberger et al., 2014). 
 
Figure 9: Effect of feeding and fasting on hunger. 
 
During and after regular feeding, there is a reduction in the production of ghrelin by the 
stomach. In contrast, production of PYY, GLP-1 and CCK from the gut is increased, and 
serum leptin levels also rise. These changes are detected by the brain, resulting in 
modulation of gene expression which result in decreased appetite and a feeling of satiety 
such that caloric intake is stopped. During fasting, the opposite situation is established, 
leading to hunger. Image from Larder and O’Rahilly, 2012. 
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I.4a3.1 – Secreted hormones 
 
Appetite and satiety are mainly controlled by the gut–brain axis via 
hormonal and neuronal signals. From the moment nutrients enter the small 
intestine in the body, a set of peptides are released in order to reduce meal size 
and ultimately terminate feeding. Hormones and cytokines secreted by peripheral 
organs also partake of this mission. In response to meals, the hormones secreted 
by the gut comprise among others:  
· CCK (Cholecystokinin), a peptide that acts as a satiety factor decreasing 
meal size (Liebling et al., 1975). 
· GLP-1 (Glucagon-like peptide-1), an incretin which increases satiety and 
promotes insulin sensitivity. Agonists are widely regarded for therapeutic 
utility and applications in metabolic disorders (Finan et al., 2013). 
· Ghrelin, a critical signal stimulating food intake and promoting weight gain, 
whose antagonists have the potential for obesity and diabetes therapy 
(Ahima and Antwi, 2008). Farhana and colleagues recently showed that 
ghrelin resistance was caused by DIO by promoting inflammation (Naznin 
et al., 2015). 
Opposing the actions of ghrelin by inhibiting hunger, a hormone to be mentioned 
is: 
· Leptin, a hormone secreted mostly by AT which has pleiotropic effects on 
glucose homeostasis and feeding behavior. It holds an imposing ability to 
acutely reduce food intake. In obesity, a decreased leptin sensitivity 
occurs, resulting in an inability to detect satiety despite high energy stores 
(Ahima and Antwi, 2008) (see I.4b). 
I.4a3.2 – Neural circuits 
 
During and after feeding, there are changes in the production the so-
described hormones. These alterations are detected by the brain, resulting in 
modulation of gene expression which normally results in decreased appetite and 
a feeling of satiety such that caloric intake is stopped. Protein levels of orexigenic 
neuropeptides [Agouti-related protein (AGRP) and neuropeptide Y (NPY)], are 
found decreased whereas anorexigenic peptides’ levels, originating from pro-
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opiomelanocortin (POMC), are found increased. During fasting, up-regulation of 
orexigenic and down-regulation of anorexigenic gene expression occurs within 
the hypothalamus, leading to hunger (Figure 9). Dieting results in a gut hormone 
profile that mimics the fasted state (Larder and O’Rahilly, 2012). 
I.4a3.3 –Rewarding effects of food 
 
Even with the existence of a beautiful panel of intricate and very well 
designed control circuits, food has pleasurable and rewarding qualities which 
drive appetite beyond metabolic needs. The motivational and premium aspects 
of feeding are mediated by the limbic system. First, although food intake is 
relatively easy to measure, it is not the precise parameter that determines the 
amount of energy brought into the system. The efficiency of calorie absorption in 
the gut, which is much more difficult to assess, and is usually ignored in practice, 
must also be accounted for. A second consideration is that the body’s response 
to alterations in energy input or expenditure is not static. In general, energy 
homeostasis is regulated to defend the highest weight achieved (Schwartz et al., 
2003). Thus voluntary reductions in food intake are countered by involuntary 
reductions in EE, making weight loss more difficult than a simple interpretation 
the previous equation (I.3a) would indicate. 
I.4b – Endocrine function 
 
An important aspect of AT endocrinology is the recognition that numerous 
other cell types, in addition to adipocytes, are also present within this tissue. 
Together, these additional cell types, which are called SVF (section I.1), play 
important roles in regulating AT function. Interestingly, even if adipocytes 
represent more than half of the total cell number, the non-adipocyte cells can 
have effects on multiple biological systems, including energy homeostasis (lipid 
and carbohydrate metabolism, thermogenesis, appetite), the immune system, the 
reproductive function, hemostasia, blood pressure, and angiogenesis. The SVF 
may also be, besides fat, the source of some secreted factors, more decorously 
known as adipokines or adipocytokines (Figure 10). 
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Figure 10: Factors released or secreted by adipose tissue.  
 
Adipocytes, immune cells, fibroblasts, endothelial cells, and others contribute to the 
release of metabolites, lipids, and adipokines. Examples of adipose tissue-derived 
molecules are provided here. Image from Fasshauer and Bluher, 2015. 
 
I will briefly describe the most influential adipokines hereafter: 
Leptin is secreted almost exclusively by fat, whose mass abundance is 
mirrored by leptin circulating levels. It does not only regulate feeding behavior, by 
repressing food intake and promoting EE, but it also serves as a bridge between 
peripheral metabolically active tissues and the central nervous system  (CNS). 
Leptin acts on the limbic system by stimulating dopamine uptake, creating a 
feeling of fullness. During the onset and progression of obesity, the dampening 
of leptin sensitivity often occurs, preventing the efficacy of leptin replacement 
therapy from overcoming obesity and its comorbidities (Santoro et al., 2015). Six 
distinct leptin receptors, LRa–LRf, derived from alternative splicing (AS) of lepr 
mRNA have been identified in mice (Myers et al., 2008). A functional leptin 
system is required for the effectiveness of some agents in the treatment of 
obesity, such as tungstate (Canals et al., 2009). 
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Adiponectin is almost exclusively produced by adipocytes, where its 
mRNA transcript is the most highly expressed. Its levels have been shown to 
inversely correlate with obesity, visceral fat distribution, T2DM, and other obesity-
related diseases (Ye and Scherer, 2013; Fasshauer et al., 2014). It protects 
against a cluster of obesity-related metabolic complications through multiple 
mechanisms (Hui et al., 2015). This is maybe due to its insulin sensitizing, anti-
inflammatory, and antiapoptotic properties. Adiponectin also acts in the brain to 
increase EE and thereby it may promote weight loss (Turer and Scherer, 2012;  
Fasshauer and Bluher, 2015). 
Apelin is a widely expressed adipokine identified over the past years as a 
new player in energy metabolism, in addition to leptin and adiponectin. Apelin 
exerts pleiotropic actions throughout the whole body (Knauf et al., 2013). By 
interacting with its receptor APJ, apelin determines many physiological metabolic 
functions such as, glucose uptake, lipids utilization, and modulation of insulin 
secretion. These actions globally lead to improvement of insulin resistance. 
Following apelin secretion by AT, glycaemia decreases due to glucose uptake 
within that same tissue, muscle, intestine and others. Even if further studies are 
required, this adipokine presents promising anti-diabetic properties given its 
beneficial roles on both EE and insulin sensitivity (Bertrand et al., 2015). 
Resistin is primarily expressed in and secreted from mature adipocytes. It 
appears as an important link between obesity and inflammatory processes. 
Levels of resistin are elevated in many murine models of obesity (Rosen and 
Spiegelman, 2006). Maybe that’s the reason why resistin was initially considered 
as a determinant of the emergence of insulin resistance in obesity. The amount 
of evidence supporting this link remains ample. Notwithstanding, since the 
number of studies presenting evidence against this statement continues to 
expand, not the entire scientific community agrees on it.  
TNF-α seems to be derived from macrophages and other cells belonging 
to the immune system, aside from adipocytes. Its levels are elevated in insulin-
resistant states such as obesity and sepsis, and in mouse models of obesity 
(Warne, 2003), undoubtedly contributing to inflammation and the maintenance of 
the obese state. 
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IL-6 is furthermore another pro-inflammatory cytokine, principally secreted 
by the macrophages present in AT (Fain, 2010). Anti-inflammatory properties are 
also noticeable through its inhibitory effects on TNF-α and other interleukins.  
Adipsin is secreted by adipocytes. It has insulin-like effects. It is positively 
related to adiposity, insulin resistance, dyslipidaemia, and cardiovascular 
disease.  
PAI-1 can be secreted by AT although it is mainly produced by the 
endothelium. Elevated levels of PAI-1 are associated with obesity. These are a 
common finding in plasma from both mice and humans, and have thus been 
considered as one of the biomarkers used to predict obesity-associated diseases 
(González et al., 2012). In addition, PAI-1 is an important regulator of extracellular 
matrix turnover, tissue remodeling, and fibrosis (Lund et al., 1988).  
FGF21 is produced by the AT, liver, and skeletal muscle, and released into 
the circulation. Its action requires the interaction with a co-receptor, β-Klotho. In 
their presence, thermogenic effects as well as glucose and lipid lowering, have 
been observed in rodent animal models (Fisher et al., 2012; Gaich et al., 2013; 
Itoh, 2014). FGF21 also stimulates glucose uptake in 3T3-L1 and primary human 
adipocytes, and this in an insulin additive fashion (Kharitonenkov et al., 2005). 
These effects could be due, at least in part, to its role in adaptive thermogenesis 
and in promoting browning of WAT. The metabolic effects of FGF21 on glucose 
homeostasis and insulin sensitivity in mice have been shown to be mediated by 
adiponectin (Lin et al., 2013). 
Some of these actions underscore the links between obesity and its related 
pathologies. For instance, in obesity there is an imbalance in adipokines 
production, which results in a process of adipose tissue dysfunction (Figure 11). 
Adipokines appear like promising candidates both for novel pharmacological 
treatment strategies and as diagnostic tools for obesity (Fasshauer and Bluher, 
2015). Some pro-inflammatory and atherothrombotic adipokines such as leptin, 
resistin, IL-6, TNF- α and PAI-1 are increased in obesity, whereas the anti-
inflammatory adipokine adiponectin tends to be decreased. 
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Figure 11: Major adipokines, their roles and variations with weight modulation. 
 
A) Insulin, catecholamines, and adiposity regulate AT adipokines production. These 
will exert next distinct metabolic effects. Image from Fernández-Sánchez et al., 
2011. 
 
B) Weight loss reverts the alterations caused by obesity typical hypertrophic and 
hyperactive adipocytes, which leads to improved insulin resistance and 
inflammation. Image from Azevedo et al., 2012. 
 
Oxidative stress & Reactive Oxygen Species 
 
Adipokines are known to induce the production of reactive oxygen species 
(ROS), generating a process known as oxidative stress. There are several 
mechanisms by which obesity produces ROS, like for instance: mitochondrial and 
peroxisomal oxidation of FA, over-consumption of O2 and alteration of oxygen 
metabolism by lipid rich diets (Chentouf et al., 2011). Upon the increase of AT, 
the activity of antioxidant enzymes such as superoxide dismutase (SOD), 
catalase (CAT), and glutathione peroxidase (GPx), was found to be significantly 
diminished. Although obesity and oxidative stress are clearly correlated, it still 
remains unclear whether this relationship is causal and if so, which factor is 
responsible for driving the other (Ristow and Wolfrum, 2013). 
A) B)
INTRODUCTION: Adipose Tissue and Obesity 
 
30 
 
I.5 – WAT associated pathologies: obesity 
 
In a worldwide fashion, but especially in industrialized first world countries, 
one of the largest public health concerns is obesity. This is a disease that results 
the common denominator of many WAT associated pathologies. Obesity is 
associated among others with: insulin resistance, diabetes, cardiovascular 
disease, nonalcoholic fatty liver disease, gallstones, Alzheimer’s disease, and 
several cancers. These are co-morbidities that can lead to further morbidity and 
mortality. In modern times, the social stigma of obesity has created negative 
psychosocial impacts and has caused disadvantages for overweight and obese 
people. Furthermore, childhood obesity is associated with a greater chance of 
premature death and disability in adulthood.  
Obesity is a chronic disease of multifactorial origin and can be defined as 
an increase in the accumulation of body fat. It develops when energy intake 
exceeds energy expenditure. Although fat accumulation is a familiar 
phenomenon to most healthy individuals, it only appears to become clinically 
relevant when abnormal changes in adipose mass are associated with health 
problems. The most common index defining obesity is the body-mass index 
(BMI). This reference number is calculated by dividing an individual’s weight (Kg) 
by the square of its height (m). A healthy status is outlined for digits comprised in 
between 20 and 25 kg/m2. When the resulting number is between 25 and 30 
kg/m2 the person in considered to be overweight. Obesity can be attributed to 
those above 30 kg/m2. And although the number of brown adipocyte-like cells is 
inversely correlated with BMI in humans (Qian et al., 2013), weight is not 
everything. People over 30 kg/m2 can be absolutely in good conditions and on 
the contrary, normal-weight individuals may be "metabolically-obese". As already 
mentioned in section I.1, fat distribution plays an important role in metabolic risk. 
Higher negative connotations are associated to visceral compared to 
subcutaneous fat (Figure 12). 
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Figure 12: Fat Distribution Influences Risks Associated with Obesity in Humans. 
 
 Adapted from Gesta et al., 2007. 
  
Lately, new definitions of obesity which take this into consideration are in 
the spotlight. Research starts distinguishing the obese people into metabolically 
healthy (MHO), or unhealthy (MUO) individuals, independently of their BMI. In 
this two groups insulin sensitivity, together with the ability to adapt to a caloric 
challenge has been shown to be different (Badoud et al., 2015).  
Lean subjects can also have a disproportionate amount of fat. These are referred 
to as TOFI (Thin-Outside-Fat-Inside), and have been described as being at higher 
risk of developing insulin resistance and T2D. The metabolic opposites are the 
‘fit fat’ or FOTI (Fat-Outside-Thin-Inside), which are MHO, presenting little internal 
fat relative to their size. 
I.5a –Rodent models 
 
Bona fide results proving that body weight and composition are regulated 
by specific genes have been provided by transgenic mice and rats models. They 
provide a powerful resource for the study of obesity, as well as the discovery of 
the underlying mechanisms and the development of drugs to fight this syndrome. 
Thanks to these models, we are now able to generate hypothesis regarding 
humans.  
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Two primary rodent models are used to study obesity, the monogenic (a 
single gene) and polygenic (more than one gene). Two of the most famed 
spontaneous mutations leading to a monogenic massive obesity are the Lep 
ob/ob and the Lepr db/db mice strains. They respectively lack leptin or have a 
loss of function of the leptin receptor, resulting in deficiency of leptin signaling. 
This causes hyperphagia and impaired thermogenesis. However, obesity in 
humans is considered a polygenic multi-factorial disease. A high energy intake 
enormously contributes to this pathology. Consequently one of the most accurate 
employed animal models is the DIO (Diet Induced Obesity).  These animals long-
term receive a HFD (high fat diet) before a research protocol can begin. 
Unfortunately, there is no easy way to select the appropriate mouse model to 
study obesity. Every one of them has got strengths and weaknesses to discuss.  
 
Table 2: Summary of mentioned animal models of Obesity and metabolic 
features of human and mouse Lipodystrophy. 
 
“[ ]” indicates mild or late phenotype. Adapted from  Lutz and Woods, 2013 and Savage, 
2009 
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Of note is that protection from obesity in different genetically engineered 
models can typically be attributed to increased nutrient oxidation, increased 
thermogenesis, increased activity, and reduced lipogenesis. Besides these 
popular models, many other KO mice are currently available into which the 
genetic engineering of one specific gene, leading to its invalidation, entails 
metabolic consequences, either obesity or lipodystrophy (Table 2), which allows 
researchers to further deepen into the intrinsic pathways of these two conditions.  
 
Having too little of AT, like having too much, leads untoward undesired 
metabolic consequences, from which the most alarming one is ectopic fat 
deposition. The severe metabolic disturbances seen in human and mouse 
syndromes of partial and complete lipodystrophy provide a cautious reminder that 
the safest place to store excess TG is certainly AT (Moitra et al., 1998; Reitman 
et al., 2000). In both cases, obesity and lipodystrophy, the lipids spill over into the 
circulation and subsequently accumulate ectopically in other tissues where their 
effects are harmful (Figure 13) (Guénantin et al., 2014). Different pathologies, 
such as laminopathies imply lipodystrophy among their symptoms. This aspect 
will be further developed in section III.5a2. 
 
 
Figure 13: Lipid overflow in obesity and lipodystrophy. 
 
Adapted from Rochford, 2014.  
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I.5b –Treatment/Clinical Approaches 
Parallel to the increase of obesity, the study of this condition has 
undergone considerable development. This has been accomplished thanks to 
research in various fields of knowledge that have broken down old paradigms 
providing a solid foundation for understanding the disease and for developing 
strategies for prevention and treatment. Even if in theory energy balance obeys 
to a “simple” rule, and focusing on diet and exercise should work, many additional 
factors kick in the presented equation (I.3a) and unluckily reality is not as simple. 
For extremely obese individuals (IBM >35) bariatric surgery is usually the answer, 
whereas for the treatment of less severe obese patients current approved medical 
therapies ordinarily aim at one or more of the following mechanisms:  
· Preventing fat absorption: Interfering with the body's ability to assimilate 
specific nutrients from food for the purpose of inhibiting digestion and 
lowering caloric absorption. For example fiber supplements or Orlistat. 
· Suppressing appetite: Drugs blocking the cannabinoid receptors or 
catecholamines and their derivatives are the main molecules used for this 
goal. The endocannabinoid system has significant effects on appetite and 
metabolism. Over nutrition activates this system, resulting in hyperphagia, 
reduction in EE and obesity.  
· Increasing the body's metabolism: Targeting EE, that is, cellular 
bioenergetics is an attractive strategy that could be used alone or in 
conjunction with other approaches. Two organs appear attractive for this 
purpose, BAT and muscle. 
BAT 
 
With the recognition that adult humans have BAT, targeting cellular 
bioenergetics has become an increasingly attractive way to dissipate energy 
excess and provides a potential therapeutic approach for the treatment and 
prevention of obesity as well as its associated diseases (Tseng et al., 2010). The 
existence of beige adipocytes, a pool of inducible brown adipocytes, mixed in with 
white adipose depots (Mori et al., 2014) encourages researchers to combine 
efforts towards this direction. In addition, thanks to modern technologies of 
fluorescence imaging, it is nowadays relatively easy to visualize BAT in living 
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mice and check whether this activation is taking place (Rice et al., 2015). In the 
past few years different approaches envisaging browning have been investigated 
(Bartelt and Heeren, 2014; Dempersmier and Sul, 2015). The Figure 14 
recapitulates different approaches based on increasing thermogenesis. 
 
 
Figure 14: Approaches to increasing thermogenesis as an anti-obesity therapy.  
 
Based on the current knowledge of bioenergetics, four potential therapeutic approaches 
could be envisioned: increasing brown fat differentiation from progenitor cells; activating 
brown fat thermogenesis; promoting skeletal muscle thermogenesis; or increasing 
general mitochondrial uncoupling. Image from Tseng et al., 2010. 
 
This approach of EE increase has already proven to be effective in 
achieving weight loss. In rodents, treatment with CL-316243, a β3-AR-specific 
agonist, substantially functioned (Harper et al., 2008). Moreover, treatment with 
resveratrol increased BAT thermogenesis markers and EE, decreasing fat 
accumulation in AT (Andrade et al., 2014) and protecting mice against DIO and 
insulin resistance while increasing lifespan (Lagouge et al., 2006; Baur et al., 
2006). Another example that has complementarily been used by humans would 
be DNP, a non-selective uncoupler of mitochondrial oxidation that lessens the 
efficiency of ATP energy production in a dose-dependent manner. As the dose 
increases, energy production is made more inefficient, hence metabolic rate 
increases, and more fat is burned in order to compensate for the inefficiency and 
to meet energy demands. 
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Muscle 
 
To burn excess energy exercising is the first thing that comes to anybody’s 
mind when pondering about weight loss. There is no doubt that to mobilize our 
muscles is an effective tactic that in addition has profound beneficial effects on 
virtually all biological systems. When we do sports we are increasing our body’s 
metabolism and the scientifically appropriate definition for what is happening in 
our organism is “exercise-induced thermogenesis”.  Together with non-exercise 
activity thermogenesis and cold-induced shivering thermogenesis, these are the 
three types of thermogenesis occurring in skeletal muscle, which will increase 
EE. Furthermore, endurance exercise training  (Himms-Hagen, 2004; Goodyear, 
2008), or chronic cold exposure (Puigserver et al., 1998; Lin, 2002) may trigger 
a remodeling of muscular fibers, helping protect against obesity and related 
metabolic disorders. In this organ different types of myofibers differ in speed of 
contraction, mitochondrial content and pattern of energy use. Type I (red) 
myofibers have a slow-twitch speed of contraction, a higher mitochondrial 
content, and thus a higher rate of oxidative metabolism. Type II (white) myofibers 
have a more rapid speed of contraction and both oxidative and glycolytic 
properties (Tseng et al., 2010). A shift in skeletal muscle fiber types has been 
reported for different genetically modified mouse models, among which we count 
p43 overexpressing mice; p43 mitochondrial T3 receptor induces a shift toward 
the contractile slow type phenotype (Casas et al., 2008). 
I.5c –Current Situation 
 
Because of the unacceptable side effects or inadequate long-term clinical 
efficacy, these medications have so far met with limited success, and thus the 
American Food and Drugs Administration (FDA) has only approved very few 
drugs specifically for weight loss. Unfortunately, effectiveness remains limited. To 
continue improving the chances of identifying most successful therapeutic 
approaches, a better understanding of the mechanisms linking adipose tissue 
development, function, and expansion is required.  
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CHAPTER II: Mitochondria and Energy Homeostasis 
Generalities 
 
In complex organisms, such as mammals, it is crucial that the metabolic 
demands of the various tissues are coordinated to ensure that the energy needs 
of the whole body are effectively met. The ability of an organism to convert 
organic molecules from the environment into energy is essential for the 
development of cellular structures, cell life, growth, differentiation and death. All 
these are attainable thanks to mitochondria. Mitochondria are organelles that 
provide about 90% of the energy required by a normal eukaryotic cell to function 
(Tao et al., 2014). The processes of glycolysis and oxidative phosphorylation 
(OXPHOS), allow for the transformation of the ‘power’ contained in the nutrients 
into a form of energy suitable for the cell: ATP; the currency of life.  
Although mitochondria are best known for this main role, they fulfill a plethora of 
other functions such as homeostasis maintenance; cell death pathways 
coordination; heat production; steroid hormones, phospholipids and amino acids 
synthesis; and participation in stress associated events (Winklhofer and Haass, 
2010;  Snyder and Stefano, 2015). Moreover, mitochondria house and regulate 
a myriad of interconnected biochemical pathways (Pagliarini et al., 2008) (Figure 
15). 
 
Figure 15: Interconnection of metabolic pathways.  
 
Image from Wang and Green, 2012. 
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Secondly, mitochondria are highly dynamic structures. They respond with 
precise architectural modifications to Ca+2 signaling and other regulatory 
mechanisms (Liesa and Shirihai, 2013). However, they are not isolated or fixed 
in the cell; but instead form a dynamic network which is tightly regulated by two 
main phenomena: fusion and fission (Jakobs, 2006). This network is associated 
with cytoskeletal microtubules and with other organelles. Tight control of 
mitochondrial dynamics and functions is essential for maintaining an adequate 
energy balance.  
Mitochondria are present in all eukaryotic cells except for red blood cells. 
They are inherited maternally via the oocyte. Their shape, size and number are 
closely related to cellular activity, cell type and energy needs. Specific tissues — 
and perhaps even different sub-cellular locations — contain mitochondria of 
markedly different protein composition (Johnson et al., 2007). Nevertheless, they 
usually have an ovoid shape, and generally range from 1-2 to 10 µm in length, 
and from 0.5 to 1 µm in width. Regarding number, a somatic mammalian cell 
carries thousands of copies of the mitochondrial DNA (mtDNA) (Ameur et al., 
2011). 
II.1 – Structure 
 
Mitochondria are surrounded by two membranes, an external (MEM) and an 
inner (MIM) membrane, which delimit two separate compartments: the matrix and 
the intermembrane space (Figure 16). 
• MEM:  lipid bilayer composed of about 50% proteins and 50% lipids. This 
membrane is highly porous. On the one hand, molecules smaller than 10 
kDa, such as ions, metabolites and the different nucleotides enter through 
channels called porins, or VDAC (voltage-dependent anion channel). On 
the other hand, proteins containing a mitochondrial targeting signal cross 
via translocases (TOM: translocase of the outer membrane). Thanks to the 
acquisition of ATP/ADP translocase, mitochondria have the ability to 
exchange ATP with the cells cytoplasm (Gabaldón and Huynen, 2004). 
The MEM also accommodates CPT-1 (Carnitine PalmitoylTransferase-1), 
which allows for the transport of the activated LCFA (Long Chain Fatty 
Acids) from the cytosol into the intermembrane space (see section II.2a). 
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• The intermembrane space is about 100 Å. It has a composition close to 
the cytosol and it is positively charged due to its richness in protons (H+). 
 
• MIM: composed of 80% proteins and 20% phospholipids. Contrary to the 
MEM, this membrane is impermeable to ions, due to the presence of a 
particular phospholipid named cardiolipin (Clostre, 2001). Only O2, H2O, 
CO2, N2O and NH4 may ‘freely’ move across. Shuttling systems, co-
transporters, symporters and carriers such as ANT (Adenine Nucleotide 
Translocator), CPT II (Carnitine Palmitoyl Transferase II), or TIM 
(Translocase of the Inner Membrane) are necessary for other molecules. 
One of the peculiarities of the MIM is the so called mitochondrial crests. 
Tomographic studies have helped to highlight these foldings which imbibe 
the complexes of the respiratory chain (RC) (Hunte et al., 2000; Dimroth 
et al., 2000). 
 
• The matrix is the inner compartment of mitochondria. Many metabolic 
pathways occur here: β-oxidation of FA, Krebs cycle, etc. It contains 
mtDNA, mitochondrial ribosomes and transfer RNA (tRNA). 
 
 
Figure 16: Structure of mitochondria. 
 
Diagram showing the internal structure of mitochondria with the convoluted MIM 
housing the RC. Image from an internet source. 
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II.2 – ATP Production 
 
The main role of mitochondria involves ATP production and energy 
metabolism. We need so much energy in the form of ATP that in average, at the 
end of one’s life we will have used over 40 kg of it (Bland and Birnbaum, 2011). 
Our cells are capable of metabolizing a variety of carbon substrates, including 
glucose, FAs, ketone bodies, and amino acids. Cellular fuel choice does not only 
fulfill specific biosynthetic needs, but also enables programmatic adaptations to 
stress conditions beyond compensating for changes in nutrient availability.  
A cycle exists which serves as a basis for the analysis of energy production 
through ATP synthesis, and which is at the center of cells energy metabolism. 
This is the Krebs cycle, also known as Tricarboxylic Acid (TCA) cycle. To fuel it, 
glucose and FAs must be metabolized, in order to produce the same common 
intermediate, acetyl-CoA, which is fed into the TCA cycle. This is made thanks to 
a dyad of processes named Glycolysis and Fatty Acid Oxidation (FAO) (Figure 
17). 
 
Figure 17: Glycolysis and FAO. 
 
 
Glycolysis and lipolysis provide Acetyl-CoA, which serves as a substrate for TCA, where 
NADH and FAD are produced. Through these two cofactors, e- are donated to the ETC 
resulting in significantly larger production of ATP. 
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Glycolysis was defined in section I.3a1 as the metabolic pathway that 
converts glucose into pyruvate. Within the mitochondria, pyruvate is converted to 
Acetyl-CoA and CO2 in a process called pyruvate decarboxylation. Subsequently, 
Acetyl-CoA enters the so mentioned TCA cycle, where it is fully oxidized (Stanley 
et al., 2014). Glycolysis is an anaerobic process, and entails a low-energy 
production compared to aerobic respiration. One molecule of glucose can enter 
glycolysis  and be fully processed to 2 pyruvate molecules, producing two NADH 
(reduced nicotinamide adenine dinucleotide) and two ATP molecules; or can 
enter the TCA cycle and generate bigger quantities of NADH, further 30 or so 
ATP molecules and another intermediary molecule: FADH2 (Flavin Adenine 
Dinucleotide). NADH and FADH2 are high energy reduced co-enzymes, which act 
as reducing equivalents, donating e- to the ETC (Electronic Transport Chain). As 
the e- pass down the chain, energy is captured in the form of a proton gradient 
which is then utilized to generate ATP. In the presence of alternative sources of 
anaerobically oxidizable substrates, such as FAs, FAO predominates over 
glycolysis regarding ATP production. Emerging evidence indicates that specific 
switches from utilization of one substrate to another, glucose to FAs and vice-
versa, can have protective or permissive roles in disease pathogenesis (Stanley 
et al., 2014). FAO will be next described. 
II.2a – Fatty Acids Oxidation (β-oxidation) 
 
 
FAO is characterized by a series of reactions that decrease the size of 
FAs, reducing the Acyl-CoA chains by two carbons at every cycle (Figure 18).  In 
this pathway, Acyl-CoAs are cyclically dehydrogenated, hydrated and 
decarboxylated, which results in the progressive shortening of the chains and the 
production of two RedOx cofactors which are: NADH and FADH2. These will then 
fuel the ETC, for ATP production. Higher quantities of them can be obtained by 
FA degradation than by glucose or pyruvate. 
Approximately 80% of the energy needed by the heart and skeletal muscle is 
provided by FAO (Carracedo et al., 2013). In addition, this process is also used 
for BAT thermogenesis. In fact, FAO implies heat production instead of ATP 
synthesis in the presence of UCP1. 
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Figure 18: Representation of the β-oxidation of palmitic acid in the mitochondria. 
 
Free Acyl-CoAs can be metabolized by FAO. FAO is characterized by a series of 
reactions that decrease the size of FAs, reducing the Acyl-CoA chains by two carbons 
at every cycle. Image from Carracedo et al., 2013. 
Interestingly, FAO progression depends on the number of carbons of the 
FAs’ aliphatic chain. Medium (6 to 12 C) and short (less than 6 C) chains can 
passively diffuse across the MEM and MIM to the matrix, where they are thought 
to be activated by different Acyl-CoA Synthetases (ACS). However, long chain 
fatty acids (LCFA), whose aliphatic chains’ length is comprised in between 13 
and 21 C, such as Palmitoyl-CoA (16:0), cannot freely diffuse through the MIM. 
Beforehand they require an activation step. To do so, LCFA are modified to fatty 
Acyl-CoAs thioesters, hence activated, by ACS located in the MEM. Then, prior 
to their entry into the intermembrane space via the carnitine shuttle, the long-
chain Acyl-CoAs are converted into acyl-carnitine derivatives by CPT1, also 
located in the MEM. These acyl-carnitine derivatives are finally translocated 
across the MIM into the mitochondrial matrix by carnitine-acylcarnitine 
translocase. Another enzyme located on the matrix side of the MIM, CPT2, 
renews the acyl-CoA units. Once carried through the MIM and inside the matrix, 
FAs are oxidized to acetyl-CoA units so that, as previously mentioned, the FA 
chain length is reduced by two carbons in every cycle of β-oxidation. Figure 19 
depicts this process. 
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Figure 19: Representation of mitochondrial FAO and OXPHOS in liver 
mitochondria. 
 Adapted from Begriche et al., 2011. 
 
It is important to mention that in response to a decrease of carbohydrate 
intake (e.g. fasting or starvation), CPT-1 will be up-regulated resulting in FAs 
entering FAO. On the contrary, upon feeding, FAs synthesis will be enhanced. 
This phenomenon is accompanied by high expression levels of malonyl-CoA, an 
allosteric inhibitor of CPT-1. 
II.2b – The tricarboxylic acid (TCA) cycle (Krebs cycle) 
 
 
It takes its name from the German Hans A. Krebs (1900-1986). Despite 
the lack of support of his supervisor Otto Warburg, who even wrote that Krebs 
would never make it to a good biochemist (Kornberg, 2000), he disemboweled a 
series of sequential, reversible and irreversible reactions of carbohydrate 
oxidation that earned him a Nobel Prize in Physiology or Medicine in 1953 (Krebs 
and Johnson, 1937). 
The TCA cycle or Krebs cycle is connected with many other metabolic pathways 
participating in cellular energy exchange (Figure 15). Glucose, lipids, amino 
acids and nucleic acids are broken down and re-synthesized in order to keep cell 
vital functions. Intracellular signaling controls the entrance of metabolites to the 
Krebs cycle and its regulation towards biosynthesis of macromolecules. Figure 
20 shows the enzymatic process related to this cycle.  
ETC
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Figure 20: Bioenergetics of the TCA/Krebs cycle. 
 
Pyruvate is converted to high-energy molecules like NADH, GTP and FADH2 through 
catalyzation by TCA/Krebs cycle enzymes. Adapted from Osellame et al., 2012. 
 
In the first step of the TCA, Acetyl-CoA plus oxaloacetate and water form 
citrate by a reaction catalyzed by the enzymatic activity of the citrate synthase. 
The next three steps, isocitrate, α-ketoglutarate and succinyl-CoA formation, are 
important for the release of NADH and CO2. The aconitase, isocitrate and α-
ketoglutarate dehydrogenases catalyze these three oxidation steps. 
Subsequently, succinyl-CoA and succinate dehydrogenases will give rise to 
succinate and fumarate, releasing GTP and FADH2 in the process. The succinate 
dehydrogenase directly connects the Krebs cycle to the ETC in a reaction that 
can be reversed. The liberated FADH2 serves as an energy carrier that feeds e- 
to the complexes of the ETC. In the next reaction, the fumarate hydratase 
catalyzes the hydration of fumarate to generate malate. Finally, closing the cycle, 
the malate dehydrogenase converts the malate to oxaloacetate again, producing 
a final NADH molecule (Quinlan et al., 2012; Stobbe et al., 2012) (Figure 20). 
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II.2c – The electron transport chain (ETC) and ATP synthesis 
 
To generate ATP, phosphorylation of ADP needs to take place. This 
reaction is catalyzed by the ATP synthase (F0F1-ATPase). This enzymatic 
complex is capable of pumping H+ back into the mitochondrial matrix thanks to 
the existence of an electrochemical gradient (ΔμH+) (Δp), also known as “the 
proton motive force” (Divakaruni and Brand, 2011).  This was the basis of the 
Chemiosmotic Theory formulated by Peter Mitchell in 1961 for which he received 
the Nobel Prize (MITCHELL, 1961). Two components might be distinguished 
within this gradient: 
§ A pH gradient (ΔpH): the matrix becomes more basic 
§ A charge gradient (Δψm): the matrix side of the MIM is negatively 
charged. 
The charge difference normally rests at -150 to -180mV. It serves as a store of 
the oxidation energy for the various processes that take place across the MIM, 
and thus couples phosphorylation and O2 consumption (respiration). Meanwhile, 
the e- are transported in successive steps through the ETC complexes, until they 
are received by O2 to generate H2O. 
The ETC is composed by five respiratory chain enzymatic complexes, held within 
the MIM (Lancaster, 2002), and together with the Pi carrier and the ATP/ADP 
translocase, they are referred to as the OXPHOS system (Figure 21). The first 
four enzyme complexes are involved in substrate oxidation and formation of the 
energy gradient, while the fifth (ATP synthase) employs this gradient to generate 
ATP. The order of intervention of these complexes is established by their RedOx 
potential, ranging from the most reducing to the most oxidant one. NADH and 
FADH2 donate e- to complexes I and II, respectively. These e- are then passed to 
complexes III and IV where 02 acts as the terminal oxygen acceptor. Oxidized 
NAD+ and FAD then re-enter the cycle. 
To maintain a constant H+ gradient, respiration rate increases when proton 
pumps undergo “slip-redox”. This fleeing phenomenon results in reduced 
pumping of H+ for the same number of e- transferred along the respiratory chain. 
This is theoretically possible in complexes I, III and IV, the three H+ pumping sites. 
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Figure 21: The OXPHOS system. 
Image from Granata et al., 2009. 
 
II.2c1 –The complexes from the mitochondrial ETC 
 
The OXPHOS complexes (Figure 21) consist of proteins encoded by both 
the nuclear (n = approximately 100 in humans) and the mitochondrial genome (n 
= 13) (Figure 22A) (van Waveren and Moraes, 2008), except for complex II which 
contains proteins exclusively coded by the nDNA (nuclear DNA). The cells 
modulate the activity of these complexes depending on their energetic 
requirements. 
II.2c1.1 – Complex I à NADH-coenzyme Q oxidoreductase 
 
Complex I consists of 45 subunits; 38 nDNA coded, and 7 mtDNA coded 
(Carroll et al., 2006). This complex catalyzes the first OXPHOS reaction which 
consists on the oxidation of NADH and the transfer of two e- to ubiquinone. The 
reaction is coupled to the translocation of two H+ from the mitochondrial matrix to 
the intermembrane space, contributing to the necessary force for driving ATP 
synthesis (Yagi and Matsuno-Yagi, 2003). Flavin mononucleotide (FMN) is the 
first e- acceptor. It contains a catalytic site consisting on a Fe-S center (Sazanov, 
2007) and it is located at the hydrophilic domain of the complex that contains the 
NADH binding site. 
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II.2c1.2 – Complex II à Succinate-Q oxidoreductase 
 
Complex II is composed by four subunits - A to D -, encoded by four 
different nuclear genes (Rustin and Rötig, 2002). It catalyzes the oxidation of 
succinate to fumarate via the intermediate oxidation of FADH2 and the reduction 
of ubiquinone, allowing the transfer of two e- to complex III. 
II.2c1.3 – Complex III à Cytochrome c oxidoreductase 
 
Complex III encloses 10 nDNA and 1 mtDNA coded subunits. It catalyzes 
the reduction of cytochrome C. During this reaction the coenzyme Q is oxidized 
and two H+ move from the matrix to the intermembrane space (Link, 1995). 
II.2c1.4 – Complex IV à Cytochrome c oxidase 
 
Complex IV accommodates 13 subunits; 10 nDNA coded, and 3 mtDNA 
coded. These proteins are synthesized in the cytoplasm and transported to the 
mitochondria (Borisov, 2002). Complex IV catalyzes the RedOx reaction from 
molecular O2 to H2O. The produced e- are transferred to complex V. During this 
reaction, two H+ are consumed and two other are transferred from the matrix to 
the intermembrane space.  
II.2c1.5 – Complex V à ATP synthase 
 
Complex V is composed of two main linked subunits, F0 and F1, located in 
the MIM and the matrix respectively. Acting as a rotor, this complex uses the 
passage of H+ to operate. The F0 portion, starts conducting the H+ from the 
intermembrane space to the matrix (Schon et al., 2001). Later, they will go 
through the F1 portion, which uses the ΔpH created thanks to the expulsion of H+ 
by complexes I, III and IV to convert ADP into ATP. This conversion depends 
upon the magnitude of Δψm and the ability of the respiratory chain to maintain it. 
The ATP formed during this reaction is anew exported to the cytosol in exchange 
for ADP.  
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II.2c2 – The Decoupling proteins àUCPs 
 
UCPs may also be considered a part of the Oxidative Phosphorylation 
Pathway. As I have just explained, in classical mitochondrial dynamics fuel 
oxidation is linked to e- transport, resulting in the development of an 
electrochemical gradient and in ATP synthesis. However, there is a tissue into 
which H+ flow back across the MIM without concomitant ATP synthesis. This 
tissue is BAT, a specialized organ which expresses the UCP1 isoform (see 
section I.1). UCP1, was actually herein discovered (Nicholls et al., 1978). This 
protein plays an indispensable role in thermogenesis, dissipating the e- gradient 
at the ETC, in order to generate heat against certain physiological situations, or 
for other purposes (Lin and Klingenberg, 1980; Cannon, 2004). In the presence 
of UCP1, FAO (section II.2.1) implies heat production instead of ATP synthesis. 
The UCP family features today five members which also locate within the 
MIM. Even if their general role in regulating cellular energy transduction has been 
described in the literature, the detailed impact of the rest of UCPs on body 
metabolism remains not fully understood. However, an association with 
conditions such as insulin resistance in diabetes and atherosclerosis, as well as 
an increase with starvation and sepsis have been shown (Cadenas et al., 1999; 
Blanc et al., 2003; Chan and Harper, 2006). Given these linkages, UCPs have 
been suggested as attractive therapeutic target for diseases rooted in metabolic 
imbalance and oxidative stress (Divakaruni and Brand, 2011). 
The rest of the isoforms, other than UCP1, were later identified in different 
tissues, based on their sequence similarity. A 57% homology is shared by both, 
UCPs -2 and -3 (Pecqueur et al., 2001). UCP2 (Fleury et al., 1997) is widely 
expressed in most mammalian tissues (Azzu et al., 2008), whereas we find UCP3 
(Boss et al., 1997) predominantly expressed in fat, skeletal and cardiac muscle 
(Krauss et al., 2003; Aguirre and Cadenas, 2010). Studies using KO animal 
models for these UCPs prevail conflicting (Nedergaard and Cannon, 2003). 
UCP3 (-/-) mice showed no changes in O2 consumption compared to WT in 
muscle mitochondria (Cadenas et al., 2002). However, one year before, an 
increase in skeletal muscle ATP synthesis in vivo in UCP3 (-/-) mice was shown 
by Gary W. and colleagues (Cline et al., 2001), which was accompanied by a 
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concomitant reduction in H+ leak (Vidal-Puig et al., 2000). Moreover, over-
expression of UCP3 in mice caused fat-specific weight loss (Clapham et al., 2000; 
Cadenas et al., 2002).  
The fourth (Mao et al., 1999) and fifth (Yu et al., 2000) members of this family , 
UCP-4 and -5, exhibit a tissue-specific distribution, being largely expressed in 
mouse brain. Furthermore, they have been suggested to be involved in tissue-
specific thermoregulation and metabolic changes associated with nutritional 
status (Yu et al., 2000). 
II.2d – The OXPHOS system regulation 
 
The OXPHOS system is mainly regulated by the cellular calcium (Ca2+) 
signaling, H+ and phosphorylation. The permeability of the MEM to Ca2+ is voltage 
dependent, meaning that the VDACs become impermeable or permeable 
according to ΔΨ. When the cell demands more energy, more Ca2+ is transferred 
to the mitochondria matrix. Here, the Ca2+ accumulation is counteracted by the 
mitochondrial Na+/Ca2+, H+/Ca2+ exchangers. 
Natural leak of H+ across the MIM is the main cause of incomplete coupling of 
mitochondria. This is at the origin of the lost as heat of some of the RedOx energy 
in substrates during oxidative phosphorylation (Brand, 2000; Divakaruni and 
Brand, 2011). “Futile” H+ cycling comes at a tremendous energetic cost: up to 
20–25% of an animal’s BMR (Basal Metabolic Rate) may be attributable to H+ 
leak (Rolfe et al., 1999). The Basal proton leak is nonetheless physiologically 
essential. It is cell-type specific, correlates with metabolic rate (Jastroch et al., 
2011), is inversely proportional to body mass (Bourne, 1993; Brand et al., 2003) 
and is exclusively related to the physicochemical properties of the MIM.  
In relation to phosphorylation, several studies have shown that all OXPHOS 
components can be phosphorylated, even the small e- carrier cytochrome C is 
Tyr phosphorylated in vivo (Hüttemann et al., 2007). 
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II.3 – Mitochondrial DNA 
II.3a – Origin and evolution 
 
The idea that mitochondria could have originated from preexistent 
prokaryotic organisms has become a paradigm in biology. Many questions 
concerning the coexistence of these two separated organisms have been raised. 
Mitochondria are thought to have joined the pre-eukaryotic cell at its very origin, 
3 billon years ago, descendants of the bacterial phylum α-proteobacteria, 
instituting an advantageous metabolic cooperation that has allowed the 
maintenance of this association over centuries (Baluka, 2009; Martin, 2010; 
Lukeš et al., 2011; Gray, 2012; Blackstone, 2013). It is difficult to clearly define 
which were the exact events that gave rise to the symbiotic alliance currently 
existing between the mitochondria and the cells. Some theories postulate that 
pre-eukaryotic cells interiorized mitochondria by phagocytosis (de Duve, 2007). 
Another hypothesis states that the mitochondrion may have been an invasive, 
parasitic bacterium and that the symbiosis emerged by a nutritional synchrony, 
based on nutrients transfer (Searcy, 2003). These queries are difficult to answer 
because there are no physical records of the extinct transition forms of 
mitochondria and eukaryotic cells, only current observations. Thus, explaining the 
first interactions between mitochondria and the eukaryotic cells is still a matter of 
debate. 
II.3b – Structure and organization 
 
Nuclear and mtDNA possess very different characteristics. Rigorously 
speaking, the replication of this last one is nuclear independent, but the enzymatic 
components required for this process, along with transcription and translation, 
have a nuclear origin (Scarpulla, 1997; Enríquez et al. 1999; Taanman, 1999).  
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Figure 22: Mitochondrial genome and intercommunication between the nucleus 
and mitochondria. 
 
A) Mitochondrial genome. Image from source internet. 
 
B) Thirteen essential polypeptide respiratory chain complex subunits are 
synthesized in the mitochondrial matrix from mtDNA. More than 1000 different 
mitochondrial proteins are synthesized in the cytosol from nuclear DNA. Image 
from Chinnery, 2003. 
 
In mammals, the mitochondrial genome is a double stranded circular DNA of 
about 16.600 bps. Concretely, in mouse, a 16.295 bps closed circular DNA has 
proved to be a model system for studies of mtDNA replication (Gillum and 
Clayton, 1978; Bogenhagen et al., 1981). The human one is 16.569 bps long 
A)
B)
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(Cotter et al., 2004), self-replicating and contains a double-stranded, circular 
DNA. The strands differ in terms of their G+T content, thus distinguishing a light 
chain (L) and a heavy chain (H), where most of the information is encoded. 
The hallmark of mammalian mtDNA organization is the extreme economy of DNA 
sequence management. The genome displays exceptional economy of space, 
with a high degree of organization. Genes lack introns and both tRNAs and 
rRNAs are unusually small, with tRNA genes interspersed between rRNA, and 
protein coding genes with zero or few non-coding nucleotides between the coding 
sequences. Some of these genes overlap and it occurs sometimes that the 
generation of the stop codons befalls post-transcriptionally (Taanman, 1999).  
The majority of proteins involved in mitochondrial function are nonetheless 
nuclear encoded. They are synthesized in the cytosol and then targeted to 
mitochondria (Elstner et al., 2009). It is estimated that more than 1000 
mitochondrial proteins are derived from nuclear genes. In mouse and human, 
mitochondrial coded genes include overall: 12S and 16S rRNAs, tRNAs required 
for protein synthesis and essential genes for OXPHOS. Mouse mtDNA is highly 
homologous in global sequence and in gene organization to the human mtDNA 
(Bibb et al., 1981). However, mouse mtDNA is unique concerning the 
translational start codon. Any of the four nucleotides may occupy the third position 
on the AUN triplet codon, whereas the only translational stop codon is the 
orthodox UAA. Figure 22A displays the mitochondrial genome and Figure 22B 
partially illustrates the so described intercommunication between the nucleus and 
mitochondria. One example worth mentioning is the mitochondrial nucleoid 
protein M19 for whom a modulatory functional link has been established with the 
activity of the ETC, leading to the regulation of major cellular processes such as 
myogenesis and insulin secretion (Cambier et al., 2012). 
II.3c – Transcription regulation 
 
As described before, mitochondria have their own genome, but it only 
encodes a part of the ETC proteins. Farther mitochondrial proteins are encoded 
by the nuclear genome. This double origin requires a detailed and coordinated 
regulation (Scarpulla, 2006). Therefore, there exist key regulatory factors 
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encoded by nDNA which will allow firstly the transcription of the mtDNA and 
secondly the expression of nuclear genes encoding mitochondrial proteins. 
Nuclear control of mitochondrial functioning 
 
The main feature of the genes coding for the members of the OXPHOS 
system is that they are located within two different genomes. The vast majority of 
them are nuclear genes, with only a few being encoded by the mitochondrial 
genome. Apart from the implications derived from the different position of both 
genomes, it is important to note that these are two very different genetic systems. 
Each of them has a particular arrangement of genes and distinct requirements 
for the transcription and translation processes (Enriquez et al., 1999b). OXPHOS 
genes which are nuclear encoded exhibit the typical characteristics of the RNA 
polymerase II transcription, thus presenting a particular number and distribution 
of introns and exons. Each strand contains a promoter for the initiation of 
transcription, the HSP (heavy strand promoter) and LSP (light strand promoter). 
Transcription results in the formation of polycistronic RNA precursors which 
encompass the entire genetic information of each strand. These RNA are 
processed to produce mRNAs, tRNAs and rRNAs. 
II.3c1 – Mitochondrial transcription factors coded by nDNA 
 
Mitochondria have their own transcription machinery, whose elements are 
encoded by the nuclear genome. 
· POLRMT (mitochondrial DNA-directed RNA polymerase): this is an 
enzyme responsible for mitochondrial gene expression as well as for 
providing RNA primers for initiation of replication of the mtDNA. To interact 
with the promoter, it requires TFAM and TFB1M or TFB2M. 
· TFAM (mitochondrial transcription factor A): this is a key activator of 
mitochondrial transcription as well as a participant in mitochondrial 
genome replication. 
· p43 (truncated c-ErbA protein): this is a mitochondrial T3 receptor that acts 
as a mitochondrial transcription factor and consequently stimulates 
mitochondrial activity and mitochondrial biogenesis (Casas et al., 1999). 
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· TFB1M and TFB2M (mitochondrial transcription factor B1 and B2): these 
enzymes act as methyltransferases regulating the assembly and stability 
of the mitochondrial ribosome.  
· mTERF (mitochondrial transcription termination factor): it plays different 
roles which are not restricted to transcription termination, but concern also 
transcription initiation and the control of mtDNA replication. 
II.3c2 – Transcriptional regulators of nuclear genes coding mitochondrial 
proteins 
 
The expression of nuclear genes encoding mitochondrial proteins, and 
regulating mechanisms of mtDNA replication and transcription is finely 
coordinated. This coordination is possible thanks to ‘actors’ such as: 
NRF1 
NRF1 (Nuclear Respiratory Factor-1) is a transcription factor which has been 
shown to interact with promoters of several genes encoding for different subunits 
of the ETC complexes, and for proteins involved in mtDNA replication and 
transcription, like POLRMT, TFAM, TFB1M and TFB2M (Scarpulla, 2006). 
NRF2 
This transcription factor has been identified as a transcriptional activator of 
the gene encoding the subunit IV of cytochrome c oxidase, TFAM, TFB1M, 
TFB2M and three of the four subunits of succinate dehydrogenase (Scarpulla, 
2002 ; Kelly and Scarpulla, 2004). 
PGC1α 
This protein belongs to a family of transcriptional coactivators playing an 
essential role in the integration and orchestration of the mitochondrial biogenesis 
program. PGC1α’s expression and activation are regulated by signaling 
pathways initiated by environmental stimuli. It represents an energy sensor 
capable of inducing the appropriate mitochondrial modifications. PGC1α notably 
interacts with NRFs, inducing the expression of genes encoding for proteins of 
the ETC as well as for factors required for mitochondrial replication and 
transcription (Scarpulla, 2006; Scarpulla, 2008). Furthermore, PGC1α regulates 
the expression of genes encoding proteins involved in the mitochondrial FAO 
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(Vega et al., 2000), by interacting with PPARα and ERRα (Estrogen Related 
Receptor alpha). 
PGC1β 
This transcriptional coactivator exhibits strong structural homology with 
PGC1α (Austin and St-Pierre, 2012). They partially co-activate several 
transcription factors; importantly those inducing the expression of genes involved 
in the regulation of mitochondrial energy metabolism (Meirhaeghe et al., 2003). 
II.4 – Mitochondrial dysfunction & disease 
 
Mitochondrial dysfunction is a generic term, which includes alteration of 
different metabolic pathways and damage to mitochondrial components 
(Begriche et al., 2011). Mitochondrial dysfunction causes over 50 diseases 
ranging from neonatal fatalities to adult-onset neurodegeneration (Dimauro and 
Schon, 2003; Lowell and Shulman, 2005; Wallace, 2005). Recent 
epidemiological studies have provided evidence that disorders of the 
mitochondrial respiratory chain affect at least 1 in 5000 of the population 
(Schaefer et al., 2004). These figures make these disorders some of the most 
common genetic diseases (Chinnery, 2003; Peng et al., 2015). Mitochondrial 
disease results in different degrees of failure of this organelle. Proceeding from 
different casualties, the consequences are collective; defeat to produce the 
energy needed for the sustainment of life and growth of an organism. Post-mitotic 
tissues, such as muscle and brain, are the most sensitive to mtDNA changes, 
due to their high energy requirements and non-proliferative status. Most of the 
damage related to mitochondria is caused in such organs, with high energy 
consumption. Less often, heart, liver and kidney are also affected. However, if 
the mitochondrial weakness happens throughout the organism, the whole system 
begins to fail.  
A growing body of research demonstrates that altered mitochondrial energy 
production, particularly in skeletal muscles, is a major anomaly capable of setting 
off a chain of metabolic events leading to obesity (Rogge, 2009). 
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Mitochondria in Obesity 
 
A normal mitochondrial function is required for maintaining the appropriate 
balance between energy storage and expenditure. Nutrient excess leads to 
mitochondrial dysfunction with the consequential effects on lipid and glucose 
metabolism (Bournat and Brown, 2010). This is partially due to the harmful effects 
of ROS. Affecting mitochondrial metabolism generally favors ROS generation 
and the subsequent development of oxidative stress. A mechanism involving a 
deleterious effect of high TG on the functioning of the mitochondrial ETC by 
promoting superoxide generation has been proposed (Martínez, 2006; Monteiro 
and Azevedo, 2010).  
Recent studies also suggest that the actions of mitochondria would extend 
beyond their conventional role as generators of heat. There is mounting evidence 
that impaired mitochondrial respiratory capacity is accompanied by attenuated 
expression of UCP1 and other BAT-selective genes, implying that mitochondria 
would exert transcriptional control  over gene programs involved in oxidative 
metabolism and thermogenesis (Nam and Cooper, 2015) (Figure 23).  
 
Figure 23: Mitochondrial transcriptional control over storage and thermogenesis 
gene programs. 
 
Transcriptional control is dependent on mitochondrial respiratory capacity. In this model, 
impaired respiratory capacity acts as a transcriptional checkpoint, whereas augmented 
respiratory capacity acts as a transcriptional trigger. Adapted from Nam and Cooper, 
2015. 
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Additionally, Gospodarska and colleagues have described differences in 
between BAT and WAT concerning mitochondrial turnover during temperature 
transitions (Gospodarska et al., 2015). Their results indicated that dynamics of 
brown adipocytes turnover during reversible transition from warm to cold may 
determine the thermogenic capacity of an individual in a changing temperature 
environment. Mitochondrial dynamics, fusion and fission, together with the two 
main regulators, mitofusis (Mfn1 and Mfn2) have also been implicated in studies 
where the participation of mitochondrial dysfunction for metabolic disorders is 
highlighted. Moreover, an important role of mitochondrial dynamics has been 
revealed regarding the neuronal populations orchestrating the regulation of 
hunger and satiety (Nasrallah and Horvath, 2014). Furthermore, it has been 
shown that when mitochondrial abnormalities cannot be dealt with, there is an 
increased chance that major illnesses like T2D, Alzheimer's disease, and cancer 
may occur (Snyder and Stefano, 2015). 
II.5 – Mitochondrial databases 
 
If we search on Pubmed for “mitochondrial databases” without any other 
filter, we will encounter a digit slightly higher than 1500 results. If we further 
specify for “homo sapiens” or “mus musculus” results are reduced to 765 and 106 
respectively (summer 2015).  
To study and illustrate the biology of this organelle, an expanded mitochondrial 
inventory and several tools are nowadays available. Among them we find: 
ChloroMitoSSRDB, GOBASE, HMPDb, InterMitoBase, MamMiBase, MitoCarta, 
MitoDat, MitoData, MitoDrome, MitoGenesisDB, MitoInteractome, MitoMiner, 
MitoProteome, MitoRes, MitoZoa, MitPred, MPIMP db, mtDB, OGRe, etc.  
Since MitoCarta, is a very complete and reliable database for rodents, this is the 
one we have used for analyzing our results. Therefore, this is the only one I will 
describe in brief in this manuscript. 
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MitoCarta 
 
MitoCarta is a compendium of genes encoding proteins with strong 
support of mitochondrial localization which is freely available in the net. The first 
version dates from seven years ago (Meisinger et al., 2008; Pagliarini et al., 
2008). A second one, MitoCarta2.0 released 2015, is in review for publication 
(Calvo, S.E., Klauser, C.R., Mootha, V.K. MitoCarta2.0: an updated inventory of 
mammalian mitochondrial proteins). MitoCarta2.0 is an inventory of 1013 human 
and 1098 mouse genes. To generate this inventory, the authors performed mass 
spectrometry of mitochondria isolated from fourteen different tissues. They 
assessed protein localization through large-scale GFP tagging and microscopy. 
Then, these results were integrated with six other genome-scale datasets of 
mitochondrial localization (Pagliarini et al., 2008).
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CHAPTER III: Pre-mRNA Splicing 
Introduction to pre-mRNA Splicing 
 
Splicing is the process by which portions of eukaryotic pre-messenger RNA 
(pre-mRNA), called introns, are removed and the remaining sets of sequences, exons, 
are ligated together to form the final mRNA product. Only the processed mRNA is 
translated into a protein or exerts a function as non-coding RNA, and so splicing plays 
an essential role in the phenotype of higher eukaryotic cells. While the majority of 
exons are constitutively included in the final mRNA, some exons, or just portions of 
exons, may be excluded from the mRNA in certain cells or under specific conditions. 
This process is referred to as Alternative Splicing (AS) and plays central role in 
generating complex proteomes from defined genomes.  
III.1 – Constitutive Splicing 
 
Introns must be defined prior to their excision. Three conserved sequence 
elements are required for efficient pre-mRNA splicing (Lim and Burge, 2001). They 
allow intron recognition and subsequent removal, and constitute the binding platform 
for the spliceosome. These essential sequences are: the 5’ splice site (5’SS) or splice 
donor, the 3’splice site (3’SS) or splice acceptor, and the branch point sequence (BPS), 
that is preceded by a polypyrimidine tract (Wahl et al., 2009) (Figure 24). 
 
 
Figure 24:  Splicing reactive sites. 
 
Conserved sequence elements within pre-mRNAs intron in metazoan. Adapted from  Wahl 
and Lührmann, 2015. 
 
 
Nuclear pre-mRNA splicing encompasses a two-step process that involves two 
transesterification reactions. These are simple chemical processes involving the 
splicing reactive sites that I have just described above. In the first place, the 
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phosphodiester bond at the 5’ SS is attacked by the 2’-hydroxyl of the adenosine of 
the BPS in the intron, which generates a free 5’ exon and an intron lariat-3’ exon. 
Subsequently, during the second step, the 3’- hydroxyl from the free 5’ exon attacks 
the phosphodiester bond at the 3’SS, leading to exon ligation and excision of the lariat 
intron (Wahl et al., 2009) (Figure 25). 
 
 
 
Figure 25: Chemistry in the splicing reaction. 
 
The splicing reaction requires two subsequent transesterification reactions, which allow for the 
excision of intron-lariat and the ligation of the 5’ and 3’ exons. Adapted from Wahl and 
Lührmann, 2015. 
 
III.2 – Alternative Splicing 
 
Alternative splicing is one of the mechanisms by which two different cells with 
the exact same genetic code can have entirely different structures and functions. So 
far, the mammal species with the highest proportion of AS is human, with 95% of multi-
exon genes showing evidence of AS (Pan et al., 2008). There are important aspects 
for specificity in AS like species specific, development stage specific, sex specific and 
tissue specific AS. Tissue specific AS events are closely associated with specific tissue 
functions (Wang and Burge, 2008; Taliaferro et al., 2011). If we compared the cells in 
our skin to the cells in our eyeball, we would see that they have virtually identical 
genetic information, despite their obvious differences. The combinatorial nature of 
expressing different parts of different genes, at different stages or conditions, literally 
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results in an infinite number of possible ways to determine how our cells look and 
behave.  
In eukaryotes, different categories of AS events can provide a multitude of 
isoforms of RNA from the same pre-mRNA (Blencowe, 2006; Wahl and Lührmann, 
2015b) . So far seven AS events compose the list of alternative mRNA processing. 
These are illustrated in Figure 26. 
 
Figure 26: Alternative Splicing Events (ASEs) in Metazoan Transcripts. 
 
Types of AS that are responsible for the generation of functionally distinct transcripts are 
depicted. Blue boxes indicate alternative exons. Adapted from Blencowe, 2006. 
 
AS regulation of eukaryotic exons is increasingly recognized as playing a central 
role in the phenotypic variation of genotypically identical cells, and the misregulation 
of AS has been implicated in many of the complex and unsolved diseases burdening 
today’s society (Matlin et al., 2005). The ability to control AS in a targeted and 
predictable fashion in vivo would give us some degree of power to control the 
phenotype of individual cells, as well as entire tissues, organs, and possibly even whole 
organisms. Potential applications of this ability include the treatment, prevention, and 
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curing of diseases driven by AS misregulation (Garcia-Blanco et al., 2004; Tang et al., 
2013) and the reprogramming of stem cells  in order to regenerate vital tissues and/or 
organs (Salomonis et al., 2010). 
III.2a – Alternative splicing determinants 
 
Splicing can occur either co- or post-transcriptionally (Pandya-Jones and Black, 
2009). A wide variety of factors are thought to contribute to AS outcome. An integrated 
model for the regulation of AS is summarized in Figure 27 (Luco et al., 2011). The 
splicing reaction is conducted by a specific set of proteins that collectively make up a 
molecular machine called the spliceosome (Matera and Wang, 2014), that will be 
further detailed in section III.3. Specific consensus sequences are recognized by 
spliceosomal components and help define the SS. Those sequences elements are 
highly conserved in yeast, but extremely degenerated in higher eukaryotes. In fact, not 
all exons contain the consensus sequences at their SS, distinguishing them as strong 
and weak. SS resembling the consensus sequence are referred to as strong, while the 
remaining are denominated weak. As their names imply, strong SS are bound 
efficiently by the spliceosome, while weak SS are not. Competition between adjacent 
SS is thought to be one of the main drivers of AS outcomes (Kornblihtt et al., 2013). 
 
Figure 27: Overview of AS determinants. 
 
Alternative splicing patterns are determined by a combination of parameters including cis-
acting RNA regulatory elements and RNA secondary structures (highlighted in orange) 
together with transcriptional and chromatin properties (highlighted in blue) that modulate the 
recruitment of splicing factors to the pre-mRNA. Image from Luco et al., 2011.  
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III.2b – Regulation of alternative splicing 
 
  Besides, the above described well characterized sequence elements (5’SS, 
3’SS and BPS), a number of other sequences have been reported to influence pre-
mRNA splicing. Splice site choice is also regulated through cis-acting splicing 
regulatory elements (SREs) and trans-acting splicing factors. Such sequences can be 
found within introns or exons and can stimulate or inhibit the splicing of a given exon. 
On the basis of their relative locations and activities, SREs are classified as exonic 
splicing enhancers (ESE), intronic splicing enhancers (ISE), exonic splicing silencers 
(ESS) or intronic splicing silencers (ISS). The recruitment of spliceosomal components 
can be enhanced or inhibited by the binding of these regions on the nascent transcript 
and by the binding of splicing factors (SF's), typically the Serine-Arginine Rich family 
of proteins (SR proteins) (Fu, 2014). Distinct SF’s modulate a set of adipogenesis-
related ASEs with biological relevance. The so far known adipose-related splicing 
regulators and events are summarized in Table 3. 
 
Table 3: Summary of Adipose-related Splicing Regulators and Events 
 
Adapted from Lin, 2015. 
Distinct SF’s modulate a set of adipogenesis-related ASEs
Exon usage and biological relevance of adipocyte-related ASEs
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Common SF's include the so-mentioned SR proteins, which recognize ESEs to 
promote splicing, as well as various heterogeneous nuclear ribonucleoproteins 
(hnRNPs), which typically recognize ESSs to inhibit splicing. These antagonistic 
activities are essential determinants of SS selection in a concentration dependent 
manner. 
SR proteins constitute a family of proteins currently integrated by 12 members 
(Figure 28). Their principal role consists on the regulation of both constitutive and 
alternative splicing, but they can also participate in other functions such as regulation 
of mRNA stability (Zhang and Krainer, 2004) and microRNA processing (Wu et al., 
2010). This family of proteins is characterized by one or more RNA recognition motifs 
in their N-terminal (RRM domain), and by a serine-arginine rich region in C-terminal 
(RS domain). Their activity is mainly regulated by posttranslational modifications of 
their RS domain, essentially serine phosphorylations. 
 
 
Figure 28: Schematic representation of the 12 human SR proteins.  
 
Adapted from Twyffels et al., 2011. 
 
The hnRNP family plays the opposite role in AS regulation, counteracting the 
activity of SR proteins. Besides this established association with the splicing 
apparatus, hnRNP proteins are involved in preventing folding of pre-mRNA into 
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secondary structures and transporting mRNA out of the nucleus. This family 
incorporates more than 20 proteins, which generally include one or more RRMs. 
Nonetheless some hnRNPs rather bind RNA via another domain. 
III.3 –The spliceosome 
 
RNA splicing, whether constitutive or alternative, is catalyzed by the 
macromolecular machinery known as the spliceosome. The spliceosome consists on 
a set of small nuclear ribonucleoprotein particles (snRNPs) such as U1, U2, U4/U6, 
and U5, which assemble together with associated proteins into different complexes. 
Many other non-snRNP proteins are also a part of this machinery (Zhou et al., 2002). 
Each snRNP consists of a snRNA (or two in the case of U4/U6) and a variable number 
of complex-specific proteins. 
The spliceosome is a highly dynamic structure that constantly re-arranges during a 
pre-mRNA splicing cycle and whose assembly on the target transcript is a stepwise 
process that requires binding and releasing of its different snRNPs as well as the other 
splicing factors. 
Step wise spliceosome assembly  
 
Although spliceosome assembly is best-understood in budding yeast, the key 
assembly steps are well conserved in evolution (Matera and Wang, 2014). First, 
assembly begins with the recognition by U1 snRNP of the 5ʹSS via base pairing of U1 
snRNA to the mRNA, forming the early complex (complex E). This process is facilitated 
by the Pol II CTD. The interaction between the 5ʹSS and U1 snRNP in complex E is 
ATP- independent and fairly weak. It is stabilized by other factors, such as members 
of the SR protein family (Cho et al., 2011) and the cap-binding complex (CBC) (Pabis 
et al., 2013). Indeed, most of the functionally important RNA-RNA interactions formed 
within the spliceosome are weak and generally require the assistance of proteins to 
enhance their stability (Wahl et al., 2009). The 3ʹSS of the pre-mRNA is recognized by 
the U2 snRNP and associated factors, such as splicing factor 1 (SF1) and U2 auxiliary 
factors (U2AFs), which are also components of the complex E. After that, U2 snRNA 
recognizes sequences around the BPS adenosine and interacts with U1 snRNP in an 
ATP-dependent manner, to form the pre-spliceosome (complex A). In a subsequent 
transition step, U1 and U2 snRNPs undergo rearrangements, which bring the 5ʹSS, 
BPS and 3ʹSS into close proximity (De Conti et al., 2013). After the assembly of 
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complex A, the U4–U6 and U5 snRNPs are recruited as a preassembled tri-snRNP to 
form complex B. At this step, major spliceosomal snRNP are recruited to the transcript. 
However, the splicing reaction does not occur yet. The resulting complex B goes 
through a series of compositional and conformational rearrangements including the 
release of U1 and U4, which result into the formation of a catalytically active complex 
B (complex B*). The activated spliceosome, complex B*, completes then the first 
catalytic step of splicing, generating complex C. Complex C undergoes then additional 
ATP-dependent rearrangements before carrying out the second catalytic step of 
splicing (Konarska et al., 2006). This results in a post-spliceosomal complex that 
contains the lariat intron and the spliced exons. Finally, the U2, U5 and U6 snRNPs 
are released from the mRNP particle and recycled for additional rounds of splicing. 
Disassembly of the post-catalytic spliceosome is also driven in an ATP-dependent 
manner (Wahl et al., 2009; Hoskins and Moore, 2012) (Figure 29). 
 
Figure 29: Dynamics of spliceosome assembly. 
 
The spliceosome assembly and disassembly cycle, with known structures of individual 
complexes, as well as the cross-intron assembly and disassembly of the major spliceosome. 
Image from Lee and Rio, 2015. 
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III.4 – Alternative Splicing and Disease: The case of the LMNA gene and HGPS 
 
Alterations in normal AS patterns are known to have a close link with disease 
(Orengo and Cooper, 2007; Tazi et al., 2009). Changes in regulatory sequences can 
drastically change or invalidate essential gene products due to the complexity of the 
process (Zhang et al., 2015). Estimates attribute up to half of human disease mutations 
to changes of splice regulatory regions (Wang and Cooper, 2007). There are also 
documented cases of disease product of overexpression of trans-acting regulation 
genes of AS in other mammals (Anczuków et al., 2012). AS has been frequently 
associated with cancer (Tazi et al., 2009; Kelemen et al., 2013), diabetes (Prokunina-
Olsson et al., 2009) and obesity (Kaminska and Pihlajamäki, 2013). In this last 
condition, splicing has moreover been correlated with changes in weight loss, FA and 
glucose metabolism (Kaminska and Pihlajamäki, 2013). 
III.4a – Lamins 
 
Lamins are intermediate filament proteins forming a fibrous meshwork, called 
nuclear lamina, between the inner nuclear membrane and peripheral heterochromatin 
of metazoan cells. Lamin functions have been proven to present cell-type specific 
differences (Zwerger et al., 2015) of which the main ones are structural function and 
transcriptional regulation in the cell nucleus. Proper integration of lamin A/C into the 
lamina is required for correct nuclear mechanical properties and nuclear envelope 
integrity. 
There are two types of lamins: A type lamins and B type lamins.  
In humans, B type lamins (B1 and B2) are coded by two different genes (LMNB1 and 
LMNB2), whereas A-type lamins are encoded by a single gene, LMNA.  Alternative 
RNA processing of LMNA pre-mRNA produces three main nuclear protein isoforms; 
that is, lamin C, progerin, and lamin A (Figure 30). 
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Figure 30: LMNA major lamin isoforms. 
 
Schematic representation showing the production of lamins C and A by the use of different 
polyadenylation sites, and the obtainment of progerin by differential AS. The main mutation 
giving rise to HGPS (C>T) is also depicted. 
 
LMNA isoforms 
 
As I just explained, the LMNA gene produces three main protein isoforms by 
RNA processing of the primary transcript. Lamins C and A originate from the use of 
different polyadenylation sites. When this process takes place at the level of exon 10, 
lamin C will be produced whereas when polyadenylation occurs at the level of exon 
12, the resulting isoform will be lamin A.  
A process of maturation is required for the procuration of Lamin A. It implicates a step 
of farnesylation that will give rise to prelamin-A, which in turn will maturate into lamin 
A. The third isoform, a shorter form of lamin A, can be obtained by AS. The regulation 
of the splicing takes place at the level of exon 11. Highly used SS will give rise to lamin 
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A, whereas less used SS will originate a truncated form of the protein, called progerin 
(Figure 30). This isoform lacks the 150 nucleotides that contain the necessary 
sequence for the farnesyl group enzymatic cleavage. Therefore it remains farnesylated 
and accumulates around the nuclear envelope, leading to dominant deleterious effects 
in nuclear organization. 
III.4b – HGPS/Progeria 
 
Progerin accumulation is largely responsible of HGPS (Hutchinson-Gilford 
Progeria Syndrome). This disease is more frequently plainly called progeria. It is an 
extremely rare genetic disease characterized by signs of premature ageing. This 
severe form of early-onset accelerated senescence is narrowly associated with 
lipodystrophy (Eriksson et al., 2003). 
Babies are born normally and healthy, but they have an accelerated senescence and 
at the age of 14 they resemble old people. The main characteristics are: stunted 
growth, alopecia, accelerated aging of the skin (subcutaneous AT loss), lipodystrophy, 
atherosclerosis, and cardiovascular problems. This last feature is usually the cause of 
death. Surprisingly, mental development is not affected, due to the presence of a 
specific microRNA in the brain: miR-9 (Jung et al., 2012; Nissan et al., 2012). 
Most cases are sporadic and caused by de novo single point silent mutations in the 
LMNA gene (c.1824C>T; p.Gly608Gly) which results in aberrant AS. This alteration on 
the process consisting on the removal of introns gives rise to an exacerbated 
production of progerin, the truncated isoform of the protein (Navarro et al., 2006). 
Consequently, as previously mentioned, abnormal progerin agglomerates at the 
nuclear periphery and causes the appearance of shape abnormalities in the nucleus. 
In the laboratory, a role of two serine-arginine (SR)-rich proteins, SRSF1 and 
SRSF6, has been elucidated for the regulation of progerin production (Figure 31A) 
(Lopez-Mejia et al., 2011). The authors portrayed a model into which the progerin 5’ 
SS was sequestered in a conserved secondary RNA structure that prevented it to be 
used (Figure 31B). The progeria mutation would disrupt this structure allowing then 
SRSF1 to indirectly favor progerin 5′SS, while SRSF6 would directly repress progerin 
production. According to their data, the mechanism by which the SS is selected 
depends then on two features. Firstly, a RNA secondary structure which prevents the 
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use of the progerin 5’ SS. The progeria mutation would open up the secondary 
structure and allow accessibility to SR proteins. Aright secondly, two SR proteins, 
SRSF1 and SRSF 6 that are described as having two opposite effects: SRSF1 
activates progerin 5′SS, while SRSF6 represses it.  
 
 
Figure 31: LMNA SS regulation by SRSF6 and SRSF1 
 
A) SRSF6 prevents usage of progerin 5′SS in fibroblasts from progeria patients. Left panel 
is the quantification of the mRNA ratio between truncated (progerin) and full-length 
(lamin A) isoforms from the RT–PCR experiment on the right panel (SRSF1 and SRSF6 
siRNA knockdown). SCR: scrambled. Adapted from Lopez-Mejia et al., 2011. 
 
B) Model of the progerin 5’ SS activation. 
In HGPS, loss of AT correlates with adipokine dysregulation, insulin resistance, 
and atherosclerosis, suggesting a critical role of AT function in controlling whole body 
energy metabolism, age-related pathologies, and longevity (Arai et al., 2011). It is 
difficult to extrapolate the metabolic abnormalities with lamin deregulation, however, it 
is known that modifications in lamin A/C may be induced by common metabolic 
pathways involved in both diabetes and obesity before hyperglycemia is established 
(Miranda et al., 2008).
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III.4c – Lamins and Metabolism 
 
Existing literature has oftentimes designated the importance of the interface 
between metabolism and lamins, nuclear proteins encoded by the LMNA gene  (Liu et 
al., 2012;  Tang et al., 2011; Lloyd et al., 2002; Rochford, 2014). Recently, our 
laboratory has shown that the production of different LMNA isoforms is causative of 
distinct physiological metabolic outcomes (Lopez-Mejia et al., 2014). The entire 
publication can be found in Annex 1. This discovery suggests that lamins would act as 
regulators of energy homeostasis. LMNA isoforms were shown to affect mitochondrial 
gene expression and contribute to metabolic adaptations of AT in mice, resulting in 
opposed energy expenditure (EE) and lifespan. Strikingly, lamin isoforms correlates 
with opposing effects on lifespan and distinct effects on mitochondrial activity (Lopez-
Mejia et al., 2014). The experiments leading to these conclusions evidently involved 
mouse models expressing different isoforms of the Lmna gene. Progeria mice 
(G609G/G609G), expressed the three main Lmna isoforms I explained above and 
were lypodistrophic. They also had a very short life span (dying usually before the age 
of 5 months), and a high EE which was related with mitochondrial activity. Wild type 
(WT) mice lived around one year and a half and their EE was intermediate. And last 
but not least, the mice expressing exclusively Lamin C lived even longer. It is important 
to remark that under normal nourishment conditions these animals became obese over 
time. The underlying explanation seems to be in connection with a low EE, which 
correlates with a low mitochondrial activity, and a capacity to compensate for the 
deleterious effects triggered by obesity; suggesting that lamin C would protect against 
increased oxidative stress associated with fat accumulation. 
To sum up, results supported the notion that RNA processing of the Lmna gene is an 
active conserved mechanism that contributes to metabolic adaptations of AT in 
mammals, ascribing Lmna an additional important role. This outcome is in line with 
previous evidence suggesting a role for lamins into metabolism, which would be 
complementary with their structural function (López-Otín et al., 2013). 
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III.5 – Other RNAs: microRNAs 
 
RNAs may carry information from the DNA to the ribosome resulting in protein 
production. This is the case for mRNAs which contain a coding sequence that will 
determine the amino acid sequel. However, many RNAs do not code for proteins. In 
eukaryotes, about 97% of the transcriptional output is non-protein-coding (Mattick, 
2003).  
Examples of these so-called non-coding RNAs are: tRNAs, rRNAs, snoRNAs, siRNAs, 
snRNAs, exRNAs, piRNAs, and microRNAs. They can be encoded by their own genes 
or derive from mRNA introns and are oftentimes conserved across species. This fact 
highlights the importance of their functions, which include among others splicing 
regulation (Kishore and Stamm, 2006; Lee and Rio, 2015) and gene expression 
(Phillips, 2008). 
MicroRNAs (miRNAs/miRs) are small non-coding RNAs of approximately 22 
nucleotides that play important roles in post-transcriptional regulation of gene 
expression and, therefore, biological processes in different tissues. A given target may 
be regulated by multiple miRNA and a given miRNA might have hundreds of different 
mRNA targets (Friedman et al., 2009). MicroRNAs are able to regulate a multitude of 
effector genes in a multi-level regulatory mechanism that profoundly affects the gene 
expression program in the cells (Makeyev and Maniatis, 2008). 
The genesis of microRNAs from the primary miRNA transcript is mediated by the 
microprocessor complex. The pri-miRNA is cleaved thanks to Drosha’s RNase III 
activity, who acts in a complex with its co-factor DGCR8 (DiGeorge syndrome critical 
region 8 homolog) to create the pre-miRNA. Later on, exportin 5 deals with the 
transport of the pre-miRNA from the nucleus to the cytoplasm, where they are 
processed by the RNA-mediated interference machinery (Gregory et al., 2004). 
Cytoplasmic pre-miRNAs will be anew cleaved by another RNase III-type enzyme, 
Dicer, who also features two TRBP co-factors. Following Dicer cleavage, the short 
RNA duplex is bound by an AGO (Argonaute) protein, a component of a complex 
termed RISC (RNA-induced silencing complex). 
Since their discovery, miRNAs have been described as repressors, but recently new 
RNA stabilization roles and thus consequent translational activation are being ascribed 
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to these RNAs (Rusk, 2008; Orang et al., 2014). Nevertheless, silencing remains the 
most studied aspect among the distinct miR functions. Different mechanisms are 
known to lead to this outcome. These presently stand: destabilization of the mRNA 
through shortening of its poly-A tail, cleavage of the mRNA strand into two pieces, and 
less efficient translation of the mRNA into proteins. Moreover, silencing is possible 
thanks to RISC but chiefly thanks to the existence of complementary sequences that 
will base-pair in between microRNAs and the 3’UTR of the corresponding mRNA 
molecules. To recognize their targets, pairing does not need to be perfect, except for 
in a region called the “seed sequence”. This area corresponds to the nucleotides in 
positions 2 to 7 of the miRNA 5’-end, and it must be perfectly complementary (Lewis 
et al., 2005). 
 
Figure 32: Schematic view of miRNA biogenesis and mechanism of action. 
 
Image from Rüegger and Großhans, 2012. 
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III.5a – MicroRNAs and Alternative Splicing 
 
Many studies point to the importance of the dialogue established between the 
microprocessor and the spliceosome to regulate miRNA biogenesis. The production of 
microRNAs might be affected by AS (Figure 32) (Melamed et al., 2013). Given that 
mammalian miRNAs are expressed from intronic, exonic or polycistronic regions, if 
inclusion and/or exclusion are stimulated, a variation within the microRNAs population 
will likely follow. 
 
 
Figure 33: Regulatory Model of SS-Overlapping miRNA Biogenesis via AS. 
 
The spliceosome and the Microprocessor complex compete for processing of the same RNA 
region, leading to two possible scenarios. Image from Melamed et al., 2013. 
 
Furthermore, the involvement of an SR protein in the production of a specific 
miR has been recently demonstrated (Wu et al., 2010). A self-regulating loop has been 
described for this regulation into which SRSF1 promotes miR-7 production by binding 
the pri-miRNA structure and in turn miR-7 targets the mRNA of the gene encoding 
SRSF1 in the cytoplasm. 
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III.5b – MicroRNAs and Adipose Tissue 
 
A major function of miRNAs in AT is to stimulate or inhibit the differentiation of 
adipocytes, and to regulate specific metabolic and endocrine functions. Moreover, 
miRNAs are likely to be involved in communication between fat cells, as well as 
between adipose and other tissues. They also play a major role in maintaining cell 
identity by fine-tuning cell-specific transcriptional networks and have been shown to 
play important roles in both brown and white fat differentiation (Mori et al., 2014).  
The miR-193b-365 cluster of miRNAs and miR-155 participate in brown 
adipogenesis, while miR-143 and miR-103 have been implicated in white adipocyte 
differentiation and insulin resistance. Likewise, miR-196a, which is expressed primarily 
in WAT progenitor cells in response to cold or adrenergic stimulation, can suppress a 
white fat gene to favor brown adipogenesis over white adipogenesis. Moreover, 
several other microRNAs are differentially expressed in various adipose depots and 
altered expression has been reported in individuals with obesity and T2D. Mori and 
colleagues described last year a collection of miRNAs in AT that changed in response 
to obesity, insulin resistance, or cold exposure (Mori et al., 2014). Figure 33 displays 
a summary of changes in miR expression related with obesity and insulin resistance, 
both in humans and rodents. Besides, miRNAs can also be secreted from fat cells into 
the circulation and serve as markers of disturbed AT function. This is the case for miR-
197, miR-23a, miR-509-5p, miR-130a-b, miR-195, miR-27a and miR-320a, whose 
expression appears dysregulated in association with metabolic syndrome (Arner and 
Kulyté, 2015). 
Finally, given their role in regulating transcriptional networks, miRNAs in AT 
might offer tangible targets for treating additional metabolic disorders They appear very 
attractive as therapeutics that can be specifically targeted to AT. 
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Figure 34: Obesity / insulin resistance-related miRNA expression changes in humans 
and in murine models.  
 
miRNAs in red font were differentially expressed in human and murine obesity with arrow 
indicating up- or down regulation. Image from Deiuliis, 2015.
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RESULTS 
Project 1: Investigation of the Mode of Action (MoA) of ABX300 
1. Aim of the project 
 
Compelling data have recently shown the association between LMNA isoforms and 
energy metabolism (Tang et al., 2011; Liu et al., 2012; López-Otín et al., 2013; 
Rochford, 2014). In addition, the idea that lamin A/C may influence obesity-related 
traits was already suggested a few years ago (Hegele et al., 2000; Hegele et al., 2001; 
Wegner et al., 2007). Furthermore, our laboratory published last year pretty conclusive 
data indicating that the different LMNA isoforms played opposite roles on metabolism  
(Lopez-Mejia et al., 2014). This finding led to the proposal that pharmacologically 
modulating this splicing could be a novel and original approach for the treatment of 
obesity. By means of two screening systems, a compound labeled ABX300 was 
selected and tested on mice models of obesity, having an enormous impact on weight 
evolution. We confirmed the influence of the identified molecule on LMNA splicing by 
studying the behavior of splicing reporters in cultured cell lines.  
The acronym labeling this molecule is comprised of the digit three hundred, which 
simply happens to refer to the position of this small compound in the ABIVAX chemical 
library; and the characters ABX, which stand for the name of this enterprise. ABIVAX 
is an emerging science-driven drug discovery company, which develops novel small 
molecule therapeutics. To do so, it focuses on the initial small molecule discovery 
through cell-based screening protocols and on the posterior development of these 
drugs. The first aim of my PhD project in ABIVAX was to investigate the mode of action 
(MoA) of the previously identified molecule, ABX300. In order to determine it, we 
carried out an extensive number of experiments. In collaboration with Ez-Zoubir Amri, 
we performed Microcomputed tomography aiming to identify the specific kinds of 
adipose tissue, if any, mostly affected by our treatment. We further completed the 
mechanistic analysis of the drug by performing indirect calorimetric analysis in concert 
with François Casas, and the help of the Metamus platform held in Montpellier. 
Furthermore, since differences in food intake were attributable to the treatment, we 
verified to which extent they were responsible for the observed phenotype. We also 
conducted a series of transcriptomic approaches to identify splicing events and/or 
microRNAs into which the treatment could have an impact.  
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In association with the Sherbrook University, we checked for favoring or limitation of 
alternative exons inclusion and exclusion. Ultimately, in parallel, we used commercial 
arrays to check for microRNAs modulations (in partnership with Pierre de la Grange), 
allowing us to decipher an apparent mitochondrial “preference” of our drug. 
2. Summary 
 
Screening experiments revealed that ABX300 associated with SRSF1, and thus 
modulated LMNA alternative splicing profile. Since the LMNA gene is known to play 
an important role into white adipose tissue (WAT) homeostasis, the compound was 
thereafter tested in diet induced obesity (DIO) mouse models to further study its mode 
of action (MoA). ABX300 treatment provoked a global reshuffling of WAT, by restoring 
a lean like profile in treated animals. This was evident in sight as well as, both at the 
splicing and the transcriptomic level.  Moreover, we found that ABX300 specifically 
modulated 10 microRNAs, and surprisingly that these importantly targeted 
mitochondria related processes. Hence, oxygen consumption, which mitochondria are 
largely responsible for, was increased after drug administration. These results present 
a new approach to obesity treatment, based on the modulation of LMNA splicing, by 
interacting with serine/arginine-rich splicing factor 1. 
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Abstract  1 
 2 
Alternative Splicing (AS) and/or polyadenylation enable the LMNA gene to 3 
originate distinct protein isoforms that yield opposing effects on energy metabolism 4 
and lifespan.  5 
Two splicing factors, SRSF1 and SRSF6, contribute to the production of these different 6 
isoforms. By pharmacological screening of compounds that potentially modulate 7 
SRSF1 activity and LMNA AS, we identified a small molecule that specifically 8 
interacted with the RS domain of SRSF1. This molecule, ABX300, affected adiposity 9 
of Diet Induced Obese (DIO) mice, leading to a global beneficial restoration of white 10 
adipose tissue (WAT) depots in vivo. Global analysis of alternative splicing in the WAT 11 
from treated and untreated animals showed that ABX300 treatment reversed most of 12 
the AS altered by obesity. Similarly, transcriptomic analysis revealed that WAT from 13 
DIO mice treated with ABX300 had the same profile as that from untreated mice fed 14 
with chow diet. Interestingly, ABX300 treatment largely affected the expression of 15 
microRNA whose target mRNAs were involved in mitochondrial metabolism. 16 
Consistently, in vivo studies showed that mice treated with ABX300 had an increase 17 
in O2 consumption, along with a switch in fuel preference toward lipids, thereby 18 
suggesting a protection against diet induced fat accumulation.  19 
Targeting SRSF1 by ABX300 represents therefore a novel and complementary 20 
approach for the treatment of obesity. 21 
22 
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Introduction 1 
Obesity, the imbalance of income and expenditure of energy, is a rapidly 2 
growing worldwide epidemic (Ng et al., 2014). The establishment of a sedentary 3 
lifestyle combined with excessive caloric intake has made the number of overweight 4 
individuals grow markedly in the last century. Obesity is characterized by increased fat 5 
mass due to energy storage in White Adipose Tissue (WAT) (Cummings and Schwartz, 6 
2003; Frayn et al., 2003). An increase in fat mass can be achieved by an increase in 7 
the size of adipocytes (hypertrophy), or by an expansion of their number (hyperplasia) 8 
(Rosen and MacDougald, 2006). In addition, obesity is associated with a collection of 9 
clinical problems known as the metabolic syndrome: insulin resistance, diabetes, 10 
cardio-vascular disease, dyslipidemia, and fatty liver (Kahn, Buse, Ferrannini, & Stern, 11 
2005; Van Gaal, Mertens, & De Block, 2006). Increased physical activity and better 12 
feeding habits are clearly a requisite to limit or reverse weight excess and its 13 
deleterious metabolic consequences. However, dietary management and exercise are 14 
not usually successful as an intervention, underscoring the need for efficient 15 
medication to treat metabolic disorders (Feige et al., 2008). Integrated metabolic 16 
networks, which are governed at the transcriptional level by transcription factors and 17 
co-regulators, enable the organism to adapt the metabolic state of different organs to 18 
nutrient availability (Spiegelman and Heinrich, 2004; Desvergne et al., 2006; Feige and 19 
Auwerx, 2007). The limited success to date in the pharmacotherapy of obesity likely 20 
reflects the existence of multiple redundant and compensatory pathways in energy 21 
homeostasis (Guan et al., 2010). Intense drug discovery efforts in the metabolic field 22 
highlight the need for novel mechanisms for the treatment of obesity. Compelling data 23 
suggest that targeting cellular bioenergetics may provide an exciting new therapeutic 24 
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approach for the treatment or prevention of this disorder (Harper et al., 2008; Tseng et 1 
al., 2010; Locke et al., 2015). 2 
We recently reported opposed Energy Expenditure (EE) and lifespan on mice, 3 
depending on LMNA isoforms (Lopez-Mejia et al., 2014). Existing literature had 4 
oftentimes designated the importance of the merge between metabolism and lamins, 5 
nuclear proteins encoded by the LMNA gene  (Liu et al., 2012;  Tang et al., 2011; Lloyd 6 
et al., 2002; Rochford, 2014). Alternative RNA processing of LMNA pre-mRNA 7 
produces three  nuclear protein isoforms; that is, lamin A, progerin, and lamin C. 8 
Mutations in lamin A/C can cause several syndromes collectively described as 9 
laminopathies which include several lipodystrophies, but also progeroid syndromes 10 
(Worman and Bonne, 2007). The lipodystrophy mutations strongly support the idea 11 
that lamins can have cell-type-specific functions (Wilson et al., 2001).  A de novo silent 12 
mutation in LMNA (c.1824C>T; p.Gly608Gly) results in aberrant Alternative Splicing 13 
(AS) of the Lamin-A isoform. This alteration, will give rise to a truncated isoform of the 14 
protein, termed progerin (Navarro et al., 2006). The importance of two serine-arginine 15 
(SR)-rich proteins, SRSF1 and SRSF6, for the regulation of progerin production was 16 
previously described by our laboratory (Lopez-Mejia et al., 2011). Exacerbated 17 
accumulation of progerin is the predominant cause of Hutchinson-Gilford Progeria 18 
Syndrome (HGPS), a severe form of early-onset premature aging associated with 19 
lipodystrophy (Eriksson et al., 2003; De Sandre-Giovannoli et al., 2003). In HGPS, loss 20 
of adipose tissue correlates with adipokine dysregulation, insulin resistance, and 21 
atherosclerosis, suggesting a critical role of adipose tissue function in controlling whole 22 
body energy metabolism, age-related pathologies, and longevity (Arai et al., 2011). 23 
The lamin isoforms, by changing the nuclear envelope architecture, may also 24 
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contribute to changes in the expression of genes involved in mitonuclear imbalance 1 
controlling longevity (Houtkooper et al., 2013). 2 
Our previous work showed how the RNA processing and thus the production of 3 
the distinct LMNA isoforms had physiopathological outcomes; affecting mitochondrial 4 
gene expression and contributing to metabolic adaptations of the adipose tissue in 5 
mammals.  Given the described antagonistic functions of the LMNA isoforms on EE, 6 
we designed two screening systems based on SFSRF1 localization and the LMNA AS, 7 
for the identification of potential candidates to treat metabolic disorders, such as 8 
obesity. 9 
In this study, we report the endorsement of an in vitro luciferase reporter assay, 10 
based on the structure of the LMNA gene.  Our lead compound, ABX300, was shown 11 
to prevent weight gain in animals under a high fat diet (HFD) and to induce weight loss 12 
on Diet Induced Obese (DIO) mice. We found that the decrease of body weight in the 13 
ABX300 treated animals was accompanied by a reduction in the food intake. However, 14 
a pair-feeding (PF) experiment determined that this phenomenon was not sufficient to 15 
explain the observed phenotype. Furthermore, the size of lipid droplets, as well as the 16 
oxygen consumption, the respiration exchange ratio (RER), and diverse mitochondrial 17 
features in conjunction with microRNA targeting mitochondria, were altered in ABX300 18 
treated mice. 19 
Our data reveal for the first time that drug screening for pharmacological 20 
modulators of LMNA AS could be a valid strategy to approach obesity therapy. We 21 
strongly believe that this unexplored/novel/original approach, based on the modulation 22 
of splicing, is of great potential, not only to treat obesity but a wide range of diseases 23 
(Soret et al., 2005). 24 
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Results 1 
Identification of ABX300 a SRSF1 partner that modulates Lmna splicing 2 
More than 6,000 molecules were screened for their ability to inhibit the kinase 3 
activity of topo I and thereby the specific phosphorylation of SR proteins. This approach 4 
had led to the identification one indole derivative (IDC16) targeting specifically the SR 5 
protein SRSF1, and inhibiting HIV multiplication in vitro (Bakkour et al., 2007). Based 6 
on IDC16 structure, a new library was developed by ABIVAX to encounter the toxic 7 
effect of this molecule. In the first place, we designed a screening based on the 8 
localization of the SRSF1 protein. We used HeLa cells expressing the GFP protein in 9 
fusion with endogenous SRSF1 protein and selected the molecules that did not disturb 10 
GFP distribution (Figure 1A). The selected molecules were farther used for a next step 11 
of screening based on the AS of the LMNA gene known to depend on SRSF1 protein 12 
(Lopez-Mejia et al., 2011). More precisely, we generated a HEK-293FRT reporter cell 13 
line (HEK-293FRT-LMNA-luc) that stably expressed luciferase fused with a portion of 14 
LMNA cDNA, under the control of the CMV promoter (Figure 1B). This cell line 15 
contained the main mutation responsible for HGPS, (c.1824C>T; p.Gly608Gly), and 16 
thus was used as reporter for the distinct use of the LMNA exon 11 5’ splice sites 17 
(5’SS), which are, as previously mentioned, under the control of SRSF1. Interestingly 18 
among 900 compounds (Figure S1A and S1B), the ones belonging to family number 19 
8 seemed to be very active in our test (Figure 1C). In this family, one lead compound 20 
was identified, ABX300. It increased luminescence in a dose-dependent manner, 21 
reaching values of 4.95 RLU/mg protein at 4.28 μM (data not shown). Notably, cell 22 
viability was not troubled under ABX300 treatment (data not shown). Moreover, 23 
following a classical fluorimetric titration protocol, we demonstrated a direct interaction 24 
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between SRSF1 and ABX300 with a stoichiometry of 1:1 (Figure 1D). To further 1 
characterize this result we generated a SRSF1 protein without the RS domain 2 
(SRSF1ΔRS), and carried out the same kind of experiments. As expected, we had a 3 
different profile of fluorescence spectra, which revealed a lack of interaction in these 4 
conditions. Besides, we used hnRNPK as a negative control (Figure S1C). This led us 5 
to conclude that ABX300 interacts with SRSF1 through its RS domain. 6 
ABX300 modulates weight evolution under High Fat Diet 7 
LMNA isoforms have been shown to play important opposite roles in the 8 
regulation of metabolic adaptations of adipose tissue in mammals. The luciferase 9 
reporting system described in Fig.1B, led us to the selection of ABX300 by revealing 10 
the distinct use of the LMNA 5’SS. To further study the effects of this compound in 11 
energy metabolism, we used a diet-induced obesity (DIO) mouse model, which we 12 
treated subsequently or simultaneously to High Fat Diet (HFD) administration. Average 13 
treatment length was one month, and the chosen dose, 50 mg/Kg. This was the highest 14 
non-toxic dosage according to the “Maximal Tolerated Dose Test” that we carried out 15 
(Figure S2A). The adequacy of the DIO animal model for mimicking human obesity 16 
had been largely recognized by the scientific community (Nilsson et al., 2012). Our 17 
treatment remarkably influenced weight evolution. In a curative context, ABX300 18 
enhanced weight loss (Figure 2A, left panel), reaching a plateau (Figure S2B left 19 
panel). In addition, ABX300 prevented weight gain in the same mouse strain, and this 20 
in a constant manner (Figure 2B, left panel). Indeed, a noticeable decrease in food 21 
intake was revealed in parallel to ABX300 administration under HFD conditions, shortly 22 
after the first administrations (Figures 2A and 2B right panels). Cumulative food intake 23 
for the whole period is shown in the bottom part of these panels, where significant 24 
differences are displayed accompanying weight transformation. Nevertheless, both 25 
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effects on body mass were steady and time persistent (Figure S2B). To assess 1 
whether the drug required the presence of fat to take action, and check for its efficiency 2 
under standard diet conditions, we prosecuted our treatment within chow diet. 3 
Monitoring of mice weight and food intake showed no differences between groups 4 
(Figure 2C), for any of the mentioned parameters. Hence, the weight loss for HFD 5 
ABX300 treated mice could result from the ingest differences. To determine to which 6 
extent this phenomenon contributed to weight loss in these mice, we pair-fed animals 7 
to restrict their daily food intake to that of the ABX300 DIO treated mice. Each day, we 8 
restricted pair-fed animals to the amount of calories consumed by ABX300 DIO treated 9 
mice on the previous day. Concurrently, we did not pair-fed untreated and ABX300 10 
DIO treated mice and instead gave these mice ad libitum access to food. 11 
Consequently, untreated mice gained weight, ABX300 DIO treated mice significantly 12 
lost weight, and the body weights of the pair-fed mice were significantly different from 13 
both of them, throughout the 30 days pair-feeding period (Figure 2D). In conclusion, 14 
these data indicate that ABX300 is an anorexigenic drug, affecting weight in a fat and 15 
food-dependent manner, but that hypophagia alone is not sufficient to explain the 16 
observed phenotype. 17 
ABX300 decreases adiposity in DIO mice 18 
We have shown in our previous results that HFD ABX300 treated mice had a 19 
significant reduction in weight. To determine which tissues were affected, animals were 20 
sacrificed and their organs were weighted. Results showed significantly reduced WAT 21 
size in ABX300 DIO treated mice when compared to untreated mice after one month 22 
of drug administration. Adipose mass was five times lower in these individuals while 23 
weight of all other organs did not vary (Figure 3A). Moreover, to have a more 24 
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comprehensive view of the fat distribution in mice, we performed a computed 1 
tomography. This technique allows to differentiate the different body parts, producing 2 
detailed three-dimensional images of soft tissue and bone structure. Our analysis 3 
revealed that ABX300 treated DIO mice were leaner and had a reduced adiposity, both 4 
in visceral and subcutaneous WAT, without marked changes on the lean mass (Figure 5 
3B), confirming the results shown in Figure 3A. Areas of low density (WAT) are 6 
represented in purple, medium density areas (organs) are shown in orange, and areas 7 
of high density (bones) are shown in white. The total fat volumes were calculated for 8 
each group, presenting a 5.5 fold decrease for ABX300 treated DIO mice, resembling 9 
animals under chow diet (Figure 3C). 10 
Using Haematoxylin-Eosin staining of representative sections of WAT, Brown Adipose 11 
Tissue (BAT), Liver and Muscle, we observed that ABX300 had a global effect on fat. 12 
Indeed, the treatment visibly reduced the strong lipid accumulation induced by HFD in 13 
WAT (figure 3D), liver and BAT (Figure S3A). These results were confirmed by the 14 
surface size quantification of adipocytes. In WAT 80% of adipocytes in treated mice 15 
were cells of small size (<2000μm²) whereas in untreated mice the WAT was 16 
composed by heterogeneous cell sizes. Interestingly, we didn’t find very large fat cells 17 
(> 10000μm²) in treated mice while we found a proportion of 10% in untreated (Figure 18 
3E). All these results suggested that ABX300 induced delipidation by a breakdown of 19 
cellular lipid stores to provide endogenous free fatty acids. To verify if enhanced 20 
lipolysis was involved in the observed effect of ABX300, we assessed glycerol, non-21 
esterified fatty acids (NEFA) and triglycerides (TGs), in plasma and serum from 22 
ABX300 treated and untreated animals. None of them differed between groups (Figure 23 
S3B) dismissing the idea of ABX300 inducing lipolysis. 24 
 25 
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ABX300 does not modulate global splicing 1 
To analyze the possible effect of ABX300 on AS we designed a large-scale 2 
screening strategy and compared a pool of RNA from treated and DIO untreated mice. 3 
Among a library of 1.330 alternatively spliced events (ASEs) we selected 537 high-4 
quality PCRs from across the alternative exons. We used these high-quality PCRs to 5 
study the ASEs expressed in WAT from ABX300-treated mice compared to untreated 6 
obese mice (535 events). We farther selected the ones with the most important 7 
variations between the two conditions (Figure S4). The portrayed Percent Splicing 8 
Index (PSI), provides useful information about the inclusion level of each exon. This 9 
measure was computed according to the formula shown in Figure 4, where it is also 10 
depicted a heat map containing the 12 ASEs into which intragroup variations fall in a 11 
homogeneous manner. To confirm these results, we performed manual end-point 12 
PCRs. In the case of Myo9e01, Myo9b02 and Pdlim5 we observed strong PSI 13 
changes, corroborating our first analysis. The 9 remaining ASEs seemed to be less 14 
affected or not at all (data not shown). Moreover, we analyzed ASEs of non-obese 15 
mice and we found that their splicing status importantly correlated with the modulations 16 
induced by ABX300 treatment (data not shown). Altogether, our data suggests that 17 
ABX300 effect on splicing is rather specific and that the treatment provokes a reversal 18 
of most of the events altered by HFD and obesity. 19 
ABX300 induces WAT restoration in DIO mice  20 
To understand how adipose tissue could be affected by the treatment, we 21 
designed an experiment into which the expression of 84 key genes involved in the 22 
differentiation and maintenance of mature adipocytes was checked. In the first 23 
comparison, we showed that 22/84 genes (26, 2 %) were significantly modulated in 24 
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treated obese mice (Figure 5A). Further, we compared the adipogenesis profile in lean 1 
mice versus obese mice and found that 8/84 genes (9, 5 %) were robustly modulated 2 
(Figure 5B). A last comparison between lean mice and treated obese mice revealed 3 
that only Shh (Sonic Hedgehog) and Gata3 (Trans-acting T-cell-specific transcription 4 
factor GATA-3) were modulated. Shh is thought to be a repressor of stem cell 5 
commitment through adipocyte lineage (Suh et al., 2006; Huang et al., 2009; James et 6 
al., 2010) (Figure 5C). A large number of genes that were modulated in the treated 7 
mice, were due to a return to a normal state of adipose tissue. This reinforced the idea 8 
that ABX300 would induce a way back to a normal healthy condition of adipose tissue. 9 
ABX300 regulates microRNA notably targeting mitochondria 10 
A biological role of alternative splicing in the regulation of miRNA biogenesis has 11 
been recently demonstrated, together with a competitive interaction between the 12 
microprocessor complex and the splicing machinery (Melamed et al., 2013). 13 
MicroRNAs (miRNAs) constitute a growing class of non-coding regulatory RNAs that 14 
primarily regulate gene expression by reducing mRNA stability and/or repressing 15 
translation. Several miRNAs exhibit tissue-specific expression, and those present in 16 
WAT are known to have crucial implications for understanding adipose tissue, 17 
connecting regulatory networks underlying adipogenesis and adipose dysfunction in 18 
obesity. In order to outright the results shown in Figure 4, and to evaluate the potential 19 
modulation of non-coding RNAs by our treatment, we determined the population of 20 
miRNAs in visceral WAT from HFD/CD Untreated and ABX300 Treated DIO mice using 21 
Affymetrix microarrays. We examined 1.111 murine miRNAs in WAT and found a set 22 
of these small RNAs fluctuating in between untreated and treated animals (Fold-23 
change≥1.5; P-value ≤0.05). More precisely, 52 miRNAs were differentially expressed 24 
for these two conditions. The heat map in Figure 6A shows the 26 elevated and the 25 
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26 down regulated miRNAs when comparing HFD Untreated to HFD Treated animals 1 
(see also Figure S5A). Similarly, Figures 6B and S5B show the shifts of the 113 2 
microRNAs (54 up-59 down regulated) varying between HFD and CD Untreated mice. 3 
Among the above mentioned variations, 42 miRNAs overlapped for the two 4 
comparisons (Figure 6C), suggesting that the treatment could restore the normal 5 
expression levels of these microRNAs, supporting observations from Figures 4 and 5. 6 
Importantly, only one microRNA was found to be significantly altered in the absence of 7 
weight loss, when the drug was administered under standard diet conditions (data not 8 
shown). Interestingly, we noticed that several miRNAs known to be up-regulated 9 
during obesity (Ortega et al., 2010; Arner et al., 2012; Chen et al., 2014) tended to be 10 
down regulated in the treated animals, and vice versa. For instance, miR-221, miR-11 
222, miR-342-3p, and miR-146b, were induced during hyper-caloric diet, and down 12 
regulated with the treatment. Conversely, miR-30c, miR-92a, miR-193b and miR-378 13 
were decreased during obesity but were upregulated in WAT from ABX300 treated 14 
mice. To test our observations more rigorously, and focus exclusively of the 15 
microRNAs that were modulated by ABX300, we centered ourselves on a set of 10 16 
miRNAs whose expression varied exclusively in response to the drug. We then 17 
compared the list of miRNAs enriched in the ABX300 DIO Treated animals, with 18 
predicted targets of miR retrieved from the miRDB database (http://mirdb.org/ miRDB; 19 
see material and methods section). Notably, a substantial number of the ABX300 20 
modulated miR had predicted miR targets addressing mitochondria (score target ≥ 80). 21 
To assay the statistical significance of these regulations, we performed a similar 22 
calculation for 1.912 additional murine miRNAs. Only 315 of them (16.47%) were 23 
predicted to target these organelles (Mouse MitoCarta), indicating that the identified 24 
ABX300-modulated miRNAs were likely mitochondrial-enriched following treatment. 25 
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Amid these eight, miR-29a has been predicted to target Slc16a1 (Figure S5D), which 1 
has been uncovered to play a critical role in the regulation of energy balance when 2 
animals are exposed to an obesogenic diet (Lengacher et al., 2013). Given that each 3 
miRNA regulates, on average, about 200 target genes, these ABX300 specific 4 
modulations of a mitochondria related miR population, could most likely have a 5 
widespread impact on protein output and partially but importantly account for the 6 
observed phenotype. We conclude that ABX300 treatment significantly influenced the 7 
modulation of relevant endogenous miRNA mitochondrial targets. 8 
ABX300 increases oxygen consumption 9 
Results on miRNA analysis showed that ABX300 modulated a series of miRNA 10 
that are regulators of several genes involved in the functioning of mitochondria. To 11 
continue the exploration we decided to study energy homeostasis more in detail by 12 
assessing the respiration at the level of the whole animal. ABX300 treated and 13 
untreated mice were placed in metabolic cages. Oxygen consumption (VO!) and CO! 14 
production (VCO!) were monitored during a 12h dark/ 12h light cycle using the Oxymax 15 
Lab Animal Monitoring System (Figure 7A). 16 
HFD ABX300 treated mice showed no differences in VO! and VCO! over a 17 
period of 24h (Figure 7B and Figure 7C right panels). However, if we focused on the 18 
light period, that is on the eight hours following ABX300 administration, treated DIO 19 
mice showed a marked tendency to display a higher O! consumption and CO! 20 
production compared to untreated DIO mice (Figure 7B and Figure 7C left panels). 21 
These eight hours corresponded to the Light period, when mice are normally in a 22 
resting state, characterized by a decrease in metabolism, at rest and their metabolism 23 
decreases. These outcomes seem to indicate an increase of the basal metabolic rate 24 
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of ABX300 treated DIO mice succeeding drug administration. The Respiratory 1 
Exchange Ratio (RER) was calculated by the ratio VCO!/VO!. Likewise, ABX300 2 
treated DIO mice demonstrated a RER close to 0.7 which indicates that fatty acids are 3 
mainly metabolized source to provide energy. In contrast, untreated animals presented 4 
a RER ratio close to 0.8, showing a mixed consumption of fat and carbohydrates 5 
(Figure 7D right panel). All these results indicate that ABX300 drives higher metabolic 6 
rates leading to a rapid metabolization of lipids, which is likely carried out by the 7 
mitochondrial β-oxidation. 8 
Material & Methods  9 
Cell culture 10 
-  HeLa cells 11 
SRSF1-GFP HeLa cells (gift from Edouard Bertrand’s group) were maintained in 12 
Dulbecco’s Modified Eagle Medium (DMEM, Invitrogen) containing 10% heat-13 
inactivated Fetal Bovine Serum (FBS, PAA), 2 mM L-Glutamine, and 1% penicillin and 14 
streptomycin (all from ThermoFisher).  15 
-  HEK-293 FRT-LMNA-Luc cells (luminescence assay) 16 
HEK-293 FRT-LMNA-Luc cells were seeded 48h prior to luminescence lecture at 17 
10,000 cells per well. Then culture medium was removed, and cells were washed with 18 
sterile DPBS once. Cells were lysed using Passive Lysis Buffer 1X (E1941, Promega, 19 
Madison, WI, United States) directly added to cells. Half of the cell lysate was then 20 
mixed with Luciferase Assay Reagent (E1501, Promega, Madison, WI, United States) 21 
and luciferase activity was measured within 1 second per well. The other half was used 22 
for protein normalization in the well (Pierce™ 660nm Protein Assay Reagent). 23 
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Immunofluorescence analysis 1 
Cells were fixed in 4% (w/v) paraformaldehyde for 20 min. The nuclei were stained 2 
with Hoechst 33342 (SIGMA). Cells were washed in PBS and water, mounted with 3 
DAKO mounting medium, and observed under the fluorescence microscope. Cell 4 
imaging was performed with a confocal Leica SP5-SMD. Images were processed using 5 
FiJi software. 6 
Fluorimetric titrations 7 
The fluorimetric titrations were performed at a constant dye concentration (ABX300) 8 
(1.2 µM) with increasing concentrations of SRSF1 in 0.6 mM guanidine buffer (up to 9 
120 µM). Fluorescence spectra were recorded on a FluoroMax-3 (Jobin Yvon), at room 10 
temperature. Measurements were performed with solutions of OD<0.1 to avoid 11 
reabsorption of the emitted light, and data were corrected with a blank and from the 12 
variations of the detector with the emitted wavelength. The binding curves were 13 
obtained by plotting the fluorescence enhancement F/F0 (F= integrated fluorescence 14 
area of the complex and F0 = integrated fluorescence area of the free dye) versus the 15 
concentration in SRSF1. 16 
Animals & Ethics Statement 17 
All animal procedures were executed according to European directive 2010/63/UE. 18 
Mice were maintained under pathogen-free conditions in our animal facility (E34-172-19 
16) and experiments were conducted by authorized personnel. The study plan was 20 
approved by the Institutional Review Board at the Animal Facility of the Institut de 21 
Génétique Moléculaire de Montpellier and the Regional Ethics Committee for Animal 22 
Experimentation of Languedoc-Roussillon (agreement n° CEEA-LR-1061). 23 
 24 
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Synchronized Pair-feeding Test 1 
DIO mice were divided into three groups and housed by experimental class. HFD 2 
untreated and ABX300 treated animals had ad libitum access to food, whereas in an 3 
Untreated Pair-Fed (PF) group, food was calorie restricted. These animals received 4 
the same amount of aliment consumed by the ABX300 treated group over the 5 
preceding 24 h. Body weight was registered twice a week. 6 
Organs Collection 7 
After one month of treatment, mice were anesthetized by intraperitoneal injection 8 
(Xylazine/Ketamine/Rompun combination) and euthanized by cervical dislocation. 9 
Organs were collected, rapidly weighed and immediately snap-frozen in liquid nitrogen 10 
or fixed in 4% Paraformaldehyde. 11 
Histological Analysis 12 
Organs fixed in 4% Paraformaldehyde were dehydrated, embedded in paraffin and 13 
stained with Haematoxylin/Eosin for histological analysis. Slides were scanned with 14 
the NanoZoomer equipment  (HAMAMATSU). Virtual slides were analyzed with the 15 
NDP.view software and Image J complemented with MRI Adipocytes Tools to measure 16 
the size of white adipose tissue cells. 17 
Micro-computed Tomography 18 
The adipose tissue quantification was performed as previously described with the 19 
similar parameters (Lopez-Mejia et al., 2014). 20 
Total RNA extraction 21 
For total RNA, extraction 30mg of WAT were grinded in liquid nitrogen and powder was 22 
dissolved in TRIreagent (SIGMA) according to the manufacturer’s protocol, followed by a 23 
DNAse digestion and a Phenol-Chloroform-Isoamyl alcohol purification. RNA quantity and 24 
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integrity were controlled by Nanodrop ND-1000 (Thermoscientific) and Agilent Bioanalyzer 1 
(Agilent Technologies) respectively. 2 
miRNAarray experiments 3 
Small non-coding RNA transcripts were assessed throughout the Affymetrix 4 
technology, where RNAs were hybridized to the Affymetrix miRNA v3.0 arrays 5 
(GenoSplice- Evry- France). 6 
Reverse-transcription and PCR   7 
1µg of RNA samples were reverse-transcripted using First-strand cDNA synthesis kit 8 
(GE Healthcare) according to the manufacturer’s instructions. Gene expression was 9 
assessed by PCR using Platinum Taq DNA Polymerase (PCR buffer 1x, MgCl! 1,5 10 
mM, primers forward and reverse 0,6 µM of each, dNTP 0,25 mM of each, Platinum 11 
Taq DNA Polymerase 2U/rxn, 1µl of cDNA and add nuclease-free water to 50 µl final 12 
volume (# 10966-034 Life Technologies). PCR was performed with Roche 13 
ThermoCycler (2 min 94°C, 35 cycles of 30 sec 94°C/30 sec 55°C/1min 72°C, 2 min 14 
72°C). Products of PCR were analyzed with Elmer Perkin Caliper. 15 
Metabolic Chamber Experiments 16 
DIO mice were switched to ad libitum CD one week before the metabolic chamber 17 
experiments. Single-housed animals were accustomed for 24 hours prior to recording. 18 
Immediately before the run, they were weighed and treated. Oxygen consumption 19 
(VO!) and Carbon dioxide production (VCO!) were monitored every “two” minutes over 20 
a 24 hours period using a Comprehensive Lab Animal Monitoring System (Columbus 21 
Instruments, Columbus, OH) thermostated at 22°C. The respiratory exchange ratio 22 
(RER) corresponds to the VCO!/VO! ratio.  23 
 24 
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Statistical analysis 1 
All results were expressed as the mean +/− standard error mean (S.E.M). Significance 2 
of differences was determined with the Student t test or Mann & Whitney test with 3 
significance at * P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. 4 
Supplemental methods 5 
Animal Feeding & Treatment 6 
Six-week old male mice C57BL/6J were purchased from Charles River Laboratory 7 
(69592 L'Arbresle) and housed under a normal light cycle (12h light-dark) and a 8 
constant temperature of 22°C, with free access to food and water. Experiments began 9 
after one week of acclimatization to our installations under CD conditions. At this point, 10 
either mice continued to receive CD (from Safe, 3% energy from fat), either they 11 
switched to a High-Fat Diet (HFD from Research Diet 58Y1, 60% energy from fat). Two 12 
treatment protocols were designed for the HFD condition. For the curative schema, 13 
mice were fed for up to ten weeks to generate diet-induced obesity (DIO) mice and 14 
were treated after. For the preventive schema the treatment started along with the diet. 15 
For both nourishment conditions, mice were divided into 2 groups of treatment, half of 16 
them received the vehicle (Labrafil M1944CS – 5% DMSO) and the other half received 17 
the active compound ABX300 at 50 mg/kg. The chose route was intragastric, to 18 
accurately manage the delivered dose. Mice were weighed weekly and food intake 19 
was measured four times per week. 20 
Target Prediction Analysis 21 
Putative miRNA targets were identified using the mirDB online database 22 
(http://mirdb.org/miRDB/), which is a database for miRNA target prediction and 23 
functional annotations. Target prediction is performed by an algorithm (MirTarget) 24 
which analyses all the NCBI RefSeq 3'-UTR in order to predict both, conserved and 25 
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non-conserved target's motifs. A target prediction score is also computed in order 1 
inform the user about the confidence he may have on the prediction. The range is 2 
comprised between 50 and 100, but below 80 cautiousness is recommended. As the 3 
microarray analysis was based on a previous version of mirBase 4 
(http://www.mirbase.org/) (v.17), the selected miRNA names were updated on the 5 
actual mirBase version (v.21). The miRNA were then applied against the mirDB 6 
database in order to retrieve all the predicted targets whose prediction score was ≥ 80. 7 
Using the MitoCarta database (https://www.broadinstitute.org/pubs/MitoCarta/), the 8 
selected target's genes were then filtered in order to retrieve exclusively specific 9 
mitochondrial’s target genes. The two heat maps presented in the Figures 6 A and B 10 
were generated by using a custom R script (https://cran.r-project.org/) containing 11 
gplots (https://cran.r-project.org/web/packages/gplots/gplots.pdf). The data were 12 
clustered using the Pearson correlation co-efficient method and the Heatmap2 function 13 
(http://www.inside-r.org/packages/cran/gplots/docs/heatmap.2). 14 
Serum and Plasma Biochemistry 15 
For blood lipid content analysis (Figure S3B), mice were fasted 5h after treatment and 16 
few microliters of blood were removed at the tail vein, every week, with anticoagulant 17 
for serum or without anticoagulant for plasma. Blood was centrifuged at 4°C, 8000 rpm 18 
for 10 minutes to analyze plasma glycerol (Free Glycerol Reagent- F6428 SIGMA, 19 
Glycerol Standard solution – G7793 SIGMA), serum triglycerides (Triglycerides FS – 20 
157609910021 DiaSys Diagnostic Systems GmbH) and serum non-esterified fatty 21 
acids (NEFA-HR(2) R1 Set – 434-91795 Wako Chemicals GmbH, NEFA-HR(2) R2 Set 22 
- 434-91995 Wako Chemicals GmbH, NEFA Standard – 270-77000 Wako Chemicals 23 
GmbH) .  24 
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Discussion 1 
In this study we developed a screening assay based on the AS regulation of the 2 
LMNA gene, and we used this assay to identify a particularly interesting compound, 3 
ABX300. This molecule was capable of enhancing weight loss in DIO animals. Our 4 
results endorse cell-based screening for modulators of LMNA AS, as a promising 5 
approach to the discovery of new metabolic drugs; henceforth an important goal of 6 
metabolic research.  7 
Most drug discovery efforts in the metabolic field have focused elsewhere. 8 
Examples are peptide targets or monoamine and cannabinoid targets (see Kennett 9 
and Clifton, 2010; Powell et al., 2011; Jackson et al., 2015 for more details). 10 
Nevertheless previous studies have already supported the relevance of AS isoforms 11 
for the regulation of metabolism  (Goodson et al., 2011; Huot et al., 2012; Ruas et al., 12 
2012; Li et al., 2014). It is important to note that AS increases the amount of functionally 13 
different protein isoforms which lead in some cases to metabolic diseases (Kaminska 14 
and Pihlajamäki, 2013). Therefore, understanding the underlying molecular 15 
mechanisms of AS may provide opportunities for new diagnostic approaches. 16 
Remarkably, compelling data have recently shown the association between LMNA 17 
isoforms and energy metabolism (Tang et al., 2011; Liu et al., 2012; López-Otín et al., 18 
2013; Rochford, 2014, Lopez-Mejia et al., 2014). In addition, the idea that lamin A/C 19 
may influence obesity-related traits was already suggested a few years ago (Hegele 20 
et al., 2000; Hegele et al., 2001; Wegner et al., 2007). These studies made LMNA a 21 
positional and biological candidate gene in the pathogenesis of type 2 diabetes, 22 
obesity, and quantitative traits of growth and metabolism. LMNA was highlighted as a 23 
collaborator in these metabolic phenotypes, following observations of altered lamin A-24 
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to-C mRNA expression ratio, which correlated with a pleiotropic impact on lipid 1 
metabolism (Aebi et al., 1986), and affected signaling cascades in adipose cells (Lin 2 
and Worman, 1993). Theoretically, changes in mRNA stability or AS favoring one lamin 3 
mRNA may cause relative differences in lamin A/C expression. In the present study, 4 
we emphasize the idea that influencing LMNA isoforms might be beneficial in obesity. 5 
Specifically, we show here that ABX300 interacts with SRSF1, and it is tempting to 6 
hypothesize that this interplay affects LMNA splicing favoring Lamin-A production. 7 
Moreover, not shown data reveal a slight increase in the expression of Lamin-A after 8 
ABX300 treatment and this specifically in several metabolic organs. This result 9 
supports the notion of a role for lamin proteins in metabolism, complementary to their 10 
structural functions (Kumaran et al., 2002; Spann et al., 2002; López-Otín et al., 2013). 11 
For concretizing our data, it would be of great interest to test ABX300 in murine models 12 
deficient for A-type lamins (Fong et al., 2006; Davies et al., 2010; Coffinier et al., 2010). 13 
We would expect a decrease of its efficiency, or even an absence of efficacy. 14 
Since we are promoting LMNA AS modulation as an attractive mechanism of 15 
anti-obesity therapies, it was necessary to demonstrate that the effect of ABX300 did 16 
not have a global effect on the AS of endogenous genes. While analyzing AS events 17 
in visceral WAT of treated animals, only a few of them were found to be altered by the 18 
molecule. Even more to our advantage, these changes pointed to a return to normality, 19 
because AS in ABX300 treated mice revisited the profile of lean animals (Figure 4D). 20 
Perhaps, the most intriguing concept opened by the results conferred here is that small 21 
molecules targeting the core splicing machinery, display tiny effects on different genes 22 
and alternative SS (Figure 4E). Understanding the molecular basis for these 23 
differential effects may pave the way towards the rational design of compounds that 24 
can modulate the versatile effects of SS selection on gene expression (Bonnal et al., 25 
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2012). Further studies using RNA-sequencing and global analysis of transcript variants 1 
and splicing regulators would be of great utility for exploring the association of AS with 2 
metabolic alterations in obesity. 3 
AS has also been described to affect microRNA biogenesis and regulation 4 
(Passetti et al., 2009). Withal it is conceivable that splicing regulation in vivo represents 5 
a system-wide response to the composition of miRNAs (Fu and Ares, 2014). 6 
Nevertheless, how the impact on gene regulation by miRNAs will affect drug 7 
metabolism remains unknown (Kwan et al., 2008). In recent years, there has been a 8 
rapidly growing interest in the role of miRNAs in fat cell development and obesity. 9 
Understanding their role in the proliferation and differentiation of adipocytes during fat 10 
cell development may provide new therapeutic targets for anti-obesity drugs and early 11 
biomarkers for clinical diagnosis ((Heneghan et al., 2010 A. McGregor and S. Choi, 12 
2011). Moreover, miRNAs have been shown to play important roles in both brown and 13 
white fat differentiation (Jordan et al., 2011; Trajkovski et al., 2011; Sun et al., 2011; 14 
Trajkovski et al., 2012; Yin et al., 2013; Mori et al., 2014) and in maintaining cell identity 15 
by fine-tuning cell-specific transcriptional networks (Christodoulou et al., 2010; Ebert 16 
and Sharp, 2012). In response to obesity, insulin resistance, or cold exposure, miRNAs 17 
have been delineated to change in adipose tissue (Xie et al., 2009; Mori et al., 2012). 18 
This is consistent with our results indicating a modulation of ABX300 of mitochondrial 19 
microRNAs (Figure 5), and seems to correlate with the observed phenotype of treated 20 
animals. 21 
Numerous are the proposals to create new therapies for obesity targeting 22 
mitochondrial dynamics and energy homeostasis. Screening of chemical libraries, as 23 
well as collections of known drugs and drug-like compounds, to determine if synthetic 24 
chemicals can activate BAT, and thus increase EE, concern among others PRDM16 25 
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(Seale, 2010) PGC1α (Vaughan et al., 2014), UCP1 (Tomás et al., 2004), and AMPK 1 
(Cool et al., 2006) . Furthermore, we have explored the browning mechanism as 2 
another possible avenue for ABX300 to reduce fat mass, but this does not seem to be 3 
the launched mechanism (data not shown). Brown and white adipocyte identity is 4 
defined during development but can be modified by a myriad of complex events 5 
including genetic factors, epigenetic factors, hormonal factors, and other 6 
environmental challenges that might occur during adipocyte differentiation (Gesta et 7 
al., 2007; Seale et al., 2008; Schulz et al., 2013). Experiments carried out with 3T3-L1 8 
and BAT cellular models did not allow us to confirm any robust effect of the molecule 9 
on the differentiation process (data not shown). 10 
Here, we provide evidence that EE and metabolic homeostasis is markedly 11 
influenced by ABX300. The drug increases basal metabolic rate during the light period 12 
(Figure 6). Besides its influence on EE, ABX300 seemed to act to control feeding, and 13 
while based on the literature we do believe that our data in vivo and biochemically are 14 
related to mitochondrial activity, we could not completely exclude the possibility that at 15 
least part of the responses observed might be related to other functions, such as its 16 
anorexigenic action. However a pair-feeding experiment demonstrated that reduced 17 
food intake alone was not sufficient to explain the observed phenotype (Figure 2D). 18 
The involvement of ABX300 in the regulation of food intake could indicate that it was 19 
exclusively acting like an appetite suppressant. ABX300, is capable of crossing the 20 
blood brain barrier (data not shown). Consequently, it could potentially act on the 21 
centers controlling hunger (Ahima and Antwi, 2008), a fact which usually relates to 22 
toxicity. Nevertheless, ABX300 selectivity (weight loss exclusively under HDF 23 
conditions) (Figure 2), pointed to a positive safety profile, and made us enthusiastic 24 
about the possibility of developing ABX300 for therapeutic purposes.  We hypothesize 25 
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that action of ABX300 is only relevant in the presence of an hyperlipidic regime, this 1 
particularity has been already been observed for other compounds (Tang et al., 2011; 2 
Ortega-Molina et al., 2012). Unfortunately, despite these facts and ABX300 efficacy, 3 
the development and clinical use of this drug is limited by some other adverse effects. 4 
In this regard, small molecules are known to be disadvantaged by the need to interact 5 
with the often more conserved active site of a target. This exquisite specificity is the 6 
basis for the existence of non-mechanistic (or ‘off-target’) toxicity, a major 7 
disadvantage of small-molecule drugs (Hughes et al., 2011). 8 
In summary, we showed that ABX300 induces weight maintenance or loss in 9 
HFD fed animals through SRSF1 interaction, which increases oxygen consumption, 10 
upregulates mitochondrial related miRNAs, and switches adipocyte size, leading 11 
altogether to metabolic tuning. Our data add more evidence to the fact that modulation 12 
of AS, specifically LMNA’s, is a valid strategy to approach obesity therapy. These 13 
results provide insights into the physiological regulation of energy balance and its 14 
perturbation in LMNA mutation states. 15 
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Figure legends 1 
Figure 1: Identification of ABX300 a SRSF1 partner that modulates lmna 2 
splicing. 3 
(A) Confocal fluorescence microscopy of SRSF1-GFP HeLa  cells ABX300 treated , 4 
ABX914 treated and control 5 
(B) Schematic representation of the in vitro screening based on the LMNA-Luc splicing 6 
reporter. 7 
(C) Classification of positive compounds from the screen. 8 
(D) Fluorimetric titration of SRSF1 with ABX300. 9 
(E) Fluorimetric titration of SRSF1ΔRS with ABX300. 10 
Figure 2: In vivo Fat-dependent Efficacy of ABX300  11 
(A) Monitoring of weight changes (left panel) along with average daily and cumulative 12 
food intake (right panel) of Untreated and Treated DIO animals (50 mg/kg) in a Curative 13 
context.  14 
(B) Monitoring of weight changes (left panel) along with average daily and cumulative 15 
food intake (right panel) of Untreated and Treated animals (50 mg/kg) in a Preventive 16 
context.  17 
(C) Monitoring of weight changes (left panel) along with average daily and cumulative 18 
food intake (right panel) of Untreated and Treated animals (50 mg/kg) under normal 19 
chow diet conditions. 20 
(D) Effect of Caloric Restriction/Pair-Feeding on body weight (left panel) along with 21 
average daily and cumulative food intake (right panel), in DIO animals. ABX300 was 22 
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orally administered once daily (50 mg/kg) exclusively in the Treated group. In the 1 
CR/PF group, mice were provided everyday with the same amount of diet/biscuits/dry 2 
food that had been consumed in the Treated cages over the preceding 24 h.  3 
Figure 3: ABX300 decrease adiposity in DIO mice 4 
(A) Weights of individual organs as fold of Untreated group after 35 days of treatment 5 
(n=10). 6 
(B) PET-CT imaging for HFD Untreated, HFD Treated and CD Untreated mice. 7 
(C) Quantification of fat tissue volume (expressed in mm³). 8 
(D) Representative images of HE-stained sections of WAT from HFD Untreated and 9 
HFD treated mice. 10 
(E) Quantification of adipocyte by size from WAT of HFD Untreated and HFD Treated 11 
mice (expressed in % of lipids droplets per size range) 12 
Figure 4: Identification of ABX300 associated Alternative Splicing signature  13 
Figure 5: Transcriptomic analysis of key genes involved in adipose tissue 14 
homeostasis. 15 
(A) Scatter Plot between HFD treated mice versus HFD untreated mice showing 16 
upregulated and down-regulated genes. 17 
(B) Scatter Plot between Chow diet mice versus HFD untreated mice. 18 
(C) Scatter Plot between HFD treated mice and Chow diet mice 19 
We used the Mouse Adipogenesis RT² Profiler™ PCR Array profiles for analyzing the 20 
expression of 84 key genes involved in the differentiation and maintenance of mature 21 
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adipocytes. Upregulated genes are represented in red boxes and down-regulated 1 
genes in green boxes. 2 
Figure 6: ABX300 modulates a population of miRNAs likely mitochondrial-3 
enriched 4 
(A)  Heat map showing the shifts for the 52 micro-RNAs (y axis) varying between DIO 5 
Untreated and Treated animals (x axis). After one month of daily drug administration 6 
(50mg/Kg), 26 micro-RNAs appear up regulated (red) and 26 RNAs appear down 7 
regulated (green). 8 
(B) Heat map showing the shifts for the 113 micro-RNAs (y axis) varying between DIO 9 
and lean Untreated animals (x axis). After three months of different nourishment 10 
conditions, 54 micro-RNAs appear up regulated (red) and 59 RNAs appear down 11 
regulated (green). 12 
(C) The Venn diagram shows the number of shared and unique miRNAs expressed 13 
upon different diet and treatment conditions. Circumference’s overlapping area refers 14 
to the 42 miRNAs that reverted to the lean level, healthy white adipose tissue, after 15 
ABX300 treatment and that are up-regulated (red) or down-regulated (green)  in HFD 16 
Untreated versus CD Untreated (green circle), or HFD Treated (blue circle). ABX300’s 17 
10-miRNA signature proved to be mitochondrial enriched. The mitochondria 18 
overlapping area shows the miRNAs involved in this organelle’s field/function/related 19 
processes. The effectuated comparisons revealed that ABX300 treatment for obesity 20 
enhanced a non-coding population set of 8 miR regulators of mitochondrial genes. The 21 
identified miRNAs are divided according to their predicted targets (miRBASE, ≥80% 22 
confidence) through Mitocarta analysis.All of the miRNAs shown here display more 23 
than 1.5 Fold-Change differences between the groups (p < 0.05). Values represent ≥ 24 
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4 animals per group; 5–6 months old. Expression of miRNAs was determined by 1 
Genosplice, Affimetrix 3.0. The Heat maps were generated by a custom R script using 2 
gplots and RcolorBrewer libraries (see material and methods). The Fold-changes and 3 
p-values of individual miRNAs have been summarized in S5. 4 
Figure 7: ABX300 modifies DIO mice metabolism. 5 
(A) Monitoring of VO! consumption (left panel) and CO! production (right panel) over 6 
24h (12h-light / 12h-dark) on HFD Untreated and HFD Treated mice. Values are 7 
normalized to body weight (n=11) 8 
(B) Mean of VO! consumption 8h after treatment (left panel) and 24h after treatment 9 
(right panel). 10 
(C) Mean of CO! production 8h after treatment (left panel) and 24h after treatment (right 11 
panel). 12 
(D) Respiratory Exchange Ratio (RER) 8h after treatment (left panel) and 24h after 13 
treatment (right panel). 14 
  15 
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Supplemental Figure  1 
Abivax 
Compound
LMNA-luc 
activity
LMNA-luc toxicity 
(MTS)
Abivax 
Compound
LMNA-luc 
activity
LMNA-luc toxicity 
(MTS)
ABX68 5,25 <10 % ABX548 3,59 10 % < x < 30%
ABX71 4,37 <10 % ABX718 4,53 <10 %
ABX75 4,92 <10 % ABX719 5,63 <10 %
ABX76 3,35 <10 % ABX720 5,47 <10 %
ABX97 4,00 <10 % ABX722 3,23 <10 %
ABX99 4,69 <10 % ABX723 3,84 <10 %
ABX106 3,05 <10 % ABX724 5,21 <10 %
ABX110 3,83 <10 % ABX725 6,20 <10 %
ABX111 3,80 <10 % ABX727 4,75 <10 %
ABX261 3,46 <10 % ABX730 5,21 <10 %
ABX268 3,77 <10 % ABX731 5,15 <10 %
ABX269 4,54 <10 % ABX732 4,53 10 % < x < 30%
ABX270 4,43 <10 % ABX733 3,84 10 % < x < 30%
ABX271 3,35 <10 % ABX743 3,13 <10 %
ABX297 4,56 <10 % ABX750 3,65 <10 %
ABX300 3,33 <10 % ABX777 2,98 <10 %
ABX330 4,57 <10 % ABX785 3,32 <10 %
ABX334 3,08 <10 % ABX791 3,11 10 % < x < 30%
ABX335 3,66 <10 % ABX832 3,21 <10 %
ABX336 3,25 <10 % ABX833 3,32 <10 %
ABX405 3,00 <10 % ABX835 3,83 <10 %
ABX415 3,15 <10 % ABX836 3,11 10 % < x < 30%
ABX416 4,58 <10 % ABX844 3,37 <10 %
ABX417 5,96 <10 % ABX846 4,30 <10 %
ABX418 6,03 <10 % ABX847 6,87 10 % < x < 30%
ABX420 4,97 <10 % ABX848 4,29 <10 %
ABX421 8,63 10 % < x < 30% ABX850 3,42 <10 %
ABX424 4,90 <10 % ABX851 4,51 <10 %
ABX432 4,59 <10 % ABX858 2,70 <10 %
ABX433 3,27 10 % < x < 30% ABX860 2,89 <10 %
ABX435 3,59 <10 % ABX861 2,80 <10 %
ABX448 3,87 10 % < x < 30% ABX863 3,46 <10 %
ABX505 3,46 10 % < x < 30% ABX865 3,29 10 % < x < 30%
ABX510 3,29 <10 % ABX877 3,22 <10 %
ABX545 2,33 <10 % ABX887 6,19 <10 %
ABX550 2,36 <10 % ABX898
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 1 
Figure S1:  Relative to Figure 1 2 
(A) Histogram recapitulating all the drugs from the ABIVAX Chemical library tested 3 
with the LMNA-luc mini gene reporter. Vertical bars represent the mean of the 4 
luciferase activity from three independent experiments. Pink bars signify the molecules 5 
tested in vivo. Threshold is depicted with a black line. 6 
(B) Catalogue of all the drugs from the ABIVAX Chemical library referred to in this 7 
text. Columns show for each compound: the ABIVAX codification, their LMNA-luc 8 
activity and their LMNA-luc toxicity (MTS) (mean from three independent experiments). 9 
Pink depicts the molecules tested in vivo. Blue delineates activities below the 10 
established threshold 11 
(C) Negative control for 1D). Under the same titration conditions, this figure exhibits 12 
an absence of interaction in between hnRNPK and ABX300. 13 
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Figure S2: Recapitulation of the Effects of ABX300 on Body Weight  1 
(A) Evaluation of ABX300 Maximal Tolerated Dose. Monitoring of weight changes 2 
of Treated DIO animals (5, 12.5, 25, 50, 100 mg/kg) under normal diet conditions. 3 
(B)  ABX300 Time Persistence. Monitoring of weight changes of Untreated and 4 
Treated DIO animals (50 mg/kg) in a Curative and a Preventive context, under HFD 5 
conditions. Steady effects on body mass are patent after one month treatment 6 
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Figure S3: Relative to Figure 3 1 
(A)    Representative images of HE-stained sections of BAT, liver and gastrocnemius 2 
muscle from HFD Untreated and HFD treated mice. 3 
(B)    Assesment of glycerol, non-esterified fatty acids (NEFA) and triglycerides, in 4 
plasma and serum of ABX300 DIO Treated and Untreated animals 5 
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 1 
  2 
Gene
Untreated ABX300
Gene
Untreated ABX300
PSI 1 (%) PSI 2 (%) ΔPS1-2 PSI 1 (%) PSI 2 (%) ΔPS1-2
Amigo1 9,3 81,4 -72,1 Fam76a 80,1 58,6 21,5
Pias2 38,4 100,0 -61,6 Hipk2 56,1 34,3 21,8
Odf2 28,5 72,0 -43,5 Pdlim5 41,1 18,3 22,8
Hexdc 9,7 51,1 -41,4 Tia1 88,6 65,2 23,4
Ncaph2 33,9 74,1 -40,2 Nlgn1 31,8 8,3 23,5
Cd200r3 21,3 61,3 -40,0 Gtpbp5 38,6 14,6 24,0
Myo9b 9,5 44,8 -35,3 Crybb3 100,0 74,2 25,8
Kctd18 55,1 87,5 -32,4 Lhx6 56,4 30,2 26,2
Cd226 64,3 93,9 -29,6 Vldlr 67,9 39,8 28,1
Ptk2b 14,4 43,9 -29,5 Pnpla6 72,9 44,6 28,3
Optc 71,9 100,0 -28,1 Pln 29,0 0,0 29,0
Il18r1 16,0 42,4 -26,4 Tcf20 29,3 0,0 29,3
Nfya 35,1 59,1 -24,0 Thap3 100,0 70,0 30,0
Zfp207 0,0 23,6 -23,6 Crem 45,1 14,8 30,3
Cd72 33,7 57,3 -23,6 Evl 72,6 41,6 31,0
Tcf7l2 23,6 46,9 -23,3 Ppm1b 43,0 11,6 31,4
Ntf3 0,0 22,2 -22,2 Cd6 100,0 68,6 31,4
Tssc4 28,9 50,0 -21,1 Dnmt3b 43,7 12,1 31,5
Espn 31,1 52,0 -20,9 Abi3bp 33,8 0,0 33,8
Mark3 63,3 84,1 -20,8 Zc3h18 44,5 10,4 34,2
Dctn3 79,3 100,0 -20,7 Mboat2 83,8 47,9 35,9
Entpd5 65,2 44,8 20,4 Ap3m2 36,2 0,0 36,2
Celsr2 34,2 13,8 20,4 Myef2 57,4 19,0 38,4
Fance 84,0 63,1 20,9 Trpt1 83,2 38,2 45,0
Kif21a 100,0 78,8 21,2 Myo9b 68,2 5,1 63,1
Zdhhc6 21,4 0,0 21,4 Ssbp2 80,2 12,9 67,3
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Figure S4: Relative to Figure 4 1 
Table recapitulating the largest PSI’s variations in between HFD Untreated and 2 
ABX300 Treated groups. 3 
 4 
 5 
  6 
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 1 
 2 
Probe Set Name
Fold 
Change
P-Value Probe Set Name
Fold 
Change
P-Value
mmu-miR-342-5p 13,04 2,77E-09 mmu-miR-34c 8,15 3,25E-03
mmu-miR-122 8,54 3,34E-03 mmu-miR-193 7,40 5,67E-05
mmu-miR-342-3p 8,40 6,38E-08 mmu-miR-141 5,36 2,06E-03
mmu-miR-222 6,22 3,83E-06 mmu-miR-429 4,98 1,34E-03
mmu-miR-221 4,72 2,63E-05 mmu-miR-200a 4,69 1,72E-02
mmu-miR-706 3,76 5,52E-04 mmu-miR-345-5p 4,43 9,68E-06
mmu-miR-382 3,60 1,46E-04 mmu-miR-193b 3,88 1,53E-05
mmu-miR-132 3,52 3,84E-07 mmu-miR-29b 3,77 3,23E-04
mmu-miR-541 3,21 1,37E-04 mmu-miR-200b 3,59 9,14E-03
mmu-miR-1946a 3,12 2,53E-02 mmu-miR-1947-star 3,55 2,23E-03
mmu-miR-5097 2,97 7,29E-04 mmu-miR-143-star 3,24 1,23E-03
mmu-miR-335-5p 2,95 1,75E-02 mmu-miR-34b-3p 3,18 1,19E-02
mmu-miR-27b-star 2,89 7,02E-03 mmu-miR-30e 3,15 3,25E-04
mmu-miR-423-3p 2,83 6,94E-04 mmu-miR-30c-2-star 3,04 9,18E-03
mmu-miR-351 2,49 1,76E-03 mmu-miR-451 2,94 2,53E-02
mmu-miR-1946b 2,41 1,43E-02 mmu-miR-378b 2,92 3,77E-08
mmu-miR-720 2,37 2,85E-03 mmu-miR-130a 2,90 2,20E-06
mmu-miR-532-3p 2,36 9,10E-04 mmu-miR-29c 2,76 3,69E-06
mmu-miR-674-star 2,27 1,49E-02 mmu-miR-199b-star 2,75 5,93E-03
mmu-miR-714 2,24 1,42E-02 mmu-miR-449a 2,50 2,52E-03
mmu-miR-1224 2,22 3,94E-03 mmu-miR-291b-5p 2,50 2,71E-04
mmu-miR-5099 2,22 2,92E-02 mmu-miR-30a 2,45 7,47E-06
mmu-miR-674 2,19 2,40E-04 mmu-miR-378 2,40 6,62E-06
mmu-miR-27b 2,15 8,06E-04 mmu-miR-34b-5p 2,37 1,71E-03
mmu-miR-5110 2,14 1,75E-02 mmu-miR-210 2,34 2,94E-03
mmu-miR-127 2,12 8,05E-04 mmu-miR-187 2,33 1,38E-02
mmu-miR-214 2,10 2,83E-05 mmu-miR-203 2,29 3,60E-03
mmu-miR-18a 2,08 1,58E-03 mmu-miR-192 2,25 2,70E-02
mmu-miR-411 2,03 6,11E-03 mmu-miR-143 2,23 2,40E-03
mmu-miR-455 2,03 1,03E-04 mmu-miR-125b-2-3p 2,22 3,67E-03
mmu-miR-504 1,99 1,07E-03 mmu-miR-378-star 2,22 1,34E-02
mmu-miR-532-5p 1,99 4,14E-04 mmu-miR-181d 2,14 1,05E-02
mmu-miR-5109 1,94 2,94E-03 mmu-miR-30c 2,10 5,87E-06
mmu-miR-3102 1,92 2,92E-02 mmu-miR-148a 2,09 9,68E-03
mmu-miR-574-3p 1,91 3,46E-04 mmu-miR-301a 2,09 5,00E-03
mmu-miR-379 1,89 3,02E-03 mmu-miR-194 2,07 2,60E-03
mmu-miR-181b 1,86 2,66E-06 mmu-miR-680 1,97 1,09E-03
mmu-miR-23b 1,81 1,52E-06 mmu-miR-322 1,96 1,86E-02
mmu-miR-5121 1,80 1,89E-02 mmu-miR-1843b-5p 1,94 2,53E-04
mmu-miR-146a 1,80 5,52E-03 mmu-miR-2183 1,89 7,40E-04
mmu-miR-494 1,78 7,08E-03 mmu-miR-92b 1,87 6,90E-04
mmu-miR-324-5p 1,78 5,93E-03 mmu-miR-1941-5p 1,78 3,51E-03
mmu-miR-15b 1,77 3,66E-04 mmu-miR-93-star 1,77 5,99E-04
mmu-miR-744 1,77 3,65E-05 mmu-miR-449b 1,75 5,57E-05
mmu-miR-151-3p 1,74 1,20E-04 mmu-miR-3092 1,72 9,89E-04
mmu-miR-146b 1,73 1,04E-02 mmu-miR-30a-star 1,71 2,60E-02
hp_mmu-mir-465a 1,68 7,10E-05 mmu-miR-345-3p 1,70 3,72E-03
mmu-miR-23a-star 1,68 1,70E-02 hp_mmu-mir-378 1,69 4,76E-05
mmu-miR-1196 1,63 1,99E-02 mmu-miR-497 1,69 1,59E-03
mmu-miR-190-star 1,62 3,70E-02 mmu-miR-30b 1,67 8,97E-04
mmu-miR-106a 1,59 2,63E-03 mmu-miR-196a 1,65 7,03E-03
mmu-miR-34a 1,58 8,68E-03 mmu-miR-375 1,61 2,97E-03
mmu-miR-20b 1,58 1,85E-02 mmu-miR-145 1,59 3,08E-02
mmu-miR-139-5p 1,51 2,46E-04 mmu-miR-193-star 1,56 1,12E-02
mmu-let-7f 1,55 2,73E-02
mmu-miR-672 1,54 1,21E-02
mmu-miR-708 1,53 7,76E-03
hp_mmu-mir-143 1,53 1,43E-02
mmu-miR-511-3p 1,50 1,43E-02
HFD Untreated vs. CD Untreated
Up-regulated Down-regulated
Probe Set Name
Fold 
Change
P-Value Probe Set Name
Fold 
Change
P-Value
mmu-miR-342-5p 10,14 3,12E-06 mmu-miR-30c-2-star 3,75 1,38E-04
mmu-miR-342-3p 5,62 1,02E-04 mmu-miR-30e 3,49 6,84E-06
mmu-miR-222 5,15 3,43E-07 mmu-miR-203 3,31 1,70E-03
mmu-miR-221 4,83 3,44E-06 mmu-miR-193b 3,20 1,22E-03
mmu-miR-541 3,09 2,66E-03 mmu-miR-210 3,13 2,42E-03
mmu-miR-146b 2,92 4,74E-03 mmu-miR-148a 2,95 4,94E-04
mmu-miR-382 2,74 5,82E-03 mmu-miR-714 2,62 1,87E-03
mmu-miR-351 2,56 4,64E-04 mmu-miR-30a 2,40 7,51E-07
mmu-miR-27b-star 2,45 1,61E-03 mmu-miR-30a-star 2,29 1,63E-04
mmu-miR-411 2,37 4,58E-03 mmu-miR-375 2,20 4,40E-02
mmu-miR-127 2,35 1,40E-03 mmu-miR-193-star 2,02 3,33E-04
mmu-miR-1946a 2,33 2,76E-02 mmu-miR-378-star 1,97 7,27E-03
mmu-miR-379 2,29 2,02E-03 mmu-miR-5122 1,86 4,41E-02
mmu-miR-18a 2,23 7,37E-03 mmu-miR-30c 1,86 1,97E-04
mmu-miR-132 1,97 2,77E-04 mmu-miR-378b 1,81 6,37E-03
mmu-miR-494 1,95 5,79E-03 mmu-miR-378 1,80 2,52E-04
mmu-miR-27b 1,85 2,41E-03 mmu-miR-29c 1,76 3,00E-02
mmu-miR-674-star 1,84 3,56E-02 mmu-miR-5130 1,65 8,90E-03
mmu-miR-674 1,83 4,94E-03 mmu-miR-26b 1,59 3,23E-03
mmu-miR-130b 1,76 6,49E-03 mmu-miR-29a 1,59 9,89E-06
mmu-miR-15b 1,76 9,48E-05 mmu-miR-187 1,57 2,20E-02
mmu-miR-181b 1,66 1,49E-04 mmu-miR-345-3p 1,56 2,37E-04
mmu-miR-504 1,62 2,68E-02 mmu-miR-708 1,55 5,56E-03
mmu-miR-362-5p 1,58 1,62E-03 mmu-miR-150 1,54 1,65E-03
mmu-miR-23b 1,53 8,42E-04 mmu-miR-29b 1,52 3,40E-03
mmu-miR-199a-5p 1,50 3,34E-02 mmu-miR-92a 1,52 2,47E-03
HFD Untreated vs. HFD Treated
Up-regulated Down-regulated
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 1 
miRNA Name
Fold 
Change
P-Value
Target 
Score
Gene 
Symbol
Gene Description
81 Atp5g1 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit C1 (subunit 9)
83 Slc16a1 solute carrier family 16 (monocarboxylic acid transporters), member 1
87 Slc25a3 solute carrier family 25 (mitochondrial carrier, phosphate carrier), member 3
94 Bdh1 3-hydroxybutyrate dehydrogenase, type 1
97 Ireb2 iron responsive element binding protein 2
100 Eln elastin
mmu-miR-714 2,62 1,87E-03 64 Oxr1 oxidation resistance 1
82 Slc25a36 solute carrier family 25, member 36
94 Slc25a32 solute carrier family 25, member 32
96 Spryd4 SPRY domain containing 4
82 Phyhipl phytanoyl-CoA hydroxylase interacting protein-like
84 Atpaf1 ATP synthase mitochondrial F1 complex assembly factor 1
86 Bak1 BCL2-antagonist/killer 1
93 Aldh5a1 aldhehyde dehydrogenase family 5, subfamily A1
96 Mtx2 metaxin 2
99 Slc25a16
solute carrier family 25 (mitochondrial carrier, Graves disease autoantigen), 
member 16
83 Them4 thioesterase superfamily member 4
85 Zadh2 zinc binding alcohol dehydrogenase, domain containing 2
95 Gng5 guanine nucleotide binding protein (G protein), gamma 5
99 Gpd2 glycerol phosphate dehydrogenase 2, mitochondrial
mmu-miR-362 1,58 1,62E-03 94 Aldh6a1 aldehyde dehydrogenase family 6, subfamily A1
82 Mat2b methionine adenosyltransferase II, beta
84 Fastk Fas-activated serine/threonine kinase
85 Hadha
hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-
Coenzyme A hydratase (trifunctional protein), alpha subunit
91 Acsl1 acyl-CoA synthetase long-chain family member 1
99 Acsl4 acyl-CoA synthetase long-chain family member 4
6,49E-03
TARGET PREDICTION
3,23E-03
1,54 1,65E-03
1,50 3,34E-02
mmu-miR-130b
mmu-miR-150
mmu-miR-199a
mmu-miR-26b 1,59
1,76
mmu-miR-29a
mmu-miR-92a
1,59 9,89E-06
1,52 2,47E-03
C
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 1 
miRNA Name Fold Change P-Value Fold Change P-Value
Target 
Score
Gene 
Symbol
Gene Description
81 Slc30a6 solute carrier family 30 (zinc transporter), member 6
98 Timm9 translocase of inner mitochondrial membrane 9 homolog (yeast)
mmu-miR-146b 2,92 4,74E-03 1,73 1,04E-02 89 Tdrkh tudor and KH domain containing protein
93 Afg3l2 AFG3(ATPase family gene 3)-like 2 (yeast)
89 Acsl1 acyl-CoA synthetase long-chain family member 1
96 Acsl4 acyl-CoA synthetase long-chain family member 4
89 Gatm glycine amidinotransferase (L-arginine:glycine amidinotransferase)
91 Lyrm1 LYR motif containing 1
89 Oxsm 3-oxoacyl-ACP synthase, mitochondrial
87 Slc25a36 solute carrier family 25, member 36
92 Kif1b kinesin family member 1B
84 Ehhadh enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A dehydrogenase
84 Gfm2 G elongation factor, mitochondrial 2
87 Glud1 glutamate dehydrogenase 1
83 Idh3a isocitrate dehydrogenase 3 (NAD+) alpha
98 Mfn2 mitofusin 2
91 Mthfd1l methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like
82 Tatdn3 TatD DNase domain containing 3
82 Tk2 thymidine kinase 2, mitochondrial
83 Rab1b RAB1B, member RAS oncogene family
81 Kif1b kinesin family member 1B
88 Rexo2 REX2, RNA exonuclease 2 homolog (S, cerevisiae)
mmu-miR-1946a 2,33 2,76E-02 3,12 2,53E-02 96 Mrpl40 mitochondrial ribosomal protein L40
85 Slc25a44 solute carrier family 25, member 44
84 Slc30a6 solute carrier family 30 (zinc transporter), member 6
85 Slc25a44 solute carrier family 25, member 44
84 Slc30a6 solute carrier family 30 (zinc transporter), member 6
82 C330018D20Rik RIKEN cDNA C330018D20 gene
90 Acss1 acyl-CoA synthetase short-chain family member 1
89 Aldh1l2 aldehyde dehydrogenase 1 family, member L2
94 Ankrd26 ankyrin repeat domain 26
98 Auh AU RNA binding protein/enoyl-coenzyme A hydratase
91 Gls glutaminase
85 Pdk4 pyruvate dehydrogenase kinase, isoenzyme 4
93 Ppif peptidylprolyl isomerase F (cyclophilin F)
83 Slc25a31 solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 31
96 Uqcrfs1 ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1
99 Aldh5a1 aldhehyde dehydrogenase family 5, subfamily A1
89 Ak2 adenylate kinase 2
93 Nln neurolysin (metallopeptidase M3 family)
92 Pdhx pyruvate dehydrogenase complex, component X
91 Pnkd paroxysmal nonkinesiogenic dyskinesia
mmu-miR-342-5p 10,14 3,12E-06 13,04 2,77E-09 90 Acsl4 acyl-CoA synthetase long-chain family member 4
96 Slc25a35 solute carrier family 25, member 35
87 Acads acyl-Coenzyme A dehydrogenase, short chain
92 Gpd1 glycerol-3-phosphate dehydrogenase 1 (soluble)
81 Iqce IQ motif containing E
95 Lactb lactamase, beta
93 Mobp myelin-associated oligodendrocytic basic protein
88 Ndufs4 NADH dehydrogenase (ubiquinone) Fe-S protein 4
90 Triap1 TP53 regulated inhibitor of apoptosis 1
mmu-miR-379 2,29 2,02E-03 1,89 3,02E-03 80 Gpd1 glycerol-3-phosphate dehydrogenase 1 (soluble)
94 Atp5c1 ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1
84 Pptc7 PTC7 protein phosphatase homolog (S, cerevisiae)
82 Sfxn1 sideroflexin 1
84 Tfam transcription factor A, mitochondrial
88 Slc25a16 solute carrier family 25 (mitochondrial carrier, Graves disease autoantigen), member 16
mmu-miR-541 3,09 2,66E-03 3,21 1,37E-04 83 Sptlc2 serine palmitoyltransferase, long chain base subunit 2
87 Mrpl49 mitochondrial ribosomal protein L49
89 Dnajc19 DnaJ (Hsp40) homolog, subfamily C, member 19
97 Atad1 ATPase family, AAA domain containing 1
98 Ucp3 uncoupling protein 3 (mitochondrial, proton carrier)
83 Akap1 A kinase (PRKA) anchor protein 1
93 Slc25a44 solute carrier family 25, member 44
83 Glrx5 glutaredoxin 5 homolog (S, cerevisiae)
90 Armc1 armadillo repeat containing 1
80 Timm8a1 translocase of inner mitochondrial membrane 8 homolog a1 (yeast)
92 Cyb5b cytochrome b5 type B
97 Atp5g3 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c (subunit 9), isoform 3
mmu-miR-210 3,13 2,42E-03 2,34 2,94E-03 83 Iscu IscU iron-sulfur cluster scaffold homolog (E, coli)
83 Slc16a1 solute carrier family 16 (monocarboxylic acid transporters), member 1
81 Atp5g1 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c (subunit 9), isoform 1
94 Bdh1 3-hydroxybutyrate dehydrogenase, type 1
100 Eln elastin
97 Ireb2 iron responsive element binding protein 2
87 Slc25a3 solute carrier family 25 (mitochondrial carrier, phosphate carrier), member 3
83 Slc16a1 solute carrier family 16 (monocarboxylic acid transporters), member 1
81 Atp5g1 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c (subunit 9), isoform 1
94 Bdh1 3-hydroxybutyrate dehydrogenase, type 1
100 Eln elastin
97 Ireb2 iron responsive element binding protein 2
87 Slc25a3 solute carrier family 25 (mitochondrial carrier, phosphate carrier), member 3
100 Acyp2 acylphosphatase 2, muscle type
85 Lyrm5 LYR motif containing 5
95 Pdk4 pyruvate dehydrogenase kinase, isoenzyme 4
83 Ptrh2 peptidyl-tRNA hydrolase 2
94 Slc25a33 solute carrier family 25, member 33
91 Abcd2 ATP-binding cassette, sub-family D (ALD), member 2
82 Coq3 coenzyme Q3 homolog, methyltransferase (yeast)
82 Cyp24a1 cytochrome P450, family 24, subfamily a, polypeptide 1
100 Ddah1 dimethylarginine dimethylaminohydrolase 1
93 Gatm glycine amidinotransferase (L-arginine:glycine amidinotransferase)
90 Oxr1 oxidation resistance 1
93 Pdss1 prenyl (solanesyl) diphosphate synthase, subunit 1
96 Pnkd paroxysmal nonkinesiogenic dyskinesia
87 Pptc7 PTC7 protein phosphatase homolog (S, cerevisiae)
90 Rab32 RAB32, member RAS oncogene family
88 Acadm acyl-Coenzyme A dehydrogenase, medium chain
80 Me3 malic enzyme 3, NADP(+)-dependent, mitochondrial
94 Mtch2 mitochondrial carrier homolog 2 (C, elegans)
85 Opa1 optic atrophy 1 homolog (human)
99 Tshz3 teashirt zinc finger family member 3
91 Abcd2 ATP-binding cassette, sub-family D (ALD), member 2
82 Coq3 coenzyme Q3 homolog, methyltransferase (yeast)
82 Cyp24a1 cytochrome P450, family 24, subfamily a, polypeptide 1
100 Ddah1 dimethylarginine dimethylaminohydrolase 1
93 Gatm glycine amidinotransferase (L-arginine:glycine amidinotransferase)
90 Oxr1 oxidation resistance 1
93 Pdss1 prenyl (solanesyl) diphosphate synthase, subunit 1
96 Pnkd paroxysmal nonkinesiogenic dyskinesia
87 Pptc7 PTC7 protein phosphatase homolog (S, cerevisiae)
90 Rab32 RAB32, member RAS oncogene family
91 Abcd2 ATP-binding cassette, sub-family D (ALD), member 2
82 Coq3 coenzyme Q3 homolog, methyltransferase (yeast)
82 Cyp24a1 cytochrome P450, family 24, subfamily a, polypeptide 1
100 Ddah1 dimethylarginine dimethylaminohydrolase 1
93 Gatm glycine amidinotransferase (L-arginine:glycine amidinotransferase)
90 Oxr1 oxidation resistance 1
93 Pdss1 prenyl (solanesyl) diphosphate synthase, subunit 1
96 Pnkd paroxysmal nonkinesiogenic dyskinesia
87 Pptc7 PTC7 protein phosphatase homolog (S, cerevisiae)
90 Rab32 RAB32, member RAS oncogene family
mmu-miR-378 1,80 2,52E-04 2,92 3,77E-08 83 Car5b carbonic anhydrase 5b, mitochondrial
94 Drg2 developmentally regulated GTP binding protein 2
83 Mtch2 mitochondrial carrier homolog 2 (C, elegans)
89 Crot carnitine O-octanoyltransferase
mmu-miR-351
mmu-miR-382
mmu-miR-494
1,66 1,49E-04 1,86 2,66E-06
2,23 7,37E-03 2,08
TARGET PREDICTION
mmu-miR-132
mmu-miR-15b
1,97 2,77E-04 3,52 3,84E-07
HFD Untreated vs.      
HFD Treated
HFD Untreated vs.      CD 
Untreated
mmu-miR-181b
mmu-miR-18a
mmu-miR-708
2,95 4,94E-04 2,09 9,68E-03
1,76 9,48E-05 1,77 3,66E-04
mmu-miR-148a
mmu-miR-30a
mmu-miR-193b
mmu-miR-203
mmu-miR-221
mmu-miR-222
mmu-miR-23b
mmu-miR-27b
mmu-miR-29b
mmu-miR-29c
mmu-miR-30a-star
mmu-miR-674
mmu-miR-30c-2-star
mmu-miR-30c
mmu-miR-30e
4,83 3,44E-06 4,72 2,63E-05
1,58E-03
3,20 1,22E-03 3,88 1,53E-05
1,85 2,41E-03 2,15 8,06E-04
1,52 3,40E-03 3,77 3,23E-04
5,15 3,43E-07 6,22 3,83E-06
1,53 8,42E-04 1,81 1,52E-06
3,31 1,70E-03 2,29 3,60E-03
2,56 4,64E-04 2,49 1,76E-03
2,74 5,82E-03 3,60 1,46E-04
1,86 1,97E-04 2,10 5,87E-06
2,40 7,51E-07 2,45 7,47E-06
3,75 1,38E-04 3,04 9,18E-03
1,76 3,00E-02 2,76 3,69E-06
1,55 5,56E-03 1,53 7,76E-03
1,95 5,79E-03 1,78 7,08E-03
1,83 4,94E-03 2,19 2,40E-04
3,49 6,84E-06 3,15 3,25E-04
2,29 1,63E-04 1,71 2,60E-02
D
Supplemental Figure 5
(continued)
Pharmacological modulation of the splicing factor SRSF1 mitigates Diet Induced Obesity in mice 
55 
 
Figure S5: Identification of ABX300 associated miRNA signature  1 
(A)      Table showing the shifts for the 52 micro-RNAs varying between DIO Untreated 2 
and Treated animals. Up-regulated miR (26) are represented in red boxes and down-3 
regulated miR (26) in green boxes. 4 
(B)      Table showing the shifts for the 113 micro-RNAs varying between DIO and lean 5 
untreated animals. Up-regulated miR (54) are represented in red boxes and down-6 
regulated miR (59) in green boxes. 7 
(C)     Table showing the fold changes with their respective P-values, for the 8 miRNAs 8 
predicted to target mitochondrial genes (≥80% confidence) selected from HFD 9 
Untreated vs. HFD Treated comparison. A description of these genes is also presented 10 
in the table. 11 
D)     Table showing the fold changes with their respective P-values, for the 37 miRNAs 12 
overlapping in between the comparisons HFD Untreated vs. CD Untreated and HFD 13 
Untreated vs. HFD Treated, that have been predicted to have a mitochondrial target 14 
(≥80% confidence). A description of these genes is also presented in the table.15 
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3. Additional explored avenues 
i) Effect of ABX300 on adipocytes differentiation 
 
We have shown that ABX300 induces a magnificent weight lost which is 
translated in terms of WAT mass reduction. A decrease in AT mass can result from a 
reduction in adipocyte size, a reduction in adipocyte number, an impaired differentiation, 
or a mix of the above. Inhibiting the differentiation of adipocytes from precursor cells 
seems attractive as a therapeutic strategy, although it is potentially laden with pitfalls. 
Peripheral anti-obesity approaches that target adipogenesis alone may prove 
problematic given the fact that co-morbidities, notably diabetes,  can result from either 
a paucity or plethora of fat tissue (Cummings and Schwartz, 2003). Many molecules 
have been shown to inhibit adipogenesis in vitro through the use of the 3T3-L1 adipocyte 
cell culture system (Grujic et al., 1997; Lin et al., 2000; Lin et al., 2001;Mallet et al., 
2002; Rajala and Scherer, 2003; Trujillo and Pajvani, 2005). Moreover, ‘anti-
differentiation’, or a loss of distinctive adipocyte morphology and function has been 
studied in this same cell model (Tamori et al., 2002). The 3T3-L1 cell line was derived 
from fibroblasts isolated from disaggregated Swiss mouse embryos, immortalized by 
continuous passage and sub-cloned according to their differentiation capacity. This cell 
line can be differentiated over a period of one week and can be induced to undergo 
adipogenesis. Detailed procedures for highly effective and reproducible 3T3-L1 cell 
differentiation are nowadays extensively available (Zebisch et al., 2012). Due to their 
potential to differentiate from fibroblasts to adipocytes, currently, 3T3-L1 cells are widely 
used for studying adipogenesis and the biochemistry of adipocytes. Although when fully 
differentiated they do not display unilocular intracellular fat stores but multilocular fat 
droplets typical of brown cells, they are considered as a relevant cellular model of WAT 
that can be used to test drugs that may affect adipogenesis.  
Our first attempt to inspect the potential effect of ABX300 on this cell model was 
to treat the cells at different moments during the differentiation process, at the 
concentration of 5 μM.  Rosiglitazone, a PPARγ agonist, was used as an additional 
prodifferentiative agent to obtain full differentiation. Within7 to 10 days, apparently 
complete differentiation was achieved. In order to characterize the differentiation rate, 
we performed ORO (oil red O) staining. The extraction of this colorant and the 
subsequent measurement of the absorbance at 520nm provide valuable information 
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about the content in lipid droplets, thus the degree of differentiation. ORO analysis 
allowed us to conclude an absence of effect for ABX300 under these specific conditions 
(Figure 35A). To try to empower the potential effect of the ABX300 molecule onto 
differentiation, we decided to remove rosiglitazone from experiments. As a 
consequence, we encountered lower differentiation rates, but still no effect of ABX300 
at 1 μM and 5 μM (Figure 35B).  
 
 
 
Figure 35: Absence of ABX300 effect on 3T3-L1 differentiation. 
 
A) Representative Images of ORO-stained Petri-dishes of differentiating 3T3-L1, at days 
0, 3, 5, 7 and 9, in the presence of rosiglitazone +/- ABX300. DMSO being the drug 
vehicle, it serves as control. 
B) Representative Images of ORO-stained 6 wells-plates of differentiating 3T3-L1, at days 
0, 3, 5, 7 and 9, in the absence of rosiglitazone. Histogram bars correspond to the 
absorbance of the extracted colorant from the plates (Abs=520nm).  
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In view of these results, rosiglitazone was further kept for every other experiment 
presented in this manuscript. Since it has been reported that the variability in 3T3-L1 
adipocyte differentiation depends strongly on the cell culture dishes  (Mehra et al., 
2007), with both culture dish provider (i.e., the material and/or processing of the plastic 
surface) and dish type being crucial factors for 3T3-L1 differentiation, I have tested this 
hypothesis into different cell-culture plates. The data shown in this manuscript are 
representative results of the many experiments I have carried out. Taken together, all 
my research data do not strongly imply a role for ABX300 in 3T3-L1 adipocyte 
differentiation. 
Consistent with these results, qPCR experiments revealed no effect of ABX300 
on differentiating 3T3-L1 cells. Three biological replicates were made per time point 
(Figure 36). As I already detailed in the introduction of this manuscript, the members of 
the C/EBP family have shown to be very important in adipogenesis. When treating with 
ABX300, mRNA expression levels of two early markers of differentiation, C/EBPδ and 
C/EBPβ, were similar between untreated and treated cells (Figure 36A left column). 
These markers additionally contribute to the transcriptional activation of PPARγ in early 
adipogenesis, and C/EBPβ redundantly activates adipogenic genes targeted by C/EBPα 
(Ryan Alexander, Harvey Lodish, 2011). Continued expression of PPARγ, a master 
transcriptional regulator of adipogenesis, is necessary for maintaining the differentiated 
state. PPARγ also activates genes involved in terminal differentiation and mature 
functions of adipocytes. Following commitment to the adipocyte lineage, preadipocytes 
undergo terminal adipocyte differentiation, acquiring a mature adipocyte morphology, 
and expressing mature adipocyte markers such as FABP4 and GLUT4. 
Relative mRNA levels of intermediate markers: C/EBPα and PPARγ, as well as late 
ones: AdipoQ, FABP4 and GLUT4, did not differ between ABX300 treated and untreated 
conditions, suggesting an equivalent degree of differentiation (Figure 36A middle and 
right columns). Furthermore, mRNA expression levels of PGC1α and UCP1 were also 
similar (Figure 36B). This evidence further indicated that ABX300 treatment did not 
significantly affect the adipocyte differentiation process. 
As a completing strategy in the study of the mechanisms of adipogenesis and 
remodulation of AT, we measured TGs content in the cell culture media of ABX300 
treated and untreated 3T3-L1, but repeatedly found no differences due to ABX300 
administration (Figure 36C).  
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Figure 36: Absence of ABX300 effect on relative expression of key genes during 3T3-L1 
differentiation. 
 
A) Relative mRNA levels of early, intermediate and late markers of differentiating 3T3-
L1, at days 0, 3, 5, 7 and 10. 
B) Relative mRNA levels of metabolic key genes in the same cells as in A). 
C) TGs supernatant content at day 10 of 3T3-L1 cells in A) and B). 
 
All qPCR results are normalized to the housekeeping genes (NoNo and b2m). 
 
The absence of ABX300 effect regarding 3T3-L1 differentiation was also 
confirmed by protein levels of key metabolic genes. Figure 37A shows western blotting 
of differentiating 3T3-L1, on PGC1α, PPARγ, UCP1 and FABP4 genes. Perilipin-A and 
ATGL were used as internal controls for checking on the differentiation process itself. 
TBP and Tubulin were used to normalize the results. 
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Figure 37: Absence of ABX300 effect on protein expression of key genes involved in 
adipogenesis and phosphorylation of SR proteins during 3T3-L1 differentiation. 
 
A) Protein expression levels of metabolic key genes in differentiating 3T3-L1, at days 0, 
3, 5, 7 and 10. 
B) SR proteins phosphorylation levels during 3T3-L1 differentiation, at days 0, 0.5, 1, 
1.25, 1.5, 2 and 3. 
 
Since we reported ABX300 to interact with SRSF1, and very likely also to interfere 
with its activity, I checked for its phosphorylation by western blotting. As already 
described in the introduction, the activity of this family of splicing regulators is principally 
dependent on their phosphorylation level. So I carried out western blotting on 
differentiation kinetics of 3T3-L1 cells with Mab104, a self-customized hybridome 
antibody which binds to phosphorylated RS domains. Seven different time points were 
evaluated. Results indicate that the drug does not have a remarkable effect on the 
phosphorylation levels at any of the tested time points, thus in theory nor on the activity 
of these proteins in these experimental conditions (Figure 37B). 
Most studies of adipocytes have been limited either to a small number of 
established cell lines, such as the previously described 3T3-L1, or to primary cell culture. 
Recently, immortalized brown adipocyte cell lines have been generated from single 
newborn mice of different KO mouse models (Klein et al., 2002; Whittle et al., 2012).  
These cell lines, presented during the introduction of this manuscript, appear as 
physiologically relevant for testing drugs that may prevent, delay or stop adipogenesis, 
and as such are likely to cause weight loss and other features.  
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Because we hadn’t been able to verify any in vitro effect on adipocyte differentiation 
using a WAT cellular model, we evaluated ABX300 taking advantage of this newly 
available cell type of BAT preadipocytes. 
After undergoing differentiation to brown adipocytes for eight days,  in a medium 
containing a high concentration of insulin, triiodothyronine (T3), dexamethasone (DEX), 
3-isobutyl-1-methylxanthine (IBMX) and indomethacin, I treated the cells during 48 
hours, at different ABX300 concentrations (1, 2.5 and 5 μM). No differences were 
observed between untreated and treated cells with regards to brown adipocyte 
morphology or ORO staining (Figures 38A and B). These experiments did not allow to 
confirm any effect of ABX300 in BAT preadipocytes differentiation. 
 
 
Figure 38: Absence of ABX300 effect on differentiated BAT preadipocytes. 
 
A) Representative Picture of ORO-stained 24 wells-plates of differentiated BAT 
preadipocytes at day 10. ABX300 treatment took place during the preceding 48 
hours. Histogram bars correspond to the mean of three independent experiments for 
the absorbance of the extracted colorant from the plates (Abs=520nm). 
B) Representative Invert Microscopy Images of cells in A). 
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Altogether the results presented in this section point to an absence of effect of ABX300 
on white and/or brown adipocytes differentiation. It is presumable that ABX300 action 
may occur via its metabolites. This would explain why we do not see any robust effect 
of the drug on the tested cell lines. Besides, it is important to note that in vitro 
differentiation of 3T3-L1 adipocytes is easily disrupted by a variety of pharmacologic 
interventions, suggesting a rather delicate balance between terminal differentiation and 
continued proliferation that may not accurately reflect in vivo adipogenesis (Trujillo and 
Pajvani, 2005). Many other features could explain the fact that we do not see an effect 
of ABX300 in vitro (see discussion section for further details).  
ii) Effect of ABX300 on adipocytes lipolysis/lipogenesis 
 
The initial phenotypic characterization of ABX300 treated mice revealed a decline 
in fat tissue. Subsequent experimental work showed a clear absence of effect on 
differentiation of white and brown AT rodent cell models in response to the treatment. 
Both, the weight loss and the reduced weight gain, in ABX300 treated mice could also 
likely be due to increased lipolysis and/or impaired lipogenesis in response to the drug 
and the hyper-caloric feeding. 
In the first place, to verify if ABX300 treatment was getting underway lipolytic 
mechanisms, we carried out a kinetics experiment in differentiated 3T3-L1 cells. Three 
different drug concentrations were tested, along with isoproterenol at 1µM, which was 
used as a positive control. Glycerol levels were assessed at five distinct time points (1h, 
2h, 4h, 6h and 8h) (Figure 39A).  In addition, NEFA, glycerol and TGs levels were dosed 
in the cell culture supernatant of differentiated cells, 24 hours after drug application 
(Figure 39B).  None of these experiments allowed the confirmation of any differences 
in between treated and untreated wells.  
Secondly, longer experiments were designed in order to check if it was a matter of time 
that impeded us to manage to prove an effect of ABX300.  We therefore focused on 
periods of one to two weeks or even one month duration. During this time, 3T3-L1 cells 
were treated every 48h with ABX300 at 5 μM. Results showed no differences between 
treated and untreated cells regarding ORO staining (Figure 39C), and TGs supernatant 
content (Figure 39D). 
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Figure 39: Absence of ABX300 effect on lipolytic/lipogenic mechanisms in 3T3-L1 cells. 
 
A) Kinetics of glycerol relative levels in differentiated 3T3-L1, at time points 1, 2, 4, 6 
and 8 (hours) under various treatment conditions. 
B) NEFA, glycerol and TGs relative levels in differentiated 3T3-L1, after 24 hours 
diverse treatment conditions. 
C) Representative picture of ORO-stained 6 wells-plates of differentiated 3T3-L1 treated 
every 48 hours for 7 or 14 days at 5 μM. Histogram bars correspond to the 
absorbance of the extracted colorant from the plates (Abs=520nm). 
D) Relative TGs levels of cells treated similarly than in C). One surplus 30 days 
condition. 
 
Because cell models are far from reproducing every single characteristic of a real 
tissue, the reason for not observing any effect of the molecule could still reside in this 
fact. Therefore additional experiments were carried out using animal explants. Wild Type 
(WT) and genetically obese mouse models (OB"!ob/ob) were used (Figure 40).  
The ob/ob mouse model was used according to the rapidity of the obtaining of the 
samples compared to the DIO model. Isoproterenol was again used as a positive control 
of lipolysis (1µM). ABX300 concentration was fixed to 5µM. Treatment times are shown 
in the legends of the figure. Of note is that the response to isoproterenol in the ob/ob 
subject’s is less good than in WT’s. This could be explained by their intrinsic defective 
metabolism due to the obese state. 
[G
ly
cé
ro
l]
 µ
g
/m
l
1 2 4 6 8
0
50
100
150
DMSO
ABX300 1µM
ABX300 5µM
ABX300 20µM
Isoproterenol 1µM
hours
R
el
at
iv
e 
u
n
it
s
NE
FA
Gl
yc
er
ol
TG
s
0.0
0.5
1.0
1.5
DMSO
ABX300 5µM
ABX300 1µM
ABX300 20µM
Isoproterenol 1µM
A) B)
F
o
ld
 C
h
an
g
e 
(a
.u
.)
[T
ri
g
ly
ce
ri
d
es
 (
µ
g
)/
P
ro
té
in
es
 (
µ
g
)]
1 
we
ek
2 
we
ek
s
1 
m
on
th
0.0
0.5
1.0
1.5
2.0
DMSO
ABX300 5µM
C)
F
o
ld
 C
h
an
g
e 
(a
.u
.)
[A
b
so
rb
an
ce
 5
20
n
m
]
1 
we
ek
2 
we
ek
s
0.0
0.5
1.0
1.5
DMSO
ABX300 5µM
D)
1 
we
ek
2 
we
ek
s
DMSO
ABX300
5μM DMSO
ABX300
5μM
RESULTS 
 
89 
 
These data suggest that neither increased lipolysis, nor reduced lipogenesis are the 
mechanisms responsible for the protection from high-fat diet-induced obesity during 
ABX300 treatment. Nevertheless, it is hard to conclude. Among the tested subjects there 
was only one adequately responding to isoproterenol. 
 
Figure 40: Absence of ABX300 effect inducing lipolysis on ex-vivo WAT explants. 
 
NEFA, glycerol and TGs relative levels in supernatants from cultured WAT explants 
derived from WT and OB animals. ABX300 and isoproterenol in-vitro treatment 
correspond to 7 hours at 5µM and 3 hours at 1µM respectively. Data are normalized 
to the corresponding non-treated DMSO. 
 
iii) Effect of ABX300 on Browning 
 
An alternative contributor to reduced fat storage in ABX300 treated mice could 
be increased thermogenesis. It has now been established for over a decade that WAT 
browning enhances this process (Cousin et al., 1992).  It is important to note that even 
though the BAT depots are present in small amounts, the activated tissue has the 
potential to substantially contribute to energy expenditure (Nedergaard et al., 2007). 
Besides, beige cells retain a remarkable ability to powerfully turn on a robust program 
of respiration and EE that is equivalent to that of classical brown fat cells (see 
introduction). To investigate the conceivable WAT browning and to determine whether 
it contributed to the observed phenotype, I firstly performed qPCR experiments. 
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Since the different fat cells; brown, white and beige/brite, have been reported to 
present a unique gene expression signature (Table 2 of the introduction section) which 
provides a powerful tool for investigating fat identity (Wu et al., 2012), I performed the 
experiments on a set of these genes. I verified the expression of a subset of the brown-
selective (Figure 41A) and beige-selective (Figure 41B) genes in the basal (not cold 
exposed or cAMP-stimulated) state via qPCR analysis. Data demonstrated that two 
beige specific genes, Tmem26 and Tbx1, appeared increased in subcutaneous WAT 
from DIO treated animals. At first sight, this could be indicative of a browning processes 
being settled. However, this hypothesis could not be totally confirmed due to the lack of 
significant variation for extra brown (Prdm16 and Cidea), and yonder beige specific 
genes (HoxC9). Besides, the experimental design was not optimal for permitting the 
investigator to observe the desired results (see the discussion section for further 
explanations).  
To complete the characterization of WAT, I checked for the expression of a few other 
relevant genes, revealing an increase in Adrb3 and PPARα, accompanied by a decrease 
in Leptin, which is logically correlated to the amount of fat in the depots of the individuals 
(Figure 41C).  
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Figure 41: Absence of a clear effect of ABX300 on browning. 
 
A) Relative mRNA expression for genes with a brown selective expression pattern was 
measured by qPCR in white and brown fat tissue isolated from inguinal WAT and 
interscapular BAT of DIO mice, in an unstimulated state. 
B) Relative mRNA expression for genes with a beige selective expression pattern in 
inguinal WAT from mice in A). 
C) qRT-PCR data showing the fold induction of the expression of the indicated genes 
in visceral WAT of Untreated and ABX300 DIO Treated mice. 
 
All qPCR results are normalized to the housekeeping genes (NoNo and b2m).  
Values are mean ±SEM (n = 7). *p < 0.05; **p < 0.01; ***p < 0.001.  
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iv) Effect of ABX300 on mitochondria and oxygen consumption  
 
Mitochondrial number and mitochondrial-based respiration is highly adaptive in 
most eukaryotes, responding to environmental conditions such as diet, physical activity, 
and temperature (Uldry et al., 2006). For example, transgenic mice with an increased 
mitochondrial number have been reported as being resistant to obesity (Kopecky et al., 
1995). Because, as I just showed, subcutaneous inguinal WAT from ABX300 treated 
mice partially acquired the appearance of BAT, expressing significantly higher levels of 
Tmem26 and Tbx1, I investigated the possibility that mitochondrial biogenesis in these 
animals occurred. Analysis using a mouse mitochondrial biogenesis qPCR Kit (72626 | 
NovaQUANT™), consisting on a qPCR plate with specific pre-aliquoted PCR primers 
showed no important variations regarding the relative mRNA levels of Oxidative 
Phosphorylation (OXPHOS) complex subunits I, II, III, IV and V. This last complex was 
represented in the plate by three different genes. Among them, significant differences 
were apparent in response to ABX300 treatment for ATP5G3 in both, white and brown 
fat tissues, and for ATP5A1 exclusively in WAT (Figures 42A and B). 
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Figure 42: ABX300 does not modulate the relative mRNA expression of key genes 
involved in mitochondrial biogenesis in WAT and BAT. 
 
A) Relative mRNA expression of OXPHOS complex subunits I, II, III, IV and V in WAT. 
B) Relative mRNA expression of OXPHOS complex subunits I, II, III, IV and V in BAT. 
 
The mRNA for the house keeping genes used in were mRPII, mRPL27 and mOAZ1.  
Individuals correspond to one month of treatment with ABX300 in a curative context. 
Values are mean ±SEM (n = 5). *p < 0.05; **p < 0.01; ***p < 0.001.  
 
Mitochondrial number was further evaluated in WAT and BAT by quantification of 
mitochondrial DNA. This was done by calculating the ratio between mitochondrial and 
genomic DNA, using commercial pre-coated plates too (72621 | NovaQUANT™). This 
kit contains a set of four optimized PCR primer pairs targeting two nuclear (BECN1 and 
NEB) and two mitochondrial (trLEV and 12s) genes Compared to the untreated 
condition, the amount of mtDNA was significantly higher in BAT from HFD ABX300 
treated mice. In contrast, no differences were observed in WAT (Figure 43A). 
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Figure 43B depicts qPCR analysis of mRNA relative expression of 
supplementary OXPHOS genes in WAT and BAT, and some of the obtained results 
encounter those previously exhibited in figure 41. The discrepancy in between these 
analysis might be due to the distinct origin of the samples or to the disparate design of 
the primers. This last factor could influence in amplicon size, as well as RT-PCR 
efficiency, which brings on a bias that could account for the intriguingly uneven results. 
Surprisingly, no differences between groups were previously apparent for complexes II, 
III and IV whereas variations are evident along the qPCR represented in the left column 
of Figure 43B, which refers to WAT. Regarding BAT, no modulations were apparent 
any of the studied genes, except for Cox1 (complex IV) (Figure 43B right column). Cox1 
is a component in the respiratory chain which catalyzes the reduction of O2 to H2O, CO-
I being the catalytic subunit of the enzyme. The possibility of novel anti-obesity therapies 
to increase oxygen consumption is a tantalizing speculation. In fact, this elevated 02 
consumption is what we have somehow shown within the Figure 7 of López Herrera et 
al. An action of ABX300 thereupon may account for the protection from high-fat diet-
induced obesity during the treatment.  
Withal, an alternative explanation for the observed phenotype would be if 
mitochondrial FAO was sufficiently elevated to prevent the accumulation of the excess 
dietary fat. We assessed genes described in the literature as being essential during β-
oxidation in WAT and BAT (Figure 43C). Out of the seven genes studied in inguinal 
WAT, results showed an absence of ABX300 regulation for Cpt1, Sirt1 and GPx1 while 
up-regulations were exhibited for Pgc1a, Cpt2 and Sod1. Nevertheless, the results 
concerning Pgc1a and Cpt1 must be interpreted cautiously because these genes were 
amplified after 30 cycles of qPCR. For Pgc1a, this situation of late peaks on the 
amplification plots was reproduced in BAT. This trouble was unexpected, since BAT is 
a tissue where the expression of this gene is known to be much more abundant. No 
changes were observed for Cpt1, nor Cpt2 in BAT. Lastly, mCAD appeared down-
regulated in both, WAT and BAT from ABX300 treated animals. 
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Figure 43: ABX300 influence on the mitochondrial amount and on the relative 
expression levels of genes implicated in mitochondrial ETC and Beta Oxidation. 
 
A) Ratio between mitochondrial and genomic DNA to evaluate mitochondrial number. 
B) Relative mRNA levels of genes from the mitochondrial ETC. 
C) Relative mRNA levels of genes involved in mitochondrial β-Oxidation. 
 
All qPCR results are normalized to the housekeeping genes (NoNo and b2m). 
Values are mean ±SEM (n = 5-8). *p < 0.05; **p < 0.01; ***p < 0.001.  
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To try to solve out the conspicuous contradictions in between figures 42 and 43, 
and check if the changes observed at the mRNA level were or not evident at the protein 
level, I carried out Western Blot analysis of the different subunits of each of the five 
complexes assembling the ETC. Protein detection with the ‘Total OXPHOS Rodent WB 
Antibody Cocktail (ab110413)’ did not allow to note any changes in WAT (Figure 44A). 
However, an increase of the protein expression levels of Cytochrome c oxidase subunit 
1 (Cox1) was shown in BAT (Figure 44B). This result is in accordance with the 
observations at the transcriptional level showed in the right panel of Figure 43B. 
 
Figure 44: Protein levels of mitochondrial total oxidative phosphorylation (OXPHOS) in 
WAT and BAT of ABX300 treated and untreated mice. 
 
A)  Representative blots of OXPHOS complexes I–V and bands intensity quantification 
(Image J) in WAT. 
B) Similar than A) but in BAT.  
Values are mean ±SEM (n = 7). *p < 0.05; **p < 0.01; ***p < 0.001.  
 
This variation could be indicative of a different activity of the ETC complexes. In 
order to evaluate if this was indeed the case, ass an adjacent step we measured oxygen 
consumption ratio (OCR) in different cell models, using the Seahorse XF24 Extracellular 
Flux Analyzer (Seahorse Bioscience, North Billerica, MA).  
These two cell lines were measured with quintuplicate wells per experimental condition. 
Cells were seeded and differentiated directly into special XF24 cell culture plates and 
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incubated at 37°C, CO2 free, for one hour in unbuffered, serum-free DMEM media prior 
to analysis. The length of differentiation was fixed to seven days for both cellular models. 
The molecule was mixed within the cell culture media and dispatched into the wells 
when changing medium, which corresponds to four times for 3T3-L1 cells (days 1, 3, 5 
and 7 of the differentiation protocol), and five times for BAT preadipocytes (days 1, 2, 3, 
5 and 7 of the differentiation protocol). In both cases the cells were as well treated during 
four hours, the morning of the Seahorse run, which took place systematically during the 
afternoon. ABX300 treatment after differentiation partook during four consecutive days 
in a daily fashion (≈96 hours). 
ABX300 Treated cells exhibited no important differences when compared to control 
(Figure 45) in 3T3-L1 (A and B) and BAT preadipocytes (C and D). I carried drug 
treatment at various concentrations both, during differentiation (A and C), and once the 
cells were differentiated (B and D) in twain cell models, without exhibiting any robust 
and reproducible effect. 
Bioenergetic profiling (Figure 45) was performed by monitoring basal oxygen 
consumption for 30 minutes followed by the sequential injection of three inhibitors. The 
final concentrations for 3T3-L1 or BAT preadipocytes, were: (a) oligomycin (1 or 3 µM), 
(b) cyanide p-trifluoromethoxy-phenylhydrazone (FCCP) (600 or 300 nM), and (c) 
rotenone (1 µM for both). Basal oxygen consumption, was calculated from the primary 
data and is represented in the histograms appearing on the left side of the figure. 
Seahorse profiles on the right part give us information about the proper conduct of the 
experiment. Analysis of the profiles more in depth would allow us to obtain hints about 
ATP production, maximal respiration, spare capacity and non-mitochondrial respiration. 
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Figure 45: ABX300 does not change profiling of Seahorse XF Stress Test 
 
A) 3T3-L1 cells treated with ABX300 during white adipocyte differentiation. 
B) 3T3-L1 cells treated with ABX300 after white adipocyte differentiation. 
C) BAT preadipocytes treated with ABX300 during white adipocyte differentiation. 
D) BAT preadipocytes treated with ABX300 after white adipocyte differentiation. 
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Because we were rather convinced that our treatment had indeed an effect on 
mitochondrial respiration, even if using the Seahorse technology we unable to clearly 
show it on these cellular models, we decided for Mouse Embryonic Fibroblasts (MEFs) 
to face a more physiological and complete conditions. Unfortunately, we were still 
unable to confirm any effect of our treatment on OCR (data not shown). In the same 
way I could not surely observe confident results when working with pieces of AT from 
distinct depots (data not shown); and ditto when trying to isolate intact mitochondria 
from the preceding tissues. 
Although we did not succeed with the demonstration of ABX300’s effect on OCR 
using in vitro cellular models, we strongly believe that ABX300 impacts mitochondrial 
activity. In fact, this is what the results from the metabolic cages experiments shown in 
López Herrera et al. suggest. Setting up the appropriate parameters to further apply the 
Seahorse technology to ex-vivo samples and isolated mitochondria would be necessary 
for the completion of the project. 
v) Effect of ABX300 on LMNA 
 
To further understand the opposing effects of the distinct isoforms encoded by 
the LMNA gene on energy metabolism, we analyzed CD/HFD ABX300 Un/Treated 
animals. We found by Western Blotting that, as a consequence of a dietary switch, 
protein expression levels of both lamin A and lamin C, were altered in WAT, whereas 
they remained unchanged in BAT (Figure 46, left panel). Nevertheless, following 
ABX300 treatment of DIO mice, changes were measurable for several metabolic organs; 
including WAT, BAT, liver and muscle, where increased expression levels of lamins A/C 
were exhibited. No differences were described for other tissues (Figure 46, right panel 
and data not shown).  
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Figure 46: Tissue specific expression of lamins depending on diet condition and 
ABX300 treatment. 
 
Protein level of Lamin A/C in WAT, BAT, Muscle, Liver, Heart and Brain were determined by 
western blot. Tubulin levels were used as a control. Analysis showing quantification of protein 
expression levels using ImageJ software. All these experiments were done with C57BL/6 mice 
(n= 6-8 /group). Values are given as mean ± SEM. **p < 0.001 and ***p <0.0001. Antibodies 
references are Lamin A/C (H-110): sc-20681 and α Tubulin (DM1A): sc-32293. 
 
For concretizing our results, we tested ABX300 in murine models exclusively 
expressing the Lamin C isoform of the LMNA gene (LCS) (Osorio et al., 2011). We put 
the animals under HFD to force them to rapid obesity and exacerbate the conceivable 
effects of the molecule (Figure 47A). WT mice lost in average 11.82 grams (Figure 
47B). On their side, results regarding the LCS animals were not concluding because, 
after 50 days, responses to ABX300 treatment differed according to the individuals’ 
genetic background.  LCS male mice breeding from heterozygous LCS progenitors 
(WT/LCS) lost in average 12.3 grams (Figure 47C).  Whereas, the LCS offspring 
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proceeding from homozygous parents (LCS/LCS), barely lost 0.3 grams (Figure 47D). 
These experiments must be redesigned keeping into higher consideration the 
provenance of the animals. Moreover, the completely epitomizing of the drug would 
require also its administration in murine models deficient for A-type lamins (Lloyd et al., 
2002; Fong et al., 2006; Davies et al., 2010; Coffinier et al., 2010). 
 
Figure 47: LCS mice response to ABX300 diverges according to their genetic 
background. 
 
A) Weight monitoring of untreated and ABX300 treated WT and LCS mice under HFD conditions. 
B) Weight monitoring of WT HFD ABX300 Treated mice. 
C) Weight monitoring of LCS HFD ABX300 Treated WT/LCS mice. 
D) Weight monitoring of LCS HFD ABX300 Treated LCS/LCS mice. 
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vi) Further phenotypic characterization of ABX300 treated mice 
 
 
To try to get rid of the kidney toxic effects in vivo (see “clinical development”) 
while maintaining efficacy, we carried out three sort of experiments. In the first kind, we 
diminished the frequency of the drug administration to three times per week (50mg/Kg) 
(Figure 48A). In the second kind we changed the administration dose, adapting the drug 
amount to the animal’s lean-mass (≈31g) (Figure 48B). Finally, in the third case, we 
diminished downright to 20mg/Kg (Figure 48C). 
In the two first cases, ABX300 had the same effect on weight evolution than when 
administrated daily at 50mg/Kg. But unfortunately, kidney toxicity was still present (data 
not shown). The third concentration was below the required threshold for an 
appreciable action, and animal groups did not present any differences regarding weight 
evolution. 
 
 
Figure 48: Different treatment schemes of ABX300 do not affect its effect on weight loss 
after one month treatment. 
 
The general diminution of the fat size, as well as the aspect of other metabolic 
organs from these three and other treatment schemes previously mentioned can be 
observed in Figure 49. 
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Figure 49: Noteworthy macroscopic effects induced by ABX300 on WAT. 
 
Pictures of metabolic organs from exemplary individuals in very many of the so-mentioned 
ABX300 protocols in this manuscript (See Figure 48 on this same page and Figure 2 of López 
Herrera et al.) 
  
The experiences depicted in Figures 48 A) and B) are quite curious because if 
we take into account the total amount of drug, and this in a weekly fashion: 50mg*3=150, 
and 20mg*7=140, which corresponds to almost the same quantity of ABX300 
administrated per week. This observation suggests the existence of some kind of 
mechanism that will not be activated if the dose is not high enough, some threshold to 
be surpassed at once, not with the potential accumulation of the compound over time. 
To study the accumulation of the molecule over time, and the memory effect of ABX300 
we designed an experiment into which we would arrest treatment and check for weight 
evolution (Figure 50).  
We monitored the weight changes of untreated and ABX300 treated mice went from a 
normal chow diet (CD) (yellow cage) to a high fat diet (HFD) (grey cage). At the start of 
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the experiment, under normal diet conditions, the mice weight did not significantly differ 
between groups. At day 60 (a), all animals were put to a HFD (a) and two groups were 
made from the initially treated group. In the one that ABX300 treatment was arrested, 
mice began to gain weight (green squares) gradually approaching the vehicle group 
(blue circles). ABX300 long term treated animals (maroon squares), maintained their 
original weight, reproducing the preventing effect of the molecule that we had already 
proven. To check for reversibility of our effect, at day 110 these two groups were 
inversed (b). The graph shows how the group that re-started the treatment, immediately 
lost weight (green triangles) and the group that had been treated for over three months, 
slightly started to re-gain weight (maroon triangles). On day 150, when the experiment 
was terminated, the weight of the mice belonging to the inversed groups was in the 
range of 22–23 g, whereas untreated animals had reached 27g. 
These data led us to conclude that lipoatrophy induced by ABX300 is reversible upon 
cessation of treatment, in other words, that ABX300 enhances weight loss in obese mice 
without inducing resistance. 
 
 
Figure 50: Long term effect and efficacy of ABX300 to enhance weight loss in obese but 
not lean mice 
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Because of this food dependent effect of ABX300 treatment, we decided to focus 
on more metabolic aspects. Regarding carbohydrates metabolization, a couple of tests 
were carried out in order to evaluate the physiological response to a given dose of 
glucose. To determine how mice’s organism broke sugar down, we carried out an OGTT 
(Oral Glucose Tolerance Test) experiment. Four hours fasting subjects were orally given 
of glucose. Blood samples were collected every thirty minutes for further glycemic 
evaluation. If insulin secretion befallen normally, data obtained in this manner would 
allow the experimenter to observe a decrease of the glucose present in the blood, and 
indeed, this was the case. Results in Figure 51A show a slight improvement in regard 
to glucose tolerance after 1 month of ABX300 treatment. Moreover, this test is usually 
used to assess diabetes, insulin resistance, and sometimes rare disorders of 
carbohydrate metabolism. 
Besides OGTT, individuals were also conducted through ITT (Insulin Tolerance Test). 
This analysis measures the body's ability to respond to an intra-peritoneal (IP) injection 
of insulin. Similarly to the previous experience, we followed the levels of blood glucose 
every fifteen minutes during the 45 minutes following insulin injection. However, this time 
not improvement of the ability of ABX300 treated mice to respond to IP injected insulin 
was observed (Figure 51B). 
 
Figure 51: ABX300 does not induce robust changes in glucose metabolism. 
 
A) ITT monitoring after insulin intra-peritoneal injection on treated and control groups. 
B) OGTT monitoring after glucose oral administration on treated and control groups. 
OGTTà 1 gram of glucose per kg; ITTà 1U insulin per kg (n=7-8/metabolic test). 
ITT
Time (min)
G
ly
ce
m
ia
 (
m
g
/d
L
) 
+
/-
 S
D
0 15 30 45 60
0
100
200
300
HFD Untreated
HFD Treated
OGTT
Time (min)
G
ly
ce
m
ia
 (
m
g
/d
L
) 
+
/-
 S
D
0 30 60
0
100
200
300
400
HFD Untreated
HFD Treated
A
U
C
 g
lu
co
se
 (
m
g
.h
/d
L
)
HFD Untreated HFD Treated
0
5000
10000
15000
20000
25000
A
U
C
 g
lu
co
se
 (
m
g
.h
/d
L
)
HFD Untreated HFD Treated
0
1000
2000
3000
4000
5000
A) B)
RESULTS 
 
106 
 
4. Clinical development of ABX300 
 
i) Adverse effects of ABX300 on hERG 
 
In preclinical safety trials, studies on the mechanisms of hERG (human Ether-à-
go-go-Related Gene) channel inhibition are nowadays an unavoidable step for the 
development process of any pharmaceutical compound. These channels are 
essential for the normal electrical activity of the heart. A molecule is considered 
acceptable when administered at 1µM, the enhanced hERG inhibition remains 
below 10%. Several blockbuster drugs have been withdrawn from the market due 
to undesirable side effects on these channels. Repercussions usually involve long 
QT syndromes, which create a concomitant risk of sudden death (Sanguinetti and 
Tristani-Firouzi, 2006). 
In the laboratory, before my arrival, extensive studies had been conducted on 
ABX300 toxicity, including evaluation of the rabbit Purkinje fibers. The obtained 
results had determined too high risks for a potential clinical development. To try to 
get rid of this conceivable cardiotoxicity, together with chemists, we worked on 
ABX300 SAR (Structure-Activity Relationship). My second project’s objective 
relates to this issue and seeks to solve it in order to obtain a druggable compound 
clinically developable. 
Unluckily, the majority of the designed ABX300 homologues which were positive 
within our screening systems (see López Herrera et al.), compounds conserved an 
unacceptable hERG (Table 4), and the ones that did not, did not prompt the desired 
in vivo response (Figure 56). 
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Table 4: Activity and cardiotoxicity of all the in vivo tested ABIVAX compounds. 
 
The three first columns show for each in vivo tested compound: the Abivax nomenclature, 
their LMNA-luc activity and their LMNA-luc toxicity (MTS) (mean from three independent 
experiments). The two last columns exhibit hERG data at 1 and 10 µM. Blue delineates 
activities below the established threshold, reed shows toxicity and green points to a safe 
cardiac response to the products. Grey illustrates the period of my PhD. 
1 µM 10 µM
ABX300 3,33 <10 % 26 70,3
ABX418 6,03 <10 % 12 20
ABX420 4,97 <10 % 9,3 15
ABX435 3,59 <10 % 14,7 48,3
ABX448 3,87 10 % < x < 30% 11 59
ABX545 2,33 <10 % 5,3 5,3
ABX550 2,36 <10 % 8 9,3
ABX719 5,63 <10 % 4 38
ABX720 5,47 <10 % 9 34
ABX722 3,23 <10 % 22 60
ABX725 6,20 <10 % 2 10
ABX730 5,21 <10 % 3 11
ABX777 2,98 <10 % 5,7 8
ABX791 3,11 10 % < x < 30% 5 13,7
ABX833 3,32 <10 % 9 22
ABX835 3,83 <10 % 5 13
ABX844 3,37 <10 % 5 55
ABX858 2,70 <10 %
ABX860 2,89 <10 % 10 43
ABX861 2,80 <10 % 7 19
ABX898 <10 % <10 %
Abivax 
Compound
LMNA-luc 
activity
LMNA-luc toxicity 
(MTS)
hERG
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ii) Adverse effects of ABX300 on kidneys 
 
When carrying out the sacrifices of the animals, we frequently noticed an 
abnormal kidney aspect on the treated mice that, we were afraid, was pointing to a 
nephrotoxicity potentially induced by the treatment. Notably, we could check that 
ABX300 induced alterations in the size, morphology and structure of these organs. 
Histopathological analyzes of kinetics (Figure 52) revealed: Clogged renal tubules 
(A), fibrosis (B), and numerous inflammatory cells infiltrations (A, B, C). These 
features were apparent after only six days of ABX300 drug administration, and this 
independently of the regime conditions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 52: Kidney sections of kidneys fro, ABX300 DIO treated mice. 
 
Haematoxylin-Eosin staining of representative sections of kidney embedded in 
paraffin after 1 month of treatment. See text for further details. 
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iii) ABX300 skin biopsies in vitro (absorption experiments) 
 
Facing the impossibility of making away with hERG and kidney side effects, we 
explored the possibility of developing an ABX300 topic treatment. Overlooking a 
potential future cream, we did some experiments on dermal absorption, using in vitro 
skin biopsies. The aim of the study that took place at C.RIS Pharma, was to evaluate 
the dermal and epidermal absorption of ABX300 by using fresh ex-vivo human skin 
biopsies (Nativeskin). Biopsies were treated at T0min and collected at T1h and T24h 
for further analysis of ABX300 content in dermal and epidermal tissues by HPLC-
MS/MS method.  
Results uncovered the ability of ABX300 to go across these samples. Scarcely 1 hour 
was sufficient to be able to detect ABX300, both in the epidermis and the dermis. 
Logically, after 24h of ABX300 exposure time, its concentration was increased (Figure 
53). We concluded a satisfactory permeability of the skin to our molecule. These 
findings imply the possibility of a potential and promising development of ABX300 with 
cosmetic purposes.  
 
 
 
 
Figure 53: In vitro ABX300 dermal absorption experiment on skin biopsies.  
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Project 2: Identification of molecules targeting LMNA splicing to avoid use 
of the progerin 5’ SS 
1. Aim of the project 
 
 
Commonly, drugs fail along the development process for two main reasons. The 
first is that they do not work, and the second is that they are not safe. For ABX300, 
case number two is what explains the “no go” decision referring to its continuity into 
clinics. Because of the many existing drawbacks to pharmaceutically develop this 
molecule, the second objective of my PhD has been the identification of novel 
molecules, mainly ABX300 analogues but not exclusively, targeting LMNA splicing, 
and thus theoretically having an impact on weight evolution. Chemical modifications 
were implemented into the principal drug skeleton. On the frame of this second project 
of my PhD, we intended to find a back-up molecule. Ideally, this drug would not have 
adverse side effects of any kind while maintaining the activity and efficacy of ABX300 
on weight modulation. 
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2. Modulation of the luciferase activity of the mini gene reporter by the ABIVAX 
Chemical Library  
 
 The ABIVAX Chemical Library is emplaced in the Curie Institute, in Paris. 
Further information about the origins of this drugs collection can be found in Soret et 
al., 2005 and Bakkour et al., 2007. Practically the entire presently existing library has 
been screened by means of the mini-gene luciferase reporter shown within Figure 1B 
of López Herrera et al. Since the beginning of this project in 2009, the number of tested 
drugs totals 887. This work has been mostly fulfilled by Julien Santo, an ABIVAX 
employee. He has also set up several parameters for the screening test, such as the 
optimal amount of cells to be seeded (104/well), the best cell clone to be used (clone 
8) and the appropriate reading time (1s).  
Because the background signal was very high in the HEK293 stable cell line, an 
elevated threshold was established in order to avoid selecting false positive 
compounds. Indeed, only molecules increasing 3 fold the luminescence signal 
compared to the control were selected for further exploration. Keeping this limit into 
consideration, 62 drugs out of the 887, are above the established threshold (Figure 
54). Additionally, a toxicity test that reflects the number of viable cells based on the 
mitochondrial respiratory chain reactions (MTS) is systematically run to discard 
potentially toxic compounds. Once this second criterion is checked for, only 52 out of 
the 887 prevail eligible. 
During the period of my PhD 110 molecules were screened from the ABIVAX chemical 
library. Only a few of these seemed to have an effect on LMNA splicing with no toxicity, 
and were investigated in vivo. 
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Figure 54: Histogram recapitulating all the drugs from the ABIVAX Chemical Library tested with the LMNA-luc mini gene reporter.  
Vertical bars represent the mean of the luciferase activity from three independent experiments. Pink bars signify the molecules tested in vivo. The 
grey rectangle illustrates the period of my PhD. Threshold is depicted with a black line. 
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i) Regulation of body weight through splicing modulation 
 
To bypass the so-mentioned negative effects of ABX300, the chemists that 
we work with, focused on ABX300’s SAR studies. A summary of the modified 
chemical moieties is depicted in figure 55. 
 
 
Figure 55: Modified moieties during the SAR studies. 
 
Countless modifications have been done in the structure. However, only 
21 ABIVAX drugs have been proved in vivo, in obesity models. They appear 
maroon colored on Figure 54. Before my arrival to the lab, the team had already 
tested six analogues (from 2009 to 2012) ABX418, ABX420, ABX545, ABX550, 
ABX725 and ABX730. Unsuccessfully none of them was proved effective relative 
to weight loss. During the period of my PhD (from 2012 to 2015), we tested 
another 14 whose in vitro activity was very close to three or beyond, and that 
corresponded elsewhere to the rest of the eligible criteria that had been 
previously determined (see text). These molecules correspond to ABX435, 
ABX448, ABX719, ABX720, ABX722, ABX777, ABX791, ABX833, ABX835, 
ABX844, ABX858, ABX860, ABX861 and ABX898. As a positive control, ABX300 
(the 21st to complete the list), was simultaneously administered in in every 
experiment. 
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Treatments were administrated daily by a tube feeding protocol. Animal groups 
were composed of 7 to 10 mice and the period of administration oscillated from 
30 to 60 days. The amount of drug was set according to the weight of each mouse 
at a dose of 50mg/Kg, and this for all of the molecules. An exceptional situation 
exists for ABX898 where three different doses were tested; 5, 25 and 50mg/Kg. 
This is because this compound is in fact a pro-drug of ABX887, into which the 
addition of a phosphate group to the scaffold of the molecule was intended to 
solubilize it rendering it more available for the organism (Gasparik et al., 2012). 
All the molecules were tested in a curative context, except for two of them, 
ABX777 and ABX791, which were administrated in a preventive manner. ABX448 
was also in vivo tested, but graphs are not shown in this manuscript because the 
treatment had to be stopped after one week due to the severe in vivo toxicity of 
the molecule. 
Unfortunately, when the totality of the compounds were tested on DIO mice 
models, none of them showed an effect on weight evolution. The weight of 
untreated animals, in blue, progressed in parallel to that one belonging to treated 
animals, in maroon (Figure 56). 
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Figure 56: Absence of in vivo efficiency on weight loss of ABX 
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GENERAL DISCUSSION 
LMNA is a gene coding for three major protein isoforms that have been 
classically implicated in nuclear architecture, gene expression, DNA replication, 
transcription signaling, chromatin organization and aging (Worman and Bonne, 
2007; Dechat et al., 2008; Worman et al., 2009; Schreiber and Kennedy, 2013). 
To procure these distinct protein products, the LMNA gene is subjected to 
alternative processing. Alternative polyadenylation will give rise to lamins A and 
C while AS will produce lamin A and progerin. In the laboratory, we have shown 
that this splicing process is mainly regulated by two SR proteins, which 
correspond to SRSF1 and SRSF6. These two factors have been reported to play 
opposite roles in LMNA splicing (Lopez-Mejia et al., 2011). Furthermore, recent 
evidence indicates that LMNA is an active player in metabolism (Tang et al., 
2011; Liu et al., 2012). Moreover, our laboratory has demonstrated that the 
different LMNA isoforms have antagonistic functions in EE and lifespan (Lopez-
Mejia et al., 2014). This gene had already been proclaimed as a potential target 
for pharmacological modulation of WAT formation and, ultimately obesity.  
Various studies had identified LMNA as a strong candidate for targeting metabolic 
disorders (Rochford, 2014), but none of them had considered targeting LMNA’s 
splicing mechanism for this purpose. To better understand how LMNA influences 
AT homeostasis and the essential link of this gene with obesity, my thesis work 
has addressed two aims: the investigation of the MoA of ABX300, a modulator of 
the LMNA gene splicing with a striking effect on weight evolution; and the 
identification of other small molecules targeting the AS of LMNA. 
Along this project, we have concretely been interested in the AS of the LMNA 
gene. We employed animal models to determine a concrete role for A-type lamins 
expression in the regulation of BMI and/or metabolism. In this regard, our data 
point to a favoring of the mechanisms leading to Lamin-A production. Our results 
are in line with previous evidence suggesting a metabolic role for lamins (Tang et 
al., 2011; Liu et al., 2012). One mechanism via which mutations in LMNA are 
proposed to influence AT is via interaction with the transcription factor SREBP1c 
(Lloyd et al., 2002). Beyond a role in regulating transcription factors, the lamins 
interact directly with many other nuclear proteins and form lamina-associated 
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domains (LADs) that are repressive regions rich in heterochromatin. By changing 
Lamin-A outcome, ABX300 could possibly affect AT-related gene expression. 
Lamin-A seems to be one important core module that modulates various 
transcriptional pathways, among which SREBP1 is comprised, in enhancing 
matrix elasticity–directed differentiation (Swift et al., 2013). 
The interaction of SREBP1 with lamins A and C was characterized more than ten 
years ago, after a yeast-two hybrid interaction screen. SREBP1c plays a key role 
in adipocyte differentiation, inducing the expression of many genes of the mature 
adipocyte (Kim and Spiegelman, 1996). It acts as a transcription factor, that 
attached to the nuclear membrane and the endoplasmic reticulum regulates the 
expression and activity of PPARγ and PGC1α. Several lines of evidence have 
suggested a role for SREBP-1 as a key mediator in the induction of lipogenesis 
during experimental caloric excess, regardless of whether the calories are 
derived largely from dietary carbohydrates or dietary fats. Furthermore, inhibition 
of SREBP by one small molecule, betulin, ameliorated obesity and increased EE 
in mice (Tang et al., 2011).  
 
In my concrete project, for selecting the compounds capable of modulating LMNA 
AS, two screening systems were designed. A first one based on SRSF1 
localization, and a second one based on the splicing event that occurs between 
exons 11 and 12 of the LMNA gene in the frame of HGPS (C>T à activation of 
progerin 5’SS). On this second reporting system, it would be advisable to test 
ABX300 on the corresponding WT/non-mutated mini-gene. By doing so, we 
would get rid of any potential transcriptional effect of the drugs and could really 
recline on this construction with a closer reliability. Alternatively, we could have 
used other approaches for compound screening. Small-molecule screening 
techniques in drug discovery have been reviewed by Kedhar and colleagues. 
(Khedkar et al., 2009). 
In the course of our experiments, we were able to establish an interaction 
between SRSF1 and ABX300. Having accomplished this, we would like to 
continue the study with other members of this same family of splicing regulators. 
With respect to the regulation of LMNA’s AS by SRSF1, a counteraction has been 
shown to be exerted by SRSF5 and SRSF6, (Fong et al., 2009; Lopez-Mejia et 
al., 2011), which enhance the use of the LMNA 5′SS at the expenses of progerin 
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5′SS. It would be intriguing to determine whether they bind to ABX300 or not. In 
addition, it is not superfluous to think that it is possible the existence of many 
other RNA Binding Proteins (RBPs) that would also interact with our candidate-
drug. Another potential RBP would be Sam68, which has been recently identified 
to control  prelamin- A (Lattanzi et al., 2014), and which in addition has been 
proposed to be a key regulator of AS during adipogenesis, by binding the 
mammalian target of rapamycin (mTOR) (Huot et al., 2012). To recover other 
potential interactions we could use techniques of affinity chromatography or SPR 
(Surface Plasmon Resonance) in combination with mass spectrometry (MS). 
SPR quantifies interactions between proteins and ligands whereas MS deciphers 
the structural features of the bound proteins. In addition, since computational 
prediction of interactions between drugs and their target proteins is of great 
importance for drug discovery and design, we could also help ourselves with in 
silico prediction methods. 
 
When we turn our attention to global expression analyses, an overall 
alteration in AT specific splicing may also contribute to the striking effect on 
weight evolution caused by ABX300 treatment in this tissue. When we evaluated 
the impact of ABX300 on cellular splicing, we determined that it did not seem to 
globally interfere with this process. The relative abundance of the alternatively 
spliced products did not show variations between conditions, suggesting no large 
impact of our treatment on AS. Moreover, it might be interesting to demonstrate 
that ABX300 does not stall the spliceosome assembly, like they do some known 
drugs, such as Spliceostatin A (Roybal and Jurica, 2010), Isoginkgetin (Bonnal 
et al., 2012) or Pladienolide B (Shi et al., 2015). One adequate method to verify 
this would be the performance of radioactive assays. To get beyond about this 
point, high-throughput analysis of RNA splicing (HTS) could shed extra light into 
how ABX300 contributes to weight loss by modulating splicing of specific pre-
mRNA in a genome-wide scale. RNA-Seq seems to be more flexible and powerful 
than microarrays. When sequencing polyA+ RNAs with stranded protocol, the 
quality of the data is very good. Besides, by using also small RNA sequencing 
(selecting RNAs of length <100nt and then sequencing this fraction), it would be 
possible to assess the effect of the treatment on miRNA biogenesis.  
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Moreover, it has been shown that primary sequence and RNA structure 
are key regulators in miRNA biogenesis (Ha and Kim, 2014). Complementary, it 
has been demonstrated that alterations in miRNA levels correlate with various 
metabolic diseases (Hartig et al., 2015). However, there is limited knowledge on 
how diet influences miRNA expression in AT. Experiments in 3T3-L1 cells and 
primary adipocytes suggest changes in miRNA expression may occur in 
response to nutrient availability (Klöting et al., 2009). Given the growing number 
of adipogenic and anti-adipogenic miRNAs identified, it is highly plausible that 
these miRNAs will also respond to dietary changes. Indeed our results show food-
dependent variations for 113 miRNA. In a correlative manner, some studies have 
shown that nutrient supplementation can reduce the adverse consequences of a 
HFD and also coincidently modulate miRNA expression in AT (Parra et al., 2010; 
Murase et al., 2011). Our work additionally shows a modulatory effect of ABX300 
on the miR found in AT. After intersection of the several generated datasets, our 
miRNA analysis demonstrated that ABX300 modulates a population of miRNAs 
likely mitochondrial-enriched, and this independently of the nutritional regime. 
Since regarding SRSF1, data are available for CLIP (cross-linking 
immunoprecipitation) and ChIP-seq (chromatin immunoprecipitation combined 
with massively parallel DNA sequencing) (Ji et al., 2013;  Pandit et al., 2013), it 
would be of great interest  to determine if this splicing factor, which interacts with 
our candidate-drug, does also bind to any of the 26 mitochondrial genes that are 
predicted to be targeted by the eight miRNAs modulated by ABX300 (miRBASE, 
≥80% confidence). Additionally, in future studies it would also be interesting to 
analyze how ABX300 affects interactions of SR proteins with mRNAs by co-IP or 
CLIP-Seq. Furthermore, it is worth noting that more direct evidence is now 
needed to document and validate the described ABX300-miR modulations, as 
well as the modulations of the miR-predicted targets. 
It has been recently reported that there exists an interplay in between 
miRNA silencing efficiency and mitochondrial activity (Huang et al., 2011). It is 
tempting to think that ABX300 treatment could possibly have an impact on RISC 
assembly, a process for which mitochondrial activity is required. Mitochondrial 
main activity is respiration, and it appears to act as a canonical central 
mechanism integrating central and peripheral regulation of energy stores. Our 
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studies highlight a mitochondrial’s major role in the regulation of the energy 
balance and suggest that the functioning of these organelles could be regulated 
by the ABX300 treatment. By the achieved comparisons we obtained information 
about the amount of these organelles in WAT and BAT. Interestingly, we showed 
that the content of these organelles was higher in BAT from treated animals. This 
finding might seem unexpected given the absence of ABX300 hearty modulations 
of the genes implicated in mitochondrial biogenesis, and the diminution we 
observe in PGC1α relative expression levels in BAT from treated animals. 
Intriguingly, these results regarding mitochondrial genes are a little bit 
convoluted, but as swiftly discussed all along the results themselves, it is possible 
that the explanation lies in the fact that both, individuals and primers were 
different between the different experiences. An increase in the number of 
individuals used for the in vivo experiments would also be recommendable.  
We presume that the mitochondrial amount could be related to mitochondrial 
activity, even if several lines of evidence suggest that this is not always 
necessarily the case (Galgani et al., 2008). Although we failed to in vitro identify 
this hypothetical increased mitochondrial activity using the Seahorse Technology, 
we believe that ABX300 treatment is inexorably linked to the functioning of this 
organelle. Nevertheless, much more complete analysis shall be performed to 
confirm this statement. 
Today’s research has described that disturbance of mitochondrial 
functioning and of fatty acid metabolism might be involved in the pathophysiology 
of obesity (Li et al., 2015). Furthermore, energy sensors such as AMPK, have 
been suggested to represent a central node linking energy metabolism to 
diseases correlated with aberrant AS (Finley, 2014). Measuring AMPK’s activity 
could help us characterize ABX300’s MoA. Besides, two recent reviews 
(Kaminska and Pihlajamäki, 2013; Lin, 2015) provided a brief overview of the 
basic aspects of splicing regulation in adipocytes differentiation, obesity and 
insulin resistance with specific examples. They suggested that understanding of 
the molecular mechanisms behind the spliced transcripts may provide 
opportunities for new diagnostic approaches. One concrete example is the 
association between a concrete spliced isoform and reduced adiposity. The 
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authors showed a selective reduction in the mass of fat depots in mice with 
skeletal muscle-specific transgenic expression of PGC-1α4, a form of PGC-1α 
that resulted from alternative promoter usage and splicing of the primary 
transcript (Ruas et al., 2012). PGC1 is a key factor in mitochondrial biogenesis 
and thermogenesis. Interestingly, PGC1α has two regions rich in serine-arginine 
pairs. These two RS domains make PGC1α an SR-like protein. Like for SR 
proteins, the activity of PGC1α is modulated by posttranslational modifications of 
the RS domain. PGC1α has been shown to be activated, together with SIRT1, by 
an outstanding compound known as resveratrol. This activation improved 
mitochondrial function and protected against metabolic disease (Lagouge et al., 
2006). Compelling data also demonstrated that specific SIRT1 activation 
mimicked low energy levels and protected against diet-induced metabolic 
disorders by enhancing fat oxidation (Feige et al., 2008). Furthermore, in 
genetically modified mice phenocopying the HGPS pathology (Zmpste24-/-), 
resveratrol was shown to activate SIRT1 in a Lamin A-dependent manner, thus 
associate with the nuclear matrix (Liu et al., 2012). SIRT1 is a NAD+-dependent 
protein deacetylase that regulates various metabolic pathways (Haigis and 
Sinclair, 2010). Loss of SIRT1 abolishes many beneficial effects of caloric 
restriction (CR). On the contrary, transgenic mice with additional copies of SIRT1 
show phenotypes resembling CR (Guarente, 2013). Putting this in context with 
our data, we could assimilate ABX300 action to resveratol’s and hypothesize that 
our molecule might act by enhancing SIRT1 action. However, experiments 
assessing potential SIRT1 activation by ABX300 would be required to affirm this. 
Lamins distribution upon ABX300 treatment should also be checked for; along 
with the locomotory activity of ABX300 treated animals. In terms of the coinciding 
effects of ABX300 and resveratrol regarding the leanness of the CR induced 
phenotype, we have demonstrated that ABX300 action on feeding cannot entirely 
explain the observed changes in body weight. Our PF results demonstrated that 
ABX300’s anorexigenic effect solo was not sufficient to explain the observed 
phenotype. It would also be interesting to determine which is the exact triggering 
effect, i.e. if diminish food intake precedes weight loss or it is the other way 
around. Additionally it would be interesting to evaluate the effects of ABX300 on 
the circulating levels of the principal neuropeptides related with appetite and 
satiety. 
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In the literature we encounter several lipolytic conditions among which 
beta-adrenoceptor agonist treatment is described. The finding that the relative 
mRNA expression of Adrb3 appeared increased in WAT from ABX300 treated 
mice is suggestive of elevated sympathetic activation. Higher sympathetic tone 
and activation of the beige cells, which are known to be present in this tissue, 
might lead to an increased EE and partially account for the observed leanness 
and DIO protection in treated animals. We could not conveniently demonstrate 
increased levels of beige adipocytes selective markers in WAT from treated 
animals. Supplementary experiments adequately challenging beige cells 
emergence would be required. This may be done by cold-exposure (4ºC), 
CL316,243 (β3-AR adrenoceptor agonist) administration, or the just described 
creatine-substrate for mitochondrial respiration enhancement in beige fat (Kazak 
et al., 2015). Alternatively, to verify the fate of FFA in ABX300 treated mice, we 
could perform metabolomics/ lipidomics analyses and trace the clearance of 
lipids by using radioactive-labeled palmitate ([13C], [1-14C], [U-14C], and [16-
14C]). Some other attainable experiences for this same purpose comprise among 
others following the lipid clearance from the circulation in response to a bolus fat 
load or the injection of lipid emulsions (olive oil for example). More readily, we 
could expose our animals to 24 hours of food deprivation and check which group 
lost more mass. We predict the observation of an exaggerated loss of fat mass 
in the ABX300 treated mice. This result would be indicative of an increase in the 
metabolic rate enhanced by the treatment. 
Indeed, when we recapitulate the experiments that we have carried out to 
check for a plausible lipolysis being established in treated cells/explants, we 
realize that in none of the experiences we have kept into consideration the likely 
re-esterification of fatty acids and glycerol. This could have been overcome by 
the addition of Triacsin C into the culture media.  Triacsin is a potent inhibitor of 
long fatty acyl CoA synthetase, and thus of triglyceride synthesis.  
The one exact mechanism by which ABX300 in fat tissue affects systemic 
metabolism remains unknown at this time. Despite our efforts to observe 
ABX300’s effect in vitro we did not succeed to prove any group differences. 
However, based on the current results we can speculate, that perhaps a 
metabolite, i.e. a molecule derived signaling molecule, enters the circulatory 
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system and subsequently affects metabolism in peripheral tissues. One 
experiment that would allow us to further confirm or dismiss this hypothesis would 
be to collect the serum from treated animals, to subsequently extract the potential 
metabolites and to thereafter use it in-vitro on different cellular models. 
Documenting the metabolites obtained from ABX300 could be doable with the 
help of techniques using microsomes. These are vesicle-like artifacts re-formed 
from pieces of the endoplasmic reticulum when eukaryotic cells are broken-up in 
the laboratory. A bank of readily available well-characterized human and animal 
hepatic microsomal fractions has been established and is available for this 
purpose (Lacarelle et al., 1991). Besides characterizing ABX300 metabolites, 
microsomal studies may also help to elucidate their pathways, and make 
suggestions for further in vivo testing (Jia and Liu, 2007). 
Historically, deciphering the mechanism of action of small molecules 
identified through cell-based screening has often brought new insights into 
biology (Schreiber and Kennedy, 2013). Such was the case for IDC16 and 
ABX464, two compounds targeting specifically SR proteins and inhibiting HIV 
RNA biogenesis respectively in vitro (Bakkour et al., 2007) and in vivo (Campos 
et al., 2015).  
For the advancement of basic science and drug development it is important to 
understand the interactions between small molecules and proteins. This can be 
approached from different perspectives. Particular methodologies have been 
developed to identify protein-small molecule and protein-metabolite interactions 
(McFedries et al., 2013). To carry out proteomics in the specific case of ABX300 
we would need to heavily rely on chemistry to link our compound to a solid support 
(different attachment sites could be tried according to prior information from 
SAR). In the drug discovery field, the classic target validation tool is the small 
bioactive molecule that interacts with and functionally modulates effector proteins 
(Hughes et al., 2011). The effector proteins that ABIVAX focuses on are namely 
the Serine/Arginine-Rich Splicing Factors (SR proteins). ABIVAX leitmotiv is to 
target the AS mechanism in order to cure various diseases. In joint collaboration 
with the CNRS (French National Center of Scientific Research), this company is 
developing novel drug candidates for the treatment of metabolic and viral 
disorders, along with exploring novel therapeutic space. Drug discovery and 
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development in ABIVAX involve the utilization of in vitro and in vivo experimental 
models. Unluckily, the leading drug candidate of my PhD project, ABX300, was 
proved to be inappropriate for the clinical advancement. Its narrow therapeutic 
index is illustrated by the adverse effects that result from early takes. Therefore, 
ABX300 research was compromised and forced to put an end before reaching 
the late stages of clinical trials phases, corresponding to human subjects.  
 
Maybe partially because of the difficulty of trespassing these last steps, few 
efficient treatments for obesity are currently available in the market, despite the 
fact that distinct possibilities for approaching these lifestyle related pandemics 
have been the subject of numerous studies over the last decade (Butsch, 2015; 
Jackson et al., 2015). Nonetheless, hopes for breakthrough therapies for obesity 
and diabetes are as high as they have ever been. The pace of discovery in the 
field of metabolism indicates that this is an area growing rapidly, and new insights 
are unfolding with each passing month (Rosen and Spiegelman, 2006). It remains 
to be seen how these discoveries will be translated into patients, because 
restrictions regarding safety concerns in obesogenic treatments are very high. At 
any rate, the transfer of ideas from bench to bedside is rarely a straight forward 
path.
APPENDIX 
126 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX 
 
  
Scientific Report
Antagonistic functions of LMNA isoforms in energy
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Abstract
Alternative RNA processing of LMNA pre-mRNA produces three main
protein isoforms, that is, lamin A, progerin, and lamin C. De novo
mutations that favor the expression of progerin over lamin A lead to
Hutchinson-Gilford progeria syndrome (HGPS), providing support for
the involvement of LMNA processing in pathological aging. Lamin C
expression is mutually exclusive with the splicing of lamin A and
progerin isoforms and occurs by alternative polyadenylation. Here,
we investigate the function of lamin C in aging and metabolism using
mice that express only this isoform. Intriguingly, these mice live
longer, have decreased energy metabolism, increased weight gain,
and reduced respiration. In contrast, progerin-expressing mice show
increased energy metabolism and are lipodystrophic. Increased mito-
chondrial biogenesis is found in adipose tissue from HGPS-like mice,
whereas lamin C-only mice have fewer mitochondria. Consistently,
transcriptome analyses of adipose tissues from HGPS and lamin
C-only mice reveal inversely correlated expression of key regulators of
energy expenditure, including Pgc1a and Sfrp5. Our results demon-
strate that LMNA encodes functionally distinct isoforms that have
opposing effects on energy metabolism and lifespan in mammals.
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Introduction
Multiple signaling pathways affect senescent decline and aging.
Studies in simple model organisms have led to remarkable
progress in understanding the molecular pathways that modu-
late aging and senescence [1–3]. However, the mechanisms
mediating senescent decline and aging in mammals remain
unclear. Thus, it is important to understand which cells or
tissues coordinate the aging process at the level of the whole
organism.
The Hutchinson-Gilford progeria syndrome (HGPS or progeria)
is a rare syndrome that causes premature aging [4]. Progeria is
typically due to a silent de novo mutation in exon 11 of the
LMNA gene (1824C > T, G608G). This mutation increases the
usage of a natural splice donor site in exon 11 of LMNA [5–7],
leading to an in-frame deletion of 150 nucleotides, including the
cleavage motif required for the last maturation step of lamin A
by the ZMPSTE24 endoprotease [8]. Both Zmpste24-deficient
mice (Zmpste24!/!) and farnesylated progerin (LmnaHG/+)
knock-in mice present HGPS-like phenotypes [8,9], implying that
defects in prelamin A processing rather than the loss of lamin A
are responsible for premature aging. Interestingly, knock-in
mouse models lacking either the lamin A (lamin C-only) or
lamin C (lamin A-only) isoform do not exhibit disease pheno-
types [9,10].
The RNA processing mechanisms leading to progerin and lamin
C production are highly conserved in humans and mice [7,10,11].
Lamin C has not yet been identified outside of the mammalian
lineage (Fig 1, [8,11]), and the polyadenylation site responsible for
lamin C production is conserved between mammals. Since progerin
expression is mutually exclusive with lamin C expression, we
examined whether lamin C and progerin have opposite effects on
lifespan. Lmna knock-in mice in which Lmna exons 11 and 12 are
not transcribed and thus progerin-specific splicing cannot be
performed were used in this study. Our results show that lamin C
and progerin trigger antagonistic signals in adipose tissue that
regulate mitochondrial biogenesis and energy expenditure. This
study introduces a characterization of lamin C-only-expressing
mouse model that exhibits obese phenotypes and increased
lifespan.
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Figure 1. LMNA RNA processing isoforms during evolution.
A Schematic view of the three variable C-termini produced by the LMNA locus. Only the region spanning over exon 10 (E10), intron 10, exon 11 (E11), intron 11, and
exon 12 (E12) is presented. pA are the polyadenylation sites producing lamin C and lamin A.
B The alignment of progerin 50 splice site shows that it is conserved in the four placental super-orders (E: Euarchontoglires; A: Afrotheria; L: Laurasiatheria; X:
Xenarthra).
C Lamin C is conserved in Therians. Alignment of the genomic sequences spanning over exon 10 and the 50 end of intron 10 (IVS 10). Boxes labeled 1 and 2 show the
high levels of conservation of the exon/intron borders and polyadenylation signals, respectively.
D Alignment of the amino acids encoded by the genomic sequences (end of exon 10 and beginning of intron 10) shown in (C).
E Occurrence of lamin A and lamin C ESTs in databases.
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Results and Discussion
Complexity of the C-terminus of lamin A during evolution
In order to infer functional relationship between LMNA isoforms,
we first examined when production of progerin and lamin C
isoforms was selected during evolution. We found that the splice
site responsible for progerin production is included in a region
highly conserved throughout the four placental super-orders but
absent in the exon 11 sequences of marsupials from three distinct
orders (Fig 1B). In contrast, lamin C transcripts and a conserved
polyadenylation signal site in intron 10 were identified in all placen-
tals and marsupials examined (Fig 1C–E). Furthermore, intron 10
nucleotide sequences proximal to the splice sites (Fig 1C) and the
corresponding encoded peptides (Fig 1D) showed extreme conserva-
tion. This supports a scenario in which lamin C production was
selected first in mammals, followed by progerin in placentals. Lamin
C lacks the residues encoded by exons 11 and 12 of the LMNA gene;
therefore, the complex maturation process involving proteolytic
cleavage of the C-terminal part of prelamin A does not occur. Failure
of prelamin A processing leads to the progeroid phenotype [8,12];
thus, the production of lamin C by alternative RNA processing may
be an evolutionary adaptation to counteract the deleterious effects
that result from inefficient prelamin A maturation. This also
suggests that the production of LMNA isoforms may have physiolog-
ical outcomes. This hypothesis was further tested here using mouse
models.
Lifespan and growth of mice carrying different Lmna alleles
The first mouse model of progeria to recapitulate the premature
aging phenotype and splicing alteration observed in HGPS was
recently described [7,10]. The progeria allele (LmnaG609G allele) was
created by a knock-in strategy involving another mutant allele that
encodes lamin C alone (LmnaLCS allele). This allele carries a floxed
neo cassette just downstream of the polyadenylation site of lamin C
and the G609G mutation in exon 11 (Fig 2A). LmnaG609G/+ and
LmnaLCS/+ mice were intercrossed to generate LmnaG609G/G609G,
LmnaG609G/+, LmnaLCS/+, and LmnaLCS/LCS mice used in this study.
Lmna+/+ obtained from both crosses were used as controls.
Specific Lmna isoform expression was confirmed by Western blot
(Fig 2A, and [7,10]).
As expected, mice homozygous for the G609G mutation lived
< 6 months. In contrast, mice carrying only one G609G allele lived
for 1 year on average. Most of the control mice died after 2 years,
whereas approximately 60% of the LmnaLCS/+ and LmnaLCS/LCS
mice remained alive (Fig 2B). The median lifespan of LmnaLCS/+
and LmnaLCS/LCS mice was about 110 weeks, which was
significantly longer than the lifespan of WT mice (P = 0.0025
and P = 0.0067, respectively) (Fig 2B). Both male and female
LmnaLCS/LCS mice demonstrated significantly increased longevity
compared to WT mice of the same gender (Supplementary Fig S1A).
Autopsies from LmnaLCS/LCS old mice showed a dramatically
increased tumor incidence compared to LmnaLCS/+ and Lmna+/+
mice (Supplementary Fig S1B). These tumors were primarily located
in the abdominal cavity. Histological analysis suggested that they
were of lymphoid origin (unpublished results). No visible tumors
were detected in younger LmnaLCS/LCS mice (less than a year old),
suggesting that lymphomas developed at a late age in these mice.
This finding suggests that the LmnaLCS/LCS mice died from the
progression of tumors that blunted their lifespan extension.
Consistent with previous observations [10], all of the mice
were macroscopically identical before weaning. However,
LmnaG609G/G609G mice failed to thrive, in contrast to the other
“mutant” mice (Fig 2C). LmnaG609G/G609G mice died at an average of
18 weeks. At 30 weeks of age, LmnaG609G/+ mice weighed less than
WT and LmnaLCS/+ mice, whereas LmnaLCS/LCS mice exhibited an
increased weight. The differences between LmnaG609G/+ mice and
LmnaLCS/LCS mice were most apparent between the ages of 35 and
45 weeks. Moreover, LmnaG609G/+ mice in that age range were not
yet cachexic. Thus, we used mice in that age group for physiological
and molecular biology studies. However, food intake was not signifi-
cantly different between control and transgenic mice at any age
tested (Fig 2C).
Weights of most of the tissues varied in proportion with the body
weight. Exceptions were the brain, spleen, and perigonadal white
adipose tissue (WAT). Brain size remained constant regardless of the
size and genotype of the animals. LmnaLCS/LCS mice accumulated
more adipose tissue, whereas LmnaG609G/+ mice were extremely
lean (Fig 2D). The adipose tissue phenotypes were interesting, as
lamin C and progerin might play opposite roles in the homeostasis of
this tissue, while having opposing effect on lifespan. The observation
on brain weight is discussed in the legend of Supplementary Fig S1C
and was not explored further.
Adipose tissue distribution and adipocyte number in LmnaLCS/LCS
and LmnaG609G/+ mice
Abdominal computed tomography (CT) was performed on 40- to 45-
week-old mice. Examination of the subcutaneous and intra-abdominal
adipose tissue volumes indicated that all adipose tissue depots were
equally affected by the expression of different Lmna splicing
isoforms (Fig 3A). We calculated the total fat volume per animal
and found that LmnaG609G/+ mice had a twofold decrease
(P = 0.0255) in AT volume. In contrast, LmnaLCS/LCS mice showed a
1.5-fold increase (P = 0.0288) in AT volume compared to the
controls (Fig 3A).
Adjusting adipose tissue weight for body weight did not “correct”
for the observed differences. Thus, we examined the potential
reason for these discrepancies. The analysis of adipose tissue slices
(Fig 3B) suggested that the differences in WAT mass were primarily
due to a decrease in the average cell surface for LmnaG609G/+ mice
and an increase in the average cell surface of LmnaLCS/LCS mice.
These results were confirmed by quantification of the surface size of
adipocytes from at least five different animals per genotype
(Fig 3C). Similar results were obtained with brown adipose tissue
slices, where the average cell surface of brown adipocytes for
LmnaG609G/+ mice was decreased, while it was slightly increased for
LmnaLCS/LCS mice (Fig 3B and C).
Preadipocytes from the perigonadal and subcutaneous WAT
depots failed to show macroscopic differences in adipocyte differen-
tiation. In addition, we did not observe differences in triglyceride
accumulation (Supplementary Fig S2A), nor in the expression of the
mature adipocyte markers aP2, Pparg, and Glut4 by RT–qPCR in
differentiated preadipocytes (Supplementary Fig S2B). These results
suggest that lamin C and progerin are more important for the fate of
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differentiated adipocytes than for preadipocyte differentiation.
Furthermore, serum lipoprotein, lipid, and cholesterol profiles did
not reveal any significant difference between mice of different geno-
types (Supplementary Fig S2C).
Metabolic tests indicated that fasting glycemia was low in
LmnaG609G/+, but not significantly different in LmnaLCS/LCS mice
compared to WT. Fasting insulin was also significantly decreased in
LmnaG609G/+ mice, while it was increased in normoglycemic
A
B
C
D
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LmnaLCS/LCS mice (Fig 3D). LmnaG609G/+ mice are more tolerant to
glucose, as measured by an intraperitoneal glucose tolerance test
(Fig 3E). Glucose tolerance of LmnaLCS/LCS mice is slightly
decreased at this age. Moreover, LmnaG609G/+ mice are more sensi-
tive to insulin as measured by fasting insulin and by an insulin
tolerance test (Fig 3D and F). On the other hand, LmnaLCS/LCS
demonstrated mild insulin resistance. High levels of insulin may
balance this resistance (Fig 3D). Overall, these results indicate that
the LmnaLCS/LCS mice are moderately insulin-resistant, whereas
LmnaG609G/+ mice are more insulin-sensitive. Increased fat storage
and insulin resistance are contrasting with the increased longevity
of LmnaLCS/LCS mice, as they are expected to lead progressively to
hyperglycemia. Surprisingly, 20-month-old LmnaLCS/LCS mice were
rather hypoglycemic (Supplementary Fig S2D), showing that they
are able to compensate for obesity and aging-induced insulin resis-
tance, thus highlighting a possible function of lamin C in the mainte-
nance of energy balance.
Energy expenditure and mitochondrial content in LmnaLCS/LCS and
LmnaG609G/+ mice
Oxygen consumption (VO2), CO2 production (VCO2), respiratory
exchange ratios (RER), and energy expenditure were monitored
with the Oxymax System. The absolute VO2 and VCO2 values are
comparable between different genotypes, but when normalized to
body weight LmnaG609G/+ mice showed a marked increase in VO2
and VCO2, whereas Lmna
LCS/LCS mice consumed less O2 and
produced less CO2 (Fig 4A). Lmna
G609G/+ mice exhibited higher
energy expenditure, whereas LmnaLCS/LCS mice exhibited lower
energy expenditure. These results indicate that progerin increases
the metabolic rate, whereas lamin C reduces overall energy
consumption. Interestingly, similar to obese mice, LmnaLCS/LCS
mice demonstrated lower RERs, suggesting that they mainly
consume fatty acids [13]. The contribution of fat oxidation to
energy expenditure calculated from Lusk equations indicated that
LmnaLCS/LCS mice burned 80% fat, WT mice used 55% fat,
whereas LmnaG609G/+ mice consumed only 41% fat. The fact that
lamin C-only mice use more fat and less carbohydrates, whereas
progerin-expressing mice do the opposite, clearly indicates a
prominent role for Lmna gene in metabolic fuel partitioning.
Interestingly, the amount of mitochondrial DNA was significantly
higher in LmnaG609G/+ mice and lower in LmnaLCS/LCS mice
compared to WT mice (Fig 4B), suggesting global mitochondrial
activity. These results were confirmed by the examination of
white and brown adipose tissue electron microscopic micrographs
(Supplementary Fig S3).
Mouse embryonic fibroblasts (MEFs) derived from LmnaG609G/+
and LmnaLCS/LCS embryos exhibited similar variations in mitochon-
drial DNA content as in the adipose tissues (Fig 4C). Mitochondrial
function was studied with a mitochondrial stress test on an XF24
seahorse analyzer. When compared to control MEFs, LmnaG609G/+
MEFs showed a basal oxygen consumption rate (OCR) that was 1.5-
fold higher, whereas LmnaLCS/LCS MEFs showed a modest but signif-
icant decrease in basal respiration (Fig 4D and E). Inhibition of ATP
synthesis by oligomycin revealed a significantly higher ATP
production in LmnaG609G/+ and a decreased ATP production in
LmnaLCS/LCS MEFs, but this difference was not significant. FCCP was
used to determine the maximal OXPHOS capacity. LmnaG609G/+
MEFs showed a 1.13-fold increase in maximal respiration and a 1.3-
fold increase in mitochondrial spare capacity, whereas LmnaLCS/LCS
showed a 1.4-fold decrease in maximal OCR and a twofold
decrease in mitochondrial spare capacity. Proton leak was signifi-
cantly increased in LmnaG609G/+ MEFs and slightly decreased in
LmnaLCS/LCS MEFs. The differences in mitochondrial basal and
maximal respiration and in proton leak could mainly be due to the
differences in mitochondrial number. However, the fact that
LmnaG609G/+ MEFs have increased spare capacity strongly suggests
that their mitochondria were more oxidative. In contrast, the
mitochondrial content of LmnaLCS/LCS MEFs was reduced and their
mitochondria have less oxidative potential. The results obtained
with MEFs are consistent with the global energy expenditure pheno-
types of both LmnaG609G/+ and LmnaLCS/LCS mice. The reduction in
oxidative capacity of the adipose tissue is expected to lead to the
obese phenotype of LmnaLCS/LCS mice that have less capacity to
burn lipids and therefore gain more weight.
Gene expression analysis of adipose tissue samples from LmnaLCS/LCS
and LmnaG609G/+ mice
PGC1a (Ppargc1a) is a master regulator of mitochondrial biogenesis
[14–16]. UCP1 (uncoupling protein 1) is a PGC1a target gene and a
key thermogenic protein. Induced expression of UCP1 in WAT
reduces obesity and improves insulin sensitivity [14,17]. The expres-
sion in adipose tissue of PGC1a and UCP1, both at RNA (Fig 5A) and
protein (Fig 5B) levels, varied in opposite ways in mice expressing
progerin versus mice expressing lamin C alone. Changes in
mitochondrial gene expression might thus be responsible for the
observed differences in energy consumption and expenditure.
RT–qPCR analysis of PGC1a target genes (Tfam, NRF1, SOD2, and
NRF2), electron transport chain (ETC) genes (ATP synthase, SDHA,
cytochrome C oxidase, and NADPH dehydrogenase), and fatty oxida-
tion genes (mCAD and CPT2) showed that expression of each gene
Figure 2. Lmna isoforms, progerin and lamin C, affect lifespan and body weight.
A Left panel, structure of the targeted allele after homologous recombination. Right panel, expression levels of lamin A, progerin, and lamin C protein isoforms in the
livers of LmnaG609G/G609G, LmnaG609G/+, Lmna+/+, LmnaLCS/+, and LmnaLCS/LCS, determined by Western blotting.
B Left panel, survival curves of male and female Lmna+/+ (n = 25), LmnaG609G/+ (n = 27), LmnaG609G/G609G (n = 25), LmnaLCS/+ (n = 21), and LmnaLCS/LCS (n = 32) mice.
Right panel, histogram showing the median lifespan of each genotype.
C Body weights of male Lmna+/+ (n = 11), LmnaG609G/+ (n = 9), LmnaG609G/G609G (n = 8), LmnaLCS/+ (n = 9), and LmnaLCS/LCS (n = 12) mice. Food intake was measured for
15- and 45-week-old mice (panels below body weight curves).
D Weights of individual organs as a percentage of total body weight for 45-week-old LmnaG609G/+ (n = 15), LmnaLCS/LCS (n = 8), and Lmna+/+ (n = 10) mice.
Data information: Results were expressed as median (B) or means (C and D) # s.e.m. The significance of differences in lifespan was determined with the log-rank
(Mantel–Cox) test.
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[17], except for NRF2, varied inversely between LmnaLCS/LCS and
LmnaG609G/+ samples (Fig 5C), suggesting that LMNA isoforms
affect mitochondrial gene expression.
In order to determine the molecular pathways altered by lamin C
and progerin expression and their roles in energy metabolism and
aging, we analyzed the WAT transcriptome in control mice and in
LmnaG609G/G609G and LmnaLCS/LCS mice, as examples of the most
extreme aging phenotypes. We used samples from fasting 4-month-old
male mice to probe Affymetrix exon arrays (results are accessible at
https://www.easana.com/). Consistent with the essential role of
lamins in nuclear architecture, WAT samples from LmnaG609G/G609G
mice demonstrated extreme variations, with 6,509 up-regulated and
3,024 down-regulated mRNAs. Large variations were also observed
at the level of alternative splicing, confirming recent observations
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Figure 3. Antagonistic adipose tissue alterations in LmnaG609G/+ and LmnaLCS/LCS mice.
A PET-CT imaging analysis showing quantification of subcutaneous fat surface, intra-abdominal fat surface, and total fat volume normalized to body weight in
LmnaG609G/+, Lmna+/+, Lmna LCS/LCS mice (n = 5 per genotype). A representative PET-CT image for each genotype is shown in the right panel.
B Representative images of HE-stained sections of WAT (upper panels) and BAT (lower panels) from Lmna+/+, LmnaG609G/+, and LmnaLCS/LCS mice.
C Quantification of adipocyte size from WAT (upper panel) and BAT (lower panel) with ImageJ software (n = 5 per genotype).
D Metabolic measurements (fasting glucose and insulin, intraperitoneal glucose tolerance test and insulin tolerance test) of Lmna+/+ (n = 6), LmnaG609G/+ (n = 10), and
LmnaLCS/LCS (n = 7) mice. Area under the curve for IPGTT and ITT was analyzed (AUC).
Data information: All experiments were conducted using 45-week-old male mice. Results were expressed as means # s.e.m. The significance of differences was
determined with the Student's t-test.
EMBO reports Vol 15 | No 5 | 2014 ª 2014 The Authors
EMBO reports Antagonistic functions of LMNA isoforms Isabel C Lopez-Mejia et al
534
Published online: March 17, 2014 
A
B
C D
E
Figure 4. LMNA isoforms modify energy expenditure and mitochondrial content in mice and in MEFs.
A Upper panels correspond to absolute values of VCO2, VO2, RER, and energy expenditure. Lower panels represent the same values normalized to body weight
(n = 5 per genotype).
B Mitochondrial DNA levels in WAT and BAT were assessed by qPCR and normalized to genomic DNA (n = 7 per genotype).
C Mitochondrial DNA levels in MEFs were assessed by qPCR and normalized to genomic DNA (n = 4 clones per genotype).
D, E MEFs oxygen consumption rates (OCR) were determined with a Seahorse XF24 Flux analyzer in basal and stimulated conditions (n = 3 clones per genotype). The
areas under the curve from different sections of the experiment are shown as individual histograms (E) for basal respiration, ATP production, maximal respiration,
mitochondrial spare capacity, and proton leak.
Data information: Results were expressed as means # s.e.m. The significance of differences was determined with the Student’s t-test. See Supplementary Table S1 for a
list of primers used for RT–qPCR.
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that progerin expression triggers a senescent phenotype character-
ized by large changes in alternative splicing [18,19]. WAT samples
from LmnaLCS/LCS mice showed also large variations, with 736
up-regulated and 1,563 down-regulated genes, and different alterna-
tive splicing of 2,691 exons (https://www.easana.com/). These
observations are consistent with a recent finding showing that lamin
A/C interacts with distinct spatially restricted subpromoter regions
associated with distinct transcriptional outcomes in human adipose
tissue stem cells [18,20].
Variations in gene expression may directly or indirectly contribute
to the different phenotypes elicited by lamin C and progerin. We
focused on 278 annotated genes (https://www.easana.com/), for
which inverse expression patterns existed between the two phenotypes.
Interestingly, KEGG pathway analysis of those genes showed that
two of the three most regulated pathways are involved in energy
metabolism (arachidonic acid metabolism and glycerolipid metabo-
lism, Fig 5D). These data also confirmed that PGC1a was one of the
inversely regulated genes, further validating our approach (Fig 5E).
In addition to PGC1a, 29 genes involved in lipid metabolism were
identified with expression controlled in an inverse way by lamin C
and progerin. These 30 genes could be involved in the process of
aging (Fig 5E).
We used dedicated qPCR arrays (Adipogenesis and Fatty acid
metabolism RT² ProfilerTM PCR Arrays) designed to study 84
genes per pathway to further confirm these results (Supplemen-
tary Fig S4A and B). Only six genes showed inverse expression
on both arrays (Ppargc1a, Lep, Sfrp5, Acot3, Acsm3, and Bdh2).
Four (Ppargc1a, Lep, Sfrp5, and Acsm3) were already on the list
of 30 genes obtained from the Affymetrix analysis. Thus, these
four genes were considered candidate genes accounting for the
phenotypes associated with the lamin isoforms. Interestingly, 29
of 84 genes involved in the regulation of fatty acid metabolism
were up-regulated in the adipose tissue from progeria mice. In
contrast, all of the genes that we examined in this pathway (8
out of 84) were down-regulated in the adipose tissue from lamin
C-only mice, further confirming that these two lamin isoforms
have antagonistic functions in the regulation of fatty acid metabo-
lism (Supplementary Fig S4B).
One of the four candidate genes, Sfrp5 suppresses oxidative
metabolism, is strongly induced during adipocyte differentiation,
and is up-regulated in adipocytes during obesity and likely counter-
acts WNT signaling [21]. Moreover, SFRP5-deficient mice are pheno-
typically similar to LmnaG609G/+ mice (same numbers of adipocytes
but fewer large adipocytes and increased mitochondrial activity,
partially mediated by PGC1a). However, changes in leptin expres-
sion cannot explain the metabolic phenotypes, since increased
expression of leptin in LmnaLCS/LCS mice would result in reduced
food intake and increased energy expenditure. While increased
adipose tissue mass is always correlated with leptin expression,
LmnaLCS/LCS mice display only slight decrease in food intake that is
not statistically significant, suggesting that the increase in the
expression of leptin mRNA is not sufficient to increase circulating
leptin levels. Alternatively, LmnaLCS/LCS mice are leptin resistant.
Concluding remarks
Our results support the notion that RNA processing of the Lmna
gene is an active conserved mechanism that contributes to meta-
bolic adaptations of adipose tissue in mammals. While some of the
phenotypes of LmnaLCS/LCS mice are contrasting with their increased
longevity, both in MEFs and mice, lamin C-only expression results
in low mitochondrial activity, whereas progerin expression strongly
increases organelle activity. Strikingly, these distinct effects on mito-
chondrial activity correlate with opposing effects of these lamins on
lifespan. Although these could be independent phenotypes, recent
studies have linked mitochondrial function to lifespan [22]. The
finding that old LmnaLCS/LCS mice are able to compensate for delete-
rious effects triggered by obesity suggests that lamin C protects
against increased oxidative stress associated with fat accumulation
[23]. In contrast, progerin increases energy expenditure and mito-
chondrial activity, which probably induces potent oxidative stress,
characteristic of senescence [24–26] and one of the central hall-
marks of the normal aging process [26]. The lamin isoforms by
changing the nuclear envelope architecture may also contribute to
changes in the expression of genes involved in mitonuclear imbal-
ance controlling longevity.
Materials and Methods
Database searches and sequence analysis
Lamin A/C gene sequences were retrieved from Ensembl (http://
www.ensembl.org/) and aligned with MAFFT in the Geneious
package (v 6.1.5 created by Biomatters, available from http://
www.geneious.com/).
The occurrence of lamin A/C ESTs in databases was determined
with BLAST (http://blast.ncbi.nlm.nih.gov) using protein and
nucleic acid queries specific for either of the lamin isoforms (exon
11 for lamin A, intron 10 for lamin C) or for a sequence common to
both isoforms (other exons). A more detailed description of
sequence analysis can be found in Supplementary Methods.
Figure 5. Gene expression profiling of WAT adipose tissue from Lmna mutant mice.
A Relative mRNA levels of PGC1a and UCP1 in WAT were determined by RT–qPCR.
B Protein levels of PGC1a and UCP1 in WAT were determined by Western blotting. Lamin A/C levels and c-tubulin levels were used as controls.
C Relative mRNA levels of mitochondrial markers in WAT were assessed by RT–qPCR.
D Table representing KEGG pathways significantly and antagonistically regulated by progerin and lamin C derived from exon array analysis of WAT from 18-week-old
LmnaG609G/G609G and LmnaLCS/LCS mice (n = 5 per genotype).
E Metabolic genes that are oppositely regulated in WAT from 18-week-old LmnaG609G/G609G and LmnaLCS/LCS mice versus Lmna+/+ mice (n = 5 per genotype).
Up-regulated genes are in red boxes, and down-regulated genes are in green boxes.
Data information: RT–qPCR and WB were performed with 45-week-old Lmna+/+, LmnaG609G/+, and LmnaLCS/LCS mice samples (n = 5 per genotype). Results were expressed
as means # s.e.m. The significance of differences was determined with the Student's t-test. See Supplementary Table S1 for a list of primers used for RT–qPCR.
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Animal experiments & ethics statement
Transgenic mice (LMNAG609G/+ and LMNA LCS/LCS) were generated
as previously described [10]. A more detailed description of the
breeding strategy, tumor evaluation, micro-computed tomography,
metabolic evaluation, and Oxymax analysis can be found in Supple-
mentary Methods.
All animal procedures were conducted in strict adherence with
the European Community Council Directive of November 24, 1986
(86-609/EEC). Mice were maintained in pathogen-free conditions in
our animal facility (E34-172-16). All experiments were conducted
by authorized personnel (agreements JT 34-236; MDT 34-433; IL-M
34-467; KC 34-028; CC has legal training) and approved by the
Institutional Review Board at the Animal Facility of the Institut de
Génétique Moléculaire de Montpellier (agreement no CEEA-LR-
12112).
Food intake was measured three times over a period of 72 h with
seven animals per genotype in individual cages.
Microarray data analysis
All the data are deposited in GEO (NCBI) under accession number
GSE51204. Affymetrix Mouse Exon 1.0 ST arrays were hybridized
by GenoSplice technology (www.genosplice.com) according to their
standard protocol. A detailed description of the procedure can be
found in Supplementary Methods.
Statistical analysis
The survival curves were completed using the Kaplan–Meier curve.
The median survival is representative of the survival curves. We use
the log-rank (Mantel–Cox) test to perform the statistical analyses of
the survival curves.
All the other results were expressed as means # standard error
of the means (s.e.m.). The significance of differences was deter-
mined with the Student's t-test, with significance defined as
P < 0.05 (*P < 0.05, **P < 0.005, ***P < 0.0005, ****P < 0.00005).
Supplementary information for this article is available online:
http://embor.embopress.org
Acknowledgements
This work was supported by grants from Fondation pour la Recherche Médi-
cale and Splicos Therapeutics. JT is senior member of the Institut Universitaire
de France. We are grateful to N. Levy and C. Lopez-Otin for providing
LmnaLCS/+ mice and the Montpellier-RIO imaging platform (Montpellier,
France), to the Histology Experimental Network of Montpellier, to the “Centre
de Ressources en Imagerie Cellulaire de Montpellier” (France), and to the
IGMM animal facilities. The authors are grateful to C. Cazevieille and C.
Sanchez for their technical assistance and P. de la Grange from Genosplice.
I.L-M. was supported by a graduate fellowship from the Ministère Délégué à
la Recherche et aux Technologies and CNRS. C. L-H is supported by ITN
RNPnet Grant.
Author contributions
ICLM and MDT performed most of the experiments and contributed to writ-
ing the manuscript. CC performed the metabolic data and contributed to
writing the paper. LL performed the qPCR experiments. EZA, GB, and FC
contributed to CT scan and metabolic cages experiments. PC contributed to
histological data. PF and KC have made the sequence alignment. LF provided
critical metabolic discussions. JT designed the study and wrote the
manuscript.
Conflict of interests
The authors declare that they have no conflict of interest.
References
1. Bishop NA, Guarente L (2007) Genetic links between diet and lifespan:
shared mechanisms from yeast to humans Nat Rev Genet 8: 835 – 844
2. Kenyon C (2005) The plasticity of aging: insights from long-lived
mutants Cell 120: 449 – 460
3. Houtkooper RH, Williams RW, Auwerx J (2010) Metabolic networks of
longevity Cell 142: 9 – 14
4. Hennekam RCM (2006) Hutchinson-Gilford progeria syndrome: review of
the phenotype Am J Med Genet A 140: 2603 – 2624
5. De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Boccaccio
I, Lyonnet S, Stewart CL, Munnich A, Le Merrer M et al (2003) Lamin a
truncation in Hutchinson-Gilford progeria Science 300: 2055
6. Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR,
Robbins CM, Moses TY, Berglund P et al (2003) Recurrent de novo point
mutations in lamin A cause Hutchinson-Gilford progeria syndrome
Nature 423: 293 – 298
7. Lopez-Mejia IC, Vautrot V, De Toledo M, Behm-Ansmant I, Bourgeois CF,
Navarro CL, Osorio FG, Freije JMP, Stévenin J, De Sandre-Giovannoli A
et al (2011) A conserved splicing mechanism of the LMNA gene controls
premature aging Hum Mol Genet 20: 4540 – 4555
8. Bergo MO, Gavino B, Ross J, Schmidt WK, Hong C, Kendall LV, Mohr A,
Meta M, Genant H, Jiang Y et al (2002) Zmpste24 deficiency in mice
causes spontaneous bone fractures, muscle weakness, and a prelamin A
processing defect Proc Natl Acad Sci USA 99: 13049 – 13054
9. Fong LG, Ng JK, Lammerding J, Vickers TA, Meta M, Coté N, Gavino B,
Qiao X, Chang SY, Young SR et al (2006) Prelamin A and lamin A
appear to be dispensable in the nuclear lamina J Clin Invest 116:
743 – 752
10. Osorio FG, Navarro CL, Cadiñanos J, Lopez-Mejia IC, Quirós PM, Bartoli
C, Rivera J, Tazi J, Guzmán G, Varela I et al (2011) Splicing-directed ther-
apy in a new mouse model of human accelerated aging Sci Transl Med
3: 106ra107
11. Peter A, Reimer S (2012) Evolution of the lamin protein family: what
introns can tell Nucleus 3: 44 – 59
12. Pendás AM, Zhou Z, Cadiñanos J, Freije JMP, Wang J, Hultenby K, Astudillo A,
Wernerson A, Rodríguez F, Tryggvason K et al (2002) Defective prelamin A
processing and muscular and adipocyte alterations in Zmpste24 metal-
loproteinase-deficient mice Nat Genet 31: 94 – 99
13. Martin TL, Alquier T, Asakura K, Furukawa N, Preitner F, Kahn BB (2006)
Diet-induced obesity alters AMP kinase activity in hypothalamus and
skeletal muscle J Biol Chem 281: 18933 – 18941
14. Fisler JS, Warden CH (2006) Uncoupling proteins, dietary fat and the
metabolic syndrome Nutr Metab (Lond) 3: 38
15. Handschin C, Spiegelman BM (2006) Peroxisome proliferator-activated
receptor gamma coactivator 1 coactivators, energy homeostasis, and
metabolism Endocr Rev 27: 728 – 735
16. Finck BN, Kelly DP (2006) PGC-1 coactivators: inducible regulators of
energy metabolism in health and disease J Clin Invest 116: 615 – 622
EMBO reports Vol 15 | No 5 | 2014 ª 2014 The Authors
EMBO reports Antagonistic functions of LMNA isoforms Isabel C Lopez-Mejia et al
538
Published online: March 17, 2014 
17. Austin S, St-Pierre J (2012) PGC1a and mitochondrial metabolism–
emerging concepts and relevance in ageing and neurodegenerative
disorders J Cell Sci 125: 4963 – 4971
18. Lund E, Oldenburg A, Delbarre E, Freberg C, Duband-Goulet I, Eskeland
R, Buendia B, Collas P (2013) Lamin A/C-promoter interactions specify
chromatin state-dependent transcription outcomes Genome Res 23:
1580 – 1589
19. Cao K, Blair CD, Faddah DA, Kieckhaefer JE, Olive M, Erdos MR, Nabel
EG, Collins FS (2011) Progerin and telomere dysfunction collaborate to
trigger cellular senescence in normal human fibroblasts J Clin Invest
121: 2833 – 2844
20. Miranda M, Chacón MR, Gutiérrez C, Vilarrasa N, Gómez JM, Caubet E,
Megía A, Vendrell J (2008) LMNA mRNA expression is altered in human
obesity and type 2 diabetes Obesity 16: 1742 – 1748
21. Mori H, Prestwich TC, Reid MA, Longo KA, Gerin I, Cawthorn WP,
Susulic VS, Krishnan V, Greenfield A, Macdougald OA (2012)
Secreted frizzled-related protein 5 suppresses adipocyte mitochondrial
metabolism through WNT inhibition J Clin Invest 122:
2405 – 2416
22. Houtkooper RH, Mouchiroud L, Ryu D, Moullan N, Katsyuba E, Knott G,
Williams RW, Auwerx J (2013) Mitonuclear protein imbalance as a
conserved longevity mechanism Nature 497: 451 –457
23. Bondia-Pons I, Ryan L, Martinez JA (2012) Oxidative stress and
inflammation interactions in human obesity J Physiol Biochem 68:
701 – 711
24. Fischer F, Hamann A, Osiewacz HD (2012) Mitochondrial quality
control: an integrated network of pathways Trends Biochem Sci 37:
284 – 292
25. Bratic A, Larsson N-G (2013) The role of mitochondria in aging J Clin
Invest 123: 951 – 957
26. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G (2013) The
hallmarks of aging Cell 153: 1194 – 1217
539ª 2014 The Authors EMBO reports Vol 15 | No 5 | 2014
Isabel C Lopez-Mejia et al Antagonistic functions of LMNA isoforms EMBO reports
Published online: March 17, 2014 
   REFERENCES 
127 
 
 
 
 
 
 
 
 
 
 
 
 
 
REFERENCES 
 
  
   REFERENCES 
128 
 
Abizaid, A., Gao, Q., Horvath, T.L., 2006. Thoughts for Food: Brain Mechanisms and 
Peripheral Energy Balance. Neuron 51, 691–702. 
doi:10.1016/j.neuron.2006.08.025 
Aguirre, E., Cadenas, S., 2010. GDP and carboxyatractylate inhibit 4-hydroxynonenal-
activated proton conductance to differing degrees in mitochondria from skeletal 
muscle and heart. Biochim. Biophys. Acta - Bioenerg. 1797, 1716–1726. 
doi:10.1016/j.bbabio.2010.06.009 
Ahima, R.S., Antwi, D. a., 2008. Brain Regulation of Appetite and Satiety. Endocrinol. 
Metab. Clin. North Am. 37, 811–823. doi:10.1016/j.ecl.2008.08.005 
Almind, K., Manieri, M., Sivitz, W.I., Cinti, S., Kahn, C.R., 2007. Ectopic brown adipose 
tissue in muscle provides a mechanism for differences in risk of metabolic 
syndrome in mice. Proc Natl Acad Sci U S A 104, 2366–2371. doi:0610416104 
[pii]\r10.1073/pnas.0610416104 
Ameisen, J.C., 2002. On the origin, evolution, and nature of programmed cell death: a 
timeline of four billion years. Cell Death Differ. 9, 367–393. 
doi:10.1038/sj.cdd.4400950 
Ameur, A., Stewart, J.B., Freyer, C., Hagström, E., Ingman, M., Larsson, N.-G., 
Gyllensten, U., 2011. Ultra-Deep Sequencing of Mouse Mitochondrial DNA: 
Mutational Patterns and Their Origins. PLoS Genet. 7, e1002028. 
doi:10.1371/journal.pgen.1002028 
Anczuków, O., Rosenberg, A.Z., Akerman, M., Das, S., Zhan, L., Karni, R., 
Muthuswamy, S.K., Krainer, A.R., 2012. The splicing factor SRSF1 regulates 
apoptosis and proliferation to promote mammary epithelial cell transformation. 
Nat. Struct. Mol. Biol. 19, 220–228. doi:10.1038/nsmb.2207 
Andrade, J.M.O., Frade, A.C.M., Guimarães, J.B., Freitas, K.M., Lopes, M.T.P., 
Guimarães, A.L.S., de Paula, A.M.B., Coimbra, C.C., Santos, S.H.S., 2014. 
Resveratrol increases brown adipose tissue thermogenesis markers by increasing 
SIRT1 and energy expenditure and decreasing fat accumulation in adipose tissue 
of mice fed a standard diet. Eur. J. Nutr. 1–8. doi:10.1007/s00394-014-0655-6 
Arai, Y., Takayama, M., Abe, Y., Hirose, N., 2011. Adipokines and aging. J. 
Atheroscler. Thromb. 18, 545–550. doi:10.5551/jat.7039 
Ardilouze, J.L., Fielding, B. a., Currie, J.M., Frayn, K.N., Karpe, F., 2004. Nitric Oxide 
and ??-Adrenergic Stimulation Are Major Regulators of Preprandial and 
Postprandial Subcutaneous Adipose Tissue Blood Flow in Humans. Circulation 
109, 47–52. doi:10.1161/01.CIR.0000105681.70455.73 
Arner, P., Kulyté, A., 2015. MicroRNA regulatory networks in human adipose tissue 
and obesity. Nat. Rev. Endocrinol. 11, 276–288. doi:10.1038/nrendo.2015.25 
Austin, S., St-Pierre, J., 2012. PGC1  and mitochondrial metabolism - emerging 
concepts and relevance in ageing and neurodegenerative disorders. J. Cell Sci. 
125, 4963–4971. doi:10.1242/jcs.113662 
   REFERENCES 
129 
 
Azevedo, R. De, Luvizotto, M., Conde, S.J., Oliveira, M. De, Sibio, M.T. De, Jr, K.N., 
Nogueira, C.R., 2012. Obesity and Weight Loss : The Influence of Thyroid 
Hormone on Adipokines. 
Azzu, V., Affourtit, C., Breen, E.P., Parker, N., Brand, M.D., 2008. Dynamic regulation 
of uncoupling protein 2 content in INS-1E insulinoma cells. Biochim. Biophys. Acta 
- Bioenerg. 1777, 1378–1383. doi:10.1016/j.bbabio.2008.07.001 
Baboota, R.K., Sarma, S.M., Boparai, R.K., Kondepudi, K.K., Mantri, S., Bishnoi, M., 
2015. Microarray Based Gene Expression Analysis of Murine Brown and 
Subcutaneous Adipose Tissue: Significance with Human. PLoS One 10, 
e0127701. doi:10.1371/journal.pone.0127701 
Badoud, F., Lam, K.P., Perreault, M., Zulyniak, M. a., Britz-McKibbin, P., Mutch, D.M., 
2015. Metabolomics Reveals Metabolically Healthy and Unhealthy Obese 
Individuals Differ in their Response to a Caloric Challenge. PLoS One 10, 
e0134613. doi:10.1371/journal.pone.0134613 
Bakkour, N., Lin, Y.L., Maire, S., Ayadi, L., Mahuteau-Betzer, F., Chi, H.N., Mettling, C., 
Portales, P., Grierson, D., Chabot, B., Jeanteur, P., Branlant, C., Corbeau, P., 
Tazi, J., 2007. Small-molecule inhibition of HIV pre-mRNA splicing as a novel 
antiretroviral therapy to overcome drug resistance. PLoS Pathog. 3, 1530–1539. 
doi:10.1371/journal.ppat.0030159 
Baluka, F., 2009. Cell-cell channels, viruses, and evolution: Via infection, parasitism, 
and symbiosis toward higher levels of biological complexity. Ann. N. Y. Acad. Sci. 
1178, 106–119. doi:10.1111/j.1749-6632.2009.04995.x 
Bartelt, A., Heeren, J., 2014. Adipose tissue browning and metabolic health. Nat. Rev. 
Endocrinol. 10, 24–36. doi:10.1038/nrendo.2013.204 
Baur, J. a, Pearson, K.J., Price, N.L., Jamieson, H. a, Lerin, C., Kalra, A., Prabhu, V. V, 
Allard, J.S., Lopez-Lluch, G., Lewis, K., Pistell, P.J., Poosala, S., Becker, K.G., 
Boss, O., Gwinn, D., Wang, M., Ramaswamy, S., Fishbein, K.W., Spencer, R.G., 
Lakatta, E.G., Le Couteur, D., Shaw, R.J., Navas, P., Puigserver, P., Ingram, D.K., 
de Cabo, R., Sinclair, D. a, 2006. Resveratrol improves health and survival of mice 
on a high-calorie diet. Nature 444, 337–342. doi:10.1038/nature05354 
Begriche, K., Massart, J., Robin, M., Borgne-sanchez, A., Fromenty, B., 2011. Review 
Drug-induced toxicity on mitochondria and lipid metabolism : Mechanistic diversity 
and deleterious consequences for the liver. J. Hepatol. 54, 773–794. 
doi:10.1016/j.jhep.2010.11.006 
Bertrand, C., Valet, P., Castan-Laurell, I., 2015. Apelin and energy metabolism. Front. 
Physiol. 6, 115. doi:10.3389/fphys.2015.00115 
Bibb, M.J., Van Etten, R.A., Wright, C.T., Walberg, M.W., Clayton, D.A., 1981. 
Sequence and gene organization of mouse mitochondrial DNA. Cell 26, 167–180. 
doi:10.1016/0092-8674(81)90300-7 
Blackstone, N.W., 2013. Evolution and cell physiology. 2. The evolution of cell 
signaling: from mitochondria to Metazoa. Am. J. Physiol. Cell Physiol. 305, C909–
   REFERENCES 
130 
 
15. doi:10.1152/ajpcell.00216.2013 
Blanc, J., Alves-Guerra, M.C., Esposito, B., Rousset, S., Gourdy, P., Ricquier, D., 
Tedgui,  a., Miroux, B., Mallat, Z., 2003. Protective role of uncoupling protein 2 in 
atherosclerosis. Circulation 107, 388–390. 
doi:10.1161/01.CIR.0000051722.66074.60 
Bland, M.L., Birnbaum, M.J., 2011. Cell biology. ADaPting to energetic stress. Science 
332, 1387–1388. doi:10.1126/science.1208444 
Blencowe, B.J., 2006. Alternative Splicing: New Insights from Global Analyses. Cell 
126, 37–47. doi:10.1016/j.cell.2006.06.023 
Bogenhagen, D., Lowell, C., Clayton, D. a, 1981. Mechanism of mitochondrial DNA 
replication in mouse L-cells. Replication of unicircular dimer molecules. J. Mol. 
Biol. 148, 77–93. 
Bonnal, S., Vigevani, L., Valcárcel, J., 2012. The spliceosome as a target of novel 
antitumour drugs. Nat. Rev. Drug Discov. 11, 847–59. doi:10.1038/nrd3823 
Borisov, V.B., 2002. Defects in mitochondrial respiratory complexes III and IV, and 
human pathologies. Mol. Aspects Med. 23, 385–412. doi:10.1016/S0098-
2997(02)00013-4 
Boss, O., Samec, S., Paoloni-Giacobino, A., Rossier, C., Dulloo, A., Seydoux, J., 
Muzzin, P., Giacobino, J.P., 1997. Uncoupling protein-3: A new member of the 
mitochondrial carrier family with tissue-specific expression. FEBS Lett. 408, 39–
42. doi:10.1016/S0014-5793(97)00384-0 
Bouchard, C. et al., 1990. The response to long-term overfeeding in identical twins. 
Bournat, J.C., Brown, C.W., 2010. Mitochondrial dysfunction in obesity. Curr. Opin. 
Endocrinol. Diabetes. Obes. 17, 446–52. doi:10.1097/MED.0b013e32833c3026 
Bourne, H., 1993. © 19 9 3 Nature Publishing Group. Nature 363. 
Brand, M.D., 2000. Uncoupling to survive? The role of mitochondrial inefficiency in 
ageing. Exp. Gerontol. 35, 811–820. doi:10.1016/S0531-5565(00)00135-2 
Butsch, W.S., 2015. Obesity medications. Curr. Opin. Endocrinol. Diabetes Obes. 22, 
360–366. doi:10.1097/MED.0000000000000192 
Cadenas, S., Buckingham, J. a., Samec, S., Seydoux, J., Din, N., Dulloo, A.G., Brand, 
M.D., 1999. UCP2 and UCP3 rise in starved rat skeletal muscle but mitochondrial 
proton conductance is unchanged. FEBS Lett. 462, 257–260. doi:10.1016/S0014-
5793(99)01540-9 
Cadenas, S., Echtay, K.S., Harper, J. a., Jekabsons, M.B., Buckingham, J. a., Grau, E., 
Abuin, A., Chapman, H., Clapham, J.C., Brand, M.D., 2002. The basal proton 
conductance of skeletal muscle mitochondria from transgenic mice 
overexpressing or lacking uncoupling protein-3. J. Biol. Chem. 277, 2773–2778. 
doi:10.1074/jbc.M109736200 
Cambier, L., Rassam, P., Chabi, B., Mezghenna, K., Gross, R., Eveno, E., Auffray, C., 
   REFERENCES 
131 
 
Wrutniak-Cabello, C., Lajoix, A.-D., Pomiès, P., 2012. M19 modulates skeletal 
muscle differentiation and insulin secretion in pancreatic β-cells through 
modulation of respiratory chain activity. PLoS One 7, e31815. 
doi:10.1371/journal.pone.0031815 
Campos, N., Renier, M., Aude, G., Audrey, V., Laure, L., Erika, N., Florence, M.-B., 
Romain, N., Pauline, F., Katjana, T., Eugénia, B., Martial, S., Julian, V.P., 
Bernard, P., Edouard, B., Wainberg, A.M., Roberto, S.F., Didier, S., Jamal, T., 
2015. Retrovirology Long lasting control of viral rebound with a new drug ABX464 
targeting Rev – mediated viral RNA biogenesis. doi:10.1186/s12977-015-0159-3 
Canals, I., Carmona, M.C., Amigó, M., Barbera, A., Bortolozzi, A., Artigas, F., Gomis, 
R., 2009. A functional leptin system is essential for sodium tungstate antiobesity 
action. Endocrinology 150, 642–50. doi:10.1210/en.2008-0881 
Cannon, B., 2004. Brown Adipose Tissue: Function and Physiological Significance. 
Physiol. Rev. 84, 277–359. doi:10.1152/physrev.00015.2003 
Carracedo, A., Cantley, L.C., Pandolfi, P.P., 2013. Cancer metabolism: fatty acid 
oxidation in the limelight. Nat. Rev. Cancer 13, 227–32. doi:10.1038/nrc3483 
Carroll, J., Fearnley, I.M., Skehel, J.M., Shannon, R.J., Hirst, J., Walker, J.E., 2006. 
Bovine complex I is a complex of 45 different subunits. J. Biol. Chem. 281, 32724–
32727. doi:10.1074/jbc.M607135200 
Casas, F., Pessemesse, L., Grandemange, S., Seyer, P., Gueguen, N., Baris, O., 
Lepourry, L., Cabello, G., Wrutniak-Cabello, C., 2008. Overexpression of the 
mitochondrial T3 receptor p43 induces a shift in skeletal muscle fiber types. PLoS 
One 3, e2501. doi:10.1371/journal.pone.0002501 
Casas, F., Rochard, P., Rodier, A., Cassar-Malek, I., Marchal-Victorion, S., Wiesner, 
R.J., Cabello, G., Wrutniak, C., 1999. A variant form of the nuclear triiodothyronine 
receptor c-ErbAalpha1 plays a direct role in regulation of mitochondrial RNA 
synthesis. Mol. Cell. Biol. 19, 7913–24. 
Chan, C.B., Harper, M.-E., 2006. Uncoupling proteins: role in insulin resistance and 
insulin insufficiency. Curr. Diabetes Rev. 2, 271–283. 
doi:10.2174/157339906777950660 
Chentouf, M., Dubois, G., Jahannaut, C., Castex, F., Lajoix, A.D., Gross, R., Peraldi-
Roux, S., 2011. Excessive food intake, obesity and inflammation process in 
Zucker fa/fa rat pancreatic islets. PLoS One 6, e22954. 
doi:10.1371/journal.pone.0022954 
Chinnery, P.F., 2003. Searching for nuclear-mitochondrial genes. Trends Genet. 19, 
60–62. doi:10.1016/S0168-9525(02)00030-6 
Cho, S., Hoang, A., Sinha, R., Zhong, X.-Y., Fu, X.-D., Krainer, A.R., Ghosh, G., 2011. 
Interaction between the RNA binding domains of Ser-Arg splicing factor 1 and U1-
70K snRNP protein determines early spliceosome assembly. Proc. Natl. Acad. 
Sci. U. S. A. 108, 8233–8238. doi:10.1073/pnas.1017700108 
   REFERENCES 
132 
 
Cinti, S., 2005. The adipose organ. Prostaglandins Leukot. Essent. Fat. Acids 73, 9–
15. doi:10.1016/j.plefa.2005.04.010 
Clapham, J.C., Arch, J.R., Chapman, H., Haynes,  a, Lister, C., Moore, G.B., Piercy, 
V., Carter, S. a, Lehner, I., Smith, S. a, Beeley, L.J., Godden, R.J., Herrity, N., 
Skehel, M., Changani, K.K., Hockings, P.D., Reid, D.G., Squires, S.M., Hatcher, 
J., Trail, B., Latcham, J., Rastan, S., Harper,  a J., Cadenas, S., Buckingham, J. a, 
Brand, M.D., Abuin,  a, 2000. Mice overexpressing human uncoupling protein-3 in 
skeletal muscle are hyperphagic and lean. Nature 406, 415–418. 
doi:10.1038/35019082 
Cline, G.W., Vidal-Puig, A.J., Dufour, S., Cadman, K.S., Lowell, B.B., Shulman, G.I., 
2001. In Vivo Effects of Uncoupling Protein-3 Gene Disruption on Mitochondrial 
Energy Metabolism. J. Biol. Chem. 276, 20240–20244. 
doi:10.1074/jbc.M102540200 
Clostre, F., 2001. [Mitochondria: recent pathophysiological discoveries and new 
therapeutic perspectives]. Ann. Pharm. françaises 59, 3–21. 
Coffinier, C., Jung, H.J., Li, Z., Nobumori, C., Yun, U.J., Farber, E. a., Davies, B.S., 
Weinstein, M.M., Yang, S.H., Lammerding, J., Farahani, J.N., Bentolila, L. a., 
Fong, L.G., Young, S.G., 2010. Direct synthesis of lamin A, bypassing prelamin a 
processing, causes misshapen nuclei in fibroblasts but no detectable pathology in 
mice. J. Biol. Chem. 285, 20818–20826. doi:10.1074/jbc.M110.128835 
Cotter, D., Guda, P., Fahy, E., Subramaniam, S., 2004. MitoProteome: mitochondrial 
protein sequence database and annotation system. Nucleic Acids Res. 32, D463–
D467. doi:10.1093/nar/gkh048 
Cousin, B., Cinti, S., Morroni, M., Raimbault, S., Ricquier, D., Pénicaud, L., Casteilla, 
L., 1992. Occurrence of brown adipocytes in rat white adipose tissue: molecular 
and morphological characterization. J. Cell Sci. 103 ( Pt 4, 931–942. 
Cummings, D.E., Schwartz, M.W., 2003. Genetics and pathophysiology of human 
obesity. Annu. Rev. Med. 54, 453–471. 
doi:10.1146/annurev.med.54.101601.152403 
Davies, B.S.J., Barnes, R.H., Tu, Y., Ren, S., Andres, D. a., Peter Spielmann, H., 
Lammerding, J., Wang, Y., Young, S.G., Fong, L.G., 2010. An accumulation of 
non-farnesylated prelamin A causes cardiomyopathy but not progeria. Hum. Mol. 
Genet. 19, 2682–2694. doi:10.1093/hmg/ddq158 
De Conti, L., Baralle, M., Buratti, E., 2013. Exon and intron definition in pre-mRNA 
splicing. Wiley Interdiscip. Rev. RNA 4, 49–60. doi:10.1002/wrna.1140 
Dechat, T., Pfleghaar, K., Sengupta, K., Shimi, T., Shumaker, D.K., Solimando, L., 
Goldman, R.D., 2008. Nuclear lamins: Major factors in the structural organization 
and function of the nucleus and chromatin. Genes Dev. 22, 832–853. 
doi:10.1101/gad.1652708 
Deiuliis, J. a, 2015. MicroRNAs as regulators of metabolic disease: Pathophysiologic 
significance and emerging role as biomarkers and therapeutics. Int. J. Obes. 1–
   REFERENCES 
133 
 
50. doi:10.1038/ijo.2015.170 
Dempersmier, J., Sul, H.S., 2015. Shades of Brown: A Model for Thermogenic Fat. 
Front. Endocrinol. (Lausanne). 6, 1–6. doi:10.3389/fendo.2015.00071 
Dimauro, S., Schon, E.A., 2003. Mitochondrial Respiratory-Chain Diseases 2656–
2668. 
Dimroth, P., Kaim, G., Matthey, U., 2000. Crucial role of the membrane potential for 
ATP synthesis by F(1)F(o) ATP synthases. J. Exp. Biol. 203, 51–59. 
Divakaruni, A.S., Brand, M.D., 2011. The regulation and physiology of mitochondrial 
proton leak. Physiology (Bethesda). 26, 192–205. doi:10.1152/physiol.00046.2010 
Dulloo,  a G., Jacquet, J., Solinas, G., Montani, J.-P., Schutz, Y., 2010. Body 
composition phenotypes in pathways to obesity and the metabolic syndrome. Int. 
J. Obes. (Lond). 34 Suppl 2, S4–S17. doi:10.1038/ijo.2010.234 
Elabd, C., Chiellini, C., Carmona, M., Galitzky, J., Cochet, O., Petersen, R., Pénicaud, 
L., Kristiansen, K., Bouloumié, A., Casteilla, L., Dani, C., Ailhaud, G., Amri, E.-Z., 
2009. Human multipotent adipose-derived stem cells differentiate into functional 
brown adipocytes. Stem Cells 27, 2753–60. doi:10.1002/stem.200 
Elstner, M., Andreoli, C., Klopstock, T., Meitinger, T., Prokisch, H., 2009. The 
mitochondrial proteome database: MitoP2. Methods Enzymol. 457, 3–20. 
doi:10.1016/S0076-6879(09)05001-0 
Enríquez, J.A., Fernández-Sílva, P., Montoya, J.,. Autonomous regulation in 
mammalian mitochondrial DNA transcription. Biol. Chem. 380, 737–47. 
doi:10.1515/BC.1999.094 
Eriksson, M., Brown, W.T., Gordon, L.B., Glynn, M.W., Singer, J., Scott, L., Erdos, 
M.R., Robbins, C.M., Moses, T.Y., Berglund, P., Dutra, A., Pak, E., Durkin, S., 
Csoka, A.B., Boehnke, M., Glover, T.W., Collins, F.S., 2003. Recurrent de novo 
point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 
423, 293–298. doi:10.1038/nature01629 
Fain, J.N., 2010. Release of inflammatory mediators by human adipose tissue is 
enhanced in obesity and primarily by the nonfat cells: A review. Mediators 
Inflamm. 2010. doi:10.1155/2010/513948 
Fajas, L., 2003. Adipogenesis: a cross-talk between cell proliferation and cell 
differentiation. Ann. Med. 35, 79–85. 
Fajas, L., Auboeuf, D., Raspé, E., Schoonjans, K., Lefebvre,  a M., Saladin, R., Najib, 
J., Laville, M., Fruchart, J.C., Deeb, S., Vidal-Puig,  a, Flier, J., Briggs, M.R., 
Staels, B., Vidal, H., Auwerx, J., 1997. The organization, promoter analysis, and 
expression of the human PPARgamma gene. J. Biol. Chem. 272, 18779–18789. 
doi:10.1074/jbc.272.30.18779 
Farmer, S.R., 2006. Transcriptional control of adipocyte formation. Cell Metab. 4, 263–
273. doi:10.1016/j.cmet.2006.07.001 
   REFERENCES 
134 
 
Fasshauer, M., Bluher, M., 2015. Adipokines in health and disease. Cell Press 36, 69–
88. doi:10.1007/978-1-4419-1607-5_4 
Fasshauer, M., Blüher, M., Stumvoll, M., 2014. Adipokines in gestational diabetes. 
lancet. Diabetes Endocrinol. 2, 488–99. doi:10.1016/S2213-8587(13)70176-1 
Feige, J.N., Lagouge, M., Canto, C., Strehle, A., Houten, S.M., Milne, J.C., Lambert, 
P.D., Mataki, C., Elliott, P.J., Auwerx, J., 2008. Specific SIRT1 Activation Mimics 
Low Energy Levels and Protects against Diet-Induced Metabolic Disorders by 
Enhancing Fat Oxidation. Cell Metab. 8, 347–358. doi:10.1016/j.cmet.2008.08.017 
Fernández-Sánchez, A., Madrigal-Santillán, E., Bautista, M., Esquivel-Soto, J., 
Morales-González, A., Esquivel-Chirino, C., Durante-Montiel, I., Sánchez-Rivera, 
G., Valadez-Vega, C., Morales-González, J. a, 2011. Inflammation, oxidative 
stress, and obesity. Int. J. Mol. Sci. 12, 3117–32. doi:10.3390/ijms12053117 
Finan, B., Ma, T., Ottaway, N., Müller, T.D., Habegger, K.M., Heppner, K.M., Kirchner, 
H., Holland, J., Hembree, J., Raver, C., Lockie, S.H., Smiley, D.L., Gelfanov, V., 
Yang, B., Hofmann, S., Bruemmer, D., Drucker, D.J., Pfluger, P.T., Perez-Tilve, 
D., Gidda, J., Vignati, L., Zhang, L., Hauptman, J.B., Lau, M., Brecheisen, M., 
Uhles, S., Riboulet, W., Hainaut, E., Sebokova, E., Conde-Knape, K., Konkar, A., 
DiMarchi, R.D., Tschöp, M.H., 2013. Unimolecular dual incretins maximize 
metabolic benefits in rodents, monkeys, and humans. Sci. Transl. Med. 5, 
209ra151. doi:10.1126/scitranslmed.3007218 
Finley, J., 2014. Alteration of splice site selection in the LMNA gene and inhibition of 
progerin production via AMPK activation. Med. Hypotheses 83, 580–587. 
doi:10.1016/j.mehy.2014.08.016 
Fisher, M., Kleiner, S., Douris, N., Fox, E.C., Mepani, R.J., Verdeguer, F., Wu, J., 
Kharitonenkov, A., Flier, J.S., Maratos-flier, E., Spiegelman, B.M., 2012. adaptive 
thermogenesis FGF21 regulates PGC-1a and browning of white adipose tissues in 
adaptive thermogenesis 271–281. doi:10.1101/gad.177857.111 
Fleury, C., Neverova, M., Collins, S., Raimbault, S., Champigny, O., Levi-Meyrueis, C., 
Bouillaud, F., Seldin, M.F., Surwit, R.S., Ricquier, D., Warden, C.H., 1997. 
Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia. Nat. 
Genet. 15, 269–72. doi:10.1038/ng0397-269 
Fong, L.G., Ng, J.K., Lammerding, J., Vickers, T.A., Meta, M., Coté, N., Gavino, B., 
Qiao, X., Chang, S.Y., Young, S.R., Yang, S.H., Stewart, C.L., Lee, R.T., Bennett, 
C.F., Bergo, M.O., Young, S.G., 2006. Prelamin A and lamin A appear to be 
dispensable in the nuclear lamina 116, 743–752. doi:10.1172/JCI27125.with 
Fong, L.G., Vickers, T. a., Farber, E. a., Choi, C., Yun, U.J., Hu, Y., Yang, S.H., 
Coffinier, C., Lee, R., Yin, L., Davies, B.S.J., Andres, D. a., Spielmann, H.P., 
Bennett, C.F., Young, S.G., 2009. Activating the synthesis of progerin, the mutant 
prelamin A in Hutchinson-Gilford progeria syndrome, with antisense 
oligonucleotides. Hum. Mol. Genet. 18, 2462–2471. doi:10.1093/hmg/ddp184 
Friedman, R.C., Farh, K.K.H., Burge, C.B., Bartel, D.P., 2009. Most mammalian 
   REFERENCES 
135 
 
mRNAs are conserved targets of microRNAs. Genome Res. 19, 92–105. 
doi:10.1101/gr.082701.108 
Gabaldón, T., Huynen, M. a., 2004. Shaping the mitochondrial proteome. Biochim. 
Biophys. Acta - Bioenerg. 1659, 212–220. doi:10.1016/j.bbabio.2004.07.011 
Gaich, G., Chien, J.Y., Fu, H., Glass, L.C., Deeg, M.A., Holland, W.L., Kharitonenkov, 
A., Bumol, T., Schilske, H.K., Moller, D.E., 2013. The Effects of LY2405319, an 
FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes. Cell Metab. 18, 
333–340. doi:10.1016/j.cmet.2013.08.005 
Galgani, J.E., Moro, C., Ravussin, E., 2008. Metabolic flexibility and insulin resistance. 
Am. J. Physiol. Endocrinol. Metab. 295, E1009–17. 
doi:10.1152/ajpendo.90558.2008 
Garcia-Blanco, M. a, Baraniak, A.P., Lasda, E.L., 2004. Alternative splicing in disease 
and therapy. Nat. Biotechnol. 22, 535–546. doi:10.1038/nbt964 
Gasparik, V., Daubeuf, F., Hachet-Haas, M., Rohmer, F., Gizzi, P., Haiech, J., Galzi, 
J.L., Hibert, M., Bonnet, D., Frossard, N., 2012. Prodrugs of a CXC chemokine-12 
(CXCL12) neutraligand prevent inflammatory reactions in an asthma model in 
vivo. ACS Med. Chem. Lett. 3, 10–14. doi:10.1021/ml200017d 
Gesta, S., Blüher, M., Yamamoto, Y., Norris, A.W., Berndt, J., Kralisch, S., Boucher, J., 
Lewis, C., Kahn, C.R., 2006. Evidence for a role of developmental genes in the 
origin of obesity and body fat distribution. Proc. Natl. Acad. Sci. U. S. A. 103, 
6676–6681. doi:10.1073/pnas.0601752103 
Gesta, S., Tseng, Y.H., Kahn, C.R., 2007. Developmental Origin of Fat: Tracking 
Obesity to Its Source. Cell 131, 242–256. doi:10.1016/j.cell.2007.10.004 
Ghorbani, M., Claus, T.H., Himms-Hagen, J., 1997. Hypertrophy of brown adipocytes in 
brown and white adipose tissues and reversal of diet-induced obesity in rats 
treated with a ??3-adrenoceptor agonist. Biochem. Pharmacol. 54, 121–131. 
doi:10.1016/S0006-2952(97)00162-7 
Gillum, A.M., Clayton, D. a, 1978. Mechanism of mitochondrial DNA replication in 
mouse L-cells: kinetics of synthesis and turnover of the initiation sequence. J. Mol. 
Biol. 119, 49–68. doi:10.1016/0022-2836(78)90269-3 
Giralt, M., Villarroya, F., 2013. White, brown, beige/brite: Different adipose cells for 
different functions? Endocrinology 154, 2992–3000. doi:10.1210/en.2013-1403 
González, M., del Mar Bibiloni, M., Pons, A., Llompart, I., Tur, J.A., 2012. Inflammatory 
markers and metabolic syndrome among adolescents. Eur. J. Clin. Nutr. 66, 
1141–5. doi:10.1038/ejcn.2012.112 
Goodyear, L.J., 2008. The Exercise Pill — Too Good to Be True? N. Engl. J. Med. 359, 
1842–1844. doi:10.1056/NEJMcibr0806723 
Gospodarska, E., Nowialis, P., Kozak, L.P., 2015. Mitochondrial Turnover: A 
Phenotype Distinguishing Brown Adipocytes from Interscapular Brown Adipose 
Tissue and White Adipose Tissue. doi:10.1074/jbc.M115.637785 
   REFERENCES 
136 
 
Granata, S., Zaza, G., Simone, S., Villani, G., Latorre, D., Pontrelli, P., Carella, M., 
Schena, F.P., Grandaliano, G., Pertosa, G., 2009. Mitochondrial dysregulation and 
oxidative stress in patients with chronic kidney disease. BMC Genomics 10, 388. 
doi:10.1186/1471-2164-10-388 
Gray, M.W., 2012. Mitochondrial evolution. Cold Spring Harb. Perspect. Biol. 4. 
doi:10.1101/cshperspect.a011403 
Green, H., Kehinde, O., 1975. An established preadipose cell line and its differentiation 
in culture. II. Factors affecting the adipose conversion. Cell 5, 19–27. 
doi:10.1016/0092-8674(75)90087-2 
Gregory, R.I., Yan, K.-P., Amuthan, G., Chendrimada, T., Doratotaj, B., Cooch, N., 
Shiekhattar, R., 2004. The Microprocessor complex mediates the genesis of 
microRNAs. Nature 432, 235–240. doi:10.1038/nature03120 
Grujic, D., Susulic, V.S., Harper, M.E., Himms-Hagen, J., Cunningham, B. a, Corkey, 
B.E., Lowell, B.B., 1997. Beta3-adrenergic receptors on white and brown 
adipocytes mediate beta3-selective agonist-induced effects on energy 
expenditure, insulin secretion, and food intake. A study using transgenic and gene 
knockout mice. J. Biol. Chem. 272, 17686–17693. doi:10.1074/jbc.272.28.17686 
Guarente, L., 2013. Calorie restriction and sirtuins revisited. Genes Dev. 27, 2072–85. 
doi:10.1101/gad.227439.113 
Guénantin,  a. C., Briand, N., Bidault, G., Afonso, P., Béréziat, V., Vatier, C., Lascols, 
O., Caron-Debarle, M., Capeau, J., Vigouroux, C., 2014. Nuclear envelope-related 
lipodystrophies. Semin. Cell Dev. Biol. 29, 148–157. 
doi:10.1016/j.semcdb.2013.12.015 
Guerra, C., Koza, R. a., Yamashita, H., Walsh, K., Kozak, L.P., 1998. Emergence of 
brown adipocytes in white fat in mice is under genetic control effects on body 
weight and adiposity. J. Clin. Invest. 102, 412–420. doi:10.1172/JCI3155 
Ha, M., Kim, V.N., 2014. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 
15, 509–524. doi:10.1038/nrm3838 
Haigis, M.C., Sinclair, D.A., 2010. Mammalian Sirtuins: Biological Insights and Disease 
Relevance. Annu. Rev. Pathol. Mech. Dis. 5, 253–295. 
doi:10.1146/annurev.pathol.4.110807.092250 
Harms, M., Seale, P., 2013. Brown and beige fat: development, function and 
therapeutic potential. Nat. Med. 19, 1252–63. doi:10.1038/nm.3361 
Harper, M.-E., Green, K., Brand, M.D., 2008. The efficiency of cellular energy 
transduction and its implications for obesity. Annu. Rev. Nutr. 28, 13–33. 
doi:10.1146/annurev.nutr.28.061807.155357 
Hartig, S.M., Hamilton, M.P., Bader, D.A., McGuire, S.E., 2015. The miRNA 
Interactome in Metabolic Homeostasis. Trends Endocrinol. Metab. 
doi:10.1016/j.tem.2015.09.006 
Hegele, R. a., Huff, M.W., Young, T.K., 2001. Common genomic variation in LMNA 
   REFERENCES 
137 
 
modulates indexes of obesity in Inuit. J. Clin. Endocrinol. Metab. 86, 2747–2751. 
doi:10.1210/jc.86.6.2747 
Hegele, R.A., Cao, H., Harris, S.B., Zinman, B., Hanley, A.J., Anderson, C.M., 2000. 
Genetic variation in LMNA modulates plasma leptin and indices of obesity in 
aboriginal Canadians. Physiol. Genomics 3, 39–44. 
Hill, B.G., 2015. Insights into an adipocyte whitening program. Adipocyte 4, 75–80. 
doi:10.4161/21623945.2014.960351 
Himms-Hagen, J.E. in a P.F. of E.E.T., 2004. Exercise in a Pill: Feasibility of Energy 
Expenditure Targets. 
Hoskins, A. a., Moore, M.J., 2012. The spliceosome: A flexible, reversible 
macromolecular machine. Trends Biochem. Sci. 37, 179–188. 
doi:10.1016/j.tibs.2012.02.009 
Huang, L., Mollet, S., Souquere, S., Le Roy, F., Ernoult-Lange, M., Pierron, G., Dautry, 
F., Weil, D., 2011. Mitochondria Associate with P-bodies and Modulate MicroRNA-
mediated RNA Interference. J. Biol. Chem. 286, 24219–24230. 
doi:10.1074/jbc.M111.240259 
Hughes, J.P., Rees, S.S., Kalindjian, S.B., Philpott, K.L., 2011. Principles of early drug 
discovery. Br. J. Pharmacol. 162, 1239–1249. doi:10.1111/j.1476-
5381.2010.01127.x 
Hui, X., Gu, P., Zhang, J., Nie, T., Pan, Y., Wu, D., Feng, T., Zhong, C., Wang, Y., 
Lam, K.S.L., Xu, A., 2015. Adiponectin Enhances Cold-Induced Browning of 
Subcutaneous Adipose Tissue via Promoting M2 Macrophage Proliferation. Cell 
Metab. 22, 279–290. doi:10.1016/j.cmet.2015.06.004 
Hunte, C., Koepke, J., Lange, C., Roßmanith, T., Michel, H., 2000. Structure at 2.3 Å 
resolution of the cytochrome bc1 complex from the yeast Saccharomyces 
cerevisiae co-crystallized with an antibody Fv fragment. Structure 8, 669–684. 
doi:10.1016/S0969-2126(00)00152-0 
Huot, M.-É., Vogel, G., Zabarauskas, A., Ngo, C.T.-A., Coulombe-Huntington, J., 
Majewski, J., Richard, S., 2012. The Sam68 STAR RNA-binding protein regulates 
mTOR alternative splicing during adipogenesis. Mol. Cell 46, 187–99. 
doi:10.1016/j.molcel.2012.02.007 
Hüttemann, M., Lee, I., Samavati, L., Yu, H., Doan, J.W., 2007. Regulation of 
mitochondrial oxidative phosphorylation through cell signaling. Biochim. Biophys. 
Acta 1773, 1701–20. 
Ibrahim, M.M., 2010. Subcutaneous and visceral adipose tissue: Structural and 
functional differences. Obes. Rev. 11, 11–18. doi:10.1111/j.1467-
789X.2009.00623.x 
Itoh, N., 2014. FGF21 as a hepatokine, adipokine, and myokine in metabolism and 
diseases. Front. Endocrinol. (Lausanne). 5, 4–7. doi:10.3389/fendo.2014.00107 
Jackson, V.M., Breen, D.M., Fortin, J.-P., Liou, A., Kuzmiski, J.B., Loomis, A.K., Rives, 
   REFERENCES 
138 
 
M.-L., Shah, B., Carpino, P.A., 2015. Latest approaches for the treatment of 
obesity. Expert Opin. Drug Discov. 1–15. doi:10.1517/17460441.2015.1044966 
Jakobs, S., 2006. High resolution imaging of live mitochondria. Biochim. Biophys. Acta 
1763, 561–575. doi:10.1016/j.bbamcr.2006.04.004 
Jastroch, M., Divakaruni, A.S., Mookerjee, S., Treberg, J.R., Martin, D., 2011. NIH 
Public Access 53–67. doi:10.1042/bse0470053.Mitochondrial 
Ji, X., Zhou, Y., Pandit, S., Huang, J., Li, H., Lin, C.Y., Xiao, R., Burge, C.B., Fu, X.-D., 
2013. SR proteins collaborate with 7SK and promoter-associated nascent RNA to 
release paused polymerase. Cell 153, 855–68. doi:10.1016/j.cell.2013.04.028 
Jia, L., Liu, X., 2007. The Conduct of Drug Metabolism Studies Considered Good 
Practice (II): In Vitro Experiments | BenthamScience. Curr Drug Metab. 
Johnson, D.T., Harris, R. a, French, S., Blair, P. V, You, J., Bemis, K.G., Wang, M., 
Balaban, R.S., 2007. Tissue heterogeneity of the mammalian mitochondrial 
proteome. Am. J. Physiol. Cell Physiol. 292, C689–C697. 
doi:10.1152/ajpcell.00108.2006 
Jung, H.-J., Coffinier, C., Choe, Y., Beigneux, A.P., Davies, B.S.J., Yang, S.H., Barnes, 
R.H., Hong, J., Sun, T., Pleasure, S.J., Young, S.G., Fong, L.G., 2012. Regulation 
of prelamin A but not lamin C by miR-9, a brain-specific microRNA. Proc. Natl. 
Acad. Sci. U. S. A. 109, E423–31. doi:10.1073/pnas.1111780109 
Kaminska, D., Pihlajamäki, J., 2013. Regulation of alternative splicing in obesity and 
weight loss 143–147. 
Karpe, F., Pinnick, K.E., 2015. Biology of upper-body and lower-body adipose tissue--
link to whole-body phenotypes. Nat. Rev. Endocrinol. 11, 90–100. 
doi:10.1038/nrendo.2014.185 
Kazak, L., Chouchani, E.T., Jedrychowski, M.P., Gygi, S.P., Bruce, M., Kazak, L., 
Chouchani, E.T., Jedrychowski, M.P., Erickson, B.K., Shinoda, K., Cohen, P., 
Vetrivelan, R., Lu, G.Z., Laznik-bogoslavski, D., Hasenfuss, S.C., Kajimura, S., 
Gygi, S.P., Spiegelman, B.M., 2015. Article A Creatine-Driven Substrate Cycle 
Enhances Energy Expenditure and Thermogenesis in Beige Fat Article A 
Creatine-Driven Substrate Cycle Enhances Energy Expenditure and 
Thermogenesis in Beige Fat. Cell 163, 643–655. doi:10.1016/j.cell.2015.09.035 
Kelemen, O., Convertini, P., Zhang, Z., Wen, Y., Shen, M., Falaleeva, M., Stamm, S., 
2013. Function of alternative splicing. Gene 514, 1–30. 
doi:10.1016/j.gene.2012.07.083 
Kelly, D.P., Scarpulla, R.C., 2004. Transcriptional regulatory circuits controlling 
mitochondrial biogenesis and function. Genes Dev. 18, 357–368. 
doi:10.1101/gad.1177604 
Kharitonenkov, A., Shiyanova, T.L., Koester, A., Ford, A.M., Micanovic, R., Galbreath, 
E.J., Sandusky, G.E., Hammond, L.J., Moyers, J.S., Owens, R. a., Gromada, J., 
Brozinick, J.T., Hawkins, E.D., Wroblewski, V.J., Li, D.S., Mehrbod, F., Jaskunas, 
   REFERENCES 
139 
 
S.R., Shanafelt, A.B., 2005. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 
115, 1627–1635. doi:10.1172/JCI23606 
Khedkar, V., Verma, J., Coutinho, E., 2009. Small-molecule screening techniques in 
drug discovery 3–7. 
Kim, J.B., Spiegelman, B.M., 1996. ADD 1/SREBP1 promotes adipocyte differentiation 
and gene expression linked to fatty acid metabolism. Genes Dev. 10, 1096–1107. 
Kishore, S., Stamm, S., 2006. The snoRNA HBII-52 Regulates 311, 230–232. 
Klöting, N., Berthold, S., Kovacs, P., Schön, M.R., Fasshauer, M., Ruschke, K., 
Stumvoll, M., Blüher, M., 2009. MicroRNA expression in human omental and 
subcutaneous adipose tissue. PLoS One 4, 2–7. 
doi:10.1371/journal.pone.0004699 
Knauf, C., Drougard, A., Fournel, A., Duparc, T., Valet, P., 2013. Hypothalamic actions 
of apelin on energy metabolism: new insight on glucose homeostasis and 
metabolic disorders. Horm. Metab. Res. 45, 928–34. doi:10.1055/s-0033-1351321 
Konarska, M.M., Vilardell, J., Query, C.C., 2006. Repositioning of the reaction 
intermediate within the catalytic center of the spliceosome. Mol. Cell 21, 543–53. 
doi:10.1016/j.molcel.2006.01.017 
Kopecky, J., Clarke, G., Enerbäck, S., Spiegelman, B., Kozak, L.P., 1995. Expression 
of the mitochondrial uncoupling protein gene from the aP2 gene promoter 
prevents genetic obesity. J. Clin. Invest. 96, 2914–2923. doi:10.1172/JCI118363 
Kornberg, H., 2000. Krebs and his trinity of cycles. Nat. Rev. Mol. Cell Biol. 1, 225–228. 
doi:10.1038/35043073 
Kornblihtt, A.R., Schor, I.E., Alló, M., Dujardin, G., Petrillo, E., Muñoz, M.J., 2013. 
Alternative splicing: a pivotal step between eukaryotic transcription and 
translation. Nat. Rev. Mol. Cell Biol. 14, 153–65. doi:10.1038/nrm3525 
Krauss, S., Cy, Z., Scorrano, L., Lt, D., St-Pierre, J., St, G., Bb, L., 2003. Superoxide-
mediated activation of uncoupling protein 2 causes pancreatic beta cell 
dysfunction.[see comment]. 112, 1831–1842. doi:10.1172/JCI19774 
Krebs, H. a, Johnson, W. a, 1937. Acetopyruvic acid (alphagamma-diketovaleric acid) 
as an intermediate metabolite in animal tissues. Biochem. J. 31, 772–779. 
Lacarelle, B., Marre, F., Blanc-Gauthier, T., Zhou, X.J., Placidi, M., Catalin, J., 
Rahmani, R., 1991. Use of human and animal liver microsomes in drug metabolic 
studies. Eur. J. Drug Metab. Pharmacokinet. Spec No 3, 458–65. 
Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., 
Messadeq, N., Milne, J., Lambert, P., Elliott, P., Geny, B., Laakso, M., Puigserver, 
P., Auwerx, J., 2006. Resveratrol improves mitochondrial function and protects 
against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127, 1109–
22. doi:10.1016/j.cell.2006.11.013 
Lancaster, C.R.D., 2002. Succinate : quinone oxidoreductases : an overview 1553, 1–6. 
   REFERENCES 
140 
 
Langin D, Frühbeck G, Frayn KN, L.M., 2009. Adipose tissue: development, anatomy 
and functions. John Wiley & Sons, Ltd, Chichester, UK. 
doi:10.1002/9780470712221 
Langin, D., 2006. Adipose tissue lipolysis as a metabolic pathway to define 
pharmacological strategies against obesity and the metabolic syndrome. 
Pharmacol. Res. 53, 482–491. doi:10.1016/j.phrs.2006.03.009 
Larder, R., O’Rahilly, S., 2012. Shedding pounds after going under the knife: Guts over 
glory—why diets fail. Nat. Med. 18, 666–667. doi:10.1038/nm.2747 
Lattanzi, G., Ortolani, M., Columbaro, M., Prencipe, S., Mattioli, E., Lanzarini, C., 
Maraldi, N.M., Cenni, V., Garagnani, P., Salvioli, S., Storci, G., Bonafè, M., 
Capanni, C., Franceschi, C., 2014. Lamins are rapamycin targets that impact 
human longevity: a study in centenarians. J. Cell Sci. 127, 147–57. 
doi:10.1242/jcs.133983 
Lee, Y., Rio, D.C., 2015. Mechanisms and Regulation of Alternative Pre-mRNA 
Splicing. Annu. Rev. Biochem. 84, 291–323. doi:10.1146/annurev-biochem-
060614-034316 
Lenhard, J.M., 2011. Lipogenic enzymes as therapeutic targets for obesity and 
diabetes. Curr. Pharm. Des. 17, 325–31. 
Lewis, B.P., Burge, C.B., Bartel, D.P., 2005. Conserved seed pairing, often flanked by 
adenosines, indicates that thousands of human genes are microRNA targets. Cell 
120, 15–20. doi:10.1016/j.cell.2004.12.035 
Li, J., Zhao, W.-G., Shen, Z.-F., Yuan, T., Liu, S.-N., Liu, Q., Fu, Y., Sun, W., 2015. 
Comparative Proteome Analysis of Brown Adipose Tissue in Obese C57BL/6J 
Mice Using iTRAQ-Coupled 2D LC-MS/MS. PLoS One 10, e0119350. 
doi:10.1371/journal.pone.0119350 
Liebling, D.S., Eisner, J.D., Gibbs, J., Smith, G.P., 1975. Intestinal satiety in rats. J. 
Comp. Physiol. Psychol. 89, 955–65. 
Liesa, M., Shirihai, O.S., 2013. Mitochondrial dynamics in the regulation of nutrient 
utilization and energy expenditure. Cell Metab. 17, 491–506. 
doi:10.1016/j.cmet.2013.03.002 
Lim, L.P., Burge, C.B., 2001. A computational analysis of sequence features involved 
in recognition of short introns. Proc. Natl. Acad. Sci. U. S. A. 98, 11193–8. 
doi:10.1073/pnas.201407298 
Lin, C.S., Klingenberg, M., 1980. Isolation of the Uncoupling Protein From Brown 
Adipose Tissue 113. 
Lin, J. et al., 2002. Transcriptional co-activator PGC-1a drives the formation of slow-
twitch muscle fibres. Nature 418, 797–801. doi:10.1038/nature00936.1. 
Lin, J.-C., 2015. Impacts of Alternative Splicing Events on the Differentiation of 
Adipocytes. Int. J. Mol. Sci. 16, 22169–22189. doi:10.3390/ijms160922169 
   REFERENCES 
141 
 
Lin, Y., Lee, H., Berg,  a. H., Lisanti, M.P., Shapiro, L., Scherer, P.E., 2000. The 
lipopolysaccharide-activated Toll-like receptor (TLR)-4 induces synthesis of the 
closely related receptor TLR-2 in adipocytes. J. Biol. Chem. 275, 24255–24263. 
doi:10.1074/jbc.M002137200 
Lin, Y., Rajala, M.W., Berger, J.P., Moller, D.E., Barzilai, N., Scherer, P.E., 2001. 
Hyperglycemia-induced Production of Acute Phase Reactants in Adipose Tissue. 
J. Biol. Chem. 276, 42077–42083. doi:10.1074/jbc.M107101200 
Lin, Z., Tian, H., Lam, K.S.L., Lin, S., Hoo, R.C.L., Konishi, M., Itoh, N., Wang, Y., 
Bornstein, S.R., Xu, A., Li, X., 2013. Adiponectin mediates the metabolic effects of 
FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 17, 
779–789. doi:10.1016/j.cmet.2013.04.005 
Link, T.A., 1995. between the precursor , the intermediate , and the mature form of the 
FeS protein from Neurospora . 34 Interestingly the FeS protein from potato un- 
dergoes only one-step processing and the cytochrome-c reductase / pro- cessing 
peptidase complex is the on 126. 
Liu, B., Ghosh, S., Yang, X., Zheng, H., Liu, X., Wang, Z., Jin, G., Zheng, B., Kennedy, 
B.K., Suh, Y., Kaeberlein, M., Tryggvason, K., Zhou, Z., 2012. Resveratrol 
rescues SIRT1-dependent adult stem cell decline and alleviates progeroid 
features in laminopathy-based progeria. Cell Metab. 16, 738–50. 
doi:10.1016/j.cmet.2012.11.007 
Lloyd, D.J., Trembath, R.C., Shackleton, S., 2002. A novel interaction between lamin A 
and SREBP1: implications for partial lipodystrophy and other laminopathies. Hum. 
Mol. Genet. 11, 769–777. doi:10.1093/hmg/11.7.769 
Lopez-Mejia, I.C., de Toledo, M., Chavey, C., Lapasset, L., Cavelier, P., Lopez-
Herrera, C., Chebli, K., Fort, P., Beranger, G., Fajas, L., Amri, E.Z., Casas, F., 
Tazi, J., 2014. Antagonistic functions of LMNA isoforms in energy expenditure and 
lifespan. EMBO Rep. 15, 529–39. doi:10.1002/embr.201338126 
Lopez-Mejia, I.C., Vautrot, V., De Toledo, M., Behm-Ansmant, I., Bourgeois, C.F., 
Navarro, C.L., Osorio, F.G., Freije, J.M.P., Stévenin, J., De Sandre-Giovannoli, A., 
Lopez-Otin, C., Lévy, N., Branlant, C., Tazi, J., 2011. A conserved splicing 
mechanism of the LMNA gene controls premature aging. Hum. Mol. Genet. 20, 
4540–55. doi:10.1093/hmg/ddr385 
López-Otín, C., Blasco, M. a, Partridge, L., Serrano, M., Kroemer, G., 2013. The 
hallmarks of aging. Cell 153, 1194–217. doi:10.1016/j.cell.2013.05.039 
Lowell, B.B., Shulman, G.I., 2005. Mitochondrial dysfunction and type 2 diabetes. 
Science 307, 384–387. doi:10.1126/science.1104343 
Lowell, B.B., S-Susulic, V., Hamann, A., Lawitts, J. a, Himms-Hagen, J., Boyer, B.B., 
Kozak, L.P., Flier, J.S., 1993. Development of obesity in transgenic mice after 
genetic ablation of brown adipose tissue. Nature 366, 740–742. 
doi:10.1038/366740a0 
Luco, R.F., Allo, M., Schor, I.E., Kornblihtt, A.R., Misteli, T., 2011. Epigenetics in 
   REFERENCES 
142 
 
alternative pre-mRNA splicing. Cell 144, 16–26. doi:10.1016/j.cell.2010.11.056 
Lukeš, J., Archibald, J.M., Keeling, P.J., Doolittle, W.F., Gray, M.W., 2011. How a 
neutral evolutionary ratchet can build cellular complexity. IUBMB Life 63, 528–
537. doi:10.1002/iub.489 
Lund, L.R., Georg, B., Nielsen, L.S., Mayer, M., Danø, K., Andreasen, P. a, 1988. 
Plasminogen activator inhibitor type 1: cell-specific and differentiation-induced 
expression and regulation in human cell lines, as determined by enzyme-linked 
immunosorbent assay. Mol. Cell. Endocrinol. 60, 43–53. 
Lutz, T.A., Woods, S.C., 2013. Overview of Animal Models of Obesity 1–22. 
doi:10.1002/0471141755.ph0561s58.Overview 
Maes, H.H., Neale, M.C., Eaves, L.J., 1997. Genetic and environmental factors in 
relative body weight and human adiposity. Behav. Genet. 27, 325–51. 
Makeyev, E. V, Maniatis, T., 2008. Multilevel regulation of gene expression by 
microRNAs. Science 319, 1789–1790. doi:10.1126/science.1152326 
Mallet, V.O., Mitchell, C., Guidotti, J.-E., Jaffray, P., Fabre, M., Spencer, D., Arnoult, D., 
Kahn, A., Gilgenkrantz, H., 2002. Conditional cell ablation by tight control of 
caspase-3 dimerization in transgenic mice. Nat. Biotechnol. 20, 1234–1239. 
doi:10.1038/nbt762 
Mao, W., Yu, X.X., Zhong, A., Li, W., Brush, J., Sherwood, S.W., Adams, S.H., Pan, G., 
1999. UCP4, a novel brain-specific mitochondrial protein that reduces membrane 
potential in mammalian cells. FEBS Lett. 443, 326–330. doi:10.1016/S0014-
5793(98)01713-X 
Mardinoglu, A., Agren, R., Kampf, C., Asplund, A., Nookaew, I., Jacobson, P., Walley, 
A.J., Froguel, P., Carlsson, L.M., Uhlen, M., Nielsen, J., 2013. Integration of 
clinical data with a genome-scale metabolic model of the human adipocyte. Mol. 
Syst. Biol. 9, 649. doi:10.1038/msb.2013.5 
Martin, G., Schoonjans, K., Staels, B., Auwerx, J., 1998. PPARg activators improve 
glucose-homeostasis by stimulating fatty- acid uptake in the adipocytes. 
Atherosclerosis 137, S75–S80. 
Martin, W., 2010. Evolutionary origins of metabolic compartmentalization in eukaryotes. 
Philos. Trans. R. Soc. Lond. B. Biol. Sci. 365, 847–855. 
doi:10.1098/rstb.2009.0252 
Martínez, J.A., 2006. Mitochondrial oxidative stress and inflammation: an slalom to 
obesity and insulin resistance. J. Physiol. Biochem. 62, 303–6. 
Matera, A.G., Wang, Z., 2014. A day in the life of the spliceosome. Nat. Rev. 34, 455–
464. doi:10.1038/nrm3742 
Matlin, A.J., Clark, F., Smith, C.W.J., 2005. Understanding alternative splicing: towards 
a cellular code. Nat. Rev. Mol. Cell Biol. 6, 386–98. doi:10.1038/nrm1645 
Mattick, J.S., 2003. Challenging the dogma: The hidden layer of non-protein-coding 
   REFERENCES 
143 
 
RNAs in complex organisms. BioEssays 25, 930–939. doi:10.1002/bies.10332 
McFedries, A., Schwaid, A., Saghatelian, A., 2013. Methods for the elucidation of 
protein-small molecule interactions. Chem. Biol. 20, 667–673. 
doi:10.1016/j.chembiol.2013.04.008 
Mehra, A., Macdonald, I., Pillay, T.S., 2007. Variability in 3T3-L1 adipocyte 
differentiation depending on cell culture dish. Anal. Biochem. 362, 281–283. 
doi:10.1016/j.ab.2006.12.016 
Meirhaeghe, A., Crowley, V., Lenaghan, C., Lelliott, C., Green, K., Stewart, A., Hart, K., 
Schinner, S., Sethi, J.K., Yeo, G., Brand, M.D., Cortright, R.N., O’Rahilly, S., 
Montague, C., Vidal-Puig, A.J., 2003. Characterization of the human, mouse and 
rat PGC1 beta (peroxisome-proliferator-activated receptor-gamma co-activator 1 
beta) gene in vitro and in vivo. Biochem. J. 373, 155–165. 
doi:10.1042/BJ20030200 
Meisinger, C., Sickmann, A., Pfanner, N., 2008. The Mitochondrial Proteome: From 
Inventory to Function. Cell 134, 22–24. doi:10.1016/j.cell.2008.06.043 
Melamed, Z., Levy, A., Ashwal-Fluss, R., Lev-Maor, G., Mekahel, K., Atias, N., Gilad, 
S., Sharan, R., Levy, C., Kadener, S., Ast, G., 2013. Alternative Splicing 
Regulates Biogenesis of miRNAs Located across Exon-Intron Junctions. Mol. Cell 
50, 869–881. doi:10.1016/j.molcel.2013.05.007 
Mifflin, M.D., St Jeor, S.T., Hill, L. a, Scott, B.J., Daugherty, S. a, Koh, Y.O., 1990. A 
new predictive equation in healthy individuals3 for resting energy. Am. J. Clin. 
Nutr. 51, 241–247. 
Miranda, M., Chacón, M.R., Gutiérrez, C., Vilarrasa, N., Gómez, J.M., Caubet, E., 
Megía, A., Vendrell, J., 2008. LMNA mRNA expression is altered in human obesity 
and type 2 diabetes. Obesity (Silver Spring). 16, 1742–1748. 
doi:10.1038/oby.2008.276 
MITCHELL, P., 1961. Coupling of phosphorylation to electron and hydrogen transfer by 
a chemi-osmotic type of mechanism. Nature 191, 144–8. 
Moitra, J., Mason, M.M., Olive, M., Krylov, D., Gavrilova, O., Marcus-Samuels, B., 
Feigenbaum, L., Lee, E., Aoyama, T., Eckhaus, M., Reitman, M.L., Vinson, C., 
1998. Life without white fat: A transgenic mouse. Genes Dev. 12, 3168–3181. 
doi:10.1101/gad.12.20.3168 
Monteiro, R., Azevedo, I., 2010. Chronic inflammation in obesity and the metabolic 
syndrome. Mediators Inflamm. 2010. doi:10.1155/2010/289645 
Mori, M. a., Thomou, T., Boucher, J., Lee, K.Y., Lallukka, S., Kim, J.K., Torriani, M., 
Yki-Järvinen, H., Grinspoon, S.K., Cypess, A.M., Kahn, C.R., 2014. Altered 
miRNA processing disrupts brown/white adipocyte determination and associates 
with lipodystrophy. J. Clin. Invest. 124, 3339–3351. doi:10.1172/JCI73468 
Murase, T., Misawa, K., Minegishi, Y., Aoki, M., Ominami, H., Suzuki, Y., Shibuya, Y., 
Hase, T., 2011. Coffee polyphenols suppress diet-induced body fat accumulation 
   REFERENCES 
144 
 
by downregulating SREBP-1c and related molecules in C57BL/6J mice. Am. J. 
Physiol. Endocrinol. Metab. 300, E122–E133. doi:10.1152/ajpendo.00441.2010 
Myers, M.G., Cowley, M. a, Münzberg, H., 2008. Mechanisms of leptin action and leptin 
resistance. Annu. Rev. Physiol. 70, 537–556. 
doi:10.1146/annurev.physiol.70.113006.100707 
Nam, M., Cooper, M.P., 2015. Role of Energy Metabolism in the Brown Fat Gene 
Program. Front. Endocrinol. (Lausanne). 6. doi:10.3389/fendo.2015.00104 
Nasrallah, C.M., Horvath, T.L., 2014. Mitochondrial dynamics in the central regulation 
of metabolism. Nat. Rev. Endocrinol. 10, 650–8. doi:10.1038/nrendo.2014.160 
Navarro, C.L., Cau, P., Lévy, N., 2006. Molecular bases of progeroid syndromes. Hum. 
Mol. Genet. 15, 151–161. doi:10.1093/hmg/ddl214 
Naznin, F., Toshinai, K., Waise, T.M.Z., Namkoong, C., Moin, A.S.M., Sakoda, H., 
Nakazato, M., 2015. Diet-induced obesity causes peripheral and central ghrelin 
resistance by promoting inflammation. J. Endocrinol. doi:10.1530/JOE-15-0139 
Nedergaard, J., Bengtsson, T., Cannon, B., 2007. Unexpected evidence for active 
brown adipose tissue in adult humans. Am. J. Physiol. Endocrinol. Metab. 293, 
444–452. doi:10.1152/ajpendo.00691.2006. 
Nedergaard, J., Cannon, B., 2013. How brown is brown fat? It depends where you 
look. Nat. Med. 19, 540–541. doi:10.1038/nm.3187 
Nedergaard, J., Cannon, B., 2003. The “novel” “uncoupling” proteins UCP2 and UCP3: 
what do they really do? Pros and cons for suggested functions. Exp. Physiol. 88, 
65–84. 
Nicholls, D.G., Bernson, V.S., Heaton, G.M., 1978. The identification of the component 
in the inner membrane of brown adipose tissue mitochondria responsible for 
regulating energy dissipation. Experientia. Suppl. 32, 89–93. 
Nissan, X., Blondel, S., Navarro, C., Maury, Y., Denis, C., Girard, M., Martinat, C., De 
Sandre-Giovannoli, A., Levy, N., Peschanski, M., 2012. Unique preservation of 
neural cells in hutchinson- gilford progeria syndrome is due to the expression of 
the neural-specific miR-9 microRNA. Cell Rep. 2, 1–9. 
doi:10.1016/j.celrep.2012.05.015 
Ntambi, J.M., Kim, Y., 2000. Symposium : Adipocyte Function , Differentiation and 
Metabolism 3122–3126. 
Orang, A.V., Safaralizadeh, R., Kazemzadeh-bavili, M., 2014. Mechanisms of miRNA-
Mediated Gene Regulation from Common Downregulation to mRNA-Specific 
Upregulation. Int. J. Genomics 2014. 
Orengo, J.P., Cooper, T.A., 2007. Alternative splicing in disease. Adv. Exp. Med. Biol. 
623, 212–23. 
Ortega, F.J., Mayas, D., Moreno-Navarrete, J.M., Catalán, V., Gómez-Ambrosi, J., 
Esteve, E., Rodriguez-Hermosa, J.I., Ruiz, B., Ricart, W., Peral, B., Fruhbeck, G., 
   REFERENCES 
145 
 
Tinahones, F.J., Fernández-Real, J.M., 2010. The gene expression of the main 
lipogenic enzymes is downregulated in visceral adipose tissue of obese subjects. 
Obesity (Silver Spring). 18, 13–20. doi:10.1038/oby.2009.202 
Ortega-Molina, A., Efeyan, A., Lopez-Guadamillas, E., Muñoz-Martin, M., Gómez-
López, G., Cañamero, M., Mulero, F., Pastor, J., Martinez, S., Romanos, E., Mar 
Gonzalez-Barroso, M., Rial, E., Valverde, A.M., Bischoff, J.R., Serrano, M., 2012. 
Pten positively regulates brown adipose function, energy expenditure, and 
longevity. Cell Metab. 15, 382–394. doi:10.1016/j.cmet.2012.02.001 
Osellame, L.D., Blacker, T.S., Duchen, M.R., 2012. Cellular and molecular 
mechanisms of mitochondrial function. Best Pract. Res. Clin. Endocrinol. Metab. 
26, 711–723. doi:10.1016/j.beem.2012.05.003 
Osorio, F.G., Navarro, C.L., Cadiñanos, J., López-Mejía, I.C., Quirós, P.M., Bartoli, C., 
Rivera, J., Tazi, J., Guzmán, G., Varela, I., Depetris, D., de Carlos, F., Cobo, J., 
Andrés, V., De Sandre-Giovannoli, A., Freije, J.M.P., Lévy, N., López-Otín, C., 
2011. Splicing-directed therapy in a new mouse model of human accelerated 
aging. Sci. Transl. Med. 3, 106ra107. doi:10.1126/scitranslmed.3002847 
Ouchi, N., Parker, J.L., Lugus, J.J., Walsh, K., 2011. Adipokines in inflammation and 
metabolic disease. Nat. Rev. Immunol. 11, 85–97. doi:10.1038/nri2921 
Pabis, M., Neufeld, N., Steiner, M.C., Bojic, T., Shav-Tal, Y., Neugebauer, K.M., 2013. 
The nuclear cap-binding complex interacts with the U4/U6·U5 tri-snRNP and 
promotes spliceosome assembly in mammalian cells. RNA 19, 1054–63. 
doi:10.1261/rna.037069.112 
Pagliarini, D.J., Calvo, S.E., Chang, B., Sheth, S. a., Vafai, S.B., Ong, S.E., Walford, G. 
a., Sugiana, C., Boneh, A., Chen, W.K., Hill, D.E., Vidal, M., Evans, J.G., 
Thorburn, D.R., Carr, S. a., Mootha, V.K., 2008. A Mitochondrial Protein 
Compendium Elucidates Complex I Disease Biology. Cell 134, 112–123. 
doi:10.1016/j.cell.2008.06.016 
Pan, Q., Shai, O., Lee, L.J., Frey, B.J., Blencowe, B.J., 2008. Deep surveying of 
alternative splicing complexity in the human transcriptome by high-throughput 
sequencing. Nat. Genet. 40, 1413–5. doi:10.1038/ng.259 
Pandit, S., Zhou, Y., Shiue, L., Coutinho-Mansfield, G., Li, H., Qiu, J., Huang, J., Yeo, 
G.W., Ares, M., Fu, X.-D., 2013. Genome-wide analysis reveals SR protein 
cooperation and competition in regulated splicing. Mol. Cell 50, 223–35. 
doi:10.1016/j.molcel.2013.03.001 
Pandya-Jones, A., Black, D.L., 2009. Co-transcriptional splicing of constitutive and 
alternative exons. RNA 15, 1896–1908. doi:10.1261/rna.1714509 
Parra, P., Serra, F., Palou, A., 2010. Expression of adipose MicroRNAs Is sensitive to 
dietary conjugated linoleic acid treatment in mice. PLoS One 5. 
doi:10.1371/journal.pone.0013005 
Pecqueur, C., Alves-Guerra, M.C., Gelly, C., Lévi-Meyrueis, C., Couplan, E., Collins, 
S., Ricquier, D., Bouillaud, F., Miroux, B., 2001. Uncoupling Protein 2, in Vivo 
   REFERENCES 
146 
 
Distribution, Induction upon Oxidative Stress, and Evidence for Translational 
Regulation. J. Biol. Chem. 276, 8705–8712. doi:10.1074/jbc.M006938200 
Peng, M., Ostrovsky, J., Kwon, Y.J., Polyak, E., Licata, J., Tsukikawa, M., Marty, E., 
Thomas, J., Felix, C. a., Xiao, R., Zhang, Z., Gasser, D.L., Argon, Y., Falk, M.J., 
2015. Inhibiting cytosolic translation and autophagy improves health in 
mitochondrial disease. Hum. Mol. Genet. 24, 4829–4847. 
doi:10.1093/hmg/ddv207 
Phillips, T., 2008. Regulation of Transcription and gene expression in eukaryotes. 
Nature Education 1(1):199 [WWW Document]. Nat. Educ. URL 
http://www.nature.com/scitable/topicpage/small-non-coding-rna-and-gene-
expression-1078 (accessed 9.27.15). 
Pisani, D.F., Djedaini, M., Beranger, G.E., Elabd, C., Scheideler, M., Ailhaud, G., Amri, 
E.-Z., 2011. Differentiation of Human Adipose-Derived Stem Cells into “Brite” 
(Brown-in-White) Adipocytes. Front. Endocrinol. (Lausanne). 2, 87. 
doi:10.3389/fendo.2011.00087 
Prokunina-Olsson, L., Welch, C., Hansson, O., Adhikari, N., Scott, L.J., Usher, N., 
Tong, M., Sprau, A., Swift, A., Bonnycastle, L.L., Erdos, M.R., He, Z., Saxena, R., 
Harmon, B., Kotova, O., Hoffman, E.P., Altshuler, D., Groop, L., Boehnke, M., 
Collins, F.S., Hall, J.L., 2009. Tissue-specific alternative splicing of TCF7L2. Hum. 
Mol. Genet. 18, 3795–3804. doi:10.1093/hmg/ddp321 
Puigserver, P., Wu, Z., Park, C.W., Graves, R., Wright, M., Spiegelman, B.M., 1998. A 
Cold-Inducible Coactivator of Nuclear Receptors Linked to Adaptive 
Thermogenesis. Cell 92, 829–839. doi:10.1016/S0092-8674(00)81410-5 
Qian, S., Tang, Y., Li, X., Liu, Y., Zhang, Y., Huang, H., Xue, R., Yu, H., 2013. BMP4-
mediated brown fat-like changes in white adipose tissue alter glucose and energy 
homeostasis 110. doi:10.1073/pnas.1215236110/-
/DCSupplemental.www.pnas.org/cgi/doi/10.1073/pnas.1215236110 
Quinlan, C.L., Orr,  a. L., Perevoshchikova, I. V., Treberg, J.R., Ackrell, B. a., Brand, 
M.D., 2012. Mitochondrial Complex II Can Generate Reactive Oxygen Species at 
High Rates in Both the Forward and Reverse Reactions. J. Biol. Chem. 287, 
27255–27264. doi:10.1074/jbc.M112.374629 
Rajala, M.W., Scherer, P.E., 2003. Minireview: The adipocyte - At the crossroads of 
energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144, 
3765–3773. doi:10.1210/en.2003-0580 
Reitman, M.L., Arioglu, E., Gavrilova, O., Taylor, S.I., 2000. Lipoatrophy revisited. 
Trends Endocrinol. Metab. 11, 410–416. doi:10.1016/S1043-2760(00)00309-X 
Rice, D.R., White, A.G., Leevy, W.M., Smith, B.D., Dame, N., Sciences, G.L., Dame, 
N., 2015. Fluorescence Imaging of Interscapular Brown Adipose Tissue in Living 
Mice 3, 1979–1989. doi:10.1039/C4TB01914H.Fluorescence 
Ristow, M., Wolfrum, C., 2013. A radical opposition in body weight control. EMBO Mol. 
Med. 5, 1147–1148. doi:10.1002/emmm.201303094 
   REFERENCES 
147 
 
Rochford, J.J., 2014. Mouse models of lipodystrophy and their significance in 
understanding fat regulation, 1st ed, Current Topics in Developmental Biology. 
Elsevier Inc. doi:10.1016/B978-0-12-397920-9.00005-6 
Rogge, M.M., 2009. The role of impaired mitochondrial lipid oxidation in obesity. Biol. 
Res. Nurs. 10, 356–373. doi:10.1177/1099800408329408 
Rolfe, D.F., Newman, J.M., Buckingham, J. a, Clark, M.G., Brand, M.D., 1999. 
Contribution of mitochondrial proton leak to respiration rate in working skeletal 
muscle and liver and to SMR. Am. J. Physiol. 276, C692–C699. 
Rosen, E.D., MacDougald, O. a, 2006. Adipocyte differentiation from the inside out. 
Nat. Rev. Mol. Cell Biol. 7, 885–896. doi:10.1038/nrm2066 
Rosen, E.D., Spiegelman, B.M., 2006. Adipocytes as regulators of energy balance and 
glucose homeostasis. Nature 444, 847–53. doi:10.1038/nature05483 
Rosen, E.D., Spiegelman, B.M., 2000. of a Dipogenesis. 
Rosenwald, M., Wolfrum, C., 2014. The origin and definition of brite versus white and 
classical brown adipocytes. Adipocyte 3, 4–9. doi:10.4161/adip.26232 
Rothwell, N.J., Rothwell, N.J., Stock, M.J., Stock, M.J., 1983. Luxuskonsumption, diet-
induced thermogenesis and brown fat: the case in favour. Clin Sci 64, 19–23. 
doi:10.1042/cs0640019 
Roybal, G. a., Jurica, M.S., 2010. Spliceostatin A inhibits spliceosome assembly 
subsequent to prespliceosome formation. Nucleic Acids Res. 38, 6664–6672. 
doi:10.1093/nar/gkq494 
Ruas, J.L., White, J.P., Rao, R.R., Kleiner, S., Brannan, K.T., Harrison, B.C., Greene, 
N.P., Wu, J., Estall, J.L., Irving, B. a, Lanza, I.R., Rasbach, K. a, Okutsu, M., Nair, 
K.S., Yan, Z., Leinwand, L. a, Spiegelman, B.M., 2012. A PGC-1α isoform induced 
by resistance training regulates skeletal muscle hypertrophy. Cell 151, 1319–31. 
doi:10.1016/j.cell.2012.10.050 
Rüegger, S., Großhans, H., 2012. MicroRNA turnover: when, how, and why. Trends 
Biochem. Sci. 37, 436–446. doi:10.1016/j.tibs.2012.07.002 
Rusk, N., 2008. When microRNAs activate translation. Nat. Methods 5, 122–123. 
doi:10.1038/nmeth0208-122a 
Rustin, P., Rötig, A., 2002. Inborn errors of complex II--unusual human mitochondrial 
diseases. Biochim. Biophys. Acta 1553, 117–122. 
Ryan Alexander, Harvey Lodish,  and L.S., 2011. MicroRNAs in adipogenesis and as 
therapeutic targets Obesity. Expert Opin Ther Targets 15, 623–636. 
doi:10.1517/14728222.2011.561317.MicroRNAs 
Salomonis, N., Schlieve, C.R., Pereira, L., Wahlquist, C., Colas, A., Zambon, A.C., 
Vranizan, K., Spindler, M.J., Pico, A.R., Cline, M.S., Clark, T. a, Williams, A., 
Blume, J.E., Samal, E., Mercola, M., Merrill, B.J., Conklin, B.R., 2010. Alternative 
splicing regulates mouse embryonic stem cell pluripotency and differentiation. 
   REFERENCES 
148 
 
Proc. Natl. Acad. Sci. U. S. A. 107, 10514–10519. doi:10.1073/pnas.0912260107 
Sanguinetti, M.C., Tristani-Firouzi, M., 2006. hERG potassium channels and cardiac 
arrhythmia. Nature 440, 463–469. doi:10.1038/nature04710 
Santoro, A., Mattace Raso, G., Meli, R., 2015. Drug targeting of leptin resistance. Life 
Sci. doi:10.1016/j.lfs.2015.05.012 
Savage, D.B., 2009. Mouse models of inherited lipodystrophy. Dis. Model. Mech. 2, 
554–562. doi:10.1242/dmm.002907 
Sazanov, L. a., 2007. Respiratory complex I: Mechanistic and structural insights 
provided by the crystal structure of the hydrophilic domain. Biochemistry 46, 
2275–2288. doi:10.1021/bi602508x 
Scarpulla, R.C., 2008. Nuclear Control of Respiratory Chain Expression by Nuclear 
Respiratory Factors and PGC-1-Related Coactivator. Ann. N. Y. Acad. Sci. 1147, 
321–334. doi:10.1196/annals.1427.006 
Scarpulla, R.C., 2006. Nuclear control of respiratory gene expression in mammalian 
cells. J. Cell. Biochem. 97, 673–683. doi:10.1002/jcb.20743 
Scarpulla, R.C., 2002. Nuclear activators and coactivators in mammalian mitochondrial 
biogenesis. Biochim. Biophys. Acta - Gene Struct. Expr. 1576, 1–14. 
doi:10.1016/S0167-4781(02)00343-3 
Scarpulla, R.C., 1997. Nuclear control of respiratory chain expression in mammalian 
cells. J. Bioenerg. Biomembr. 29, 109–19. 
Schneeberger, M., Gomis, R., Claret, M., 2014. Hypothalamic and brainstem neuronal 
circuits controlling homeostatic energy balance. J. Endocrinol. 220, T25–T46. 
doi:10.1530/JOE-13-0398 
Schon, E. a, Santra, S., Pallotti, F., Girvin, M.E., 2001. Pathogenesis of primary defects 
in mitochondrial ATP synthesis. Semin. Cell Dev. Biol. 12, 441–448. 
doi:10.1006/scdb.2001.0281 
Schreiber, K.H., Kennedy, B.K., 2013. When lamins go bad: nuclear structure and 
disease. Cell 152, 1365–75. doi:10.1016/j.cell.2013.02.015 
Schwartz, M.W., Woods, S.C., Seeley, R.J., Barsh, G.S., Baskin, D.G., Leibel, R.L., 
2003. Is the energy homeostasis system inherently biased toward weight gain? 
Diabetes 52, 232–238. doi:10.2337/diabetes.52.2.232 
Sethi, J.K., Vidal-Puig, A.J., 2007. Thematic review series: adipocyte biology. Adipose 
tissue function and plasticity orchestrate nutritional adaptation. J. Lipid Res. 48, 
1253–1262. doi:10.1194/jlr.R700005-JLR200 
Shao, X., Wang, M., Wei, X., Deng, S., Fu, N., Peng, Q., Jiang, Y., Ye, L., Lin, Y., 
2015. Peroxisome Proliferator-Activated Receptor-γ: master regulator of 
adipogenesis and obesity. Curr. Stem Cell Res. Ther. 
Shi, Y., Burn, P., 2004. Lipid metabolic enzymes: emerging drug targets for the 
treatment of obesity. Nat. Rev. Drug Discov. 3, 695–710. doi:10.1038/nrd1469 
   REFERENCES 
149 
 
Shi, Y., Joyner, A.S., Shadrick, W., Palacios, G., Lagisetti, C., Potter, P.M., Sambucetti, 
L.C., Stamm, S., Webb, T.R., 2015. Pharmacodynamic assays to facilitate 
preclinical and clinical development of pre-mRNA splicing modulatory drug 
candidates. Pharmacol. Res. Perspect. 3, n/a–n/a. doi:10.1002/prp2.158 
Sikaris, K. a, 2004. The clinical biochemistry of obesity. Clin. Biochem. Rev. 25, 165–
181. 
Snyder, C., Stefano, G.B., 2015. Mitochondria and chloroplasts shared in animal and 
plant tissues: significance of communication. Med. Sci. Monit. 21, 1507–11. 
doi:10.12659/MSM.894481 
Soret, J., Bakkour, N., Maire, S., Durand, S., Zekri, L., Gabut, M., Fic, W., Divita, G., 
Rivalle, C., Dauzonne, D., Nguyen, C.H., Jeanteur, P., Tazi, J., 2005. Selective 
modification of alternative splicing by indole derivatives that target serine-arginine-
rich protein splicing factors. Proc. Natl. Acad. Sci. U. S. A. 102, 8764–9. 
doi:10.1073/pnas.0409829102 
Soukas, A., Socci, N.D., Saatkamp, B.D., Novelli, S., Friedman, J.M., 2001. Distinct 
Transcriptional Profiles of Adipogenesis in Vivo and in Vitro. J. Biol. Chem. 276, 
34167–34174. doi:10.1074/jbc.M104421200 
Spalding, K.L., Arner, E., Westermark, P.O., Bernard, S., Buchholz, B. a, Bergmann, 
O., Blomqvist, L., Hoffstedt, J., Näslund, E., Britton, T., Concha, H., Hassan, M., 
Rydén, M., Frisén, J., Arner, P., 2008. Dynamics of fat cell turnover in humans. 
Nature 453, 783–787. doi:10.1097/01.ogx.0000325910.81966.ac 
Stanley, I. a., Ribeiro, S.M., Giménez-Cassina, A., Norberg, E., Danial, N.N., 2014. 
Changing appetites: The adaptive advantages of fuel choice. Trends Cell Biol. 24, 
118–127. doi:10.1016/j.tcb.2013.07.010 
Stobbe, M.D., Houten, S.M., van Kampen,  a. H.C., Wanders, R.J. a., Moerland, P.D., 
2012. Improving the description of metabolic networks: the TCA cycle as example. 
FASEB J. 26, 3625–3636. doi:10.1096/fj.11-203091 
Swift, J., Ivanovska, I.L., Buxboim, A., Harada, T., Dingal, P.C.D.P., Pinter, J., 
Pajerowski, J.D., Spinler, K.R., Shin, J.-W., Tewari, M., Rehfeldt, F., Speicher, 
D.W., Discher, D.E., 2013. Nuclear lamin-A scales with tissue stiffness and 
enhances matrix-directed differentiation. Science 341, 1240104. 
doi:10.1126/science.1240104 
Taanman, J.W., 1999. The mitochondrial genome: structure, transcription, translation 
and replication. Biochim. Biophys. Acta 1410, 103–123. doi:10.1016/S0005-
2728(98)00161-3 
Taliaferro, J.M., Alvarez, N., Green, R.E., Blanchette, M., Rio, D.C., 2011. Evolution of 
a tissue-specific splicing network. Genes Dev. 25, 608–620. 
doi:10.1101/gad.2009011 
Tamori, Y., Masugi, J., Nishino, N., Kasuga, M., 2002. Role of peroxisome proliferator-
activated receptor-?? in maintenance of the characteristics of mature 3T3-L1 
adipocytes. Diabetes 51, 2045–2055. doi:10.2337/diabetes.51.7.2045 
   REFERENCES 
150 
 
Tang, J.J., Li, J.G., Qi, W., Qiu, W.W., Li, P.S., Li, B.L., Song, B.L., 2011. Inhibition of 
SREBP by a small molecule, betulin, improves hyperlipidemia and insulin 
resistance and reduces atherosclerotic plaques. Cell Metab. 13, 44–56. 
doi:10.1016/j.cmet.2010.12.004 
Tang, J.-Y., Lee, J.-C., Hou, M.-F., Wang, C.-L., Chen, C.-C., Huang, H.-W., Chang, 
H.-W., 2013. Alternative splicing for diseases, cancers, drugs, and databases. 
ScientificWorldJournal. 2013, 703568. doi:10.1155/2013/703568 
Tao, M., You, C., Zhao, R., Liu, S., Zhang, Z., Zhang, C., Liu, Y., 2014. Animal 
Mitochondria : Evolution , Function , and Disease 1–10. 
Tazi, J., Bakkour, N., Stamm, S., 2009. Alternative splicing and disease. Biochim. 
Biophys. Acta - Mol. Basis Dis. 1792, 14–26. doi:10.1016/j.bbadis.2008.09.017 
Thompson, D., Karpe, F., Lafontan, M., Frayn, K., 2012. Physical Activity and Exercise 
in the Regulation of Human Adipose Tissue Physiology. Physiol. Rev. 92, 157–
191. doi:10.1152/physrev.00012.2011 
Trujillo, M.E., Pajvani, U.B., 2005. ND ES SC ACKNOWLEDGEMENTS 
BACKGROUND RIB 8, 1141–1145. 
Tseng, Y.-H., Cypess, A.M., Kahn, C.R., 2010. Cellular bioenergetics as a target for 
obesity therapy. Nat. Rev. Drug Discov. 9, 465–482. doi:10.1038/nrd3138 
Turer,  a. T., Scherer, P.E., 2012. Adiponectin: Mechanistic insights and clinical 
implications. Diabetologia 55, 2319–2326. doi:10.1007/s00125-012-2598-x 
Twyffels, L., Gueydan, C., Kruys, V., 2011. Shuttling SR proteins: More than splicing 
factors. FEBS J. 278, 3246–3255. doi:10.1111/j.1742-4658.2011.08274.x 
Uldry, M., Yang, W., St-Pierre, J., Lin, J., Seale, P., Spiegelman, B.M., 2006. 
Complementary action of the PGC-1 coactivators in mitochondrial biogenesis and 
brown fat differentiation. Cell Metab. 3, 333–341. doi:10.1016/j.cmet.2006.04.002 
van Waveren, C., Moraes, C.T., 2008. Transcriptional co-expression and co-regulation 
of genes coding for components of the oxidative phosphorylation system. BMC 
Genomics 9, 18. doi:10.1186/1471-2164-9-18 
Vega, R.B., Huss, J.M., Kelly, D.P., 2000. The coactivator PGC-1 cooperates with 
peroxisome proliferator-activated receptor alpha in transcriptional control of 
nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol. Cell. 
Biol. 20, 1868–76. doi:10.1128/MCB.20.5.1868-1876.2000 
Vidal, H., 2001. Gene expression in visceral and subcutaneous adipose tissues. Ann. 
Med. 33, 547–55. 
Vidal-Puig,  a J., Grujic, D., Zhang, C.Y., Hagen, T., Boss, O., Ido, Y., Szczepanik,  a, 
Wade, J., Mootha, V., Cortright, R., Muoio, D.M., Lowell, B.B., 2000. Energy 
metabolism in uncoupling protein 3 gene knockout mice. J. Biol. Chem. 275, 
16258–16266. doi:10.1074/jbc.M910179199 
Vohl, M.-C., Sladek, R., Robitaille, J., Gurd, S., Marceau, P., Richard, D., Hudson, T.J., 
   REFERENCES 
151 
 
Tchernof, A., 2004. A survey of genes differentially expressed in subcutaneous 
and visceral adipose tissue in men. Obes. Res. 12, 1217–22. 
doi:10.1038/oby.2004.153 
Wahl, M.C., Lührmann, R., 2015a. SnapShot: Spliceosome Dynamics I. Cell 161, 
1474–1474.e1. doi:10.1016/j.cell.2015.05.050 
Wahl, M.C., Lührmann, R., 2015b. SnapShot: Spliceosome Dynamics II. Cell 162, 456–
456.e1. doi:10.1016/j.cell.2015.06.061 
Wahl, M.C., Will, C.L., Lührmann, R., 2009. The spliceosome: design principles of a 
dynamic RNP machine. Cell 136, 701–18. doi:10.1016/j.cell.2009.02.009 
Wallace, D.C., 2005. A mitochondrial paradigm of metabolic and degenerative 
diseases, aging, and cancer: a dawn for evolutionary medicine. Annu. Rev. Genet. 
39, 359–407. doi:10.1146/annurev.genet.39.110304.095751 
Wang, G.-S., Cooper, T. a, 2007. Splicing in disease: disruption of the splicing code 
and the decoding machinery. Nat. Rev. Genet. 8, 749–761. doi:10.1038/nrg2164 
Wang, H., Eckel, R.H., 2009. Lipoprotein lipase : from gene to obesity 80045. 
doi:10.1152/ajpendo.90920.2008. 
Wang, R., Green, D.R., 2012. Metabolic checkpoints in activated T cells. Nat. Immunol. 
13, 907–915. doi:10.1038/ni.2386 
Wang, Z., Burge, C.B., 2008. Splicing regulation: from a parts list of regulatory 
elements to an integrated splicing code. RNA 14, 802–813. 
doi:10.1261/rna.876308 
Warne, J.P., 2003. Tumour necrosis factor alpha: a key regulator of adipose tissue 
mass. J. Endocrinol. 177, 351–355. doi:10.1677/joe.0.1770351 
Weights, A., Confri, S., n.d. EMOTION AND PERSPIRATIO INSENSIBILIS 541, 2–4. 
Whittle, A.J., Carobbio, S., Martins, L., Slawik, M., Hondares, E., Vázquez, M.J., 
Morgan, D., Csikasz, R.I., Gallego, R., Rodriguez-Cuenca, S., Dale, M., Virtue, S., 
Villarroya, F., Cannon, B., Rahmouni, K., López, M., Vidal-Puig, A., 2012. BMP8B 
increases brown adipose tissue thermogenesis through both central and 
peripheral actions. Cell 149, 871–885. doi:10.1016/j.cell.2012.02.066 
Winklhofer, K.F., Haass, C., 2010. Mitochondrial dysfunction in Parkinson’s disease. 
Biochim. Biophys. Acta 1802, 29–44. doi:10.1016/j.bbadis.2009.08.013 
Worman, H.J., Bonne, G., 2007. “Laminopathies”: A wide spectrum of human diseases. 
Exp. Cell Res. 313, 2121–2133. doi:10.1016/j.yexcr.2007.03.028 
Worman, H.J., Fong, L.G., Muchir, A., Young, S.G., 2009. Laminopathies and the long 
strange trip from basic cell biology to therapy. J. Clin. Invest. 119, 1825–1836. 
doi:10.1172/JCI37679 
Wu, H., Sun, S., Tu, K., Gao, Y., Xie, B., Krainer, A.R., Zhu, J., 2010. A Splicing-
Independent Function of SF2/ASF in MicroRNA Processing. Mol. Cell 38, 67–77. 
doi:10.1016/j.molcel.2010.02.021 
   REFERENCES 
152 
 
Wu, J., Boström, P., Sparks, L.M., Ye, L., Choi, J.H., Giang, A.-H., Khandekar, M., 
Virtanen, K. a, Nuutila, P., Schaart, G., Huang, K., Tu, H., van Marken Lichtenbelt, 
W.D., Hoeks, J., Enerbäck, S., Schrauwen, P., Spiegelman, B.M., 2012. Beige 
adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell 
150, 366–76. doi:10.1016/j.cell.2012.05.016 
Xu, H., Barnes, G.T., Yang, Q., Tan, G., Yang, D., Chou, C.J., Sole, J., Nichols, A., 
Ross, J.S., Tartaglia, L. a., Others, 2003. Chronic inflammation in fat plays a 
crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 
112, 1821–1830. doi:10.1172/JCI200319451.Introduction 
Xue, B., Rim, J.-S., Hogan, J.C., Coulter, A. a, Koza, R. a, Kozak, L.P., 2007. Genetic 
variability affects the development of brown adipocytes in white fat but not in 
interscapular brown fat. J. Lipid Res. 48, 41–51. doi:10.1194/jlr.M600287-JLR200 
Yagi, T., Matsuno-Yagi, A., 2003. The proton-translocating NADH-quinone 
oxidoreductase in the respiratory chain: The secret unlocked. Biochemistry 42, 
2266–2274. doi:10.1021/bi027158b 
Ye, R., Scherer, P.E., 2013. Adiponectin, driver or passenger on the road to insulin 
sensitivity? Mol. Metab. 2, 133–141. doi:10.1016/j.molmet.2013.04.001 
Yu, X.X., Mao, W., Zhong,  a, Schow, P., Brush, J., Sherwood, S.W., Adams, S.H., 
Pan, G., 2000. Characterization of novel UCP5/BMCP1 isoforms and differential 
regulation of UCP4 and UCP5 expression through dietary or temperature 
manipulation. FASEB J. 14, 1611–1618. doi:10.1096/fj.14.11.1611 
Zebisch, K., Voigt, V., Wabitsch, M., Brandsch, M., 2012. Protocol for effective 
differentiation of 3T3-L1 cells to adipocytes. Anal. Biochem. 425, 88–90. 
doi:10.1016/j.ab.2012.03.005 
Zechner, R., Kienesberger, P.C., Haemmerle, G., Zimmermann, R., Lass, A., 2009. 
Adipose triglyceride lipase and the lipolytic catabolism of cellular fat stores. J. 
Lipid Res. 50, 3–21. doi:10.1194/jlr.R800031-JLR200 
Zechner, R., Zimmermann, R., Eichmann, T.O., Kohlwein, S.D., Haemmerle, G., Lass, 
A., Madeo, F., 2012. FAT SIGNALS - Lipases and lipolysis in lipid metabolism and 
signaling. Cell Metab. 15, 279–291. doi:10.1016/j.cmet.2011.12.018 
Zhang, J., Lieu, Y.K., Ali, A.M., Penson, A., Reggio, K.S., Rabadan, R., Raza, A., 
Mukherjee, S., Manley, J.L., 2015. Disease-associated mutation in SRSF2 
misregulates splicing by altering RNA-binding affinities. Proc. Natl. Acad. Sci. 
201514105. doi:10.1073/pnas.1514105112 
Zhang, Z., Krainer, A.R., 2004. Involvement of SR proteins in mRNA surveillance. Mol. 
Cell 16, 597–607. doi:10.1016/j.molcel.2004.10.031 
Zhou, Z., Licklider, L.J., Gygi, S.P., Reed, R., 2002. Comprehensive proteomic analysis 
of the human spliceosome. Nature 419, 182–5. doi:10.1038/nature01031 
Zwerger, M., Roschitzki-voser, H., Zbinden, R., Denais, C., Herrmann, H., 2015. 
Altering lamina assembly identifies lamina-dependent and -independent functions 
   REFERENCES 
153 
 
for A-type lamins Journal of Cell Science Accepted manuscript 41.
   
154 
 
 
